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Attenuation	 of	 neo-angiogenesis	 with	 targeted	 therapy	 in	 metastatic	
renal	cell	carcinoma	may	account	for	its	therapeutic	effect	and	could	be	
measured	radiologically.	The	prediction	of	therapeutic	response	to	anti-
angiogenic	 agents	 may	 be	 improved	 by	 methodological	 changes	 in	
interpretation	of	standard	tumour	imaging.		
	
(Anup	Vinayan	2017)	
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Abstract	 	
	
Background	
Drugs	targeting	angiogenic	pathway	remain	the	mainstay	of	treatment	for	metastatic	
renal	cell	carcinoma	(mRCC).	Tyrosine	Kinase	Inhibitors	(TKI)	as	Sunitinib,	Pazopanib	
as	 single	 agents	 and	 humanised	 monoclonal	 antibody	 bevacizumab	 (Bev)	 in	
combination	with	Interferon-	α2a	(IFN)	have	established	as	the	first-line	therapy	for	
mRCC.	 Despite	 improvements	 in	 treatment,	 there	 are	 multiple	 questions	 which	
remain	unanswered.	In	the	combination	of	Bev	and	IFN,	the	respective	role	of	each	
drug	and	whether	any	additional	anti-angiogenic	activity	 is	gained	by	adding	IFN	to	
Bev	remains	unknown.	As	the	clinical	benefit	obtained	with	these	cytostatic	agents	
does	not	always	correlate	with	the	conventional	response	assessment	techniques	as	
RECIST,	 it	 is	necessary	to	reconsider	the	methods	by	which	we	assess	benefit	 from	
these	therapies.	In	this	thesis,	I	report	three	studies	aiming	to	answer	these	questions.			
	
Methods	
With	the	clinical	trial	reported	here,	I	explore	whether	Bev	induced	changes	in	vascular	
parameters	measured	by	Dynamic	Contrast	Enhanced	MRI	(DCE-MRI)	is	significantly	
enhanced	by	the	addition	of	IFN.	In	a	phase	II,	randomised,	open	labelled,	multicentre	
trial,	treatment	naïve	mRCC	patients	were	randomised	to	receive	Bev	on	its	own	or	in	
combination	with	a	low	dose	(3MU)	or	standard	dose	(9MU)	IFN.		DCE-MRI	was	used	
to	 assess	 the	 changes	 in	 vascularity	 with	 the	 primary	 endpoint	 being,	 changes	 in	
transfer	coefficient	(Ktrans)	after	six	weeks	of	treatment.			
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I	 also	 report	 two	 retrospective	 imaging-based	 studies,	 using	 contrast-enhanced	CT	
scans,	 performed	 to	 improve	 the	 methodology	 of	 response	 assessment	 for	 these	
antiangiogenic	therapeutics.	Here	I	explore	the	use	of	a)	combining	changes	 in	size	
and	arterial	phase	contrast	enhancement	measured	using	CT	scan	and	b)	changes	in	
CT	texture	as	methods	of	therapeutic	response	assessment	in	mRCC	patients	treated	
with	TKI.			
	
Results	
With	the	phase	2	clinical	trial,	we	faced	significant	difficulty	in	recruitment	as	a	result	
of	restrictions	in	access	to	treatment	in	NHS,	other	competing	studies	and	restrictions	
proposed	 by	 the	DCE-MRI	 inclusion	 criteria.	With	 slow	 recruitment,	 an	 unplanned	
analysis	was	performed	after	21	patients	were	recruited.	Analysis	of	primary	endpoint	
showed	no	trend	in	the	difference	between	arms	with	no	correlation	found	between	
change	in	Ktrans	and	addition	of	IFN	to	bevacizumab.	Effect	size	analysis	performed	
due	to	the	small	numbers	recruited	failed	to	show	any	significance	in	the	observed	
difference	in	Ktrans.	Change	in	Ktrans	and	Kep	may	identify	a	group	of	patients	likely	
to	have	PFS	>	6	months,	but	this	observation	needs	to	evaluation	in	a	larger	sample	
size.		
	
Measuring	size	and	change	in	arterial	phase	enhancement	retrospectively	using	CT,	a	
new	 criterion	 "modified"	 Choi,	 which	 prerequisite	 a	 combination	 of	 a	 decrease	 in	
arterial	 phase	 density	 by	 15%	 and	 a	 decrease	 in	 size	 by	 10%	 for	 response	 was	
Abstract	
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proposed.	Response	assessment	was	measured	with	RECIST,	Choi	and	modified	Choi	
individually	 in	 20	 evaluable	 patients	 retrospectively	 and	 clinical	 benefit	 compared	
with	Kaplan-Meier	statistics	and	Log-Rank	test.	Response	assessment	as	defined	by	
the	modified	Choi	criteria	successfully	identified	patients	who	received	clinical	benefit	
from	the	treatment.	Time	to	progression	(TTP)	was	448	days	for	the	partial	response	
and	 89	 days	 for	 stable	 disease	 as	 per	 the	 new	 criteria	 which	 were	 statistically	
significant	with	a	p-value	of	0.002.	
	
The	second	retrospective	analysis	explored	the	textural	changes	in	enhanced	CT	scan.	
Performed	in	collaboration	with	researchers	from	Brighton	University	who	developed	
the	 software	 algorithm	 used	 to	 assess	 changes	 in	 entropy	 and	 uniformity,	 87	
metastases	 from	 39	 patients	with	mRCC	were	 analysed	 at	 baseline	 and	 after	 two	
cycles	of	TKI	treatment.	Textural	parameters	and	response	assessment	criteria	were	
correlated	with	TTP.		After	two	cycles	of	TKI,	the	decrease	in	tumour	entropy	was	3%-
45%,	 and	 increase	 in	 uniformity	 was	 5%-21%.	 At	 a	 threshold	 change	 of	 -2%	 with	
uniformity,	 on	 a	 coarse	 scale	 of	 2.5,	 the	 textural	 change	 was	 able	 to	 separate	
responders	 from	 non-responders.	 With	 Kaplan-Meier	 analysis	 comparing	 all	 four	
criteria,	the	percentage	change	in	uniformity	was	statistically	more	significant	than	for	
RECIST,	Choi,	and	Modified	Choi	criteria.	Cox	regression	analysis	showed	that	texture	
uniformity	was	an	independent	predictor	of	time	to	progression.	
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Discussion	
With	 the	 studies	 reported	 here,	 I	 was	 able	 to	 demonstrate	 the	 importance	 of	
improving	the	methodology	in	assessment	of	therapeutic	response	to	targeted	anti-
angiogenic	therapy	in	metastatic	renal	cell	carcinoma.	Even	though	the	clinical	trial,	
terminated	early	due	to	slow	recruitment,	did	not	reach	its	primary	endpoint,	changes	
in	other	vascular	parameters	as	Kep	combined	with	changes	Ktrans	showed	tendency	
towards	identifying	a	group	of	patients	who	derived	clinical	benefit	of	>6months	with	
these	therapies.	This	is	particularly	exciting	as	given	the	vascular	stabilisation	effect	
proposed	 for	 bevacizumab,	 the	 effusion	 parameter	 Kep	 may	 be	 a	 better	 tool	 in	
assessing	 response	 rather	 than	Ktrans	and	warrants	 further	assessment	 in	a	 larger	
cohort.	 Modified	 choi	 criterion	 and	 textural	 analysis	 are	 two	 important	
methodological	 improvements	in	response	assessment	of	cytostatic	anti-angiogenic	
therapy.	In	the	analyses	reported	here,	both	techniques	have	shown	superiority	over	
RECIST	in	response	assessment	and	differentiating	mRCC	patients	who	is	likely	to	gain	
clinical	benefit	by	TKI	therapy.	Validation	of	these	criteria	on	a	larger	patient	cohort	is	
important.	 As	 these	 criterions	 are	 assessed	 on	 standard	 enhanced	 CT	 scans,	
incorporating	these	criteria,	especially	modified	choi	criterion,	as	part	of	standard	CT	
assessment	could	be	performed	and	will	provide	a	real	world	validation.	Retrospective	
assessment	using	larger	cohort	of	patients	from	previous	phase	3	trials	or	inclusion	of	
these	parameters	prospectively	in	phase	3	trials	would	also	help	us	in	evaluating	these	
modalities	further.
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1.1. Renal	Cell	Carcinoma	(RCC)	
1.1.1. Background	
Renal	cell	cancer	(RCC)	accounts	for	approximately	3%	of	adult	malignancy	incidence	
worldwide.	 The	 annual	 incidence	 in	 the	 UK	 in	 2013	 was	 11,873	 (CRUK	 2013).	
Increasing	trends	of	incidence	have	been	noted	since	1970	(CRUK	2013,	ONS.GOV.UK	
2015).	RCC	is	strongly	related	to	age	with	more	than	half	of	the	patients	presenting	
are	above	the	age	of	70.	Cigarette	smoking	is	shown	to	be	a	significant	risk	factor	for	
the	development	of	RCC	(Ferlay,	Autier	et	al.	2007).	The	disease	is	also	associated	with	
obesity	shown	by	case-control	and	cohort	studies	and	industrial	exposure	to	cadmium	
exposure	is	also	suggested	as	a	potential	risk	factor	(Chris	Protzel	2012).	40-50%	of	
these	cancers	present	while	the	disease	is	still	confined	within	kidneys,	a	significant	
proportion	 of	 which	 is	 detected	 as	 an	 incidental	 finding.	 Despite	 having	 curative	
nephrectomy,	30	–	50%	of	these	patients	recur	with	metastatic	disease	while	another	
1/3rd	 patients	 present	with	metastatic	 disease	 de	 novo	 (CRUK	 2013).	 Prognosis	 of	
metastatic	 kidney	 cancer	 remains	 very	 poor	 with	 the	 majority	 of	 patients	 with	
metastatic	disease	dying	within	two	years	of	diagnosis.	Five-year	survival	in	patients	
presenting	with	metastatic	disease	is	around	5-6%.	Management	of	advanced	RCC	has	
always	been	a	challenge	as	these	group	of	disease	never	showed	a	clinically	relevant	
response	to	traditional	cytotoxic	chemotherapeutic	drugs	(Hartmann	and	Bokemeyer	
1999).	With	 increased	knowledge	of	pathogenesis	of	these	tumours,	the	treatment	
landscape	of	this	disease	has	undergone	significant	change	over	the	last	decade.	
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1.1.2. Pathophysiology	of	renal	cell	carcinoma	
Renal	cell	carcinoma	includes	a	heterogeneous	group	of	cancer	with	different	genetic	
and	molecular	alterations.	Major	histological	subtypes	in	this	group	of	disease	include	
clear	 cell,	 papillary	 (type	 1	 and	 2)	 and	 chromophobe	 RCC.	 	 These	 3	 groups	 form	
approximately	90%	of	 the	 renal	malignancies	 (Lopez-Beltran,	 Scarpelli	 et	 al.	 2006).	
Other	 less	 common	 histological	 subtypes	 include	 medullary,	 collecting	 duct,	
multilocular	cystic,	unclassified	etc.	The	International	Society	of	Urological	Pathology	
(2012)	 has	 further	 described	 new	 distinct	 epithelial	 tumours.	 These	 include	
tubulocystic,	acquired	cystic	disease	associated,	clear	cell	tubulo	papillary,	MiT	family	
translocation	associated	and	hereditary	leiomyomatosis	associated	RCC.	
	
In	 most	 cases	 of	 clear	 cell	 renal	 cell	 carcinoma	 (ccRCC),	 whether	 sporadic	 or	
hereditary,	structural	alterations	of	the	short	arm	of	chromosome	3	have	been	noted.	
Significantly,	Von	Hippel-Lindau	protein	(VHL)	is	coded	at	short	arm	of	chromosome	3	
(3p25).	VHL	is	a	tumour	suppressor	gene	and	80%	of	clear	cell	renal	cell	carcinoma	
harbour	somatic	or	epigenetic	alterations	in	this	gene	resulting	in	inactivation	of	the	
gene	(Gnarra,	Tory	et	al.	1994,	Brugarolas	2014).		
	
VHL	tumour	suppressor	gene	has	a	significant	role	 in	cellular	oxygen	sensing	which	
materializes	through	its	interaction	with	hypoxia	inducible	factor	(HIF)	in	the	cells.	HIF	
plays	a	pivotal	role	in	renal	tumorigenesis	as	it	acts	as	a	transcription	factor	for	genes	
involved	in	angiogenesis,	proliferation,	cell	survival,	apoptosis	etc	(Turner,	Moore	et	
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al.	2002,	Semenza	2003).	Preclinical	studies	suggest	a	causal	role	in	deregulation	of	
HIF	subunit,	HIF2!,	in	RCC	pathogenesis	(Kondo,	Kim	et	al.	2003).		
	
Hypoxia	inducible	factor	(HIF)	
HIF	has	!	 (HIF-1α,	HIF-2α,	HIF-3α)	 and	β	 (HIF-1β/ARNT)	 subunits.	 The	!	 subunit	 is	
generally	 unstable	 except	 under	 hypoxic	 conditions.	 HIF-!	 subunits	 acts	 as	 a	
transcription	 factor	 for	 a	 variety	 of	 proteins	 including	 vascular	 endothelial	 growth	
factor	(VEGF).			
	
Under	normoxic	conditions,	VHL	protein	(pVHL)	stimulates	degradation	of	HIF-α	and	
thus	 resulting	 in	 inactivation	of	 its	 transcription.	 In	 the	 state	of	normoxia,	HIF-α	 is	
hydroxylated	with	proline	hydroxylases.	pVHL	recognises	and	binds	to	HIF-α	with	the	
help	of	two	other	proteins	(elongins).	This	complex	undergoes	poly-ubiquitination	and	
degradation	through	proteasomes.		
	
In	conditions	of	cellular	hypoxia,	proline	hydroxylase	fails	to	hydroxylate	HIF-α,	this	
results	in	little	or	no	ubiquitination	of	HIF-α.	Excess	HIF-α	in	cell,	translocate	to	the	
nucleus	and	heterodimerises	with	the	β	subunit	of	HIF.	The	complex	stabilizes	the	!	
subunit.	HIF-!/	HIF-β	complex	binds	to	hypoxia	response	elements	(HRE)	on	nuclear	
DNA	 and	 stimulates	 the	 transcription	 of	 genes	 involved	 in	 growth,	 angiogenesis,	
survival/apoptosis	etc.	including	VEFG.	This	interaction	is	represented	schematically	
in	figure	1.1.		
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Figure	1.1	 HIF-1	and	its	regulation	by	VHL	
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Most	 sporadic	 ccRCC	harbor	 changes	 in	 the	VHL	 gene	which	 render	 them	 inactive	
resulting	in	constitutive	activation	of	HIF-1!/2!	(Banks,	Tirukonda	et	al.	2006,	Kaelin	
2007).	 Further	 studies	 have	 shown	 that	 HIF-2!	 activation	 significantly	 impacts	
development	of	renal	cell	carcinoma	(Kondo,	Kim	et	al.	2003).	
	
Stabilisation	of	!	subunits	of	HIF	can	also	happen	through	other	oncogenic	pathways	
as	 phosphatidylinositol	 3-OH	 kinase	 (PI3K/AKT)	 and	 MAPK	 (mitogen	 associated	
protein	 kinase)	 pathways.	 Activation	 of	 PI3K	 pathway	 produces	 mTOR	 dependent	
translation	of	HIF!	(Rochlitz,	Peter	et	al.	1992,	Hay	2005,	Brugarolas	2014).		
Several	other	driver	genes	have	been	noted	to	be	active	in	pathogenesis	of	renal	cell	
carcinoma.	 These	 include	PBRM1,	BAP1,	 SETD2,	 TCEB1	and	KDM5C.	 The	effects	of	
these	 mutations	 are	 still	 not	 fully	 understood	 (Ibragimova,	 Maradeo	 et	 al.	 2013,	
Brugarolas	2014).		
 
Multiple	hereditary	forms	of	RCC	are	also	known	with	its	associated	specific	sites	of	
mutations	(Pavlovich	and	Schmidt	2004).		
a) Von	Hippel-Lindau	associated	–	VHL3p25-26	
b) Hereditary	papillary	RCC	–	MET7q31-34	
c) Birt-Hogg-Dubé	syndrome	–	FLCN	17p11	
d) Hereditary	leiomyomatosis	associated	(HLRCC)	–	FH1q42-43	
e) Tuberous	sclerosis	associated	–	TSC1	9q34	/	TSC2	16p13	 	
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1.1.3. Staging	of	renal	cell	carcinoma	
Renal	cell	carcinoma	is	classified	using	TNM	staging.	TNM	classification	 is	based	on	
primary	 tumour	 character	 (T),	 Nodal	 status	 (N)	 and	 Metastatis	 (M).	 Since	 its	
introduction,	TNM	staging	is	one	of	the	widely	accepted	methods	of	tumour	staging.		
Current	TNM	staging	7.0	classifies	RCC	as	below	(Edge	and	Compton	2010).	
T	staging	
T1:	Confined	to	Kidney	<7cm	
T1a:	confined	to	kidney	<4cm	
T1b:	confined	to	kidney	>4cm<7cm	
T2:	Confined	to	Kidney	>7cm	
T2a:	confined	to	kidney	>7cm<10cm	
T2b:	confined	to	kidney	>10cm	
T3:	Tumour	or	tumour	thrombus	extension	to	major	veins	or	perinephric	tissue	
T3a:	Spread	to	renal	vein.		
T3b:	extension	to	infra	diaphragmatic	IVC	
T3c:	Spreads	to	supra	diaphragmatic	IVC	or	invades	vessel	walls.		
T4:	Involvement	of	Ipsilateral	adrenal	gland/involvement	of	Gerota’s	fascia	
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N	–	Nodal	staging	
N0:	No	nodal	involvement	
N1:	metastatic	involvement	of	regional	nodes.		
 
M	–	Metastasis	
 
M0:	No	distant	metastasis	
M1:	Distant	metastasis.	
 
Table	1.1	 	Staging	of	RCC		
Staging	 TNM	character	
Stage1	 T1N0M0	
Stage2	 T2N0M0	
Stage	3	 T3	or	N1	
Stage	4	 T4	or	M1	
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1.1.4. Systemic	therapy	of	metastatic	renal	cell	carcinoma	
Renal	cell	carcinoma	has	traditionally	been	thought	of	as	a	chemotherapy-resistant	
and	 radiotherapy-resistant	 disease.	 Immunotherapy	 with	 interferon-α	 (IFN-α)	 and	
interleukin-2	 (IL-2)	 have	 been	 the	 treatment	 of	 advanced	 RCC	with	 the	 treatment	
benefiting	only	a	small	minority	(8%)	with	significant	associated	toxicities	(A	Ritchie	
1999,	Coppin,	Porzsolt	et	al.	2000)	.		With	improved	knowledge	of	pathophysiology	of	
RCC,	 targeted	 treatment	 with	 agents	 that	 target	 angiogenesis	 and	 growth	 factor	
signaling	have	become	the	standard	of	treatment	for	this	disease.		
	
Several	 targeted	 therapeutic	 drugs	 have	 been	 approved	 by	 regulatory	 bodies	 for	
management	of	advanced	renal	cell	carcinoma.	These	include	multi-targeted	tyrosine	
kinase	inhibitors	as	sunitinib	(Motzer,	Hutson	et	al.	2007),	sorafenib	(Escudier,	Eisen	
et	al.	2009),	pazopanib	(Motzer,	Hutson	et	al.	2013),	axitinib	(Hutson,	Lesovoy	et	al.	
2013),	 mTOR	 inhibitors	 as	 temsirolimus	 (Motzer,	 Hudes	 et	 al.	 2007),	 everolimus	
(Motzer,	Escudier	et	al.	2008)	and	recombinant	monoclonal	antibody	against	VEGF	–	
bevacizumab	(Escudier,	Bellmunt	et	al.	2010).			
	
Sunitinib,	pazopanib,	temsirolimus	and	Avastin	(bevacizumab)	were	licensed	for	first	
line	 systemic	 therapy,	 while	 sorafenib	 and	 axitinib	 were	 approved	 for	 use	 post	
progression	on	other	treatment	lines.		
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Sunintib	was	assessed	in	comparison	with	interferon!	(Motzer,	Hutson	et	al.	2007).	A	
phase	3	trial	with	750	patients	showed	a	progression	free	survival	(PFS)	of	11	months’	
vs	5	months	in	favour	of	sunitinib.		
Pazopanib	 was	 trialled	 in	 three	 different	 phase	 3	 trials;	 against	 placebo,	 against	
sunitinib	in	first	line	metastatic	setting	and	against	placebo	in	cytokine-refractory	RCC	
(Sternberg,	Davis	et	al.	2010,	Motzer,	Hutson	et	al.	2013,	Sternberg,	Hawkins	et	al.	
2013).	 PFS	 advantage	 was	 noted	 for	 the	 trial	 against	 placebo	 (11.1months	 Vs	
2.8months)	with	no	overall	survival	benefit	likely	due	to	early	cross	over	from	placebo	
to	 treatment	 arm.	 Similar	 efficacy	 was	 noted	 for	 pazopanib	 and	 sunitinib	 with	
different	 toxicity	 profile.	 Quality	 of	 life	 was	 noted	 to	 be	 better	 in	 patients	 who	
received	pazopanib	(Motzer,	Hutson	et	al.	2013).		
	
Sorafenib	and	axitinib	were	approved	as	second	line	therapy	and	a	PFS	advantage	of	
2.4months	 was	 observed	 against	 placebo	 for	 sorafenib	 while	 axitinib	 showed	 a	
2.0months	 PFS	 advantage	 over	 sorafenib	 in	 patients	 previously	 exposed	 to	 anti-
angiogenic	therapy	(Escudier,	Eisen	et	al.	2007,	Hutson,	Lesovoy	et	al.	2013).		
	
Bevacizumab	 a	 recombinant	 humanised	 monoclonal	 antibody	 against	 VEGF	 was	
assessed	in	combination	with	interferon-!2a	against	 interferon-!2a	in	two	phase	3	
trials.	AVOREN	trial	(Escudier,	Bellmunt	et	al.	2010)	demonstrated	an	improvement	in	
median	 PFS	 from	 5.4months	 in	 the	 interferon	 only	 arm	 to	 10.2	 months	 in	 the	
combination	arm	with	a	hazard	ratio	of	0.63	in	favour	of	the	combination.	CALBG	trial	
with	a	similar	design	of	AVOREN	study	also	showed	a	similar	outcome	with	a	hazard	
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ratio	 of	 0.71	 in	 favour	 of	 bevacizumab.	 Overall	 response	 rate	 in	 these	 study	 was	
around	25%	(Rini,	Halabi	et	al.	2008).	Again	no	overall	survival	benefit	was	shown	by	
any	of	these	trials.	AVOREN	trial	was	un-blinded	as	an	interim	analysis	showed	clinical	
benefit	and	patients	were	crossed	over	to	the	treatment	arm.	The	confounding	effect	
of	this	crossover	and	availability	and	use	of	other	targeted	therapy	as	salvage	is	likely	
to	have	influenced	the	overall	survival	assessment	of	these	cohort	of	patients.	Phase	
3	registration	trials	of	these	drugs	and	their	out-come	are	listed	here	table	1.2.		
	
More	recently,	anti-CTLA4	antibody	ipilimumab	and	check	point	inhibitor	drugs	such	
as	nivolumab	have	shown	promising	benefits	in	treatment	of	metastatic	RCC	which	
has	progressed	through	other	lines	of	therapy.	In	a	phase	3	study	comparing	against	
everolimus	 in	 metastatic	 RCC	 patients	 who	 have	 progressed	 on	 previous	 line	 of	
treatment	nivolumab	showed	an	improvement	in	overall	survival	25.0	months	Vs	19.6	
months	with	a	hazard	ratio	of	0.71.	Nivolumab	has	since	been	granted	license	for	use	
in	metastatic	RCC	as	a	second	or	later	line	therapy	(Motzer,	Escudier	et	al.	2015).	
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Table	1.2	
	Phase	3	trials	of	targeted	therapy	approved	for	m
anagem
ent	in	m
etastatic	renal	cell	carcinom
a	
Drug	
Type	
Line	of	
therapy	
Treatm
ent	
PFS	(HR)	
O
S	
Bevacizum
ab	
Recom
binant	hum
anised	
m
onoclonal	antibody	against	
VEGF	
1
st	line	
Bevacizum
ab+interferon	vs	
interferon	
10.2	vs	5.4	
(0.63)	
23.3	vs	21.3	
1
st	line	
Bevacizum
ab+interferon	vs	
interferon	
8.5.	vs	5.2	
(0.72)	
18.3	vs	17.4	
Sunitinib	
VEGFR/PDGF	inhibitor	
1
st	line	
Sunitinib	vs	interferon!		
11.0	vs	5.0	
(0.42)	
---	
Pazopanib	
VEGF/PDGF/c-kit	inhibitor	
1
st	line	
Pazopanib	vs	placebo	
11.1	vs	2.8	
(0.40)	
22.0	vs	23.5	
	
Pazopanib	vs	sunitinib	
8.4	vs	9.5	
28.3	vs	29.1	
Post	
cytokine	
Pazopanib	vs	placebo	
7.4	vs	4.2	
(0.54)	
22.7	vs	18.7	
Sorafenib	
VEGFR2/PDGF/M
APK/M
EK	
inhibitor	
2
nd	line	
Sorafenib	vs	placebo	
5.5	vs	2.8	
(0.44)	
17.8	vs	15.2	
Axitinib	
VEGF1-3,PDGF,	c-kit	
inhibitor	
2
nd	line	
Axitinib	vs	sorafenib	
6.7	Vs	4.7	
(0.66)	
	
Tem
sirolim
us	
m
TO
R	inhibitor	
1
st	line	
Tem
sirolim
us	vs	interferon	
3.8	vs	1.9	
10.9	vs	7.3	
1
st	line	
Tem
sirolim
us	+bevacizum
ab	vs	
interferon	+	bevacizum
ab	
9.1	vs	9.3	
25.8	vs	25.5	
2
nd	line	
Tem
sirolim
us	vs	sorafenib	
4.3	vs	3.9	
(0.87)	
12.3	vs	16.6	
Everolim
us	
m
TO
R	inhibitor	
2
nd	line	
Everolim
us	vs	placebo	
4.0	vs	1.9	
(0.30)	
-	
Nivolum
ab	
Anti	PD-1	antibody	
2
nd	line	
Nivlum
ab	vs	everolim
us	
	
25.0	vs	19.6	
• 
PFS=progression	free	survival	in	m
onths,	HR	=	hazard	ratio,	OS=	overall	survival	in	m
onths.
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1.1.5. Treatment	response	assessment	
Accurate	 therapeutic	 response	 assessment	 is	 a	 significant	 part	 of	 any	 treatment.	
Critical	decisions	are	made	whether	to	continue	a	particular	treatment	or	change	to	
another	 regime	 based	 on	 these	 assessments.	 Methods	 of	 treatment	 response	
assessment	 need	 to	 be	 validated	 and	 accepted.	 Identification	 of	 non-responders	
earlier	 than	 any	 clinical	 symptoms	 avoid	 unnecessary	 side	 effects	 and	 allow	 the	
patient	 and	 clinician	 to	 decide	 on	 switching	 to	 a	 potentially	 beneficial	 treatment.	
Along	with	 clinical	 benefit	 in	day	 to	day	 treatment,	 this	has	 an	 important	 role	 the	
development	of	new	drugs.	Identification	of	potential	responders	or	non-responders	
and	identification	of	at	risk	population	for	side	effects	would	identify	patients	who	will	
have	maximum	benefit	from	a	specific	intervention.		
	
Current	method	of	standard	treatment	assessment	for	most	of	anti-cancer	treatment	
is	 based	on	 imaging	defined	 response	 assessment	 criteria	 called	RECIST	 (Response	
Evaluation	 Criteria	 in	 Solid	 Tumours).	 This	 continues	 to	 be	 the	 case	 for	 response	
assessment	 of	 treatment	 in	 advanced	 renal	 cell	 carcinoma.	 RECIST	 response	
assessments	are	based	solely	on	changes	in	size	of	the	target	lesions	(NCI	2000,	Patrick	
Therasse,	 Richard	 S.	 Kaplan	 et	 al.	 2000).	 The	 treatment	 paradigm	 of	 different	
malignancies	has	changed	significantly	over	the	years.	Cytostatic	targeted	agents	are	
now	being	used	as	standard.	It	is	also	common	that	these	drugs	are	now	being	used	
continuously	as	a	maintenance	treatment.	With	the	changes	that	are	ongoing,	 it	 is	
important	that	we	rethink	whether	the	response	assessment	tools	that	we	use	are	fit	
for	purpose.	
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Over	the	last	decade,	since	proposal	of	Choi	criteria	in	2006	for	assessment	of	imatinib	
response	 in	 Gastro	 Intestinal	 Stromal	 Tumours	 (Choi,	 Charnsangavej	 et	 al.	 2007),	
different	research	groups	have	assessed	options	of	using	patterns	of	changes	noted	in	
standard	 imaging	 modalities	 (e.g.:	 contrast	 enhancement	 changes,	 volumetric	
changes	etc.)	and	newer	imaging	defined	criteria	as	response	assessment	tools.	This	
is	discussed	further	in	this	thesis	in	chapter	5	where	I	explore	the	option	of	combining	
size	and	change	in	arterial	density	in	treatment	response	assessment	of	solid	tumours.	
Along	 with	 CT	 based	 imaging	 criteria,	 18FDG	 PET-CT	 (Fluorodeoxyglucose	 positron	
emission	tomography),	functional	MRI	scans	as	Dynamic	Contrast	Enhanced	MRI	(DCE-
MRI),	Diffusion-Weighted	Imaging	MRI	(DWI-MRI),	perfusion	 imaging	etc.	are	being	
used	more	and	more	for	response	assessment	calculation.	In	Chapter	4.0	of	this	thesis,	
I	 detail	 a	 study	 where	 DCE-MRI	 was	 used	 in	 measuring	 antiangiogenic	 effects	 of	
bevacizumab	and	interferon	in	mRCC	patients.	
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1.2. Tumour	Vasculature	
1.2.1. Angiogenesis	
Angiogenesis	 is	 the	 process	 of	 new	 blood	 vessel	 formation	 from	 pre-existing	
vasculature.	Angiogenesis	is	a	physiological	process	and	is	involved	in	normal	growth,	
physiologically	 in	 placenta,	 endometrium	 and	 is	 also	 involved	 in	 pathological	
conditions	such	as	wound	healing.	The	concept	of	angiogenesis	as	a	fundamental	step	
of	 tumour	 growth	 and	 metastasis	 was	 proposed	 by	 Dr.	 Judah	 Folkman	 in	 1971.	
Folkman	proposed	 that	beyond	 the	diffusion	 limit	of	oxygen	 (1-2mm),	 tumour	 cell	
growth	required	angiogenesis	(Folkman,	Merler	et	al.	1971,	Folkman	and	Shing	1992).		
	
The	process	of	angiogenesis	is	monitored	and	regulated	by	a	complex	mechanism	of	
interaction	involving	a	growing	number	of	proangiogenic	and	antiangiogenic	factors	
(Poon,	Fan	et	al.	2001,	Clamp	and	Jayson	2005).	The	intricate	communication	between	
these	factors	are	responsible	for	stimulation,	 inhibition	and	control	of	angiogenesis	
and	vascular	remodelling	(Risau	1997,	Carmeliet	and	Jain	2000).	
	
RCC	 is	 a	 highly	 vascular	 tumour	 which	 is	 not	 surprising,	 given	 its	 pathogenesis	
involving	the	VHL-HIF-angiogenic	pathway	as	described	earlier.	Vascular	Endothelial	
Growth	Factor	A	(VEGF-A)	or	simply	VEGF,	 is	a	key	mediator	of	angiogenesis	and	is	
known	to	be	significantly	over	expressed	in	ccRCC	(Minardi,	Santoni	et	al.	2015,	Zeng,	
Zeng	et	al.	2016).	Expression	of	tumour	VEGF	is	also	noted	to	correlate	with	tumour	
stage	 and	 surrogate	 for	 prognosis	 in	 ccRCC.	 The	 VEGF	 family	 consists	 of	 five	
glycoproteins:	VEGF-A,	VEGF-B,	VEGF-C,	VEGF-D	and	placental	growth	factor	(PGF)	of	
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which	 the	 best	 characterised	 is	 VEGF-A.	 The	 actions	 of	 VEGF-A	 are	 mediated	
principally	via	the	VEGF	receptors	1	and	2	(Rosen	2002).	VEGF	is	a	potent	stimulator	
of	neovascularisation	 leading	 to	 the	development	of	a	structurally	and	 functionally	
abnormal	vasculature	which	may	impair	the	effective	delivery	of	chemotherapy.		The	
presence	of	 VEGF	promotes	 the	 survival	 of	 these	 new	 vessels	 by	 upregulating	 the	
expression	of	anti-apoptotic	proteins	bcl-2	and	XIAP	(Gerber,	Dixit	et	al.	1998,	Gerber,	
McMurtrey	et	al.	1998).	Multiple	mechanisms	of	VEGF	action	have	been	proposed	
including	endothelial	cell	proliferation	and	survival,	increased	migration	and	invasion	
of	 endothelial	 cells,	 increased	 permeability	 of	 existing	 vasculature,	 homing	 of	
endothelial	cell	precursors	as	well	as	autocrine	effects	on	tumour	cell	function	(Ellis	
and	Hicklin	2008).	
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1.2.2. Tumour	blood	flow	
According	 to	 Poiseuille’s	 law,	 blood	 flow	 through	 a	 single	 rigid	 cylindrical	 vessel	 is	
proportional	to	the	pressure	difference	between	the	ends	of	the	tube	and	inversely	
proportional	 to	 the	 fourth	 power	 of	 vessel	 radius.	 Blood	 vessels	 in	 newly	 formed	
tumours	are	usually	immature	and	chaotic	(Benjamin,	Golijanin	et	al.	1999).	With	a	
network	 of	 complex	 immature	 and	 leaky	 vessels,	 calculation	 of	 blood	 flow	 is	
complicated	as	it	is	also	dependent	on	vascular	morphology,	vessel	number,	branching	
pattern	and	interstitial	pressure.		
	
It	 has	 been	 shown	 that	 interstitial	 pressure	 in	 solid	 tumours	 is	 high	 in	 both	
experimental	 condition	 and	 in	 vivo	 conditions	 (Less,	 Posner	 et	 al.	 1992,	 Griffon-
Etienne,	Boucher	et	al.	1999).	Increase	in	interstitial	pressure	is	likely	due	to	increased	
leakiness	of	tumour	vasculature	and	absence	of	any	lymphatic	vessels	in	the	tumour.		
Increased	proliferation	of	tumour	cells	and	change	in	viscosity	could	also	contribute	
to	the	changes	in	interstitial	pressure	(Griffon-Etienne,	Boucher	et	al.	1999).		
	
Perfusion	 pressure	 in	 tumours	 will	 depend	 on	 the	 feeding	 arteriolar	 and	 venous	
pressures	 and	 could	 be	 hence	 significantly	 different	 depending	 on	 the	 site	 of	
metastasis.	 All	 of	 the	 above	 factors	 hence	 would	 contribute	 to	 significant	
heterogeneity	in	tumour	blood	flow.	
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Jain	 et.al	 in	 2005	 hypothesised	 that	 anti-angiogenic	 treatment	 results	 in	 vascular	
normalisation	of	tumour	blood	vessels	(Jain	2005).	Even	though	this	effect	is	probably	
short	lived,	resulting	in	a	normalisation	window,	it	is	suggested	that	maturing	of	these	
blood	 vessels	 would	 lead	 to	 a	 homogenous	 blood	 flow	 and	 result	 in	 reduction	 of	
hypoxia	and	 increased	delivery	and	possible	efficacy	of	 systemic	 therapeutic	drugs	
(Goel,	Wong	et	al.	 2012).	 The	precise	effect	of	anti-VEGF	 related	normalisation	on	
tumour	control	remains	controversial.	
	
1.2.3. Methods	to	measure	tumour	blood	flow	
Measurement	of	blood	 flow	 through	a	 tumour	 tissue	 is	 complex.	 Several	methods	
exist	which	can	be	used	to	assess	the	blood	flow	rate	in	tissue.	These	include	direct	
and	indirect	measurements.	Indirect	measurement	of	tumour	blood	flow	can	be	made	
by	using	three	principles:	1)	Measuring	the	mean	transit	time	of	a	tracer	through	a	
tissue,	 2)	 modelling	 the	 uptake	 kinetics	 of	 a	 tracer	 or	 3)	 measuring	 fractional	
distribution	of	the	cardiac	output.		
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1.2.4. Kety	model	
Kety	suggested	a	model	of	tissue	uptake	of	a	freely	diffusible	tracer	based	on	the	Fick	
principle	and	adapted	it	for	determination	of	regional	blood	flow	rate	by	measuring	
local	clearance	of	a	radioactive	tracer	(Kety	1949).	The	model	was	further	developed	
to	allow	quantification	of	blood	flow	rate	using	an	intravenous	bolus	injection	of	an	
inert,	 freely	 diffusible	 tracer	 iodoantipyrine.	 The	 relation	 between	 tissue	
concentration	 (Ct)	 ,	blood	 flow	 rate	 (F),	 arterial	 concentration	 (Ca)	 is	 shown	by	 the	
following	equation	called	Kety	equation	(Kety.S	1960(a),	Kety.S	1960(b),	Tozer,	Shaffi	
et	al.	1994).		
	
	
Kety	Equation:		
	 !" # = 	&' !()*+,- .*" /0.1  
 
	
E	=Extraction	fraction	(fractional	loss	from	blood	to	tissue	in	a	single	passage)	
F	is	blood	flow	rate	(ml	whole	blood	per	g	of	tissue	per	minute)	λ	is	the	tissue-blood	partition	coefficient	of	the	substance	
Ca	is	the	arterial	blood	concentration	
Ct	is	the	tissue	concentration		
T	is	the	time	factor	for	measurement	of	Ct	
t	is	the	time	of	onset	
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Dynamic	 Contrast	 Enhanced	Magnetic	 Resonance	 Imaging	 (DCE-MRI)	 uses	models	
based	on	the	Kety	equation	(Tofts	1997,	Tofts,	Brix	et	al.	1999).	The	gadolinium-based	
tracers	used	in	MRI	scans	such	as	gadopentetate	dimeglumine	(Gd-DTPA)	brings	about	
another	degree	of	complexity	in	the	calculation	as	they	do	not	have	the	character	of	
free	diffusibility	and	are	also	not	purely	intravascular.	In	such	situations,	the	result	will	
be	influenced	by	the	permeability	of	tissue	vessels	and	vascular	surface	area.	DCE-MRI	
and	its	contrast	kinetic	parameters	are	discussed	later	in	this	chapter	(section	1.4.2)	
and	 also	 in	 chapter	 4.0	 where	 DCE-MRI	 parameters	 are	 used	 to	 assess	 vascular	
changes	in	response	to	therapy.	
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1.3. Biomarkers	
1.3.1. Definition	
In	1998,	the	National	Institutes	of	Health	(NIH)	Biomarkers	definitions	working	group	
defined	a	biomarker	as	a	“a	characteristic	that	is	objectively	measured	and	evaluated	
as	 an	 indicator	 of	 normal	 biological	 processes,	 pathogenic	 processes,	 or	
pharmacologic	 responses	 to	 a	 therapeutic	 intervention.”	
(Biomarkers_Definitions_Working_Group	2001,	Strimbu	and	Tavel	2010).	Biomarkers	
should	be	accurately	measurable	and	also	reproducible.	These	should	be	evaluated	
and	validated	for	use	as	a	surrogate	indicator	that	would	represent	a	clinical	outcome.		
	
1.3.2. Predictive	and	Prognostic	biomarkers	
A	predictive	biomarker	is	a	biomarker	which	can	identify	a	subpopulation	of	patients	
who	 are	 likely	 to	 respond	 to	 a	 therapeutic	 intervention.	 In	 contrast,	 prognostic	
biomarkers	provide	information	on	the	likely	course	of	the	disease	without	treatment.	
Validated	tools	which	could	identify	the	likely	course	of	the	disease	or	clinical	benefit	
from	a	therapy	are	invaluable	and	would	lead	to	significant	improvement	in	clinical	
management.	Early	identification	of	the	group	of	patients	who	would	derive	little	or	
no	benefit	from	the	treatment	is	beneficial	as	we	could	avoid	them	being	exposed	to	
these	medications	and	thus	their	potential	side	effects.		
	
Biomarkers	have	a	significant	role	in	drug	development	where	the	target	population	
for	a	new	drug	could	be	defined	more	accurately	to	assess	the	clinical	effectiveness.	
This	has	importance	as	significant	number	of	molecules	which	have	proven	its	efficacy	
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clinically	 have	 failed	 to	 pass	 the	 health-economic	 assessment	 of	 reimbursement	
authorities.	Identifying	the	sub-population	of	patients	who	would	derive	most	benefit	
from	the	drug	would	alter	the	cost-effectiveness	analyses	of	regulatory	authorities.		
	
1.3.3. Imaging	techniques	as	biomarkers		
Imaging	techniques	used	as	a	biomarkers	are	appealing	as	they	are	often	non-invasive	
and	could	be	repeated	at	intervals	to	assess	disease	status	or	response	to	a	therapy.	
Imaging	defined	RECIST	criteria	has	been	the	gold	standard	for	treatment	response	
assessment	since	its	 introduction	in	2000	(Patrick	Therasse,	Richard	S.	Kaplan	et	al.	
2000).	Various	imaging	techniques	have	been	researched	exhaustively	to	evaluate	as	
possible	biomarker	in	a	variety	of	malignancies.	These	involve	further	exploration	of	
elements	of	standard	imaging	techniques	like	CT	or	USS	(e.g.	contrast	enhancement,	
volumetric	assessment)	or	use	of	newer	and	functional	imaging	as	DCE-MRI,	Diffusion	
Weighted	 Imaging	 (DWI)	MRI,	 DCE-CT/USS	 etc.	 DCE-MRI	 has	 been	 studied	 in	 this	
setting,	providing	proof	of	mechanism	of	action	of	antiangiogenic	therapy	on	tumour	
vasculature	with	reductions	 in	Ktrans	observed	(Flaherty,	Rosen	et	al.	2008).	DCE-MRI	
derived	 vascular	 parameters	 also	 hold	 promise	 as	 predictive	 biomarkers	 for	 VEGF	
inhibition	 in	 other	 solid	 tumours	 such	 as	 glioblastoma	 (Batchelor,	 Sorensen	 et	 al.	
2007)	colorectal	 cancer	 (Morgan,	Thomas	et	al.	2003)	and	RCC.	With	pathogenesis	
involving	the	angiogenesis	pathway,	high	vascularity	noted	in	the	tumour	and	use	of	
anti-angiogenic	 agents	 as	 standard	 therapy,	 RCC	 is	 an	 ideal	 tumour	 where	 these	
techniques	 could	 be	 evaluated.	 A	 review	 of	 the	 published	 literature	 which	 uses	
imaging	as	a	biomarker	in	RCC	is	comprehensively	described	in	chapter	2.0.	 	
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1.4. MRI	methods	
1.4.1. Overview	of	MRI	Principles	
MRI	is	based	on	the	principle	of	directional	magnetic	field	associated	with	movement	
of	charged	particles.	Each	nucleus,	with	different	number	of	protons	or	neutrons	is	
thought	to	have	its	characteristic	spinning	motion	(precession).	Any	moving	charged	
particle	 will	 have	 an	 associated	 magnetic	 field.	 In	 human	 body,	 up	 to	 70%	 is	
constituted	by	water	molecules.	 The	 single	 proton	 in	 a	 hydrogen	 atom	of	 a	water	
molecule	is	positively	charged	and	is	spinning	continuously.	As	these	molecules	are	
exposed	to	an	external	magnetic	field,	the	protons	move	around	depending	on	the	
direction	 of	 the	magnetic	 field.	 Frequency	 of	 the	 precession	movement	 for	 these	
protons	(resonance,	or	Larmor	frequency:	3o)	for	a	given	magnetic	strength	Bo,	can	
be	calculated	by	the	equation	below.		
Equation	1.1	 45 	= 	675	8=	gyromagnetic	ratio,	B0	magnetic	strength,	45	=	lamor	frequency	
	
The	net	magnetic	moment	adding	up	all	the	vectors	of	all	the	precessing	protons	align	
along	B0	and	is	the	net	magnetic	moment	vector	(M).	On	using	radiofrequency	(RF)	
pulses,	proton	alignment	in	any	object	can	be	temporarily	altered	and	pushes	the	net	
magnetic	moment	(M)	away	from	the	direction	of	the	external	magnetic	field.	When	
RF	 signal	 is	 removed,	 nuclei	 realign	 themselves	 back	 to	 equilibrium.	 This	 is	 called	
relaxation.	The	relaxivity	of	a	tissue	can	be	described	as	longitudinal	relaxation	time	
(T1)	and	transverse	relaxation	time	(T2).	During	relaxation,	nuclei	lose	energy	which	
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is	emitted	as	an	RF	signal	called	Free	 Induction	Decay(FID).	By	using	magnetic	 field	
gradients	 in	 different	 planes,	 FID	 from	 all	 planes	 can	 be	 calculated	 and	 spatial	
information	and	construction	of	the	2D	or	3D	images	of	signal	intensity	measured.	The	
pattern	and	duration	of	RF	pulses	and	field	gradients	can	be	adjusted	to	give	different	
signal	intensities	for	a	single	tissue.		Even	though	it	is	possible	to	use	intrinsic	contrast,	
use	 of	 external	 paramagnetic	 contrast	 will	 result	 in	 improvement	 of	 soft	 tissue	
contrast.	
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1.4.2. DCE-MRI	
DCE-MRI	involves	the	rapid	acquisition	of	sets	of	T1-weighted	images	through	a	tissue	
or	 tumour	as	 an	 intravenous	bolus	of	 gadolinium-based	 contrast	 agent	 is	 injected.		
This	low	molecular	weighted	extrinsic	paramagnetic	contrast	agent	has	a	small	local	
magnetic	field	that	induces	a	shortening	of	relaxation	times	of	surrounding	protons	
resulting	in	a	change	in	signal	intensity	of	tissues.	Signal	intensity	changes	over	time	
are	 converted	 into	 contrast	 agent	 concentration	 data	 and	 with	 pharmacokinetic	
modeling	of	contrast	agent	uptake,	allow	for	the	quantitative	estimation	of	vascular	
characteristics	(Hayes,	Padhani	et	al.	2002).		
 
Quantitative	kinetic	parameters	can	be	derived	for	whole	tumour	regions	of	interest	
and	on	a	pixel-by-pixel	basis.	Ktrans	(transfer	constant;	units:	min-1)	is	a	parameter	which	
describes	the	rate	of	trans-endothelial	flow	of	contrast	medium	from	plasma	into	the	
interstitium.	kep	(washout	rate	constant;	units:	min-1)	describes	the	diffusion	of	contrast	
agent	 back	 into	 the	 vasculature	 from	where	 it	 is	 excreted,	 usually	 by	 the	 kidneys.	
Other	derived	quantitative	kinetic	parameters	include	the	fractional	plasma	volume	
(vp;	 units:	 %)	 and	 the	 fractional	 extravascular,	 extracellular	 space	 (ve,	 units	 %).	
Mathematical	relation	of	these	parameters	are	as	detailed	by	equations	1.3	and	1.4	
which	are	explained	later	in	this	chapter.		
	
Another	useful	parameter	in	assessment	of	tumour	permeability	and	leakage	space	is	
the	 initial	 area	 under	 the	 gadolinium	 concentration	 curve	 (IAUGC).	 IAUGC	 is	
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standardly	 calculated	 in	 our	 department	 in	 the	 first	 60s	 post	 contrast	 injection	
IAUGC60.	
	
With	the	help	of	the	kinetic	parameters,	Dynamic	contrast-enhanced	MRI	(DCE-MRI)	
is	 able	 to	 provide	 information	 on	 tumour	 perfusion	 and	 permeability.	 Thus	 the	
technique	 yields	 detailed	 insights	 into	 tumour	 vascular	 function	 by	 assessing	 the	
kinetics	of	extracellular	contrast	agents.	
	
Based	on	the	tissue,	its	vasculature	structure,	perfusion	and	permeability	of	vessels	
and	 extracellular	 space,	 the	 observed	 kinetics	 of	 the	 paramagnetic	 contrast	 agent	
varies.	Different	curves	of	enhancement	pattern	have	been	identified	based	on	this.		
	
Type	1	curve	–	Slow	progressive	enhancement	pattern	typically	seen	in	benign	tissue.	
Low-grade	malignancies	can	also	show	this	type	of	enhancement.	
	
Type	 2	 curve	 –	 Rapid	 enhancement	 followed	 by	 a	 plateau	 phase.	 These	 tissue	
enhancement	pattern	can	be	 suspicious	but	 could	not	be	definitive	of	malignancy.	
Some	benign	tissue	could	also	show	this	enhancement	pattern.		
	
Type	 3	 curve	 –	 Rapid	 onset	 of	 enhancement	 followed	 by	 a	 rapid	washout.	 This	 is	
characteristic	of	tumour	tissue	with	high	vascularity	but	with	premature	vessels	with	
high	permeability.	mRCC	tissue	are	highly	vascular	and	 immature	 irregular	vascular	
supply	and	would	expect	to	show	type	3	enhancement	characteristics.		
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Figure	1.2	 Types	of	DCE-MRI	Curves	
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1.4.2.1. Theory	of	DCE-MRI	
The	Kety	equation	(equation	1.2)	for	a	freely-diffusible	tracer	forms	the	basis	of	the	
theory	underlying	the	use	of	DCE-MRI	to	measure	physiological	parameters	as	tissue	
blood	flow	and	permeability	(Kety.S	1960(b),	Tofts	and	Kermode	1991,	Tofts,	Brix	et	
al.	1999)		
	
Equation	1.2	
9: ; = 	<= 9>?*<=@ ;*: A:;5 	
	
E	is	the	extraction	fraction	(fractional	loss	from	blood	to	tissue	in	a	single	passage)	
F	is	blood	flow	rate	(ml	whole	blood	per	g	of	tissue	per	minute)	λ	is	the	tissue-blood	partition	coefficient	of	the	substance	
Ca	is	the	arterial	blood	concentration	
Ct	is	the	tissue	concentration		
T	is	the	time	factor	for	measurement	of	Ct	
t	is	the	time	of	onset	
	
DCE-MRI	provides	information	of	tumour	vascular	function	including	information	on	
tumour	 perfusion	 and	 permeability.	 To	 incorporate	 the	 use	 of	 extracellular	 tracer	
material,	this	equation	can	be	further	adapted	as	equation	1.3		
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Equation	1.3	
9: ; = 	B:C>DE 9F(:)?*B?F(;I:)A:;5  
	
Cp	is	arterial	plasma	concentration	of	Gd-DTPA,	Ktrans	is	the	volume	constant	for	the	
transfer	of	Gd-DTPA	from	the	vessel	into	the	extracellular	extravascular	space	(EES)	
and	kep	is	the	rate	constant	for	the	transfer	of	Gd-DTPA	from	the	EES	back	into	the	
plasma	(Tofts	and	Kermode	1991,	Tofts,	Brix	et	al.	1999)				
	
Vessel	permeability	will	be	heterogeneous	in	tumours.	In	this	situation,	Ktrans	could	be	
determined	by	a	combination	of	flow,	permeability	and	vessel	surface	area.	The	ratio	
of	Ktrans	to	kep	gives	the	volume	of	EES	per	unit	volume	of	tissue,	ve,	otherwise	known	
as	the	leakage	space.	Mathematically	this	can	be	represented	with	the	equation	(1.4)	
below.	
	
 
Equation	1.4	
J? = B:C>DEK?F 	
	
	
This	 model	 assumes	 an	 instantaneous	 bolus,	 instant	 mixing	 of	 gadolinium-based	
contrast	within	the	blood	and	within	the	leakage	space	after	transfer	from	the	vessel,	
and	ignores	the	contribution	of	intravascular	tracer	to	the	tissue	concentration.	
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1.4.2.2. DCE-MRI	for	monitoring	vascular	targeting	therapy	
DCE-MRI	is	one	of	the	most	validated	MRI	technique	in	assessing	vascular	changes.	
The	 studies	 include	 direct	 correlative	 assessment	 with	 traditional	 measures	 of	
angiogenesis	 as	 mean	 vascular	 density	 (MVD)	 of	 blood	 vessels	 assessed	 via	
immunohistochemistry	 or	 tissue	 expression	 of	 proangiogenic	 factors	 as	 VEGF	
(Buckley,	Drew	et	al.	1997,	Su,	Cheung	et	al.	2003).	Broad	correlation	has	been	noted	
between	DCE-MRI	estimates	and	MVD	in	these	studies.	
	
Several	 studies	 have	 assessed	 use	 of	 DCE-MRI	 in	 assessment	 of	 response	 to	 anti-
vascular	therapy	(Galbraith,	Maxwell	et	al.	2003,	Nathan,	Zweifel	et	al.	2012).	In	2008	
in	a	pilot	study,	DCE-MRI	assessment	in	metastatic	RCC	patients	treated	with	sorafenib	
showed	that	reduction	in	Ktrans	was	associated	with	improved	progression	free	survival	
(PFS)	 (Flaherty,	 Rosen	 et	 al.	 2008).	 A	 second	 phase	 2	 study	 published	 around	 the	
similar	 time	showed	good	correlation	of	high	baseline	Ktrans	with	better	PFS	 (Hahn,	
Yang	et	al.	2008).	
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1.5. Aims	of	the	thesis	
Therapeutic	agents	which	target	antiangiogenic	pathway	are	now	well	established	as			
treatment	of	metastatic	RCC.	These	include	multi-targeted	tyrosine	kinase	inhibitors	
(sunitinib,	 pazopanib	 etc)	 and	 recombinant	 humanized	 monoclonal	 antibody	
bevacizumab	in	combination	with	interferon-α2a.	Therapeutic	response	assessment	
on	 use	 of	 these	 newer	 “targeted”	 treatments	 have	 always	 been	 a	 challenge	 with	
RECIST	 assessment	 not	 successful	 in	 identifying	 all	 groups	 of	 patients	 who	 derive	
clinical	 benefit	 from	 the	 treatment.	 	 The	high	 vascularity	 of	 RCC	makes	 it	 an	 ideal	
target	 to	 use	 arterial	 enhancement	 imaging	 and	 to	 assess	 potential	 changes	 in	
vascularity	in	response	to	therapy.	With	the	projects	included	in	this	thesis	I	intend	to	
explore	the	use	of	three	imaging	based	techniques	in	assessing	effects	of	treatment	
in	metastatic	RCC	with	drugs	that	target	anti-angiogenic	pathway.		
	
1. To	use	DCE-MRI	to	assess	whether	addition	of	interferonL2a	to	bevacizumab	
would	add	to	the	antiangiogenic	effect	of	bevacizumab	in	metastatic	RCC.	
2. To	assess	if	change	in	DCE-MRI	parameters	correlates	with	treatment	response	
in	metastatic	RCC.	
3. To	assess	efficacy	of	combining	size	and	arterial	phase	contrast	enhancement	
in	prediction	of	treatment	response	to	tyrosine	kinase	inhibitors	in	metastatic	
RCC.		
4. To	assess	the	use	and	efficacy	of	contrast	enhanced	CT	texture	in	prediction	of	
treatment	response	to	tyrosine	kinase	inhibitors	in	metastatic	RCC.	
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2.1. Introduction	
Based	on	the	theme	of	this	dissertation,	a	literature	review	was	performed	to	assess	
the	 research	 available	 where	 imaging	 techniques	 have	 been	 used	 as	 possible	
biomarkers	 in	 RCC.	 	 This	 literature	 search	 was	 performed	 using	 online	 resources	
Medline/Pubmed	and	supplemented	by	hand	searching	of	abstracts	from	American	
Society	of	Clinical	Oncology	and	European	Society	of	Medical	Oncology	meetings.	The	
search	strategy	included	terms	such	as	renal	cell	carcinoma,	RCC,	functional	imaging,	
dynamic	 imaging,	 biomarker,	 response	 assessment,	 prognostic,	 predictive.	 Only	
studies	published	in	English	language	were	selected.	The	results	were	then	separated	
as	 possible	 predictive	 biomarkers	 which	 predicts	 benefit	 from	 a	 therapy	 and	
prognostic	biomarker	which	could	provide	an	 insight	 into	the	natural	course	of	the	
disease	according	to	the	modality	used.	The	review	was	published	in	a	peer	reviewed	
journal	 Therapeutic	 Advances	 in	 Medical	 Oncology	 as	 “Imaging	 techniques	 as	
predictive	 and	 prognostic	 biomarkers	 in	 renal	 cell	 carcinoma”;	 Ther	 Adv	 Med	
Oncol.2013	Mar;5(2):119-31.	This	review	forms	the	basis	of	this	chapter.	
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2.2. Predictive	and	prognostic	biomarker	
The	 National	 Institute	 of	 Health	 definition	 of	 a	 biomarker	 is	 discussed	 in	 the	 last	
chapter	(section	1.3.1).	RCC	is	a	heterogeneous	group	of	disease	with	differing	natural	
history.	Reliable	identification	of	the	subtypes	and	assessment	of	extent	/	stage	of	the	
disease	is	of	utmost	importance	and	would	guide	therapy	options.	With	introduction	
of	multiple	therapies	which	work	through	varying	mechanisms,	it	is	becoming	more	
and	more	important	to	match	the	therapy	and	subgroup	of	patients	who	would	derive	
maximal	benefit	or	avoid	the	group	that	would	not	gain	any	clinical	benefit.	Validated	
tools	 which	 predict	 the	 clinical	 benefit	 or	 identify	 risk	 of	 toxicity	 would	 help	 to	
personalise	treatment	and	avoid	exposing	patients	to	unnecessary	side	effects	from	a	
treatment	that	offers	marginal	benefits.		
	
Biomarkers	 also	 have	 significant	 importance	 in	 drug	 discovery	 and	 development	
where	evidence	of	drug	activity	can	help	in	selecting	the	functional	dose	of	a	drug.		
	
At	 present,	 we	 can	 name	 multiple	 examples	 where	 treatments	 with	 evidence	 of	
clinical	benefit	being	declined	for	use	by	regulatory	authorities	on	the	grounds	of	cost	
effectiveness.	 By	 identifying	 the	 patient	 group	 who	 is	 likely	 to	 benefit	 from	 the	
treatment,	biomarkers	will	improve	the	cost-effectiveness	analyses	and	thus	impact	
on	decisions	made	by	regulatory	authorities.	This	will	lead	to	a	higher	chance	of	new	
treatments	being	available	to	the	patients	for	whom	it	matters.		
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Imaging	as	biomarker	 is	an	attractive	and	 indispensable	option	due	to	the	minimal	
invasiveness	in	this	approach.	This	would	mean	that	a	significant	number	of	imaging	
modalities	could	be	repeated	at	 intervals	to	monitor	the	progress	 in	a	patient	with	
minimal	chance	of	harm.		
	
Imaging	based	response	assessment	criteria	 (RECIST)	have	been	the	cornerstone	 in	
treatment	response	assessment	in	oncology.	RECIST	criteria	is	discussed	in	chapter	1	
and	in	chapter	5.0	(section	5.1.1).	Unidimensional	size	based	assessment	with	RECIST	
criteria	have	been	useful	in	therapy	assessment	with	cytotoxic	chemotherapy.	With	
the	 introduction	 of	 cytostatic	 targeted	 therapy	 where	 response	 in	 size	 may	 not	
correlate	with	the	clinical	benefit	obtained,	use	of	RECIST	assessment	on	its	own	may	
not	 be	 adequate.	 A	 retrospective	 analysis	 of	 39	 patients	 published	 by	 Teo	 et.al	
suggested	 that	 some	 patients	 continue	 to	 derive	 clinical	 benefit	 despite	 showing	
progressive	disease	according	to	RECIST	criteria	(MinYuen	Teo	and	incorporating	the	
National	Children's	Hospital	2012).	RCC	is	a	highly	vascular	tumour	which	makes	it	an	
attractive	target	to	assess	change	in	vascularity	or	change	in	contrast	enhancement.	
Since	the	proposal	of	Choi	criteria	in	Gastrointestinal	stromal	tumours	(GIST),	which	
takes	 into	 account	 changes	 in	 contrast	 enhancement	 along	 with	 changes	 in	 size,	
researchers	 have	 been	 trying	 different	 imaging	 based	 criteria	 which	 could	 act	 as	
potential	biomarker	in	response	to	targeted	therapy.	
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2.3. Biomarkers	based	on	CT	imaging	
2.3.1. Multi-slice	CT	to	assess	RCC	histological	subtypes	
Sher	and	colleagues	 retrospectively	assessed	87	patients	and	compared	CT	 images	
with	 histopathology.	 Images	 were	 acquired	 during	 unenhanced,	 cortico-medullary	
phase	 (CMP)	 and	 excretory	 phase	 (EP)	 (30	 and	 300	 s	 after	 contrast	 injection	
respectively).	Degree	of	enhancement	in	the	CMP	and	EP	was	noted	to	be	the	most	
valuable	parameter	in	attempting	to	differentiate	between	histological	subtypes	(p	<	
0.001).	 Histological	 subtypes	 showed	 different	 mean	 CT	 attenuation	 (+2	 standard	
deviations)	in	CMP.	For	clear	cell	RCC	this	was	138.2	±	38.0	HU	while	for	papillary	and	
chromophobe	 tumours	 this	was	89.2	±	31.4	HU	and	55.17	±	24.0	HU	 respectively.	
Enhancement	 in	 excretory	 phase	 also	 showed	 significant	 difference	 between	
histological	 subtypes	with	 clear	 cell	 carcinoma	 showing	an	enhancement	of	73.0	±	
17.6	HU	while	papillary	and	chromophobe	had	an	enhancement	of	70.0	±	10.4	and	
33.9	±	12.1	HU	respectively.	The	cut-off	value	 for	highest	accuracy	 for	diagnosis	of	
clear	cell	carcinoma	was	83.5	HU	for	CMP	and	64.5	HU	for	EP	(Sheir,	El-Azab	et	al.	
2005).	
	
Intra-tumoural	necrosis	noted	on	CT	scan	was	shown	to	be	an	independent	predictor	
of	high	Fuhrman	grade	by	Oh	et.al	 in	2016.	A	 retrospective	 review	of	169	patients	
showed	that	presence	of	intra-tumoural	necrosis	was	associated	with	high	odds	for	
high	Fuhrman	grade	(p	<0.03)	(Oh,	Sung	et	al.	2016)	
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2.3.2. New	criteria	for	response	assessment	
2.3.2.1. Choi	criteria	
 
Choi	et.al	proposed	an	alternate	criterion	which	takes	into	account	either	a	change	in	
size	or	change	 in	contrast	enhancement	has	been	shown	to	be	better	 in	predicting	
response	to	 imatinib	 in	GIST	(Choi	2008).	 In	RCC,	Vander	Veldt	 (2010)	showed	that	
Choi	 criteria	 correlated	 to	 time	 to	 progression	 better	 than	 RECIST	 (van	 der	 Veldt,	
Meijerink	et	al.	2010).	In	a	55	patient	retrospective	analysis	of	metastatic	RCC	patients	
treated	with	sunitinib,	responders	according	to	Choi	criteria	had	significantly	better	
predictive	value	for	PFS	and	OS	(p	<	0.001	for	both)	than	RECIST	(p	=	0.689	and	0.191	
respectively)	at	the	 initial	assessment	on	treatment.	The	predictive	value	of	RECIST	
rose	to	a	statistically	significant	level	only	when	best	response	during	treatment	was	
taken	into	account.	Hittinger	et.al	(2011)	compared	Choi	and	RECIST	in	a	22	patient	
cohort	treated	with	sorafenib	where	Choi	criteria	was	able	to	differentiate	patients	
who	had	increased	PFS	or	OS	(Hittinger,	Staehler	et	al.	2011).		
	
2.3.2.2. Modified	Choi	criteria	
Based	on	combination	of	change	 in	size	and	arterial	based	enhancement,	we	have	
proposed	a	modification	of	the	Choi	criteria	and	assessed	whether	this	could	reliably	
identify	 responders	 (Nathan,	 Vinayan	 et	 al.	 2010).	 The	 results	 of	 this	 study	which	
forms	part	of	this	thesis	is	described	in	chapter	5.0.		 	
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2.3.2.3. SACT	criteria	
Proposed	 by	 Smith	 et.al	 (Smith,	 Lieber	 et	 al.	 2010)	 SACT	 criteria	 used	 CT	 based	
volumetric	attenuation	along	with	size		for	response	assessment.	According	to	SACT	
criteria,	favourable	response	is	defined	as	any	of	the	following:	
• Decrease	in	tumour	size	of	at	least	20%		
• 	Decrease	 in	 tumour	 size	 of	 at	 least	 10%	 and	 at	 least	 half	 of	 non-lung	 target	
lesions	with	decreased	mean	attenuation	of	at	least	20	Hounsfield	units	(HU)		
• One	or	more	lung	lesions	with	decreased	mean	attenuation	by	at	least	40	HU.	
	
Un-favourable	response	was	defined	as		
• Increase	in	tumour	size	of	at	least	20%;		
• New	metastasis	
• Marked	central	fill	in	of	a	target	lesion	
• New	enhancement	in	a	homogenously	hypo-attenuating	non-enhancing	mass.	
	
The	study	compared	SACT	criteria	with	RECIST	and	a	volumetric	attenuation	data	in	
predicting	a	PFS	greater	than	250days.	Favourable	response	as	per	SACT	criteria	had	
a	sensitivity	of	75%	and	specificity	of	100%	in	identifying	the	group	of	patients	with	
PFS	>250	days.	Sensitivity	and	specificity	for	RECIST	was	16%	and	100%	and	93%	and	
44%	for	this	volumetric	analysis.	
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2.3.2.4. MASS	criteria	
MASS	 criteria	 (Morphology,	 Attenuation,	 Size	 and	 Structure)	was	 proposed	 by	 the	
same	 group	 who	 proposed	 SACT	 criteria	 (Smith,	 Shah	 et	 al.	 2010).	 MASS	 criteria	
defines		
favourable	response	as		
• No	new	lesion	and		
• Any	of		
o Decrease	in	tumour	size	by	20%	
o One	or	more	predominantly	enhancing	solid	enhancing	lesions	with	
marked	central	necrosis	
o Marked	decrease	in	attenuation	(≥40HU)	
• 	
Unfavourable	response	according	to	MASS	criteria	were	defined	as		
• Increase	 in	 tumour	 size	 of	 at	 least	 20%	 in	 the	 absence	 of	marked	 necrosis	 or	
marked	decreased	attenuation	
• New	metastasis	
• Marked	central	fill-in	
• New	increased	enhancement.		
	
The	MASS	criteria	showed	an	increased	sensitivity	of	86%	and	specificity	of	100%	in	
recognizing	good	responders	(TTP	and	improved	disease	specific	survival	p	<	0.0001).	
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2.3.2.5. Tumour	burden	and	growth	rate	
In	69	patients	with	metastatic	RCC	treated	with	VEGF-targeted	therapy,	Bassapa	and	
colleagues	assessed	the	tumour	burden	(TB).	With	multivariate	analysis,	total	number	
of	 metastases	 (<10)	 and	 TB	 above	 the	 diaphragm	 (<6.5	 cm)	 at	 baseline	 were	
independent	positive	predictors	of	OS	[Basappa	et	al.	2011].	TB	(p	=	0.003)	and	total	
metastases	(≤12)	were	noted	as	predictors	of	OS	at	the	time	of	disease	progression	
(Basappa,	Elson	et	al.	2011).		
	
Predictive	effect	of	the	initial	tumour	size	and	the	rate	of	size	reduction	in	response	
to	targeted	therapy	was	also	reported	by	Yuasa	and	colleagues	(Yuasa,	Urakami	et	al.	
2011).	A	 linear,	moderate	 to	 strong	association	was	noted	between	pre-treatment	
tumour	size	and	reduction	in	growth	rate	on	therapy	(correlation	coefficient	–0.441,	
p	<	0.001)	in	a	139	patient	retrospective	analysis.	When	a	threshold	value	of	23.9	mm	
was	applied,	it	was	noted	that	smaller	tumours	showed	a	better	rate	of	shrinkage	(p	
<	0.001).		 	
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2.3.3. DCE-CT	in	assessing	vascularity	and	treatment	response	
DCE-CT	 to	 assess	 tumour	 vascularity	 was	 performed	 by	 Wang	 et.al	 (2006).	 They	
showed	that	enhancement	characteristics	 in	DCE-CT	correlated	well	 to	 the	 tumour	
micro	 vascular	 density	 (MVD)	 (Wang,	 Min	 et	 al.	 2006).	 This	 technique	 does	 hold	
promise	as	concentration	kinetics	of	CT	contrast	are	related	directly	and	linearly	to	
the	visualised	enhancement	and	analysis	is	therefore	relatively	straight	forward	(Miles	
2002).	 A	 Danish	 renal	 cancer	 group	 study	 published	 in	 2014	 showed	 that	 a	 high	
baseline	blood	 flow	 (BF)	and	 reduction	 in	BF	and	blood	volume	early	 in	 treatment	
corresponded	to	 improved	treatment	outcome	to	bevacizumab	and	 interferon-L2a	
treatment	(Mains,	Donskov	et	al.	2014).		
Potential	guidelines	for	DCE-CT	image	acquisition	and	analysis	has	been	published	by	
Miles	 et.al	 in	 2012	 (Miles,	 Lee	 et	 al.	 2012)	 but	 there	 still	 remains	 little	 general	
agreement	 about	 the	 techniques	 to	 use	 for	 modelling	 and	 further	 quantitative	
analysis.	
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2.4. Biomarkers	based	on	US	imaging	
2.4.1. DCE-US	as	a	predictive	marker	
Use	of	DCE-US	as	a	predictive	tool	 in	treatment	response	assessment	 in	metastatic	
renal	cell	carcinoma	was	investigated	by	Lamuraglia	and	colleagues.	In	a	randomised	
control	 trial	 comparing	 sorafenib	and	placebo,	DCE-US	was	performed	at	baseline,	
week	3	and	week6.	Responders	defined	by	stable	or	decrease	in	tumour	size	along	
with	 decrease	 in	 contrast	 uptake	 >10%	 at	week3	 showed	 a	 statistically	 significant	
improvement	in	PFS	(p<0.0004)	and	OS	(p<0.0004)	(Lamuraglia,	Escudier	et	al.	2006).	
Lassau	 et.al	 (2012)	 in	 a	 large	multi-centric	 trial	 investigated	 the	 use	 of	 DCE-US	 as	
predictive	biomarker	in	patients	treated	with	anti-angiogenic	agents	(Nathalie	Lassau,	
Louis	Chapotot	et	al.	2012).	157	RCC	patients	were	included	in	this	study,	recruited	
from	19	centres	 in	France.	DCE-US	was	performed	at	baseline,	day7,	day14,	day30,	
day60	and	2	monthly	thereafter.	Study	suggested	that	a	decrease	in	area	under	curve	
(AUC)	by	>40%	at	one	month	was	predictive	of	time	to	progression.		
	
A	third	study	assessing	DCE-US	performed	by	Williams	and	colleagues	(2011)	showed	
a	 decrease	 in	 median	 tumour	 blood	 volume	 by	 73.2%	 at	 2	 week	 of	 treatment	
(Williams,	Hudson	et	al.	2011).	But	these	changes	did	not	show	any	correlation	to	PFS.			
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2.5. Biomarkers	based	on	PET	imaging	
2.5.1. FDG-PET	in	RCC	diagnosis	and	staging	
Different	studies	have	reported	wide	variation	in	sensitivity	of	FDG-PET	CT	scan	in	RCC	
diagnosis	 and	 staging	 (32%	 -	 100%)	 (Montravers,	 Grahek	 et	 al.	 2000,	 Nakatani,	
Nakamoto	et	al.	2011).	The	largest	of	these	series,	published	by	Kang	and	colleagues,	
included	66	patients	with	RCC	and	showed	a	 sensitivity	of	60%	 (Kang,	White	et	al.	
2004).	Nakatani	et.al	suggested	a	higher	FDG	sensitivity	for	RCC	metastasis	but	this	is	
yet	 to	be	 validated	 (Nakatani,	Nakamoto	et	 al.	 2009).	 Even	 though	PET-CT	 is	 used	
currently	as	a	standard	technique	in	multiple	tumour	types	to	assess	metastasis	(eg:	
upper	GI,	Lung),	it	has	been	found	to	be	inferior	than	whole	body	MRI	scan	in	assessing	
RCC	metastasis.	This	could	be	due	to	the	frequency	of	metastatic	spread	to	the	bone,	
liver	etc	from	RCC	(Antoch,	Vogt	et	al.	2003,	Schmidt,	Baur-Melnyk	et	al.	2005).		
	
2.5.2. FDG-PET	as	a	prognostic	biomarker	
Baseline	SUVmax	from	pretreatment	FDG-PET	as	a	prognostic	marker	was	evaluated	
by	Nakaigawa	in	2012.	With	67	enrolled	patients,	wide	variation	of	SUVmax	was	noted	
in	 renal	 cell	 carcinoma	with	 increasing	 levels	 of	 SUVmax	 showing	 a	 trend	 towards	
poorer	 survival	 (p<0.0001).	 Stratified	 SUVmax,	 (<7.0,	 7.0	 –	 12	 and	 >12)	 showed	 a	
median	PFS	1229	days,	446	and	95	days	representatively.	High	baseline	SUV	was	again	
noted	as	a	poor	prognostic	factor	in	a	separate	study	of	35	patients	with	metastatic	
RCC	treated	with	TKI	(Ueno,	Yao	et	al.	2012).	
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2.5.3. FDG-PET	in	treatment	response	assessment	
Le	Moulec	and	colleagues	assessed	the	role	of	baseline	enhancement	and	change	in	
enhancement	 of	 FDG-PET	 with	 clinical	 outcome	 (S.	 Le	 Moulec	 2010).	 The	 group	
reported	 that	 negative	 PET-CT	 at	 baseline	 showed	 a	 better	 outcome	 with	 clinical	
benefit	of	increased	median	survival	(p=0.05).	Patients	with	baseline	SUVmax	>5.7	had	
a	short	PFS	(3months	vs	9	months	p=0.03)	and	OS	(9.1months	vs	23months).		
	
Ueno	et.al	(2012)	assessed	FDG-PET	scan	as	a	predictive	biomarker	and	suggested	that	
change	 in	 SUVmax	 at	 one	 month	 after	 treatment	 initiation	 with	 tyrosine	 kinase	
inhibitors	can	be	predictive	of	PFS	and	OS	(Ueno,	Yao	et	al.	2012).		In	35	patients	with	
metastatic	 RCC	 treated	 with	 TKI,	 they	 noted	 that	 good	 responders	 defined	 as	 no	
increase	in	tumour	size	(sum	of	all	target	lesions)	with	decrease	in	SUVmax	of	≥20%	
showed	 statistically	 significant	 improvement	 in	 PFS	 and	 OS	 than	 non-responders	
(Ueno,	Yao	et	al.	2012).	
	
Sequential	FDG-PET	in	response	assessment	of	Sunitinib	was	reported	by	Powles	et.al	
in	2011.	They	assessed	this	with	3	FDG-PET	CT	at	baseline,	week	4	and	week	16	on	
treatment.	In	this	phase	2	study	with	44	metastatic	RCC	patients,	though	metabolic	
response	was	noted	in	57%	of	patients	in	4	weeks,	no	significant	correlation	was	noted	
between	change	in	SUVmax	at	4weeks	and	PFS	or	OS.	The	study	showed	correlation	
between	poor	OS	and	progressive	disease	diagnosed	with	FDG-PET	at	16weeks	on	
treatment	(Kayani,	Avril	et	al.	2011).	 	
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2.6. Biomarkers	based	on	MR	imaging	
2.6.1. MRI	to	assess	RCC	histological	subtypes	
Pedrosa	and	colleagues	assessed	the	possibility	of	diagnosing	histological	subtypes	of	
RCC	using	MRI.	MRI	scans	were	sub-grouped	 into	8	groups	based	on	size,	 location,	
necrosis,	signal	intensity	type	and	extent	of	fat	and	contrast	enhancement,	peri-renal	
far	 invasion	 etc.	 On	 comparing	 with	 histopathology,	 MRI	 classification	 had	 93%	
sensitivity,	and	75%	specificity	in	diagnosing	ccRCC.	Sensitivity	and	specificity	was	80%	
and	94%	respectively	in	assessing	papillary	subtype	(Pedrosa,	Chou	et	al.	2008).					
	
DCE-MRI	scan	as	tool	for	differentiation	of	histological	subtypes	was	assessed	by	Sun	
and	colleagues	(Sun,	Ngo	et	al.	2009).	Analysing	the	contrast	enhancement	both	 in	
cortico-medullary	 (CMP)	and	nephrographic	phase,	 these	 researchers	were	able	 to	
distinguish	between	clear	cell	and	papillary	subtypes.	Signal	intensity	change	at	CMP	
was	noted	to	be	the	most	significant	tool	in	this	with	a	sensitivity	of	93%	and	specificity	
of	96%.	
Palmowski	 also	 reported	 that	 DCE-MRI	 could	 predict	 nuclear	 grade	 of	 RCC.	 High	
perfusion	values	noted	in	the	entire	tumour	and	most	vascular	area	corresponded	to	
high	grade	tumours	(p<0.05)	(Palmowski,	Schifferdecker	et	al.	2009).	
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Diffusion	 weighted	 (DW)-MRI	 was	 also	 shown	 to	 be	 a	 useful	 non-invasive	 tool	 to	
predict	RCC	nuclear	grade	(Goyal,	Sharma	et	al.	2012)	.	Similar	results	were	shown	by	
Mirka	and	colleagues.	In	a	139	patient	cohort,	DW-MRI	on	a	3.0T	(Tesla)	scan,	ADC	
maps	 were	 able	 to	 differentiate	 between	 low	 and	 high	 grades	 of	 RCC	 and	 also	
differentiate	between	clear	cell	and	other	histological	subtypes	(p=0.002	for	papillary,	
p=0.048	for	chromophobe)	(Mirka,	Korcakova	et	al.	2015)	
	
2.6.2. Whole	body	MRI	in	assessment	of	skeletal	metastasis	
With	development	in	MRI	technology,	we	are	now	able	to	perform	whole	body	MRI	
(WBMRI)	 imaging.	 Use	 of	 WBMRI	 in	 assessment	 of	 skeletal	 metastasis	 has	 been	
investigated	(Chan,	Chan	et	al.	1997,	Tamada,	Nagai	et	al.	2000).	In	RCC,	Shohaib	and	
colleagues	assessed	the	usefulness	of	whole	body	MRI	in	comparison	with	standard	
99Tc	nuclear	medicine	based	whole	body	bone	scan	in	assessing	skeletal	metastasis.	
47patients	were	analysed	in	this	prospective	study.	Both	MRI	and	bone	scan	showed	
high	specificity	(97%	vs	94%)	but	MRI	scan	was	noted	to	be	significantly	superior	with	
regard	 to	sensitivity	 (94%	vs	62%	p=0.0007)	 in	skeletal	metastasis	detection.	Using	
MRI	scan	also	has	advantage	of	being	able	to	assess	soft	tissue	disease	simultaneously	
(Sohaib,	Cook	et	al.	2009).		
In	 comparison	 with	 CT	 scan,	 reported	 by	 Platzek	 and	 colleagues,	WBMRI	 showed	
higher	 accuracy	 in	 diagnosing	metastasis	 especially	 in	 the	musculoskeletal	 system	
(97%	vs	82%	p<0.000)	(Platzek,	Zastrow	et	al.	2010).	
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2.6.3. DCE-MRI	as	a	predictive	biomarker	
Use	of	DCE-MRI	as	a	biomarker	of	angiogenesis	and	vascularity	has	been	researched	
and	 validated	 over	 the	 last	 decade	 in	 multiple	 tumour	 types.	 This	 includes	 direct	
correlation	of	vascularity	using	immuno-histochemical	assessment	of	micro	vascular	
density	 (MVD)	 (Buckley,	 Drew	 et	 al.	 1997).	 Varying	 results	 have	 been	 shown	 on	
attempting	 to	 correlate	 imaging	 with	 tissue	 expression	 of	 proangiogenic	 growth	
factors	including	VEGF	(Padhani	and	Dzik-Jurasz	2004,	Schlemmer	HP	2004).		
	
Unlike	 DCE-CT,	 where	 relationship	 of	 image	 enhancement	 and	 contrast	 kinetics	 is	
linear	and	depends	directly	on	concentration	and	timing	of	contrast,	contrast	kinetics	
with	change	in	signal	intensity	in	DCE-MRI	scan	is	non-linear	and	and	hence	complex	
(Kiessling,	Jugold	et	al.	2007).	In	DCE-MRI,	this	relationship	also	depends	on	imaging	
sequence,	machine	setup,	heterogeneity	of	the	tumour	and	inherent	relaxation	rate	
of	 the	 tissue	 (Padhani	 2003).	 Imaging	 dependent	 vascular	 parameters	 as	 Ktrans	
(transfer	co-efficient	–	influx	of	contrast	from	plasma	to	interstitial	space),	Kep	(efflux	
back	 to	 vasculature),	 Ve	 (volume	 of	 distribution),	 rBF	 (relative	 blood	 flow),	 rBV	
(relative	blood	volume)	and	IAUGC	(Initial	area	under	gadolinium	curve)	need	to	be	
assessed	and	fitted	with	known	statistical	model	for	reliable	assessment	of	contrast	
kinetics.		
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DCE-MRI	was	used	for	assessment	of	metastatic	RCC	patients	treated	with	sorafenib	
in	a	pilot	study	published	by	Flaherty	and	colleagues	in	2008	(Flaherty,	Rosen	et	al.	
2008).	With	 this	 study	 the	 researchers	 showed	a	 statistically	 significant	 correlation	
between	reduction	of	Ktrans	and	improved	PFS	(p=0.01).	High	baseline	Ktrans	was	also	
noted	as	a	predictive	marker	for	good	treatment	response	(p<0.002).		
	
Relation	of	high	Ktrans	at	baseline	with	 improved	PFS	was	also	noted	by	Stadler	and	
colleagues	again	with	sorafenib	treatment	in	metastatic	RCC	(p<0.027).	No	correlation	
of	change	between	Ktrans	and	PFS	was	noted	in	this	study	(Hahn,	Yang	et	al.	2008).		
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2.6.4. Role	of	functional	MRI	with	no	external	contrast	
2.6.4.1. Arterial	Spin	labelled	(ASL)-	MRI		
This	technique	utilises	the	inherent	nuclear	spin	of	protons	in	water	to	magnetically	
label	arterial	blood.	As	labelled	blood	flows	through	the	tissue	of	interest,	its	kinetics	
could	 be	 quantitatively	 measured.	 Capability	 of	 this	 technique	 to	 predict	 anti-
angiogenic	 therapy	 response	 was	 investigated	 by	 de	 Bzelaire	 and	 colleagues	 (De	
Bazelaire,	Rofsky	et	al.	2005).	In	a	feasibility	study	of	10	patients	both	ASL-MRI	and	
DCE-MRI	 were	 used	 to	 assess	 treatment	 response	 to	 antiangiogenic	 agent	
(PTK787/ZK222584)	in	metastatic	RCC.	This	study	demonstrated	correlation	of	blood	
flow	changes	as	measured	by	ASL-MRI	at	1	month	with	change	 in	tumour	size	at	4	
months	or	at	disease	progression	(de	Bazelaire,	Alsop	et	al.	2008).	 	Given	the	non-
contrast	dependent	imaging,	ASL-MRI	could	be	a	good	addition	in	imaging	biomarker	
if	validated.		
	
2.6.4.2. Blood	oxygen	level	dependent	(BOLD)-MRI	
BOLD-MRI	utilises	the	difference	in	magnetic	property	of	oxy-haemoglobin	and	deoxy-
haemoglobin	and	hence	can	be	related	to	tumour	hypoxia.	In	a	multi-parametric	MRI	
assessment	study	by	Notohamiprodjo	it	was	noted	that	perfusion	parameters	shown	
by	DCE-MRI	correlated	broadly	to	R2*	maps	of	BOLD	MRI	(Notohamiprodjo,	Staehler	
et	al.	2013).		A	histogram	analysis	of	BOLD	MRI	based	R2*	and	ADC	mapping	with	DW-
MRI	was	also	found	to	be	of	use	in	differentiating	high	grade	from	low	grade	tumours	
(Zhang,	Wu	et	al.	2015).		 	
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2.6.4.3. Diffusion	weighted	(DW)-MRI.	
This	 non-contrast	 dependent	MRI	 technique	 exploits	 the	 Brownian	motion	 of	 the	
water	molecule	in	the	tissue	to	acquire	functional	images.		
DW-MRI	as	a	predictive	biomarker	of	antiangiogenic	therapy	response	was	assessed	
by	Desar	and	colleagues.	They	reported	the	capability	of	this	technique	to	detect	anti-
angiogenic	effects	of	sunitinib	in	RCC	as	early	as	3-10days	from	treatment	initiation	
(Desar,	ter	Voert	et	al.	2011).		
	
Bharwani	 et.al	 in	 2012	 showed	 that	 in	mRCC	 patients	 treated	with	 sunitinib,	 47%	
showed	significant	changes	 in	whole	tumour	ADC	(Apparent	Diffusion	Co-efficient).	
Even	though	changes	in	ADC	did	not	correlate	with	outcome,	high	baseline	and	greater	
than	median	 increase	 in	 AUC	 (defined	 as	 the	 proportion	 of	 the	 tumour	with	 ADC	
values	below	the	25th	percentile	of	ADC	histogram)	showed	reduced	overall	survival	
(Bharwani,	Miquel	et	al.	2014).		
	
Goyal	and	colleagues	 investigated	the	role	of	DW-MRI	as	a	non-invasive	prognostic	
biomarker.	 They	 aimed	 to	 compare	 the	 DW-MRI	 parameters	 and	 histology	 and	
concluded	that	lower	mean	ADC	on	DW-MRI	correlates	with	high	nuclear	grade	of	RCC	
(Goyal,	Sharma	et	al.	2012).	
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3.1. Introduction	
In	this	chapter	I	detail	the	methods	used	in	the	three	studies	described	as	part	of	this	
dissertation.	 Three	 projects	 were	 carried	 out	 based	 on	 different	 imaging-based	
techniques	to	assess	the	effects	induced	and	also	to	assess	the	effectiveness	of	these	
techniques	in	assessing	treatment	related	response	in	metastatic	RCC	patients	when	
treated	with	targeted	treatment	which	acts	through	the	anti-angiogenic	pathway.	
	
	In	the	first	study	described,	Dynamic	Contrast-Enhanced	(DCE)	MRI	scans	were	used	
to	assess	whether	addition	of	interferonL2a	to	bevacizumab	would	add	to	the	anti-
angiogenic	effect	of	bevacizumab	 in	metastatic	RCC.	This	was	a	prospective,	multi-
centric,	 randomised,	 open-labelled	 clinical	 trial	 which	 I	 co-ordinated.	 Along	 with	
assessing	the	anti-angiogenic	effect	by	measuring	DCE-MRI	vascular	parameters,	we	
also	 explored	 whether	 these	 vascular	 changes	 could	 correlate	 with	 response	 to	
treatment	 or	 clinical	 effectiveness	 and	 thus	 whether	 they	 could	 act	 as	 an	 early	
predictive	biomarker.	In	the	first	section	of	this	chapter	(3.2),	I	explain	this	study	in	
detail;	 “DCE-MRI	 associated	 vascular	 changes	 with	 bevacizumab	 with	 or	 without	
interferon-L	2a	in	advanced	RCC”.	Results	of	the	study	are	discussed	in	chapter	4.0	of	
this	thesis.		
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In	 the	 second	 and	 third	 part	 of	 this	 chapter	 (sections	 3.3	 and	 3.4),	 I	 detail	 two	
retrospective	studies	which	were	performed	to	assess	CT	defined	criteria	in	assessing	
response	 to	 treatment	 in	 metastatic	 RCC	 patients	 treated	 with	 tyrosine	 kinase	
inhibitors	which	affect	the	anti-angiogenic	pathway.	In	the	study	described	in	section	
3.3,	I	assessed	the	role	of	change	in	arterial	enhancement	along	with	change	in	tumour	
size	as	a	predictive	biomarker	in	metastatic	RCC	patients	treated	with	tyrosine	kinase	
inhibitors	 and	 propose	 a	 new	 criterion	 named	 as	 “modified”	 Choi	 criterion.	 The	
background,	outcome	and	discussion	of	this	study	is	described	in	chapter	5.0	of	this	
thesis.		
	
The	 third	 study	 in	 this	 thesis	 assesses	 the	 role	 of	 CT-defined	 textural	 analysis	 in	
prediction	of	treatment	response	in	metastatic	RCC.	This	was	a	collaborative	project	
with	a	group	of	researchers	from	University	of	Sussex	and	Brighton	who	developed	
the	 algorithm	 for	 textural	 analysis.	 Textural	 analysis	 study	 used	 retrospective	
approach	where	metastatic	RCC	patients	treated	with	tyrosine	kinase	inhibitors	were	
studied	and	their	baseline	and	treatment	response	scans	analysed	with	the	textural	
analysis.	Background	and	results	of	this	study	is	discussed	in	detail	in	chapter	6.0	of	
this	thesis.	
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3.2. DCE-MRI	assessment	of	vascular	changes	 induced	with	
bevacizumab	 with	 or	 without	 interferon-L2a	 in	
advanced	renal	cell	carcinoma	
3.2.1. Introduction	
3.2.2. Study	design	and	assessments	
This	clinical	trial	was	designed	as	a	three-arm	randomised	multi-centric	open-labelled	
phase	2	study.	Metastatic	(stage	IV)	or	locally	advanced	(inoperable	stage	III)	RCC	with	
good	or	intermediate	prognosis	by	Motzer	score	(Motzer,	Bander	et	al.	1996,	Motzer,	
Bacik	et	al.	2002)	who	were	systemic	treatment	naïve	in	metastatic	setting	formed	the	
subjects	of	this	trial	(Appendix	9.2).		
	
Recruitment	was	planned	from	three	UK	centres	-	Mount	Vernon	Hospital,	The	Royal	
Marsden	Hospital,	Addenbrooke’s	Hospital.	Eligible	patients	were	randomised	to	one	
of	the	three	treatment	arms	(10	patients	per	arm),	with	treatment	regimens	as	below:		
	
• Arm	A:	Bevacizumab	10mg/kg	every	2	weeks		
• Arm	 B:	 Bevacizumab	 10mg/kg	 every	 2	 weeks	 plus	 low-dose	 IFN-α2a	 3MU	
Three	times	in	a	week	(t.i.w),	commencing	on	Day	0.		
• Arm	C:	Bevacizumab	10mg/kg	every	2	weeks	plus	standard	dose	IFN-α2a	9	MU	
t.i.w.	Patients	will	commence	on	IFN-α	3MU	t.i.w	on	Day	0,	and	escalate	dose	
to	9MU	t.i.w	on	Day	14.		
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All	patients	continued	on	their	randomised	treatment	regimen	until	the	first	tumour	
assessment	at	week	8.	At	this	point	the	decision	to	introduce	or	modify	the	interferon-
α2a	dosage	was	made	at	the	discretion	of	the	treating	physician.	Bevacizumab	dosing	
remained	unchanged	unless	clinically	indicated	as	explained	in	section	(3.2.5).	
	
Treatment	with	both	study	drugs	continued	until	disease	progression,	unacceptable	
toxicity,	or	consent	was	withdrawn.	 In	 the	event	of	 interferon-α2a-related	 toxicity,	
dose	reduction	was	allowed.	 In	case	of	withdrawal	of	 interferon-α2a,	bevacizumab	
was	continued	until	disease	progression.		
	
Patients	in	all	arms	underwent	two	baseline	DCE-MRI	scans	in	the	week	pre-treatment	
and	then	further	scans	at	weeks	2	(prior	to	IFN	dose	escalation	in	Arm	C),	and	6	post-
commencement	of	bevacizumab.	Two	baseline	DCE-MRI	were	performed	to	assess	
the	 reproducibility	 of	 these	 imaging	 parameters.	 This	 is	 explained	 in	 detail	 in	 this	
chapter	in	section	3.2.7.4.	
	
Patients	 also	 underwent	 CT	 scans	 of	 the	 chest,	 abdomen	 and	 pelvis	 performed	 at	
baseline,	 at	week	 8	 and	 three-monthly	 thereafter.	 This	 is	 standard	 practice	 in	 our	
institution	and	hence	patients	were	not	exposed	to	extra	CT	scans	and	unnecessary	
radiation.	 Tumour	 response	was	 to	be	 assessed	by	RECIST	 criteria	 as	per	 standard	
practice.	
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Patients	 all	 had	 the	 required	 haematological	 and	 biochemistry	 tests	 analysed	 as	
standardly	 required	 for	TKI	 therapy.	 In	addition,	patients	had	peripheral	blood	and	
serum	samples	taken	to	be	analysed	for	surrogate	biomarkers.	The	samples	required	
and	their	handling	are	explained	in	section	3.2.4.8	of	this	chapter	and	in	Appendix	9.7.		
	
A	total	of	thirty	subjects	were	to	be	recruited	to	the	study	over	a	planned	recruitment	
period	of	9	months	(please	refer	to	section	3.2.9	for	the	statistical	details).	Patients	
were	randomised	to	one	of	the	three	arms	as	described	before.	An	online	software	
randomization.com	(www.randomization.com)	was	used	to	randomise	patients.	This	
software	uses	a	pseudo-random	number	generator	of	Winchmann	and	Hill	(1982)	as	
modified	by	McLeod	(1985).	The	randomisation	list	was	produced	from	the	software	
and	individual	patient	allocation	performed	with	the	seed	generated	from	the	primary	
randomisation.	Study	sites	contacted	the	study	coordinator	at	Mount	Vernon	site	for	
allocation	of	treatment	for	individual	patients	and	their	trial-specific	number.	
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3.2.2.1. Inclusion	and	exclusion	criteria	
Pre-defined	 inclusion	and	exclusion	criteria	were	 stipulated	with	 the	 trial	protocol.	
Eligibility	of	potential	patients	were	initially	assessed	by	the	treating	investigator	at	
individual	sites	according	to	the	protocol.	This	was	reassessed	by	the	co-ordinating	
investigator	 at	 the	 sponsor	 site	 prior	 to	 recruitment.	 The	 inclusion	 and	 exclusion	
criteria	used	for	patient	selection	are	as	below.	
	
3.2.2.2. Inclusion	criteria	
1. Written	informed	consent		
2. Male	or	female	subjects	≥	18	years		
3. Patients	 with	 previously	 untreated	 metastatic	 (stage	 IV)	 or	 locally	 advanced	
(inoperable	stage	III)	RCC	
4. Histologically	and/or	cytologically	confirmed,	advanced	RCC,	for	whom	a	majority	
component	of	conventional	clear-cell	type	is	mandatory.		
5. Good	or	intermediate	prognosis	disease	as	defined	by	Motzer	score.	
6. RECIST	measurable	lesion(s),	which	is	amenable	to	DCE-MRI	scanning	
7. Life	expectancy	of	at	least	12	weeks	
8. Eastern	Co-operative	Oncology	Group	(ECOG)	performance	status	0-2	
9. Adequate	haematological	function	–	absolute	neutrophil	count	(ANC)	≥1.5	x	109/L,	
Platelet	 count	 ≥100	 x	 109/L	 and	 haemoglobin	 ≥8	 g/dL	 (may	 be	 transfused	 to	
maintain	or	exceed	this	level)	
10. Adequate	liver	function:	
11. Total	bilirubin	<1.5	x	upper	limit	of	normal	(ULN)	AND		
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12. Asparagine	 aminotransferase	 (AST),	 alanine	 aminotransferase	 (ALT)	 <2.5	 x	ULN	
(without	liver	metastases);	<5	x	ULN	(liver	metastases).	
13. Adequate	renal	function:		
14. Serum	creatinine	≤1.5	x	ULN			
15. Urine	 dipstick	 for	 proteinuria	 <2+.	 If	 ≥2+	 proteinuria	 on	 dipstick	 urinalysis	 at	
baseline,	24hour	urine	collection	must	show	protein	<1	g/24hrs.	
	
Requirement	for	renal	 function	was	amended	 in	a	substantial	amendment	so	as	to	
include	creatinine	clearance	measurement	either	by	direct	calculation	of	glomerular	
filtration	using	ethylenediaminetetraacetic	acid	test	(51Cr-EDTA)	or	by	using	calculated	
creatinine	 clearance	 using	 Cockcroft-Gault	method	 (see	 Appendix	 9.4).	 Changes	 in	
substantial	amendment	are	detailed	in	the	next	section	of	this	chapter.		
	
16. International	normalised	ratio	(INR)	≤1.5	within	7	days	prior	to	enrolment	if	not	
on	anticoagulants.	Patients	on	anticoagulants	should	have	stable	INR	with	a	target	
range	less	than	3.0.	
	
Women	 of	 childbearing	 age	 must	 have	 a	 negative	 pregnancy	 test	 and	 must	 use	
adequate	contraception	during	the	treatment	phase	of	the	study	and	for	9	months	
afterwards.	Women	who	wish	to	breastfeed	are	not	eligible	for	the	study.	
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3.2.2.3. Exclusion	criteria	
17. Diagnosis	 of	 brain	 metastasis.	 CT	 or	 MRI	 brain	 scan	 was	 to	 be	 performed	 to	
exclude	brain	metastases	if	there	was	a	clinical	suspicion	
18. Major	 surgery	 (incl.	 open	 biopsy)	 or	 radiation	 therapy	within	 28	 days	 prior	 to	
enrolment	(palliative	radiotherapy	to	painful	bone	lesions	was	allowed	within	14	
days	prior	to	enrolment)	
19. Core	biopsy	or	other	minor	surgical	procedure,	excluding	placement	of	a	vascular	
access	device,	within	7	days	prior	to	enrolment	
20. Congestive	 heart	 failure	 (NYHA	 Class	 II,	 II,	 or	 IV),	 unstable	 angina	 pectoris,	 or	
myocardial	infarction	within	6	months	prior	to	enrolment	
21. Inadequately	controlled	hypertension	(defined	as	a	blood	pressure	of	>	150	mmHg	
systolic	 and/or	 >	 100	 mmHg	 diastolic	 on	 medication),	 or	 any	 prior	 history	 of	
hypertensive	crisis	or	hypertensive	encephalopathy	
22. CVA	or	transient	ischemic	attack	within	6	months	of	enrolment	
23. Significant	 vascular	 disease	 (e.g.,	 aortic	 aneurysm,	 aortic	 dissection),	 or	
symptomatic	peripheral	vascular	disease	
24. Evidence	or	history	of	recurrent	thromboembolism	(>1	episode	of	DVT/PE)	during	
the	past	6	months,	bleeding	diathesis	or	coagulopathy	
25. Chronic	daily	intake	of	aspirin	>325	mg/day	or	clopidogrel	>75	mg/day,	or	steroids	
(prednisone	>	12.5	mg/day	or	dexamethasone	>	2	mg/day).	
26. History	of	abdominal	or	tracheo-oesophageal	fistula,	gastrointestinal	perforation,	
or	intra-abdominal	abscess	within	6	months	prior	to	study	enrolment	
27. Serious,	non-healing	wound,	ulcer,	or	bone	fracture	
28. Pregnant	or	breast-feeding	mothers	
29. No	contraindication	to	MRI	scanning		
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30. Current	active	second	malignancy	
31. Patients	with	a	history	of	allergic	reactions	to	contrast	agents	
32. Patients	with	gross	ascites	
33. Seizure	disorder	requiring	medication		
34. HIV/Hep	B/Hep	C/	other	infection	>CTC	2;		
35. Other	investigational	drug	during	trial	or	within	30	days	
36. Adjuvant	anti-angiogenic	therapy	within	6	months	of	enrolment	
37. Any	 significant	 medical	 illness	 or	 significant	 abnormal	 laboratory	 finding	 that	
would,	 in	 the	 investigator’s	 judgment,	make	 the	 patient	 inappropriate	 for	 this	
study,	or	would	increase	the	risk	associated	with	the	patients’	participation	in	the	
study.		
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3.2.2.4. Amendments	
Initial	 trial	 protocol	 was	 amended	 to	 increase	 safety	 and	 aimed	 at	 avoiding	 any	
confounding	treatment	with	anti-angiogenics.	The	amendments	included:	
	
1. Change	of	renal	function	inclusion	criteria	from	serum	creatinine	<1.5	times	
upper	limit	of	normal	to	calculated	creatinine	clearance	or	51Cr-EDTA	(GFR)	≥	
50ml/min.	Calculated	creatinine	clearance	calculation	was	to	be	performed	by	
Cockcroft-Gault	formula		(see	appendix	9.4);	51Cr-EDTA	test	could	also	be	used	
by	 the	 investigator	 to	 measure	 the	 renal	 function	 if	 calculated	 creatinine	
clearance	is	<50ml/min	and	if	the	investigator	felt	that	this	was	not	an	accurate	
representation	of	patient’s	renal	function.	We	felt	that	calculated	creatinine	
clearance	 and	 51Cr-EDTA	 GFR	 are	 better	 markers	 of	 renal	 functions	 than	
absolute	 value	 of	 creatinine	 in	 plasma	 and	 thus	 increasing	 the	 safety	 of	
patients.	 The	 Cockcroft-Gault	 formula	 is	 the	 most	 commonly	 used	
standardised	technique	for	the	calculation	of	creatinine	clearance.	
	
2. To	exclude	patients	who	have	had	anti-angiogenics	in	the	last	6	months	prior	
to	enrolment	in	trial.	Prior	recent	usage	of	anti-angiogenic	therapy	may	affect	
the	vascularity	of	a	metastatic	lesion.	A	6	month	wash-out	period	is	believed	
to	 reduce	effects	of	 such	 therapy,	 to	avoid	any	confounding	of	 the	primary	
endpoint	analysis.		
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3.2.3. Randomisation	
Patients	 were	 randomised	 into	 3	 arms	 using	 an	 online	 software	
(www.randomization.com).	The	software	utilises	a	pseudo-random	number	generator	
of	Winchmann	and	Hill	(1982)	as	modified	by	McLeod	(1985).	A	randomisation	list	was	
produced	 from	 this	 software	 and	 individual	 patient	 allocation	 performed	with	 the	
seed	 generated	 from	 the	 primary	 randomisation.	 The	 randomisation	 list	 was	
controlled	by	the	trial	co-ordinator	at	Mount	Vernon	and	was	unavailable	to	any	of	
the	 investigators	 with	 any	 patient	 contact.	 Study	 sites	 contacted	 the	 study	 co-
ordinator	at	Mount	Vernon	for	allocation	of	patients	to	the	trial	arms.	The	contact	
number	of	the	trial	co-ordinator	was	easily	available	to	the	investigators	and	sites	and	
was	provided	in	the	trial	protocol	and	site	files.	
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3.2.4. Schedule	of	clinical	assessments	and	procedures	
3.2.4.1. Patient	identification	
Patients	 were	 identified	 by	 the	 investigators	 in	 individual	 recruiting	 centres	 and	
approached	 regarding	 potential	 participation	 in	 the	 clinical	 trial.	 The	 patient	
information	leaflet,	approved	by	National	and	Local	Research	Ethics	Committees,	was	
provided	to	all	patients	and	the	trial	was	explained.	Patients	were	reviewed	in	clinic	
usually	in	a	week	after	they	had	had	a	chance	to	review	the	trial	information	and	other	
treatment	options	and	had	a	chance	to	discuss	any	questions	regarding	this.			
	
All	subjects	were	asked	to	provide	written	informed	consent	before	any	study	specific	
assessments	or	procedures	were	performed.	The	written	informed	consent	form	used	
was	a	version	controlled	document	approved	by	the	Ethics	Committee	(Appendix	9.5).	
All	assessments	and	trial	procedures	were	performed	in	compliance	with	the	most	up	
to	date	version	of	the	protocol,	including	principles	of	ICH-GCP,	any	relevant	research	
governance	and	other	regulatory	requirements	as	appropriate.	
	
Patients	who	fulfilled	all	 inclusion	and	none	of	the	exclusion	criteria	were	accepted	
into	 the	 study.	 Inclusion	 of	 any	 subject	who	 did	 not	meet	 these	 criteria	was	 only	
considered	 after	 discussion	with	 the	 Chief	 Investigator	 who	 could	 grant	 a	 waiver.	
Investigators	or	site	coordinators	contacted	the	trial	co-ordinator	at	Mount	Vernon	
for	 a	 temporary	 registration	 to	 consider	 patient	 for	 screening.	 This	 allowed	 us	 to	
capture	the	number	of	patients	who	were	considered	for	trial	but	failed	screening.	
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3.2.4.2. Clinical	assessment	
Patients	were	continually	assessed	as	per	trial	protocol.	The	procedures	that	were	to	
be	performed	varied	according	to	the	trial	period	of	individual	patients.	This	is	detailed	
further	in	this	section.	
	
3.2.4.3. Screening	and	enrollment	period	
Following	 investigations	 and	 procedures	 were	 performed	 within	 28	 days	 prior	 to	
starting	treatment;	
1. Written	informed	consent.	
2. Histological	confirmation	of	RCC	with	majority	clear	cell	element.	
3. Whole	body	CT	scans	(chest,	abdomen	and	pelvis)	with	RECIST	measurement	
of	target	lesions.	
4. Medical	history	was	noted	to	rule	out	any	significant	comorbidities.	
5. Demographic	data:	age,	sex,	height,	weight,	ethnicity	were	also	collected.		
Investigations	and	procedures	performed	within	14	days	prior	to	start	of	treatment;	
1. Urine	or	serum	pregnancy	test	for	women	of	childbearing	age	
2. Full	Physical	Examination,	including	12	lead	ECG	
3. Vital	Signs	(BP,	pulse,	respiration	rate)	
4. ECOG	performance	status	
5. Record	of	all	concomitant	medications	
6. Full	blood	count(FBC):	Haemoglobin,	differential	WBC	and	platelet	count		
7. Urea,	electrolytes	&	biochemistry	panel	(LFT,	LDH,	glucose,	Calcium)	
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8. Dipstick	urinalysis	
9. Coagulation	panel	(prothrombin	time	or	INR)	
	
Following	completion	of	 screening:	Randomisation	was	performed	 followed	by	 the	
research	MRI	Scans.	Research	MRI	-	2	baseline	scans	(DCE-MRI	along	with	Diffusion	
and	 BOLD	 imaging).	 Blood	 for	 biomarkers	 was	 collected	 simultaneously	 with	 the	
treatment,	and	urine	for	proteomics	was	performed	once	during	the	period.	
	
3.2.4.4. Treatment	period	
Visits	in	the	treatment	phase	occurred	on	Days	0,	14	and	at	Week	6.		Assessments	at	
these	visits	included	the	following:		
1. Investigations	7-14	as	per	screening/enrolment	period	
2. Recording	of	dosing	of	bevacizumab	and	interferon.	
3. Recording	 of	 all	 adverse	 events.	 CTC	 grading	 and	 causality	 recorded	 as	 per	
protocol	
4. Blood	samples	for	biomarker	analysis	at	week	2,	6	and	8	
5. MRI	 at	Week	 2	 and	Week	 6	 (In	 Arm	 C,	MRI	 was	 performed	 prior	 to	 dose	
escalation.	
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3.2.4.5. Follow-up	period	
Visits	 in	 the	 follow-up	 phase	were	 performed	 every	 12	weeks	 after	 completion	 of	
primary	end	point	at	week	8.	This	continued	until	disease	progression.		Assessments	
at	these	visits	included	all	the	tests	as	in	treatment	phase	(section	3.2.4.4)	except	for	
MRI	 and	 peripheral	 blood	 biomarker	 analysis.	 Treatment	 response	 assessment	
continued	with	whole	body	CT	scan	(chest,	abdomen,	pelvis)	as	per	the	local	rules.	
	
3.2.4.6. Final	visit	at	discontinuation	
A	 final	 visit	 was	 performed	 at	 either	 30	 days	 after	 last	 dose	 of	 drug	 or	 at	 study	
discontinuation.	All	assessments	as	per	section	3.2.4.4	along	with	blood	sample	for	
biomarker	assessment	were	performed	at	that	visit.	Once	treatment	had	ceased	due	
to	disease	progression,	 follow-up	occurred	by	 routine	 follow-up	visits	 according	 to	
local	policy,	or	by	telephone.	
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3.2.4.7. Radiological	assessment	
Patients	 underwent	 two	 baseline	 research	 MRI	 scans	 in	 the	 week	 pre-treatment	
followed	by	further	scans	at	weeks	2	and	6	(assessment	of	primary	endpoint).	
The	main	requirement	in	these	MRI	scans	were	the	acquisition	of	DCE-MRI	images.	
Use	of	DCE-MRI	in	assessing	change	in	vasculature	has	been	discussed	earlier.	DCE-
MRI	 scan	acquisition	 involved	 imaging	pre-	 and	post-administration	of	 intravenous	
contrast	agent	-	intravenous	gadoteric	acid	formed	with	gadolinium	oxide	and	DOTA	
(2.5mmol/kg	body	weight	Gd-DOTA,	Guerbet).	In	addition,	we	planned	to	perform	a	
Blood	 Oxygenation	 Level-Dependent	 (BOLD)	 scan	 (prior	 to	 administration	 of	 the	
contrast	agent)	to	assess	the	oxygenation	status	of	red	blood	cells	in	perfused	regions,	
and	a	Diffusion-Weighted	(DW)	MRI	scan	to	assess	cellularity	along	with	the	DCE-MRI.	
With	these	scans	we	aimed	to	characterise	the	spatial	patterns	of	angiogenesis	across	
the	full	extent	of	the	tumour,	to	quantify	the	perfusion	characteristics	of	the	tumour	
(in	terms	of	flows	and	permeability),	and	to	assess	any	drug-induced	changes	in	tissue	
oxygenation	and	cellularity.	Details	of	image	acquisition	and	processing	can	be	found	
in	section	3.2.7.2.		
	
Additionally,	CT	scans	of	chest,	abdomen	and	pelvis	were	performed	at	baseline	and	
at	8	weeks.		This	allowed	a	formal	assessment	of	the	comparison	between	change	in	
tumour	size	and	DCE-MRI-defined	changes	in	Ktrans.	Further	imaging	with	CT	scans	in	
follow	up	phase	was	performed	every	12	weeks	or	as	per	local	policy	as	long	as	the	
patient	continued	on	trial	i.e.	until	disease	progression.	
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3.2.4.8. Laboratory	assessment	
Laboratory	assessments	included	regular	samples	and	assessments	required	for	safe	
delivery	 of	 anti-angiogenic	 medication	 and	 samples	 required	 for	 biomarker	
assessment	for	the	clinical	trial.	Regular	samples	for	haematology,	clinical	chemistry	
and	coagulation	were	collected	as	per	study	sites	standard	procedure	in	management	
of	patients	on	bevacizumab	and	or	interferon.		
	
Additional	 samples	 for	 biomarker	 assessment	were	 taken	 as	 per	 the	 trial	 protocol	
(please	refer	to	Table	3.1	and	Appendix	9.7).	A	total	of	25ml	of	blood	was	collected	at	
each	time	point	twice	during	screening,	week	2,	week	6,	week	8	and	finally	at	drug	
discontinuation.		
	
Samples	for	biomarker	analyses	were	collected	in	2x	10ml	samples	in	EDTA	vials	and	
1x	5ml	sample	in	a	lithium	heparin	vial.	We	also	collected	15ml	of	urine	once	during	
the	screening	phase.	A	sample	handling	manual	was	available	for	all	recruiting	sites	to	
process	the	sample	according	to	protocol	(Appendix	9.7).		
	
The	planned	biomarker	assay	included:	
1. Circulating	 endothelial	 cells,	 peripheral	 blood	 analysis	 of	 angiogenic	 and	
hypoxia	regulated	markers.		
2. Peripheral	blood	analysis	for	microRNA	
3. Proteomics	
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Biomarker	assay	was	performed	at	Oxford	under	the	general	overview	of	Prof	Adrian	
Harris	 and	Dr.	 John	Smythe.	 The	10ml	EDTA	 sample	 for	 circulating	endothelial	 cell	
assessment	 was	 transferred	 on	 the	 day	 of	 collection	 at	 room	 temperature	 to	 the	
National	Blood	Service	and	Stem	cell	research	at	John	Radcliffe	Hospital	for	circulating	
endothelial	cell	assay.		
	
The	 rest	 of	 the	 samples	 (1x10ml	 of	 blood	 in	 EDTA	 and	 1x5ml	 of	 blood	 in	 Lithium	
heparin	vacutainers)	were	processed	at	site	and	stored	at	-80oC.	These	samples	were	
planned	to	be	transferred	as	a	batch	(once	all	time	points	from	each	individual	patient	
were	 reached)	 to	 Oxford	 for	 proteomics	 and	 microRNA	 assessment.	 The	 sample	
handling	manual	 detailed	 all	 of	 the	 procedures	 that	 the	 sites	 required	 for	 sample	
processing	(see	Appendix	9.7).	In	addition,	all	site	teams	involved	in	sample	handling	
were	 provided	 with	 face-to-face	 training	 by	 the	 co-ordinating	 investigator	 from	
Mount	Vernon.	
	
A	 multi-parameter	 flow	 cytometric	 assay	 was	 used	 in	 measuring	 CEC	 (circulating	
endothelial	 cells)	 and	 CEPC	 (circulating	 endothelial	 progenitor	 cells)	 on	 the	 day	 of	
collection.	Endothelial	cell	populations	were	quantified	by	flow	cytometry	with	a	BD	
LSRII	machine	(Beckton	Dickinson).	Antibodies	recognising	CD34,	CD45,	CD133,	CD144	
and	Tie2	were	used	in	characterisation	and	measurement	of	endothelial	cells.	CEC	was	
defined	as	CD45-/dim,	CD34+,	CD144+	and	CEPC	was	defined	as	CD45-/dim,	CD133+	
and	 tie2+.	 Quantification	 of	 the	 target	 population	 in	 relation	 to	 haemopoetic	
progenitor	cells	was	quantified	by	numbers	gated	in	relation	to	the	total	mononuclear	
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cell	gate	cross	referenced	by	the	mononuclear	cell	concentration	in	the	original	blood	
sample.	Immunofluorescence	using	CalceinAM	were	used	in	assessing	total	and	viable	
CEC	cells.	Variation	of	these	cellular	parameters	during	treatment	has	been	calculated	
in	individual	patients	and	statistical	significance	of	the	changes	assessed.	
	
3.2.4.9. Histopathological	specimen	
Paraffin-embedded	blocks	were	requested	to	be	sent	to	the	sponsor	site	at	Mount	
Vernon	 Hospital.	 These	 specimens	 were	 to	 be	 transferred	 to	 the	 John	 Radcliffe	
Hospital,	Oxford	for	further	analysis	after	anonymizing	appropriately.	It	was	planned	
that	 immunohistochemical	 analysis	 (IHC),	 fluorescence	 resonance	 energy	 transfer	
(FRET)	and	fluorescence	lifetime	imaging	(FLIM)	will	be	performed	on	these	samples.	
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Table	3.1	
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	Table	3.1	cont.	
 
Screening/Baseline 
Treatm
ent Phase 
Follow
-up 
 
 
 
 
 
 
V
isit until 
progression 
Final V
isit at 
D
iscontinuation 
D
ay 
-28  to -1 
-14  to -1 
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eek 8 / 3 
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Adverse events j 
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X 
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Blood sam
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l 
 
X (tw
ice) 
 
X 
X 
X
m 
X 
U
rine sam
ple for proteom
ics 
 
X 
 
 
 
 
 
b	Serum
	or	urine,	for	w
om
en	of	childbearing	potential.	To	be	perform
ed	w
ithin	14	days	before	inclusion.	If	not	perform
ed	w
ithin	7	days	
prior	to	the	first	infusion,	a	confirm
atory	urine	test	w
ill	be	required.	
c	As	per	standard	of	care	
d	Includes	w
hite	blood	cell	count	(W
BC)	w
ith	differential,	platelet	count,	red	blood	cell	count	(RBC)	and	hem
oglobin	(Hgb)	at	baseline.	
e	Includes	prothrom
bin	tim
e	(PT),	and	partial	throm
boplastin	tim
e	(PTT)	w
ithin	14	days	before	inclusion.	Patients	com
m
enced	on	
anticoagulant	therapy	should	have	anticoagulation	checked	regularly		
f	To	include	creatinine	(if	dipsticks≥	2+	proteinuria)	AST,	ALT,	LDH	at	baseline.		
g	Subjects	discovered	to	have	a	≥	2+	proteinuria	on	dipstick	urinalysis	at	baseline	should	undergo	24-hour	urine	collection	and	m
ust	
dem
onstrate	≤	1g	of	protein	in	24	hours	to	be	eligible.	Thereafter,	urine	dipstick	or	24	hour-protein	determ
ination	perform
ed	prior	to	
each	bevacizum
ab	dose.	In	case	of	2+	or	greater	dipstick	proteinuria,	a	24	hour-urine	collection	is	m
andatory.	
h	For	patients	in	Arm
	C,	DCE-M
RI	assessm
ent	m
ust	be	perform
ed	prior	to	escalation	of	IFN	dose		
i	Subjects	in	Arm
	B	w
ill	receive	IFN	3	M
U	tiw
;	Subjects	in	Arm
	C	w
ill	com
m
ence	on	IFN	3	M
U	tiw
	on	Day	0	and	escalated	to	9M
U	tiw
	on	
Day	14.	
j	Serious	and	non-serious	adverse	events	to	be	collected	up	to	28	days	after	the	last	bevacizum
ab	infusion.	Serious	adverse	events	(SAEs)	
related	to	bevacizum
ab	should	be	reported	for	the	duration	of	the	study.	
k	Baseline	CT	tum
our	assessm
ent	m
ay	be	based	on	the	original	diagnostic	CT	if	perform
ed	w
ithin	28	days	of	starting	treatm
ent	
m	only	at	8	w
eek	visit. 	l	Blood	sam
pling	for	biom
arker	assessm
ent	w
ill	include	a	single	baseline	sam
ple	for	preparation	of	genom
ic	DNA,	
and	sam
ples	of	peripheral	blood	and	blood	serum
	w
ill	be	collected	at	each	visit	indicated	
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3.2.5. Investigational	medicinal	product	
Bevacizumab	 and	 Interferon	 alpha	 2a	 were	 considered	 as	 Investigational	 Medical	
Product	(IMP)	for	this	study.	Even	though	both	these	drugs	are	individually	approved	
for	use	with	multiple	indications	and	the	combination	of	bevacizumab	and	interferon-
α2a	is	approved	for	use	in	management	of	advanced	RCC,	with	the	use	of	different	
doses	of	 interferon-α2a	and	a	bevacizumab-only	 arm	used	 in	 the	 trial,	 these	were	
classified	 as	 IMP.	 Both	 bevacizumab	 and	 interferon-α2a	 were	 supplied	 by	 Roche	
Products	Ltd	®,	referred	to	as	Roche.	
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3.2.5.1. Bevacizumab	
Bevacizumab	was	supplied	by	Roche,	appropriately	labelled	as	IMP,	to	the	pharmacy	
departments	 at	 participating	 investigational	 sites.	 Bevacizumab	 was	 supplied	 as	 a	
clear	 to	 slightly	opalescent,	 colourless	 to	pale	brown,	 sterile	 liquid	 for	 intravenous	
infusion	in	single-use	glass	vials	(25mg/mL),	which	are	preservative-free.	Shelf	life	and	
handling	instructions	were	provided	by	Roche.		Bevacizumab	was	provided	as	single	
use	400mg	and	100mg	vials	and	the	dose	required	was	drawn	up	at	individual	site	as	
per	pharmacy	protocols.	
	
3.2.5.2. Interferon-!2a	
Interferon-α2a	 was	 supplied	 by	 Roche,	 in	 its	 commercial	 presentation	 to	 the	 site	
pharmacies.	 Appropriate	 labelling	 as	 IMP	 was	 performed	 at	 the	 individual	 sites.	
Interferon-α2a	 was	 supplied	 as	 0.5ml	 prefilled	 syringes	 with	 3,	 6	 or	 9	 MIU	 for	
subcutaneous	administration	only.	Shelf	life	and	handling	instructions	were	provided	
by	Roche.	
	
3.2.5.3. Dose	and	schedule	
Patients	were	 randomised	 to	 three	arms	as	explained	before.	All	patients	 received	
bevacizumab	10mg/kg	every	two	weeks.	Patients	in	Arm	B	and	C	had	subcutaneous	
injections	of	interferon-α2a	administered	three	times	a	week.		
Patients	in	Arm	B	had	interferon-α2a	at	the	dose	of	3MIU/dose	while	patients	in	Arm	
C	had	 interferon-α2a	at	 the	dose	of	3MIU/dose	 for	 the	 first	2	weeks	prior	 to	dose	
escalation	to	9MIU/dose.	All	patients	continued	on	their	randomised	treatment	for	
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the	 first	 8	 weeks	 until	 response	 assessment.	 The	 decision	 to	 introduce	 or	modify	
interferon-α2a	 was	 made	 at	 the	 investigator’s	 discretion.	 The	 bevacizumab	 dose	
continued	unchanged.		
All	patients	continued	on	their	respective	treatment	until	progression,	unacceptable	
toxicity	 or	 if	 consent	 was	 withdrawn.	 In	 the	 event	 of	 IFN-related	 toxicity,	 dose	
reduction	was	allowed;	in	case	of	withdrawal	of	IFN,	bevacizumab	was	allowed	to	be	
continued	until	disease	progression.	
	
3.2.5.4. Adverse	event	monitoring	
Any	 adverse	 event,	 clinical	 or	 lab	 abnormality	was	 noted	 on	 every	 clinical	 review.	
These	were	recorded	and	reported	through	the	CRF	forms.	Common	Toxicity	Criterion	
3.0	was	used	to	assess	toxicities.	Intensity	of	all	adverse	events	were	graded	according	
to	the	NCI	Common	Terminology	Criteria	for	Adverse	Events	v	3.0	(CTCAE)	on	a	five-
point	scale	(Grade	1	to	5)	and	reported	in	detail	on	the	CRF.	Only	the	highest	grade	of	
each	toxicity	in	an	individual	patient	was	reported	in	the	study.		
	
The	causality	of	each	toxicity	to	the	IMPs	were	documented	as	a	Yes	or	No.	If	there	
was	a	reasonable	suspected	causal	relationship	to	the	study	medication	i.e.	there	was	
evidence	or	arguments	to	suggest	a	causal	relationship,	drug-event	relationship	was	
assessed	as	Yes.	
 	
Chapter	3	-	Materials	and	methods	
 97	
3.2.5.5. Serious	adverse	event	monitoring	
Any	serious	adverse	events	(SAE)	affecting	the	participant	patients	were	immediately	
reported	as	per	MHRA	regulations.	SAE,	SAR	(Serious	Adverse	Reactions)	and	SUSAR	
(Suspected	Unexpected	 Serious	 Adverse	 Reactions)	were	 defined	 according	 to	 ICH	
GCP	definitions	and	reported	with	an	initial	report	being	filed	within	24h	of	knowledge	
of	the	event.	SAE	reports	were	sent	to	Roche	by	the	investigating	team	with	a	copy	to	
the	sponsor	site.	Reporting	of	these	events	to	the	regulatory	body	was	done	via	Roche.	
	
3.2.5.6. Dose	modification	and	delays	
Dose	modifications	were	specified	in	the	trial	protocol	(see	Appendix	9.8).	This	was	
planned	according	to	the	observed	toxicity	grade	and	causality	of	the	toxicity.	Patients	
with	grade	4	toxicity	/unacceptable	grade	3	toxicity	came	of	the	 IMP	permanently.	
With	any	grade	3	 toxicity	attributed	 to	 interferon-!2a,	 the	drug	was	withheld	and	
restarted	 once	 the	 toxicity	 resolved	 to	 ≤grade	 1.	 Dose	 reduction	was	mandated	 if	
there	had	been	>	2weeks	of	delay	due	to	toxicity.	Dose	reductions	were	predefined	in	
the	protocol.	
	
With	bevacizumab-related	toxicity,	dose	reduction	was	not	allowed.	It	was	mandated	
that	 any	 patients	 permanently	 discontinued	 bevacizumab	 if	 they	 developed	
gastrointestinal	perforation,	arterial	thromboembolic	event,	Grade	3/4	haemorrhagic	
events,	grade	4	hypertension	or	grade	4	proteinuria.	Management	of	bevacizumab-
specific	hypertension	and	proteinuria	is	detailed	in	the	protocol	and	attached	here	as	
an	appendix	(9.8).		
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3.2.6. Independent	safety	monitoring	
Safety	of	the	treatment	provided	was	evaluated	as	a	planned	interim	analysis.	A	safety	
analysis	was	performed	after	15	patients	completed	their	primary	trial	endpoint.	The	
safety	 analysis	 population	 included	 all	 subjects	 who	 received	 at	 least	 one	
dose/infusion	 and	 had	 a	 safety	 assessment	 performed	 at	 baseline.	 All	 safety	
parameters	 are	 summarised	 and	 presented	 in	 the	 Chapter	 4.0	 (section	 4.5.2).	 In	
patients	who	were	considered	for	safety	analysis,	all	adverse	events	including	clinical	
and	 laboratory	 events	were	 collected	 and	 graded	 according	 to	 CTCAE	 version	 3.0.	
Causality	of	adverse	events	and	relation	to	IMP’s	were	assessed	as	explained	earlier	
in	this	chapter	(section	3.2.5.4).	Data	obtained	was	analysed	by	an	expert	experienced	
in	managing	RCC	patients	and	was	 independent	of	 the	management	of	 the	clinical	
trial.		
	
Adverse	 event	 data	 was	 to	 be	 reported	 according	 to	 overall	 and	 intensity	 of	 the	
adverse	events.	Subjects	who	experienced	the	same	event	on	more	than	one	occasion	
were	counted	only	once	in	the	calculation	of	the	event	frequency.	
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3.2.7. DCE-MRI	data	collection	and	analysis	
3.2.7.1. Lesion	suitability	criteria	for	DCE-MRI	
Along	with	the	clinical	and	laboratory	inclusion	exclusion	criteria,	we	had	to	make	sure	
that	 the	 target	 lesions	 used	were	 analysable	 using	 DCE-MRI.	 Patients	with	 lesions	
unsuitable	for	DCE-MRI	analysis	were	excluded	from	trial.		
• Tumour	mass	had	to	be	≥	3cm	in	size.	Ideally	4-12	cm	lesions	were	preferred.	
• Cystic	and	largely	necrotic	tissues	ideally	avoided.		
• Lesions	had	to	be	away	from	pulsatility	artefacts.		
• Lesions	of	the	lungs	were	in	general	excluded.	Large	lesions	in	lung	≥4cm	were	
permitted	provided	they	were	away	from	large	vessels	and	heart.		
• Bony	metastases	were	excluded	unless	they	had	a	sizeable	and	clearly-defined	
soft	tissue	component.	
• Liver	lesions	had	to	be	>	3	cm	and	well	defined.	Liver	lesions	had	preferably	to	be	
in	 the	 right	 hepatic	 lobe	 (the	 left	 lobe	 suffers	 from	 transmitted	 cardiac	
pulsations).	
• Previously	 irradiated	 lesions	 could	 not	 be	 used	 as	 targets	 for	 DCE-MRI	
assessment.		
	
Patient-specific	factors	made	them	ineligible	for	DCE-MRI	assessment.	
• Allergic	reaction	to	MRI	/	CT	contrast	agents	
• Patients	with	gross	ascites	as	the	dose	calculation	of	contrast	becomes	difficult	
• Medications	which	could	potentially	change	vascular	permeability	or	blood	flow	
were	kept	at	a	constant	level	during	until	the	primary	end	point.		
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3.2.7.2. MRI	image	acquisition	
MRI	examinations	were	performed	on	either	a	1.5T	(tesla)	Siemens	Symphony	scanner	
(©Siemens	Medical	System,	Erlangen	Germany)	–	MVCC	or	1.5T	Toshiba	vantage	Elan	
scanner	(©Toshiba	Medical	Systems	Europe)	–	Addenbrooke’s.	Target	lesions	to	be	
assessed	were	predetermined	from	baseline	CT	imaging	according	to	the	suitability	
criteria	as	explained	earlier	in	this	chapter.	Care	was	taken	to	position	the	patient	in	
exactly	the	same	position	for	subsequent	scans.	
	
Dedicated	 coils	 BO1-2	 SP1-4	 were	 used	 to	 obtain	 the	 images.	 Initial	 localiser	 and	
diagnostic	T1-	and	T2-weighted	were	obtained	 through	 the	 tumour	 in	 coronal	 and	
axial	planes	followed	by	DWI	and	T2*	images.	Pre-bolus	proton	density–weighted	and	
T1	gradient-echo	sequences	(TR	139ms,	TE	4.76ms	and	flip	angle	of	70o)	were	then	
collected	 in	 the	coronal	–	 sagittal	plane	along	 the	aorta	 followed	by	T2*	weighted	
images	collected	along	the	same	axis.	Volume-interpolated	breath-hold	examination	
(VIBE)	sequences	were	then	acquired	with	dynamic	T1-weighted	images		(TR	4.50ms,	
TE	1.42ms	and	flip	angle	of	3o	and	21o)	matched	to	the	plane	of	proton	density	scans	
every	5	seconds	(60	scans)	for	the	purpose	of	T1	mapping	(Parker,	Suckling	et	al.	1997,	
Galbraith	S	M	2002)	 	 Intravenous	gadoteric	acid	formed	with	gadolinium	oxide	and	
DOTA	(2.5mmol/kg	body	weight	Gd-DOTA,	Guerbet)	was	injected	at	4ml/s	during	the	
fifth	acquisition	point	followed	by	a	20ml	saline	flush	at	4ml/s.	Post	contrast	T1	fat	
saturated	images	were	collected	with	TR	227ms,	TE	4.76ms	and	flip	angle	70	o.	MR	
image	acquisition	sequence	factors	are	detailed	in	table	4.2.	
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DOTAREM®		
Gd-DOTA	Meglumine	(DOTAREM®)	was	used	as	the	contrast	agent	for	DCE-MRI	scans.	
DOTAREM	 is	 a	 well-researched	macrocyclic	 gadolinium	 based	 contrast	 agent	 with	
gadoteric	 acid	 as	 the	 active	 ingredient	 (MHRA	 2002).	 DOTA	 has	 paramagnetic	
properties	which	increase	the	contrast	enhancement	in	MRI.	Distribution	of	gadoteric	
acid	is	within	extracellular	fluids	of	the	body	and	does	not	bind	to	plasma	albumin.	
This	 accounts	 for	 the	 use	 of	 DOTA	 in	 imaging	 of	 blood	 vessels.	 	 DOTA	 has	 been	
compared	to	the	more	established	Gd-DTPA	(Magnevist®)	in	mouse	models.	This	has	
shown	that	DOTA	is	as	safe	and	efficacious	as	Magnevist	(Oudkerk,	Sijens	et	al.	1995).	
	
DOTAREM®	 has	 a	 good	 safety	 profile.	 The	 main	 side	 effect	 of	 concern	 is	 allergic	
reaction	 to	 the	 agent.	 Nephrogenic	 systemic	 fibrosis	 is	 a	 rare	 but	 a	 recognised	
complication	 of	 the	 contrast	 agent	 with	 higher	 risk	 associated	 with	 poor	 renal	
function.	Hence	renal	function	monitoring	is	of	significant	importance	with	use	of	Gd-
DOTA.
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Table	3.2	
M
R	im
age	acquisition	sequences	
Sequence 
Im
aging 
Plane 
B
reath 
H
old 
TR
 
(m
s) 
TE (m
s) 
Flip A
ngle 
(degrees) 
Turbo / EPI 
factor 
A
vera
ges 
B
 values 
(s/m
m
2) 
N
o. of 
Slices 
Slice 
Thickne
ss (m
m
) 
Tim
e of 
acquisition 
(M
inutes) 
T2 FSE 
axial 
Yes 
3500 
111 
 
29 
1 
 
13 
8 
0.18 
T1 G
E 
axial 
Yes 
139 
4.76 
70 
 
1 
 
13 
8 
0.14 
T1 G
E 
C
oronal 
Yes 
139 
4.76 
70 
 
1 
 
13 
8 
0.15 
T2 FSE 
C
oronal 
Yes 
3220 
111 
 
29 
1 
 
13 
8 
0.17 
T2 FSE 
C
oronal 
Yes 
2000 
99 
 
29 
1 
 
4 
5 
0.11 
T1 G
E 
C
oronal 
Yes 
138 
4.76 
70 
 
1 
 
4 
5 
0.15 
T2 FSE 
C
oronal 
Yes 
2200 
107 
 
29 
1 
 
8 
5 
0.12 
T1 G
E 
(D
ixon) 
C
oronal 
Yes 
170 
4.92 / 
2.22 
70 
 
1 
 
8 
5 
0.14 
D
iffusion 
(epi) 
C
oronal 
N
o 
3100 
60 
 
192 
6 
0,25,50,100,250,
500,750 
20 
5 
6.04 
D
iffusion 
(epi) 
C
oronal 
N
o 
2900 
66 
 
108 
6 
0,800 
20 
5 
3.19 
ISW
I 
C
oronal 
Yes(x8) 
100 
5,10,30,
45,60 
25 
 
1 
 
8 
5 
1.08 
3 degree 
VIB
E 
C
oronal 
Yes 
4.5 
1.42 
3 
 
3 
 
14 
5 
0.12 
21 degree 
VIB
E 
C
oronal 
Yes 
(x95) 
4.5 
1.42 
21 
 
1 
 
14 
5 
10.32 
T1 G
E + 
fs 
C
oronal 
Yes 
227 
4.76 
70 
 
1 
 
14 
5 
0.19 
GE-gradient	echo	sequence,		
FSE-fast	spin	echo,		
VIBE–volum
e	interpolated	breath-hold	exam
ination,		
TR-repetition	tim
e,		
TE-Echo	
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3.2.7.3. MRI	data	analysis	
Quantitative	 parameter	 calculation	 from	 DCE-MRI	 images	 was	 performed	 using	
specialist	MRI	software	(MRIW	version	4.3,	Institute	of	Cancer	Research,	London,	UK)	
(James	A	D'Arcy,	David	Collins	 et	 al.	 2006).	 The	 software	 is	 used	under	 a	 research	
agreement	between	ICR	and	Paul	Strickland	Scanner	Centre	(at	Mount	Vernon).		
	
Quantitative	 analysis	 required	 conversion	 of	 MR	 signal	 intensities	 to	 contrast	
concentration	changes	(Parker,	Suckling	et	al.	1997).	Individual	DCE-MRI	images	were	
imported	 into	 MRIW®	 software	 and	 regions	 of	 interest	 (ROI)	 drawn	 on	 the	 T1-
weighted	 subtraction	 images.	 ROI	 were	 drawn	 around	 the	 tumour	 by	 a	 single	
investigator	 and	 this	 was	 reviewed	 by	 a	 consultant	 radiologist	 experienced	 in	
analysing	MR	images.	Images	acquired	in	the	coronal	plane	was	used	for	delineation	
of	 ROI.	 Peripheral	 slices	 were	 discarded	 so	 as	 to	 avoid	 uncertainty	 of	 the	 MR	
parameters	 at	 the	 edge	 of	 the	 imaging	 fields.	 Up	 to	 eight	 central	 slices	 from	 the	
tumour	were	selected	and	ROI	contoured.	If	movement	artefact	was	noted,	motion	
correction	with	the	software	was	performed	prior	to	ROI	delineation.		
	
Patient	weight,	volume	of	contrast	infused	and	reference	flip	angles	were	all	reviewed	
at	this	stage	of	image	analysis.	The	reference	flip	angle	was	assessed	by	reviewing	a	
known	 T1	 value	 of	 fat	 which	 at	 1.5T	 should	 be	 300ms	 (Galbraith	 S	M	 2002).	 The	
Arterial	Input	Function	(AIF)	was	assumed	using	the	population	mean	(Parker,	Roberts	
et	al.	2006)	
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and	extended	Kety	model	was	used	in	this	assessment	(Tofts	1997).	Modelling-	based	
quantitative	analysis	 is	discussed	 in	chapter	1.0	 (section	1.2.4)	and	calculations	are	
discussed	in	the	next	section	(3.2.7.4).		Contrast	concentration	-	time	data	obtained	
from	the	resultant	calculation	was	reviewed	to	assess	fitness	to	the	model.	Results	
from	individual	image	slices	were	saved	as	.txt	and	.xml	files	for	post	processing.	Post-
processing	of	these	.txt	and	.xml	files	was	performed	by	Dr.	N.J.	Taylor	to	obtain	the	
quantified	values	of	the	DCE	–	MRI	imaging	parameters.		
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3.2.7.4. Statistical	consideration	of	DCE-MRI	
3.2.7.4.1. Repeatability	and	reproducibility	
	
Repeatability	 (of	 results	 of	 measurements):	 NIST	 definition	 for	 repeatability	 is	 as	
follows:	 “Closeness	 of	 the	 agreement	 between	 the	 results	 of	 successive	
measurements	of	the	same	measure	and	carried	out	under	the	same	conditions	of	
measurement”	 (nist.gov	 1994).	 Conditions	 suggested	 by	 the	 definition	 are	 called	
repeatability	conditions.	These	include:	
1) Identical	procedure	being	measured		
2) Measurement	done	by	the	same	instrument	and	conditions	
3) Performed	by	the	same	observer	at	the	same	location	
4) It	also	requires	that	the	procedure	is	performed	within	a	short	time	period		
 
Quantitative	expression	of	repeatability	could	be	seen	in	the	dispersion	characteristic	
of	the	data.	Data	showing	smaller	dispersion	is	likely	to	increase	the	repeatability	of	
the	 data.	 Methods	 to	 assess	 repeatability	 were	 developed	 by	 Bland	 and	 Altman	
(Altman	DG	1983,	Bland	and	Altman	1986,	Bland	and	Altman	1996).	The	coefficient	of	
repeatability	(r)	represents	the	value	below	which	the	absolute	difference	between	
two	repeated	test	results	may	be	expected	to	lie	within	a	probability	of	95%.	
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Reproducibility	(of	results	of	measurements):			
Reproducibility	of	the	tests	describes	the	agreement	between	the	same	test	results	
carried	out	under	different	conditions.	This	shows	the	ability	of	the	test	results	to	be	
replicated	by	another	person	or	group	working	independently	from	the	initial	reporter	
(nist.gov	1994).		
	
3.2.7.4.2. Calculation	of	repeatability	with	DCE-MRI	
	
Classic	 repeatability	 is	 almost	 impossible	 to	achieve	with	 the	definition	above.	We	
were	unable	to	repeat	the	DCE-MRI	scan	on	the	same	day	due	to	the	contrast	injection	
which	is	required	to	collect	the	necessary	data.	Repeating	the	contrast	on	the	same	
day	risks	affecting	the	renal	function	and	hence	must	be	avoided.	A	minimum	of	24	h	
was	 needed	 for	 the	 contrast	 to	 be	 cleared	 from	 the	 system,	 hence	DCE-MRI	 scan	
repeatability	was	performed	on	separate	days,	attempting	to	keep	the	other	variables	
the	same.		
	
For	each	patient,	the	difference	“d”	between	the	two	measurements	of	the	parameter	
measured	was	 calculated.	 The	 Shapiro-Wilk	 test	 is	 used	 to	 test	 “d”	 for	 normality.	
Kendall’s	tau	is	then	calculated	to	test	for	a	correlation	of	the	absolute	difference	of	
“d”	with	the	mean	of	the	measurements.	If	the	Shapiro-Wilk	test	indicates	non-normal	
data,	 then	 the	data	was	 transformed	using	natural	 logarithms	before	 the	 statistics	
were	calculated.	This	returns	the	distribution	to	normal.		
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Once	the	data	has	been	tested	and	transformed	(if	necessary),	the	following	statistical	
measures	 of	 reproducibility	 can	 be	 obtained	 from	 a	 one-way	 analysis	 of	 variance	
(ANOVA):	95%	confidence	interval	(CI)	for	change	is	calculated	by	equation	3.1:		
	
Equation	3.1	 !" = 	± &. ()*+,- 	
	
n=	number	of	patients.		
dSD	=	Mean	squared	difference	in	a	group	of	n		dSD	 = 123 		
Any	change	in	a	group	of	n	greater	than	this	value	would	be	significant	at	the	5%	level,	
and	is	presented	as	a	percentage	of	the	overall	mean.		
	
The	within	patient	standard	deviation	(wSD)	is	derived	from	the	dSD	using	equation	
3.2:	
Equation	3.2:	 4+, = *+,5 	
	
Within	patient	coefficient	of	variation	wCV	using	equation	3.3.	
	
Equation	3.3	 4!6 = 4+,789:;<<	=9;-	7>	?@9	A;:;=9?9:	
	
The	repeatability	of	a	parameter,	r	for	an	individual	patient	is	given	by	equation	3.4.	
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Equation	3.4	 : = 5. BB4+,	
or	 : = &. ()*+,	
	
The	r	value,	and	more	usefully,	r	as	a	%	of	the	mean	value,	was	used	to	define	the	95%	
confidence	intervals	for	a	real	change.	Excel	Spreadsheets	were	used	for	calculating	
all	the	individual	patients’	percentage	changes.		
		
Cohort	data	
Patients	were	grouped	into	three	treatment	cohorts.	These	cohorts	are	a	subset	of	
the	study	patients,	and	to	work	out	if	the	mean	change	for	all	the	patients	in	a	cohort	
is	 significant,	 95%	 confidence	 intervals	 for	 the	 relevant	 number	 of	 patients	 in	 the	
cohort	 were	 used.	 With	 the	 reproducibility	 spreadsheet,	 required	 values	 were	
calculated	by	changing	the	number	of	patients.		
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3.2.8. 	Statistical	consideration	and	analytical	plan	
3.2.8.1. Primary	variable	
The	primary	 efficacy	 endpoint	 for	 a	 subject	was	DCE-MRI-defined	 changes	 in	 Ktrans	
from	baseline	to	after	6	weeks	of	bevacizumab	monotherapy	or	bevacizumab	and	low	
or	standard	dose	interferon-α2a	combination	therapy.	
	
3.2.8.2. Secondary	variables	
3.2.8.2.1. Vascular	endpoint	
• Change	in	vascular	permeability	(Ktrans)	from	baseline	to	2,	and	6	weeks	post	
commencement	of	bevacizumab	
• Correlation	 of	 DCE-MRI	 defined	 changes	 in	 Ktrans	 with	 clinical	 benefit	 and	
symptoms	
• Correlation	of	DCE-MRI	defined	changes	in	Ktrans	with	surrogate	biomarkers	
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3.2.8.2.2. Efficacy	endpoints	
• Progression-free	survival	(PFS)	
• Comparison	of	PFS	with	MRI	parameters	
• Overall	response	
Progression-free	 survival:	 was	 defined	 as	 the	 time	 in	 days	 from	 the	 date	 of	
randomization	to	the	date	of	the	first	event.	Progression	events	considered	were:	
– progression	during	or	after	treatment	for	subjects	who	had	stable	disease	or	no	
response	
– progression	during	or	after	treatment	for	subjects	with	partial	response	
– relapse	for	subjects	with	a	complete	response	(CR)		
– death	from	any	cause		
Subjects	who	had	not	experienced	an	event	at	the	data	cut-off	date	were	censored	at	
the	last	date	of	disease	assessment.	For	composite	endpoints,	the	earliest	date	of	all	
available	individual	censoring	times	was	used.		
	
Comparison	of	PFS	was	performed	between	 the	 treatment	arms	and	also	with	 the	
MRI-derived	vascular	parameters.		
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3.2.8.2.3. Safety	endpoints	
	
Safety	 end	 points	 reviewed	 were	 as	 below.	 These	 were	 assessed,	 reviewed	
independently	and	reported	with	descriptive	statistics:	
• Treatment	duration	of	bevacizumab	and	IFN	
• treatment	withdrawal	
• dose	modification	
• Incidence	of	adverse	events	(worst	grade)	
	
3.2.8.2.4. Exploratory	endpoints	
	
Exploratory	end	points	included	measurement	of	other	surrogate	biomarker	analysis	
from	 peripheral	 blood	 analysis	 of	 circulating	 endothelial	 cells	 (CEC),	 circulating	
endothelial	progenitors	(CEPC),	and	pro-angiogenic	monocytic	cells.	
		
Diffusion	MRI	and	BOLD	MRI	images	were	also	acquired	during	screening,	treatment	
phase	and	follow-up	phase.	
 	
Chapter	3	-	Materials	and	methods	
 112	
3.2.9. Statistical	model	
3.2.9.1. Sample	size	and	power	calculation	
	
Effective	analysis	of	a	randomised	control	trial	prerequisites	careful	determination	of	
the	power	function	and	determination	of	the	sample	size	and	effect	size.	Components	
required	for	a	sample	size	calculation	includes	
1. Type	1	error	(α)	–	which	denotes	the	chance	of	a	false	positive	result	
2. Type	2	error	(β)	–	which	denotes	the	chance	of	a	false	negative	result	
3. Power	(1-	β)	–	assesses	the	probability	of	detecting	a	statistically	significant	
difference	when	a	specified	difference	between	group	exist	
4. Effect	size	–	minimal	difference	between	groups	that	is	clinically	plausible	
5. Variance	–	Variability	of	outcome	measures	expressed	as	standard	deviation	
of	a	continuous	outcome.	
	
Certain	variables	are	assumed	in	the	statistical	consideration	of	a	randomised	control	
trial	based	on	general	acceptance	 for	calculation	of	 sample	size/effect	 size.	Type	1	
error	(α)	is	usually	fixed	at	0.05	which	limits	the	chance	of	a	false	positive	conclusion	
to	<5%.	 It	 is	 also	possible	 that	 the	outcomes	draw	a	 false	negative	 conclusion	 (β).	
Conventionally	this	is	set	to	20%.	The	Power	(1-	β)	of	a	study	is	set	to	reflect	the	ability	
to	identify	80%	chance	a	true	effect	that	is	present	in	the	sample.	General	variance	in	
the	population	for	a	given	variable	is	expressed	as	its	standard	deviation.	This	is	usually	
an	 unknown	 quantity	 and	 hence	 could	 be	 estimated	 from	 a	 previous	 pilot	 study.	
Finally,	effect	of	 interest	 is	regarded	as	the	minimal	difference	which	is	 likely	to	be	
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clinically	significant	and	be	reliably	detected.	In	a	given	randomised	control	trial,	if	the	
sample	size	is	already	fixed	based	on	availability,	the	effect	size	that	would	determine	
a	real	effect	could	be	determined	by	power	calculation.				
	
In	 this	 trial,	decisions	 regarding	power	calculations	were	based	on	a	 trial	design	 in	
which	 there	 are	 3	 arms;	 A)	 Bevacizumab,	 B)	 Bevacizumab	 +	 3MU	 Interferon,	 C)	
Bevacizumab	+	3mu	rising	to	+9mu	after	2/52	Interferon.	Sample	size	was	restricted	
to	a	total	of	n=30	according	to	the	IMP	availability	for	the	trial.	It	was	hence	decided	
that	there	will	be	10	patients	in	each	arm	of	the	study.		Patients	are	scanned	2x	pre-
treatment,	1x	at	2/52,	and	1x	at	6/52.		The	primary	aim	of	the	study	is	to	determine	
the	extent	to	which	changes	in	Ktrans	differ	between	the	arms	of	the	study.	In	order	to	
assess	the	statistical	significance	of	the	outcome,	previously	collected	DCE-MRI	data	
from	Paul	Strickland	Scanner	Centre	for	change	in	Ktrans	was	used.		
	
To	assess	changes	in	Ktrans	from	before	to	after	treatment:	We	assumed	a	two-sided	
paired	 test,	 with	 α=0.05.	 	 From	 previously-collected	 data	 at	 the	 Paul	 Strickland	
Scanner	Centre,	we	estimated	that	the	standard	deviation	of	the	change	in	Ktrans	from	
before	to	after	treatment	to	be	0.128.		For	1-β=0.80,	a	change	in	Ktrans	of	0.128	will	be	
reliably	detectable.		The	power	function	is	provided	in	figure	3.2.	
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Figure	3.2	 Power	function	Ktrans	before	and	after	treatment	
	
For	two-sided	paired	test,	assuming	α=0.05,	1-β=0.80,	and	the	standard	deviation	of	
the	change	to	be	0.128.	
	
	
Comparisons	between	treatment	arms:	
	Comparisons	were	made	between	the	treatment	arms	at	week	2	and	week	6.		At	week	
2,	the	two	interferon	arms	have	been	treated	the	same,	giving	an	allocation	ratio	of	
2:1.	Assuming	two-sided	independent	test	with	α=0.05	and	1-β=0.80,	a	difference	in	
Ktrans	 of	 0.144	 will	 be	 reliably	 detectable.	 Similarly,	 at	 the	 third	 follow-up	 where	
treatment	allocation	is	equal,	a	difference	in	Ktrans	of	0.170	will	be	reliably	detectable.		
The	power	functions	can	be	observed	in	Figures	3.3	and	3.4.	
	
Observation	 of	 changes	 in	 Ktrans	 between	 these	 treatment	 groups	 has	 not	 been	
observed	before,	so	the	size	of	the	effects	to	be	observed	was	unknown.		The	data	
collected	hence	should	provide	a	robust	estimate	of	the	effect	size,	providing	valuable	
data	upon	which	to	base	future	studies.	
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Figure	3.3	 Power	function	-	Ktrans	between	treatment	arms	at	week2	
	
At	week	2,	Arm	B	and	C	are	considered	together	giving	a	randomisation	of	2:1	
For	a	two	sided	independent	test,		
Total	n=30	with	an	allocation	of	2:1	between	two	groups	
α	=	0.05	and	Power	(1-	β)	=	0.8		
Standard	Deviation	of	variance	=	0.128	
Detectable	change	in	Ktrans	=	0.144		 	
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Figure	3.4	 Power	function	-	Ktrans	between	treatment	arms	at	week6	
	
At	week	6,	we	have	equal	randomisation	for	all	3	arms.		
For	a	two	sided	independent	test		
n	=	10	in	each	group	with	a	1:1:1	randomisation	
α	=	0.05	(<5%	chance	of	the	results	to	be	false	positive)	
Power	(1-	β)	=	0.8	(80%	chance	that	the	effect	is	true)	
Standard	Deviation	of	variance	=	0.128	
Detectable	change	in	Ktrans	=	0.170	 	
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3.2.9.2. Analysis	of	DCE-MRI	vascular	endpoint	
	
The	primary	objective	of	the	study	was	to	characterise	bevacizumab-induced	changes	
in	Ktrans,	and	any	IFN	dose	response	in	potentiating	bevacizumab	induced	changes	in	
this	 vascular	 parameter.	 	 	 Given	 the	 limited	 sample	 size	 the	 analyses	 focuses	 on	
estimating	the	magnitude	of	changes	in	Ktrans	in	each	arm	of	the	study.		There	are	two	
sets	of	analyses,	the	first	comparing	the	bevacizumab	only	arm	to	the	other	two	arms	
at	2	weeks	follow	up	(where	the	INF	treated	patients	have	had	the	same	dose),	and	
the	second	comparing	changes	in	Ktrans	between	all	three	arms	of	the	study	specifically	
to	 determine	 if	 an	 IFN	 dose	 response	 exists	 (e.g.	 between	 the	 IFN	 treated	 arms).		
Before-to-after	 comparisons	 within	 each	 arm	 were	 evaluated	 using	 paired	
comparisons	(either	a	paired	t-test	or	a	non-parametric	test	where	appropriate),	and	
aimed	 to	 characterise	 the	magnitude	 of	 the	 change	 in	 each	 arm	 with	 confidence	
intervals.	 	 Comparison	 between	 the	 groups	 focuses	 on	 determining	 whether	 the	
change	in	Ktrans	differs	between	the	arms	was	evaluated	using	independent	group	tests	
(either	an	 independent	t-test	or	a	non-parametric	 test	where	appropriate)	and	the	
magnitude	of	the	changes	in	Ktrans	in	each	arm	estimated	with	confidence	intervals.			
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3.2.9.3. Efficacy	analysis	
	
Efficacy	 analysis	 was	 based	 on	 the	 intent-to-treat	 population	 defined	 as	 all	
randomized	subjects	who	receive	at	least	one	dose	of	bevacizumab.		The	end	points	
are	defined	as:		
Progression-free	survival	(PFS)	
Comparison	of	PFS	with	MRI	parameters.	
Response	rate	
	
As	 the	 sample	 size	 is	 relatively	 small,	 power	 is	 limited	 for	 these	 analyses	 and	
interpretation	 of	 the	 outcomes	 of	 the	 analysis	 will	 focus	 on	 defining	 confidence	
intervals.	
	
PFS	(as	defined	in	section	3.2.8.2.2)	was	determined	for	each	patient	in	days,	allowing	
the	survival	functions	to	be	estimated	from	continuous	time.		Analysis	for	end	point,	
progression-free	 survival,	 followed	 the	 same	 scheme.	 	 The	 survival	 function	 for	
patients	in	each	of	the	three	arms	were	estimated	using	the	Kaplan-Meier	method,	
and	comparison	of	survival	evaluated	using	the	log-rank	test.	
Spearman	correlation	was	used	to	ascertain	the	correlation	of	PFS	to	the	different	MRI	
parameters	Ktrans,	Kep,	Ve	and	IAUGC60.	
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Treatment	response	of	tumours	were	defined	according	to	the	RECIST	criteria.	The	
analysis	evaluated	the	extent	to	which	different	proportions	of	patients	fall	into	each	
response	category	across	different	treatment	conditions	using	an	appropriate	test	for	
proportions	 (χ2),	 which	 is	 reported	 with	 confidence	 intervals.	 	 As	 response	 was	
determined	early	after	the	onset	of	treatment,	comparisons	were	performed	between	
the	bevacizumab	arm	and	the	two	bevacizumab	+	interferon-α2a	arms.	
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3.3. CT	response	assessment	combining	reduction	in	size	and	
arterial	enhancement	in	metastatic	RCC	patients	treated	
with	targeted	therapy	
3.3.1. Materials	and	methods	
3.3.1.1. Patient	selection	
Patients	with	metastatic	 clear	 cell	RCC,	who	started	 treatment	with	multi-targeted	
tyrosine	 kinase	 inhibitors	 (TKI’s),	 were	 the	 target	 group	 in	 this	 study.	 All	 patients	
selected	 were	 enrolled	 in	 either	 one	 of	 two	 clinical	 trials,	 a	 phase	 II	 clinical	 trial	
(Eudract	 2006-002455-33)	 receiving	 Cediranib	 (a	 mult-targeted	 tyrosine	 kinase	
inhibitor)	or	an	expanded	access	study	(Eudract	2005-002097-30)	of	Sunitinib	(mult-
targeted	tyrosine	kinase	inhibitor).		
	
These	patients	were	recruited	 into	the	above-mentioned	trials	between	November	
2005	and	February	2008	at	Mount	Vernon	Cancer	Centre.	All	patients	selected	had	
good	 or	 intermediate	 prognosis	 according	 to	Motzer	 score	 (Motzer,	 Bander	 et	 al.	
1996,	Motzer,	Bacik	et	al.	2002)	and	had	good	performance	status	(PS	0-1)	 (ECOG-
ACRIN	1982,	Oken,	Creech	et	al.	1982).	Patients	from	this	cohort	who	continued	on	
study	drug	until	progressive	disease,	unacceptable	toxicity	or	withdrawal	of	consent	
were	selected	for	this	retrospective	analysis.		
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3.3.1.2. Inclusion	criteria	
	
1. Metastatic	RCC	with	no	previous	exposure	to	anti-angiogenic	TKI	
2. Patients	started	on	anti-angiogenic	tyrosine	kinase	inhibitors	
3. Baseline	 contrast	 enhanced	 CT	 staging	 scan	 within	 4	 weeks	 of	
treatment	initiation	
4. Measurable	disease	according	to	RECIST	criteria	
	
3.3.1.3. Exclusion	criteria	
1. Previous	exposure	to	tyrosine	kinase	inhibitors	
2. Non-contrast	 enhanced	 CT	 scan	 either	 at	 baseline	 or	 at	 response	
assessment		
3. Patients	who	stopped	treatment	due	to	toxicities	rather	than	disease	
progression	
	
Patients	with	impaired	renal	function	or	allergies	that	precluded	a	contrast	enhanced	
CT	scan	were	excluded	from	this	study.	Patients	who	stopped	treatment	because	of	
toxicities	rather	than	progression	of	their	disease	were	also	excluded	from	analysis	as	
we	wished	to	correlate	imaging	features	with	time	to	progression	of	disease	whilst	on	
treatment.	
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3.3.1.4. Radiological	assessment	
	
All	patients	had	a	contrast	enhanced	staging	CT	scan	at	baseline	performed	within	4	
weeks	of	 initiation	of	 treatment	and	had	a	response	assessment	CT	scan	at	 twelve	
weeks	after	initiation	of	treatment.		
	
CT	scanning	was	performed	with	a	multi	detector	CT	(Siemens	Sensation	16®,	Siemens	
Medical	Solutions,	Forccheim,	Germany).	Iodinated	contrast	agent	(Optiray®,	Covidien	
Healthcare,	Mansfield,	MA,	USA)	was	used	as	the	contrast	agent.	The	contrast	agent	
was	 injected	with	a	pump	injector	at	the	rate	of	4ml/sec	and	followed	by	saline.	A	
dose	of	100ml	of	the	contrast	was	used	(350mg/ml)	which	is	the	standard	protocol	in	
our	 institution.	 Imaging	 was	 performed	 at	 both	 arterial	 and	 portal	 venous	 phase.	
Arterial	phase	 imaging	was	acquired	with	a	25sec	delay	and	 images	captured	 from	
supraclavicular	fossa	to	the	iliac	crest.	Portal	venous	phase	imaging	was	performed	to	
image	abdomen	and	pelvis	from	dome	of	diaphragm	to	the	pubis	with	a	delay	of	70sec	
from	injection.		
In	our	institution,	this	has	been	the	standard	imaging	protocol.	The	advantage	of	this	
approach	is	that	it	enables	capture	of	early	enhancement	as	seen	with	highly	vascular	
tumours	as	RCC	(Raptopoulos,	Blake	et	al.	2001,	Lee,	Heiken	et	al.	2005).		
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3.3.1.5. Radiological	data	analysis	
All	CTs	(baseline	and	12-week	scan)	were	analysed.	Target	 lesions	were	selected	 in	
each	patient	using	the	baseline	scan.	The	size	of	the	target	lesions	was	recorded	in	
centimetres	(cm)	and	the	sum	of	the	target	lesion	size,	where	multiple	target	lesions	
were	present,	was	calculated	as	per	RECIST	criteria.	Total	change	in	the	sum	of	the	
target	 lesion	 size	 before	 and	 after	 treatment	 in	 cm	 and	 the	 percentage	 change	
compared	to	the	baseline	were	calculated.		
	
To	 calculate	 the	 change	 in	 enhancement,	 target	 lesions	were	 delineated	 from	 the	
surrounding	tissue	by	manual	assessment	and	a	region	of	interest	(ROI)	was	identified	
by	 the	 investigator.	 Care	 was	 taken	 to	 ensure	 the	 ROI	 included	 the	 entire	 visible	
tumour	(Goh,	Halligan	et	al.	2008).	ROI	was	cross-checked	by	an	experienced	radiology	
consultant.		Hounsfield	unit	(HU)	density	at	the	arterial	phase	of	enhancement	was	
recorded	in	each	ROI	and	mean	enhancement	at	baseline	and	twelve-week	scan	and	
change	 in	enhancement	between	 the	 scans	were	calculated.	Percentage	change	 in	
mean	enhancement	was	noted.		
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3.3.1.6. Response	assessment	
	
Patients	 were	 assigned	 to	 progressive	 disease	 (PD),	 stable	 disease	 (SD)	 or	 partial	
response	(PR)	using	each	of	the	following	criteria:	RECIST,	Choi	and	“modified	Choi”		
		
RECIST	criteria	-	mandates	a	30%	decrease	in	the	size	of	sum	of	longest	diameters	of	
the	 target	 lesions	 for	 a	partial	 response	 (PR)	 and	a	20%	 increase	 in	 size	of	 sum	of	
longest	diameters	of	the	target	lesions	for	progressive	disease	(PD).	Changes	less	than	
a	30%	reduction	in	size	or	a	20%	increase	in	size	are	assigned	as	stable	disease	(SD).		
Choi	criteria	require	either	a	10%	reduction	in	size	or	a	15%	decrease	in	the	density	of	
target	tumours	for	a	PR.		
	
With	the	modified	Choi	Criteria,	it	was	mandated	that	both	the	10%	decrease	in	size	
and	15%	decrease	in	enhancement	in	arterial	phase	were	required	to	amount	for	a	
partial	 response	 (PR).	 If	 only	 one	 factor	 was	 present	 it	 was	 categorised	 as	 stable	
disease	(SD).	Please	see	Chapter	5.0	section	5.1.3	for	further	details.	
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3.3.1.7. Clinical	data	
	
The	 gold	 standard	method	 of	 assessing	 benefit	 of	 cancer	 drugs	 is	 to	measure	 the	
overall	survival	(OS)	data,	where	death	of	patients	constitutes	the	endpoint.	As	more	
and	more	active	agents	are	now	available,	cancers	are	being	 treated	with	multiple	
lines	of	treatment.	Serial	therapies	may	potentially	confound	the	benefit	derived	by	a	
single	 treatment.	 This	 also	 requires	a	 long	period	of	 follow	up.	The	use	of	 time	 to	
disease	progression	(TTP)	as	a	surrogate	has	been	evaluated	(Zhuang,	Xiu	et	al.	2009).	
It	has	been	suggested	that	TTP	and	progression	free	survival	(PFS)	could	be	used	as	an	
effective	 surrogate	 to	measure	 treatment	effectiveness.	 TTP	directly	measures	 the	
treatment	effect	of	the	drug	and	is	not	confounded	by	subsequent	treatments	or	non-
cancer	related	deaths.		
	
For	the	present	study,	we	selected	time	to	disease	progression	(TTP)	as	the	clinical	
end	point	as	this	clearly	demonstrates	the	duration	of	therapeutic	response.	TTP	was	
defined	as	the	time	from	the	time	period	in	days	from	the	start	of	systemic	therapy	
with	the	planned	tyrosine	kinase	agent	to	the	date	where	disease	progression	was	
documented	radiologically.	The	clinical	records	for	individual	patients	were	obtained	
and	analysed.	 The	date	of	 the	baseline	CT	 scan	and	 initiation	of	 the	 therapy	were	
noted.	All	patients	had	a	clinic	visit	at	least	every	6	weeks	and	had	CT	scans	performed	
for	response	assessment	every	3	months	during	their	follow	up.	Each	of	the	follow	up	
CT	 scans	was	 examined	 and	 status	 of	 the	 disease	was	 analysed.	 The	 date	 disease	
progression	was	reconfirmed.		
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The	date	of	stopping	the	systemic	therapy	was	also	reviewed	analysed	to	confirm	that	
therapy	was	stopped	due	to	disease	progression	or	lack	of	clinical	benefit	rather	than	
due	to	toxicity.		
	
	TTP	was	defined	as	the	number	of	days	measured	from	the	start	of	therapy	to	the	day	
in	which	progression	was	confirmed	by	standard	RECIST	radiological	criteria.	In	order	
to	compare	the	three	response	criteria,	individual	patients	were	assigned	to	either	the	
SD	or	PR	groups	defined	by	each	of	the	three	response	criteria.		The	clinical	data	was	
then	correlated	with	each	of	the	criteria	in	further	statistical	analysis	described	here	
with	results	detailed	in	chapter	5.0.		
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3.3.2. Statistical	analysis	
Post	categorisation	to	PR	and	SD	groups	with	each	of	the	criteria,	SPSS	software	was	
used	 in	 the	 statistical	 analysis	 (SPSS	 v	 16.0	 copyright	 ©	 SPSS	 inc1989-2007).	 In	
analysing	time	to	progression	data	for	PR	and	SD	groups	of	different	criterion	and	in	
calculating	the	statistical	significance,	the	options	were	to	calculate	the	mean	time	to	
progression	and	use	a	non-parametric	 test	as	Mann-Whitney	U	test	 to	analyse	 the	
significance	of	difference	between	groups.	We	also	considered	plotting	the	Kaplan-
Meier	curve	for	TTP	data,	calculating	median	TTP	from	the	curve	and	using	log	rank	
test	to	determine	the	significance	(p-value).	As	the	study	involved	analysing	time	to	
event	data,	the	second	method	was	chosen	in	analysis.	Kaplan-Meier	survival	curves	
were	plotted	for	PR	and	SD	groups	for	each	response	criteria.	Median	TTP	with	95%	
confidence	intervals	was	calculated	from	the	Kaplan-Meier	curves.	Median	TTP	was	
correlated	 with	 the	 SD	 and	 PR	 classifications	 for	 the	 three	 response	 assessment	
criteria.	Log	rank	test	was	used	to	assess	the	significance	of	differences	obtained	in	
the	 analysis.	 Additionally,	 a	 scatter	 plot	 was	 created	 plotting	 size	 change	 against	
density	change	with	data	grouped	into	TTP	<100	days,	100-199	days,	200-399	days	
and	 >400	 days.	 The	 scatter	 plot	 enabled	 an	 exploratory	 analysis	 of	 alternative	
thresholds	for	response	other	than	those	defined	by	the	response	criteria	discussed	
above.		
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3.4. CT	texture	as	a	potential	biomarker	of	response	
This	section	describes	the	methods	used	for	a	retrospective	analysis	where	response	
assessment	for	metastatic	RCC	treated	with	anti-angiogenic	tyrosine	kinase	inhibitors	
was	correlated	to	textural	analysis	based	on	contrast	enhanced	CT	scan.	The	study	
background	and	its	results	are	explained	in	chapter	6.0	of	this	thesis.	
	
3.4.1. Materials	and	methods	
3.4.1.1. Clinical	assessments	
Patients	 with	 metastatic	 RCC	 treated	 with	 TKIs	 at	 our	 institution	 (Mount	 Vernon	
Cancer	Centre)	 from	2005	 to	2009	were	 identified	 retrospectively	 from	the	clinical	
database.	 Institutional	 review	 board	 waiver	 was	 obtained	 for	 this	 retrospective	
analysis.	Patients	were	selected	from	the	database	for	the	analysis	based	on	a	pre-
planned	inclusion	and	exclusion	criteria.	
	
3.4.1.1.1. Inclusion	criteria	
	
1. TKI	naïve	patients	receiving	TKI	as	first	or	second	line	treatment	for	metastatic	
renal	cell	carcinoma.		
2. Baseline	contrast	enhanced	CT	within	4	weeks	of	treatment	commencement.	
3. Contrast	enhanced	CT	following	treatment	to	assess	response.		
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3.4.1.1.2. Exclusion	criteria	
1. Contraindications	to	contrast	enhanced	CT.	These	included:		
a. Hypersensitivity	reaction	to	iodinated	contrast.		
b. Renal	impairment	-	Serum	creatinine	>120	µmol.		
2. Failure	of	intravenous	cannulation	resulting	in	non-contrast	CT	scan.	
3. Suboptimal	contrast	enhancement	(aortic	enhancement	<200	HU	at	25s).		
	
Individual	patient	notes	and	pathological	 reports	were	analysed	 in	detail	 to	collect	
clinical	 details.	 Histological	 details	 of	 the	 tumour	 including	 histological	 variants,	
Fuhrman	grade,	and	presence	of	necrosis	or	sarcomatoid	elements	were	noted	from	
the	 pathology	 report.	 Clinical	 characteristic	 at	 diagnosis,	 details	 of	 treatment	 and	
follow	 up	 were	 collected	 from	 patient’s	 clinical	 notes	 and	 clinic	 letters.	 Details	
collected	included:		
1. Patient	demographics	
2. Date	of	diagnosis	
3. Risk	criteria	according	to	Motzer	criteria	(Motzer,	Mazumdar	et	al.	1999)	
4. Previous	treatment	details	if	applicable		
5. Current	treatment	regime	
6. Start	date	of	current	treatment	regime		
7. Stop	date	where	current	treatment	regime	was	discontinued		
8. Best	response	obtained	with	the	current	treatment	regime		
9. Time	to	progression	
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Time	to	progression	of	the	disease	(TTP)	was	calculated	as	the	number	of	days	from	
beginning	of	current	systemic	treatment	to	the	time	progression	of	disease	was	noted,	
either	 by	 radiology	 according	 to	 RECIST	 criteria,	 or	 if	 there	 was	 definite	 clinical	
evidence	of	disease	progression.	
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3.4.1.2. Radiological	assessments	
	
All	patients	had	contrast	enhanced	CT	scans	prior	to	initiation	of	treatment.	This	is	the	
standard	policy	of	our	institution.	A	mandatory	cut	off	of	4	weeks	has	been	used	to	
make	sure	that	all	patients	have	had	a	recent	imaging	done.	Patients	who	did	not	have	
baseline	imaging	within	4	weeks	prior	to	initiation	of	treatment	were	excluded	from	
this	study.	This	created	a	quality	control	where	treatment	response	can	be	effectively	
analyzed.	Follow	up	CT	scans	were	performed	after	2	cycles	of	treatment,	which	was	
performed	between	week	10	and	12	of	initiation	of	treatment.		
	
All	patients	had	contrast	enhanced	multi	detector	CT	scans	(Somatom	Definition	or	
Sensation	 16,	 Seimens	 Healthcare,	 Forchheim	Germany).	 Iodinated	 contrast	 agent	
(Optiray	 350,	 Covedien	Healthcare,	Mansfield,	MA,	USA)	was	 used	 as	 the	 contrast	
agent.		
100ml	of	350mg/ml	concentration	agent	was	injected	followed	by	a	50ml	saline	flush	
injected	via	a	pump	at	4ml/sec.	Arterial	phase	enhancement	imaging	were	collected	
for	thorax	and	upper	abdomen	(supraclavicular	fossa	to	top	of	iliac	crest)	and	porto-
venous	phase	enhancement	imaging	was	used	further	to	image	abdomen	and	pelvis	
(dome	of	diaphragm	to	pubis).	Arterial	phase	enhancement	images	were	collected	at	
25sec	delay	and	porto-venous	phase	images	were	collected	at	70	sec	delay.	This	is	the	
standard	imaging	protocol	for	our	institution.		
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Acquisition	parameters	for	the	CT	scan	included:	
• 120kV	
• Effective	mAs	150	–	thorax	
• Effective	mAs	200	–	abdomen	and	pelvis	
• Dose	modulation	positive	
• Pitch	-	1.2	
• Detector	configuration	-	24x1.2mm	
• Slice	collimation	–	3mm	
• Scan	field	of	view	–	300-450mm	
• Matrix	–	512mm		
	
Target	lesions	were	identified	and	defined	on	baseline	scan	as	per	RECIST	criteria	1.1	
(5	target	lesions	with	maximum	2	per	organ)(Patrick	Therasse,	Richard	S.	Kaplan	et	al.	
2000,	Eisenhauer,	Therasse	et	al.	2009).	Target	 lesions	were	delineated	by	drawing	
ROI	 around	 the	 target	 lesion	 to	 encompass	 the	 lesion	 completely.	 Once	 ROI	 was	
drawn,	this	was	cross	checked	by	a	consultant	oncology	radiologist	with	more	than	10	
years	of	experience	in	treatment	response	assessment	of	cancer	patients.		
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Size	of	each	target	lesions	were	calculated	separately	as	the	largest	unidimensional	
measurement	and	total	sum	of	the	size	of	target	lesions	calculated.	Enhancement	in	
aorta	was	calculated	initially	to	make	sure	that	there	is	optimal	enahcement.	Aortic	
enhancement	 of	 <200	 HU	was	 defined	 as	 suboptimal.	 Enhancement	 in	 each	 pixel	
inside	 the	 ROI	 is	 calculated	 by	 the	 standard	 CT	 imaging	 software	 and	 average	
enhancement	 was	 calculated.	 Post	 treatment	 contrast	 enhanced	 CT	 scan,	 was	
reviewed	 to	 assess	 treatment	 response.	 ROI	 was	 drawn	 around	 the	 same	 target	
lesions	used	in	baseline	scan.	The	largest	unidimensional	diameter	noted	for	all	target	
lesions	and	mean	density	in	HU	is	calculated	for	all	lesions.	Treatment	response	was	
evaluated	by	RECIST,	Choi	and	modified	Choi	criteria.	Patients	are	classified	according	
to	the	response	obtained	as	stable	disease	(SD),	partial	response	(PR)	and	progressive	
disease	(PD)	by	each	criteria	separately.	Images	from	pre	and	post	treatment	scans	
were	anonymysed	before	it	was	transferred	for	textural	analysis.			 	
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3.4.2. Textural	analysis	
	
Textural	 analysis	was	 performed	with	 a	 software	 TexRad®	 assessing	 arterial	 phase	
images.	TexRAD®	is	a	computer	program	that	has	been	developed	by	researchers	of	
the	University	of	Sussex	and	Brighton	(Ganeshan.B,	Miles.K).	Algorithm	for	TexRAD®	
was		
Initially	formed	and	developed	in	MATLAB	(technical	computing	language,	Mathworks	
Inc,	Natick,	USA)	as	a	research	prototype.	This	was	further	developed	as	a	standalone	
prototype	 for	 clinical	 analysis	 and	assessed	 in	different	 tumour	 types.	 Founders	of	
TexRAD®	 eventually	 entered	 into	 a	 partnership	with	Miles	Medical	 Pt	 Limited	 and	
Cambridge	 Computing	 Imaging	 Limited	 and	 Imaging	 equipment	 limited	 to	 form	
TexRAD	limited.	This	technique	comprised	of	an	initial	filtration	step	using	Laplacian	
of	Gaussian	(LoG)	spatial	band-pass	filter	to	selectively	extract	features	of	different	
sizes	and	intensity.		
	
Textural	analysis	comprises	of	two	main	stages:		
1. Image	filtration	
2. Quantification	of	texture	
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3.4.2.1. Image	filtration	
	
The	 first	 step	 of	 analysis	 is	 image	 filtration.	 Filtration	 technique	with	 Laplacian	 of	
Gaussian	(LoG)	spatial	band-pass	filter	was	chosen	to	selectively	extract	features	with	
different	sizes	and	intensity.	Laplacian	of	Gaussian	technique	is	one	of	the	first	and	
also	 most	 common	 methods	 to	 detect	 regions	 in	 a	 digital	 image	 that	 differ	 in	
properties.	 	 At	 first	 second	 order	 (2	 dimensional)	 Gaussian	 distribution	 (G)	 of	 the	
image	was	calculated.	The	following	equation	(3.5)	was	used	for	this	calculation:	
	
Equation	3.5:	 C(E, G) = 9IE5JK55L5  
 “G”	–	Gaussian	distribution		“x”	and	“y”	are	co-ordinates	of	the	image	matrix.	 “σ”	-	Standard	deviation	of	the	Gaussian	distribution.	
	
	
Calculation	of	two-dimensional	Gaussian	distribution	of	the	image	results	in	selection	
of	parts	of	the	image	according	to	the	sigma	of	Gaussian	distribution.	Areas	of	image	
which	are	smaller	than	the	sigma	of	Gaussian	distribution	are	effectively	blurred	and	
wiped	out.	Thus	the	Gaussian	distribution	consistent	with	a	particular	σ	value	allows	
to	 accent	 textural	 features	 of	 a	 particular	 scale	 on	 contrast	 agent-enhanced	 CT	
images.	This	filtration	technique	was	used	in	this	study	to	filter	out	textural	features	
of	 varying	 scale:	 fine	 scale	 enhances	 parenchyma,	 while	 medium	 or	 coarse	 scale	
enhances	blood	vessels.		
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Use	of	Laplacian	(∇2)	of	Gaussian	was	selected	as	it	provides	one	of	the	most	isotropic	
output	 with	 less	 burden	 on	 the	 computational	 resources.	 Laplacian	 is	 useful	 in	
assessing	areas	of	rapid	intensity	changes	in	the	image.	These	areas	could	represent	
zero	crossing	of	the	filter.	After	filtration,	negative	value	pixels	are	given	a	value	of	
zero.		Equation	3.6	is	used	to	compute	the	Laplacian	of	Gaussian	filter	(∇2G).		
	
Equation	3.6:	
	 d5C E, G = 	 −&fLg & − E5 + G55L5 i E5JG55L5  
	
	
Assessing	the	above-described	equation	with	different	j	values	can	give	a	measure	of	
the	width	of	 the	 filter	 in	pixel	values.	This	 represents	 the	diametric	opposite	areas	
where	zero	 is	crossed	 in	 this	circularly	symmetric	 filter.	Sigma	j	value	seems	to	be	
directly	proportional	to	the	bandwidth	of	the	filter	in	the	spatial	domain	and	inversely	
proportional	 to	 the	 pass-band	 region	 of	 the	 filter	 in	 the	 frequency	 domain.	 Thus	
smaller	 j 	sigma	 value	 results	 in	 a	 smaller	 filter	 width	 of	 the	 cancer	 and	 thus	
highlighting	 finer	 details.	 Conversely,	 a	 higher	 sigma	 value	 will	 result	 in	 higher	j ,	
which	will	be	used	to	assess	coarse	features	in	the	image.		
	
Though	filtration	can	be	performed	either	in	spatial	domain	or	in	frequency	domain,	
we	selected	to	apply	filter	in	the	frequency	domain	for	this	study.	This	is	due	to	the	
fact	 that	 filtration	 in	 spatial	 domain,	 involves	 intense	 computation.	 Quantization	
errors	are	also	known	to	be	more	when	using	filtration	in	spatial	domain.	This	is	more	
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so	in	using	small	j	values.	It	is	hence	more	efficacious	to	use	the	frequency	domain	
and	image	in	spatial	domain	can	be	achieved	with	inverse	Fourier	transformation	of	
the	filtered	spectrum	(Chen,	Crownover	et	al.	1999).	
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3.4.2.2. Quantification	of	texture	
	
For	quantification	of	texture,	ROIs	were	initially	delineated	around	the	target	lesions	
by	an	investigator.	Once	ROI	of	all	target	lesions	were	defined,	this	was	assessed	by	a	
consultant	 oncological	 radiologist	 with	more	 than	 10-year	 experience	 in	 assessing	
treatment	response	in	oncology	patients.	ROI	was	further	refined	by	exclusion	of	areas	
with	air.	This	was	performed	with	a	thresholding	procedure	that	removed	any	pixels	
with	attenuation	values	less	than	-50HU.		
	
Same	patient	specific	ROI	was	used	for	texture	analysis	of	different	j	values.	For	this	
study	we	selected	filter	parameters	between	1.0	and	2.5.	1.0	will	hence	indicate	fine	
texture	and	2.5	indicating	coarse	texture.		Values	between	1.0	and	2.5	(1.5,	1.8	and	
2.0)	will	 represent	medium	 texture.	Any	pixels	with	a	negative	 value	were	given	a	
value	of	 zero.	By	using	mathematical	equations,	heterogeneity	within	 this	ROI	was	
quantified.	 Heterogeneity	 was	 calculated	 with	 and	 without	 image	 filtration	 by	
estimating	 the	 entropy	 (irregularity,	 e)	 as	 per	 equation	 3.7	 and	 uniformity	
(distribution	 of	 gray	 level,	 u)	 as	 according	 to	 equation	 3.8.	 Both	 equations	 are	
described	below.		
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Equation	3.7:		 i = 	− [l(m)nop& mqr5 l m  
	
	
	
Equation	–	3.8:		 s = 	 l m 5nmp&  
e = entropy 
u = uniformity 
I is the pixel value (between I =1 to k) in the the ROI and  
p(I) the probability of the occurrence of that pixel value.  
	
Heterogeneity	is	represented	by	values	of	higher	entropy	and	lower	uniformity	(Ng,	
Kozarski	et	al.	2013).	Entropy	and	uniformity	were	recorded	for	absolute	scale	values	
for	each	patient’s	tumor	on	the	baseline	CT	and	CT	following	2	cycles	of	treatment.		
Percentage	change	in	image	entropy	and	uniformity	were	also	recorded.	
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3.4.3. Statistical	analysis.	
	
Individual	patient	data	from	baseline	and	treatment	response	scan	were	assessed	to	
ascertain	the	average	textural	measurements.	Percentage	change	from	baseline	was	
used	here	for	statistical	analysis.	Statistical	analysis	was	performed	using	(SPSS	version	
17.0.	 2008,	 SPSS	 Statistics	 for	 Windows	 Chicago:	 SPSS	 Inc.	 and	 also	 MedCalc	 for	
Windows,	 version	 9.2.0.0;	 Medcalc,	 Mariakerke,	 Belgium).	 The	 ability	 of	 texture	
parameters	to	predict	for	TTP	was	assessed	by	Kaplan-Meier	analysis.	The	relationship	
between	 textural	 analysis,	 RECIST,	 Choi	 and	 modified	 Choi	 criteria	 was	 assessed.	
Receiver	 Operating	 Characteristic	 (ROC)	 curve	 was	 used	 to	 analyse	 the	 threshold	
values	of	the	textural	analysis.	The	area	under	the	ROC	curve	was	recorded	and	the	
point	on	the	ROC	curve	furthest	from	the	line	of	discrimination	was	considered	as	the	
optimum	 threshold.	 Non-parametric	 log	 rank	 test	 was	 utilized	 to	 evaluate	 the	
differences	between	Kaplan	Meier	curves	for	PR,	SD,	and	PD.	Statistical	significance	
was	set	at	5%.	In	order	to	determine	independent	predictors	of	time	to	progression,	
Cox	regression	analysis	was	performed	with	all	significant	parameters.		
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4.1. Introduction	
	
In	this	chapter,	I	discuss	the	background	and	results	of	a	prospective	clinical	trial	to	
explore	 whether	 addition	 of	 interferon	 enhances	 the	 anti-angiogenic	 effect	 of	
bevacizumab	in	advanced	RCC	patients	measured	by	changes	in	vascular	parameters	
of	dynamic	contrast	enhanced	MRI	scan	 (DCE-MRI).	The	methods	employed	 in	 this	
study	 is	 detailed	 previously	 in	 Chapter	 3	 Section	 3.2.	 This	was	 a	 prospective	 open	
labelled	randomised	multi-centric	clinical	trial.	I	was	the	co-ordinating	investigator	of	
the	trial	involved	in	the	set-up,	day	to	day	running	and	analysis	of	the	study.		
	
Treatment	of	advanced	RCC	has	changed	significantly	since	the	introduction	of	agents	
that	target	angiogenesis	and	growth	factor	signalling.	With	the	improved	knowledge	
of	the	pathophysiology	of	RCC	as	explained	in	Chapter	1	Section	1.1,	multiple	agents	
have	been	found	to	have	efficacy	in	controlling	RCC	and	has	received	regulatory	body	
approval.	These	include	multi-targeted	tyrosine	kinase	inhibitors	as	sunitinib	(Motzer,	
Hutson	et	al.	2007),	sorafenib	(Escudier,	Eisen	et	al.	2009),	pazopanib	(Motzer,	Hutson	
et	 al.	 2013)	 and	 recombinant	 humanized	 monoclonal	 antibody	 bevacizumab	 in	
combination	with	interferon-α2a	(Escudier,	Pluzanska	et	al.	2007).		
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4.1.1. Bevacizumab	+IFN	in	treatment	of	advanced	renal	cell	carcinoma.	
	 	
Role	of	bevacizumab	and	interferon-α2a	in	management	of	advanced	RCC	is	discussed	
in	chapter	1.0	of	this	thesis.	Interferon-α2a	is	known	to	have	therapeutic	benefit	in	
treatment	of	RCC	with	modest	survival	advantage	benefitting	a	small	proportion	of	
patients	exposed	to	it.		
	
A	 three-arm	randomised-phase	 II	 study	 in	RCC	with	bevacizumab	at	a	dose	of	3	or	
10mg/kg	 every	 2	 weeks	 vs.	 placebo	 demonstrated	 a	 10%	 response	 rate	 and	 a	
statistically	 significant	 improvement	 in	progression-free	survival	 (2.5	months	 to	4.8	
months)	in	patients	who	received	high-dose	bevacizumab	(Yang,	Haworth	et	al.	2003).		
	
The	 interim	 results	 of	 the	 AVOREN	 study,	 a	 double	 blind,	 placebo-controlled		
randomised	study	of	bevacizumab	+	IFN	versus	IFN,	demonstrated	an	improvement	in	
median	PFS	from	5.4	months	in	the	IFN	alone	arm	to	10.2	months	in	the	combination	
arm	 (HR	 0.63,	 p<0.0001)	 (Escudier,	 Pluzanska	 et	 al.	 2007).	 In	 addition,	 an	 interim	
analysis	 from	 a	North	 American	 study	with	 a	 similar	 design	 to	 AVOREN	 showed	 a	
benefit	of	bevacizumab	in	combination	with	IFN	over	IFN	alone	for	both	progression	
free-survival	 (HR=	 0.71,	 p<0.0001),	 and	 overall	 response	 rates	 (25.5%	 vs.	 13%,	
respectively,	p<0.0001)	(Rini,	Halabi	et	al.	2008).	
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Based	upon	the	results	of	the	AVOREN	study,	the	EMEA	granted	the	following	licence	
in	December	2007:	“Avastin	in	combination	with	interferon	alfa-2a	is	indicated	for	first	
line	treatment	of	patients	with	advanced	and/or	metastatic	renal	cell	cancer.”	
	
As	there	was	no	single	agent	bevacizumab	arm	in	the	AVOREN	study,	it	is	unknown	
what	degree	of	additional	antiangiogenic	activity	is	provided	by	the	addition	of	IFN	to	
bevacizumab.	IFN	has	anti-angiogenic	activity	(von	Marschall,	Scholz	et	al.	2003)	and	
it	 is	 therefore	 possible	 that	 there	 is	 an	 additive	 or	 synergistic	 effect	 of	 IFN	 and	
bevacizumab	on	tumour	vasculature.	It	is	also	unknown	what	dose	of	IFN	is	required	
to	do	so.		
	
Data	from	two	independent	studies	suggest	that	the	combination	of	an	angiogenesis	
inhibitor	and	lower	dose	IFN	may	be	as	effective	as	standard	dosing	of	IFN.		As	part	of	
the	AVOREN	study,	the	protocol	allowed	dose	reduction	in	the	event	of	grade	3	IFN-
attributable	adverse	events	(AEs).		A	retrospective	sub-group	analysis	of	patients	who	
received	reduced	doses	of	IFN	in	combination	with	bevacizumab	compared	to	those	
patients	that	had	no	dose	reduction	was	equivalent	for	both	progression-free	survival	
and	 response	 rates	 (Melichar,	 Koralewski	 et	 al.	 2008).	 	 Prospective	 data	 from	 a	
randomised	phase	II	study	comparing	sorafenib	in	combination	with	either	standard	
dose	(9MiU	tiw)	or	low	dose	(3MiU	tiw)	IFN,	demonstrated	similar	outcomes	in	terms	
of	progression	free	survival	and	overall	clinical	benefit	(Bracarda,	Porta	et	al.	2013).	
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This	study	aims	to	address	the	important	question	whether	IFN	confers	an	additional	
anti-vascular	effect	to	that	seen	with	bevacizumab	and	if	so,	to	identify	the	dose	of	
IFN	required.	 	
	
4.1.2. DCE-MRI	in	monitoring	anti-angiogenic	therapy	in	humans	
	
DCE-MRI	is	one	of	the	most	researched	and	validated	MRI-based	techniques	targeted	
to	use	as	a	biomarker	for	angiogenesis.	Several	studies	involving	the	use	of	DCE-MRI	
to	assess	anti-vascular	therapies	have	been	reported,	including	three	Phase	I	studies	
involving	 combretastatin	 A4	 phosphate	 (CA4P)	 (Dowlati,	 Robertson	 et	 al.	 2002,	
Galbraith,	Maxwell	et	al.	2003,	Stevenson,	Rosen	et	al.	2003,	Nathan,	Zweifel	et	al.	
2012).	These	 results	 revealed	variability	 in	DCE-MRI	measured	 tumour	 response	 to	
differing	 doses	 of	 CA4P	 and	 furthermore	 also	 revealed	 marked	 intra-tumoural	
heterogeneity	of	 vascular	 response.	Another	 study	 investigating	 the	effect	of	dose	
escalation	of	PTK787	on	metastatic	colorectal	cancer	reported	that	the	authors	were	
able	 to	 generate	 a	dose	 response	 curve	 comparing	 the	drug	 area	under	 the	 curve	
exposure	 to	 the	 vascular	 inhibitory	 effect	 (Morgan,	 Thomas	 et	 al.	 2003).	 	 Use	 of	
DCE-MRI	in	monitoring	physiological	responses	for	dose	findings	could	be	a	potentially	
important	aspect	when	evaluating	agents	with	minimal	systemic	toxicities.			
	
DCE-MRI	has	also	been	used	in	studies	to	assess	effectively	the	antiangiogenic	effects	
of	 bevacizumab,	 in	 combination	 with	 other	 agents,	 in	 a	 variety	 of	 malignancies	
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including	locally	advanced	breast	cancer,	ovarian	cancer	and	glioblastoma	(Wedam,	
Low	et	al.	2006,	Hsu,	Ferl	et	al.	2013).		
	
As	discussed	in	chapter	2.0,	there	is	limited	published	data	on	the	use	of	DCE-MRI	in	
assessing	responses	to	vascular	targeted	therapies	in	RCC.	In	a	Phase	II	study	involving	
sorafenib,	patients	from	one	institution	underwent	DCE-MRI	before	and	after	the	start	
of	therapy.	Interestingly	in	this	group,	not	only	were	large	reductions	seen	in	the	Ktrans	
values	but	also	an	association	was	observed	between	initial	tumour	Ktrans		and	time	to	
tumour	 progression.	 A	 second	 phase	 2	 study	 published	 at	 about	 the	 same	 time	
showed	good	correlation	of	high	baseline	Ktrans	with	better	PFS	(Flaherty,	Rosen	et	al.	
2008)	(Hahn,	Yang	et	al.	2008).		
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4.2. Ethics	committee	and	MHRA	approval	
The	 planned	 study	 was	 submitted	 for	 approval	 of	 both	 National	 Research	 Ethics	
Committee,	 and	 Medicines	 and	 Health	 Regulatory	 Authority	 (MHRA).	 Version-
controlled	 documents	 of	 Protocol,	 Patient	 information	 sheet	 (Appendix	 -	 9.5),	
Informed	consent	form	(Appendix	–	9.6.),	GP	letter,	patient	diary	card,	peer	review	
reports	were	reviewed	by	the	ethics	committee	and	favourable	approval	was	received	
after	minor	amendment	of	the	Patient	information	sheet.	Local	research	and	ethics	
committee,	and	Research	and	Development	approval	were	also	needed	at	individual	
sites	 prior	 to	 recruitment	 of	 patients	 at	 that	 Centre.	 As	 the	 trial	 included	 use	 of	
bevacizumab	and	interferon-α2a,	approval	from	MHRA	was	also	obtained.		
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4.3. Objectives	
4.3.1. Primary	Objective	
The	primary	objectives	of	the	study	are:		
1. To	establish	whether	bevacizumab-induced	changes	in	DCE-MRI	vascular	
parameters	are	significantly	enhanced	by	the	addition	of	interferon-α2a.		
And	if	so:	
2. To	 establish	 whether	 there	 is	 an	 interferon-α2a	 dose	 response	 in	
potentiating	 bevacizumab	 induced	 changes	 in	 DCE-MRI	 vascular	
parameters.	
	
4.3.2. Secondary	Objectives	
1. To	correlate	changes	in	DCE-MRI	vascular	parameters	for	each	treatment	
group	with	the	following:	
a. Progression-free	survival	
b. Tumour	response	and	changes	in	tumour	size	
c. Other	surrogate	biomarkers		
2. To	 assess	 the	 degree	 of	 change	 in	 baseline	 Ktrans	 within	 each	 arm	 of	
treatment.	
3. To	 investigate	 changes	 in	 diffusion	 and	BOLD	MRI	 and	 their	 correlation	
with	other	pharmaco-dynamic	endpoints.		
4. To	assess	the	efficacy	and	safety	profile	of	bevacizumab	monotherapy	or	
in	combination	with	low	or	standard	doses	of	IFN	
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4.4. Study	design	and	assessments	
This	was	a	prospective	multi-centric	randomised	open	labelled	phase	2	clinical	trial.	
The	trial	schema	is	as	follows.	The	methods	including	planned	analysis	and	statistical	
consideration	is	detailed	in	Chapter	3.0	Section	3.2		
Figure	4.1	 Flow	chart	of	trial	protocol		
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4.5. Results	
4.5.1. Recruitment	and	randomisation	to	arms	
Of	the	three	sites	open	for	recruitment,	only	two	sites	recruited	patients	for	the	trial.	
The	first	Centre	was	opened	for	recruitment	in	September	2009,	and	the	first	patient	
recruited	 in	 December	 2009.	 25	 patients	 were	 screened	 for	 the	 study	 between	
December	2009	and	February	2012.	As	the	recruitment	was	very	slow,	the	steering	
committee	 decided	 to	 perform	an	 un-planned	 interim	 analysis	 after	 24	months	 of	
recruitment	to	assess	for	any	trends	to	justify	continued	recruitment	in	the	trial.	At	
this	point,	excluding	 the	4	screen	 failures,	21	patients	were	 randomised	 into	 three	
arms.	 Analysis	 of	 the	 primary	 endpoint	 data	 (change	 in	 Ktrans)	 showed	 no	 trend	 in	
difference	between	the	arms	and	the	decision	was	taken	that	 it	would	be	 futile	 to	
complete	the	planned	accrual	of	a	further	10	patients.		
	
6	patients	 received	bevacizumab	only,	6	patients	had	bevacizumab	 in	 combination	
with	standard	dose	(9MU)	IFN	and	9	patients	were	randomised	to	bevacizumab	and	
low	dose	IFN	(3MU).	One	patient	in	the	bevacizumab	monotherapy	arm	was	taken	off	
the	trial	before	the	week	8	primary	end	point	analyses	and	hence	was	replaced	as	per	
protocol.	All	remaining	20	patients	completed	the	primary	end	point.	All	patients	had	
metastatic	disease	with	no	prior	systemic	treatment.	6	patients	had	the	primary	renal	
tumour	in-situ.	Lesions	used	as	targets	for	analysis	with	DCE-MRI	are	listed	in	Table	
4.1	 	
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Table	4.1	 Lesions	used	for	DCE-MRI	analysis	
Primary	renal	tumour	 6	
Abdominal	LN	 3	
Mediastinal	LN	 3	
Lung	metastasis/chest	wall	 2	
Peritoneal	metastasis	 2	
Adrenal	metastasis	 3	
Renal	bed	recurrence	 1	
	
At	the	time	of	data	collection,	all	20	patients	had	progressed	on	treatment	and	had	
been	taken	off-study.	A	total	of	5	patients	had	to	be	excluded	from	the	primary	DCE-
MRI	 analysis	 due	 to	 technical	 reasons.	 These	 included	 movement	 and	 cardiac	
artefacts,	technical	failure	of	MRI	to	load,	breath-hold	failure	and	one	where	the	lesion	
in	the	chest	wall	was	too	small	to	characterise	with	DCE-MRI.	15	evaluable	patients	
and	hence	60MRI	(2	pre-treatments	and	two	on	treatment	per	patient)	scans	were	
thus	 analysed:	 Four	patients	 in	 the	bevacizumab	monotherapy	 arm,	 four	 receiving	
bevacizumab	and	standard	dose	IFN	(9MU)	and	7	patients	treated	with	bevacizumab	
and	3MU	IFN.	
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4.5.2. Safety	analysis	
A	planned	 independent	safety	analysis	was	performed	after	15	patients	completed	
their	 primary	 end	 point	 on	 the	 study.	 All	 adverse	 events	 including	 clinical	 and	
laboratory	AE	were	collected	and	graded	according	to	CTCAE	version	3.0.	Causality	of	
the	AE	were	determined	as	per	Section	3.2.5.2.	The	data	obtained	was	analysed	by	an	
independent	 expert.	 The	 methods	 are	 detailed	 earlier	 in	 the	 section	 3.2.6.		
Assessment	of	adverse	events	(AE)	in	this	cohort	is	explained	here.			
	
G1-G2	Adverse	Events	
With	bevacizumab	monotherapy	(Arm	A),	4	patients	(80%)	developed	AEs.	14	adverse	
events	were	reported	in	this	group	with	an	average	of	2.8	AEs	per	patient.	In	Arm	B,	
where	patients	had	bevacizumab	and	3MU	of	 interferon-t2a,	all	5	patients	 (100%)	
had	 low	 grade	 adverse	 events.	 This	 group	 had	 45	 adverse	 events	 reported	 so	 on	
average	each	patient	developed	9	AEs.	All	5	patients	in	Arm	C	(100%)	developed	AE	
with	41	adverse	events	in	total.	On	average	each	patient	developed	8.2	AEs.	
	
G3-G4	Adverse	Events		
High-grade	 side	 effect	 detection	 is	 of	 paramount	 importance.	 Grade	 3/4	 AE	were	
noted	 in	 1	 of	 the	 5	 patients	 treated	 with	 bevacizumab	 monotherapy	 (20%).	 On	
addition	of	low	dose	of	IFN,	3	of	the	5	patients	(60%)	developed	high-grade	side	effects	
with	a	total	of	4	high	grade	AEs.		
When	high	dose	interferon-t2a	was	used	(Arm	C),	interestingly	only	20%	i.e.	1	of	the	
5	patients	developed	a	higher	grade	AE.		
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SAEs	
Six	(40%)	of	the	15	patients	had	a	SAE.	Only	1	of	the	6	SAE	reported	was	treatment-
related	which	required	intervention.	No	deaths	due	to	adverse	events	were	reported.		
	
Drug	discontinuations:	Treatment	was	discontinued	only	in	one	patient	(arm	A)	due	
to	an	unrelated	SAE.	Dose	reduction	and	delays	have	not	been	reported.		
	
G3-G4	adverse	events	were	seen	in	5	(30%)	of	the	15	patients,	one	patient	developed	
two	G3-G4	adverse	events.	Given	the	small	number	of	G3-G4	AEs	it	was	difficult	to	
remark	with	confidence	on	the	difference	in	incidence	of	AEs	between	the	3	treatment	
arms.	The	percentage	of	with	G3-G4	adverse	events	is	noted	to	be	smaller	than	that	
observed	in	similar	trials.	In	the	AVOREN	trial	(Escudier,	Pluzanska	et	al.	2007),	60%	of	
the	patients	treated	with	Interferon	and	bevacizumab	had	G3-G4	adverse	events	and	
80%	of	the	patients	who	had	the	same	treatment	noted	G3-G4	toxicities	within	the	
CALGB	 90206	 trial	 (Rini,	 Halabi	 et	 al.	 2008).	 Such	 differences	 could	 be	 due	 to	 the	
smaller	sample	size	and	to	the	different	treatment	doses.	No	definite	trial	data	exists	
regarding	the	overall	 frequency	of	G3-G4	AEs	 in	renal	cancer	patients	 treated	with	
bevacizumab	only.		
	
Apart	from	one	patient	in	Arm	A	(Patient	4),	all	the	patients	in	the	study	experienced	
G1	-	G2	AEs.	The	incidence	of	G1-	G2	AEs	was	smaller	in	arm	A	compared	with	arm	B	
and	arm	C.		An	average	of	2.8	AEs	per	patient	were	seen	in	arm	A	compared	with	9	
and	8.2	AEs	per	patient	in	arm	B	and	C	respectively.	This	was	not	unexpected	as	most	
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of	the	AEs	were	caused	by	the	interferon.	The	incidence	of	G1	–	G2	AEs	was	virtually	
identical	between	arm	B	and	arm	C	although	the	patients	in	arm	C	had	a	higher	dose	
of	interferon.	Previous	studies	have	shown	that	a	lower	interferon	dose	is	associated	
with	fewer	G3	-	G4	AEs	but	no	data	are	available	regarding	the	incidence	of	G1	-	G2	
AEs	(Melichar,	Koralewski	et	al.	2008,	Bracarda,	Porta	et	al.	2013).	It	is	likely	that	the	
similar	incidence	of	AEs	was	due	to	the	small	patient	number	and	the	fact	that	low	
grade	adverse	events	are	very	common	with	interferon.		
Thus	with	the	safety	analysis,	no	unexpected	toxicities	were	observed	in	the	group.	
An	expected	increase	of	AEs	was	observed	in	patients	treated	with	the	combination	
of	bevacizumab	and	interferon	although	no	dose	reductions	or	dose	delays	have	been	
reported.		
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4.5.3. Reproducibility	of	DCE-MRI	parameters	
Assessment	of	reproducibility	of	the	DCE-MRI	parameters	was	performed	as	detailed	
in	Section	3.2.7.4.	The	difference	between	two	measurements	(d)	was	assessed	for	
normality	 with	 Shapiro-Wilk	 test.	 Then	 Kendall’s	 Tau	 was	 calculated	 to	 test	 the	
correlation	of	“d”	with	the	mean	of	the	measure	(Bland	and	Altman	1996).	ANOVA	
was	used	to	assess	the	statistical	measures.	These	include,	
1) Mean	Squared	difference	dSD	=	 *5-  
2) Group	Confidence	interval		!" = 	± &.()*+,-  
3) Within	patient	standard	deviation	4+, = *+,5  
4) Within	patient	coefficient	of	variation	4!6 = 4+,789;<<	=9;-	7>	?@9	A;:;=9?9: 
5) Reproducibility	coefficient	: = 5. BB4+, 
	
Individual	 values	which	 fall	 outside	 “r”	 is	 likely	 due	 to	 be	 a	 true	 effect	 and	 hence	
significant.	Group	95%	CI	in	a	cohort	is	calculated	by	using	the	relevant	n	numbers	in	
the	cohort.		
Values	were	calculated	for	Ktrans,	kep,	ve	and	IAUGC60	individually.	The	outcome	values	
are	summarized	in	the	following	Table	4.4.	
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Table	4.2	
Reproducibility	statistics	for	DCE-M
RI	param
eters	
Param
eter	
K
trans	
k
trans		
(no	outliers)	
k
ep 	
k
ep 		
(no	outliers)	
v
e 	
v
e 	
(no	outliers)	
IAUGC
60 	
IAUGC
60 	
(no	outliers)	
dSD	
0.0913	
0.0715	
0.7762	
0.1246	
0.0401	
0.0175	
4.4273	
2.5064	
group	CI	
0.0447	
0.0467	
0.3928	
0.0677	
0.0203	
0.0114	
2.1694	
1.4182	
as	%
	m
ean	
12.5128	
11.0957	
29.3427	
5.0294	
7.2819	
3.7547	
7.8399	
4.9644	
w
SD	
0.0646	
0.0506	
0.5488	
0.0881	
0.0283	
0.0124	
3.1306	
1.7723	
w
CV	
0.1806	
0.1201	
0.4100	
0.0654	
0.1017	
0.0406	
0.1131	
0.0620	
r	
0.1788	
0.1401	
1.5203	
0.2440	
0.0785	
0.0342	
8.6718	
4.9093	
r	as	%
	
50.0177	
33.2649	
113.5677	
18.1215	
28.1836	
11.2565	
31.3385	
17.1858	
Shapiro-W
ilk	
norm
al	
norm
al	
norm
al	
norm
al	
norm
al	
norm
al	
norm
al	
norm
al	
F	
13.633	
22.843	
1.764	
77.975	
39.611	
221.841	
36.104	
75.752	
ICC	
0.855	
0.906	
0.244	
0.973	
0.947	
0.990	
0.943	
0.972	
tau	
0.283	
0.500	
0.048	
0.103	
0.048	
0.000	
0.200	
0.091	
p	
0.139	
0.075	
0.846	
0.675	
0.846	
0.920	
0.306	
0.737	
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4.5.4. Primary	variable	analysis	(Ktrans)	
Aim	of	the	primary	analysis	was	to	assess	the	changes	in	DCE-MRI	defined	parameter	
Ktrans	from	baseline	to	week	6	on	treatment	between	the	three	arms	of	the	trial.	Please	
refer	to	Section	3.2.8	and	4.3	where	this	is	described.		
Value	of	Ktrans	over	the	different	time	points	in	the	trial	is	graphically	represented	here	
in	Figure	4.2	and	4.3.		
	
Figure	4.2	 Box	and	whisker	plot	Ktrans	over	different	trial	time	points.	
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Figure	4.3	 Variation	in	Ktrans	in	individual	patient	over	the	trial	
	
	
To	 assess	 the	 true	 change	 in	 Ktrans	 due	 to	 treatment,	 baseline	 reproducibility	 was	
initially	calculated	as	explained	in	Section	3.2.7.4.	After	normalising	and	excluding	any	
outliers,	these	values	as	percentage	for	individual	patients	were	noted	to	be	33.26	for	
Ktrans,	18.12	for	kep,	11.25	for	ve	and	17.18	for	IAUGC60.		
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The	mean	decrease	in	Ktrans	for	all	patients	was	-2.25%	at	week2	and	-11.33%	at	week	
6.	Analysing	treatment	cohorts,	between	baseline	and	week	6,	Arm	A	had	a	decrease	
in	Ktrans	of	26.44%	(95%CI	-17.42	to	-35.46).	Changes	in	Ktrans	 in	Arm	B	and	C	were	-
4.56%	and	32.84%	(SD	of	35.09)	respectively.	Changes	in	Ktrans	at	week	6	(compared	
to	 baseline)	 was	 statistically	 significant	 for	 Arms	 A	 and	 C	 but	 not	 for	 Arm	 B.	 No	
statistical	 significance	 or	 trend	 were	 noted	 in	 the	 observed	 change	 between	
treatment	arms.	This	has	been	detailed	along	with	the	other	MRI	parameter	changes	
in	Table	4.3		
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4.5.5. Secondary	variable	analyses	
Secondary	 analyses	 included	 assessment	 of	 other	 DCE-MRI	 associated	 vascular	
endpoints,	efficacy	analyses,	safety	endpoints	and	exploratory	assessments	including	
laboratory	endothelial	cells	quantification.	Please	refer	to	Section	3.2.8.		
	
4.5.5.1. Secondary	MRI	variable	analyses	(Vascular	end	point)	
At	 week	 2	 comparison	 was	 made	 in	 the	 changes	 of	 Ktrans	 from	 baseline	 between	
bevacizumab	alone	group	(Arm	A)	vs	bevacizumab	+	interferon-α2a	groups	(Arms	B	+	
Arm	C).	Arm	A	showed	a	change	of	-0.03%	in	Ktrans	from	baseline	and	combined	IFN	
groups	showed	a	change	in	Ktrans	of	-1.360	with	a	standard	deviation	of	33.06.	These	
values	were	also	not	considered	to	represent	a	true	i.e.	statistically	significant	change.		
Similar	calculations	have	been	performed	for	all	the	other	MRI	parameters	including	
kep,	ve	and	IAUGC60.	Changes	in	all	MRI	parameters	from	baseline	to	week	2	and	week	
6	are	reported	in	Table	4.3		
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Table	4.3	 Change	of	MRI	parameters	at	different	time	points	in	trial.	
		
baseline	
(mean)	
Week2		
(change	in	%)	
Week6		
(change	in	%)	
Arm	A	(bev)	 	 	 	
Ktrans	 0.3445	 -0.03	 -26.439	
kep	 1.022	 -2.877	 -9.017	
ve	 0.319	 3.015	 -10.559	
IAUGC60	 28.11	 9.952	 -10.593	
	
Arm	B		
(bev	+3MU	IFN)	 		 		 		
Ktrans	 0.3997	 18.12	 -4.56	
kep	 1.358	 -2.808	 -11.947	
ve	 0.304	 17.684	 7.213	
IAUGC60	 34.99	 8.506	 -6.114	
	
Arm	C		
(bev+9MU	IFN)	 		 		 		
Ktrans	 0.3726	 -35.45	 -32.841	
kep	 1.997	 -15.111	 -20.08	
ve	 0.1865	 -21.369	 -17.181	
IAUGC60	 24.648	 -16.043	 -29.646	
	
Combined	ArmB+C		 		 		 		
Ktrans	 0.3885	 -1.36	 		
kep	 1.59	 -7.282	 		
ve	 0.261	 3.482	 		
IAUGC60	 31.229	 -1.313	 		
	
No	statistically	significant	changes	in	secondary	outcome	measurements	was	seen.	A	
trend	of	decrease	of	the	Kep	values	was	noted	between	the	arms	at	week	6	was	seen	
(p=0.862	Arm	A	vs	B	and	p=0.450	Arm	A	vs	C).		 	
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4.5.5.2. Clinical	outcome	analysis	(efficacy	end	points)	
With	clinical	outcome	analysis,	median	progression-free	survival	(PFS)	of	all	evaluable	
patients	 was	 308	 days.	 With	 cohort	 analysis	 comparing	 the	 PFS,	 Kaplan-Meier	
statistics	were	used	and	a	log-rank	test	used	to	assess	the	significance.	Median	PFS	for	
Arm	A	was	108	days	(95%	CI	0	-147).	PFS	was	308	days	(95%	CI	-95.0	-	520.9)	for	Arm	
B	and	378	days	(95%	CI	0	–	775)	for	Arm	C.	No	significance	was	noted	with	p	value	
obtained	by	log-rank	test.	Kaplan-Meier	curve	for	PFS	is	shown	in	Figure	4.4		
	
Figure	4.4	 Kaplan	Meier	curve	comparison	of	PFS	between	the	treatment	arms.		
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Log-rank	test	was	performed	for	overall	analysis	and	paired	comparison	between	two	
arms	each.	χ2	test	was	performed	and	p	value	calculated	from	the	log-rank	test.	This	
is	 detailed	 in	 Table	 4.4.	 Log-rank	 test	 showed	 no	 significance	 between	 any	 of	 the	
treatment	arms	in	Kaplan-Meier	analysis.		
	
Table	4.4	 Log-rank	test:	Significance	of	PFS	difference	between	treatment	arms	
Pairwise	Comparisons	(PFS	vs	Treatment	arms)	
	 Treatment	
ArmA	 ArmB	 ArmC	
χ2	 p-value	 χ2	 p-value	 χ2	 p-value	
Log-
rank	
(Mantel-
Cox)	
ArmA	 	 	 .573	 .449	 1.669	 .196	
ArmB	 .573	 .449	 	 	 1.589	 .208	
ArmC	 1.669	 .196	 1.589	 .208	 	 	
	
	
4.5.5.3. Comparison	of	PFS	with	MRI	parameters	
PFS	was	 plotted	 against	 the	 vascular	 parameters	 of	 Ktrans,	 kep,	 ve	 and	 IAUGC60	 and	
Spearman	Correlation	coefficient	“r”	was	calculated	to	assess	if	there	is	any	trend	for	
correlation	(Table	4.5)		
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Table	4.5	 Spearman	correlation	coefficient	comparing	the	vascular	parameters	
and	progression-free	survival	
Spearman	correlation	coefficient	(rho):	MRI	parameters	vs	PFS	
	 Baseline	
Percentage	Change	
of	MRI	parameter	in	
Week2	
Percentage	Change	
of	MRI	parameter	in	
Week6	
Ktrans	 0.165	(0.557)	 -0.391	(0.167)	 -0.279	(0.313)	
kep	 0.287	(0.33)	 -0.585*	(0.028)	 -0.47	(0.077)	
IAUGC60	
-0.165	
(0.557)	 -0.359	(0.228)	 -0.111	(0.693)	
ve	
-0.0276	
(0.319)	 -0.166	(0.572)	 0.043	(0.879)	
	
	
Rho	for	two	tailed	test	according	to	Spearman’s-coefficient	with	alpha	0.05.	Values	in	
parenthesis	suggests	significance	of	the	correlation	(Zar	1972).		
	
No	 significant	 statistically	 correlation	 was	 noted	 between	 PFS	 and	 Ktrans	 values	 at	
baseline	 or	 the	 changes	 in	 Ktrans	 during	 treatment.	 Subsequent	 analysis	 performed	
similar	analysis	 for	all	MRI	parameters	reviewed	here	 including	kep,	ve	and	 IAUGC60	
measured	at	baseline,	week	2	and	week	6.	Correlation	was	noted	with	change	of	kep	
at	Week	2	and	PFS	but	this	was	not	sustained	in	the	change	of	kep	at	week	6.		
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4.5.5.4. Clinical	benefit	
	
The	aim	of	this	analysis	was	to	assess	whether	MRI	vascular	parameters	at	baseline,	
week	2	or	week	6	could	predict	and	identify	patients	who	get	any	meaningful	clinical	
benefit	with	the	treatment.	We	felt	that	with	the	median	progression	free	survival	of	
10.5	months	with	 the	 combination	 treatment	 of	 bevacizumab	 +	 interferon-α2a	 as	
reported	 by	 the	 trials,	 (Escudier,	 Bellmunt	 et	 al.	 2010),	 	 the	 patients	 could	 be	
categorised	into	two	groups	with	a	PFS	cut-off	of	6	months.		
	
Patients	who	had	PFS	≤	6months	and	>6months	were	re-categorised	from	the	trial	
data.	Baseline	and	mean	change	in	the	parameters	were	assessed	and	Mann-Whitney	
U	test	was	used	to	assess	the	significance	of	difference	between	the	groups	(table	4.6a	
and	4.6b)	
	
Table	4.6a	 Comparison	of	vascular	parameters	(Ktrans,	kep)	with	clinical	benefit	
(PFS).	
	 Ktrans	 kep	
	 Baseline	 Change	at	Wk2	
Change	
at	wk6	 Baseline	
Change	at	
Wk2	
Change	at	
wk6	
Group	1	PFS	<6m	 0.349	 12.18	 0.959	 1.302	 13.62	 9.41	
Group2	PFS	>6m	 0.3802	 -3.274	 -17.479	 1.507	 -10.63	 -17.21	
p	value	 0.662	 0.423	 0.582	 0.756	 0.033	 0.197	
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Table	4.6b	 Comparison	of	vascular	parameters	(ve	&	IAUGC)	with	clinical	benefit	
(PFS)	
	 ve	 IAUGC60	
Group	1	PFS	<6m	 0.301	 -0.88	 -10.88	 30.59	 2.01	 -11.94	
Group2	PFS	>6m	 0.264	 5.75	 -0.6	 30.7	 0.97	 -14.41	
p	value	 0.6672	 0.596	 0.756	 0.857	 *	 0.952	
	
	
There	was	no	statistically	significant	difference	in	MRI	vascular	parameters	between	
the	groups	of	patients	who	derived	clinical	benefit	of	>6months	compared	to	those	
who	 did	 not.	 Greater	 changes	 in	 Ktrans	 and	 kep	were	 seen	 in	 patients	with	 PFS	 >	 6	
months	however	due	 to	 the	small	 sample	size	 these	changes	were	not	 statistically	
significant.	Even	though	changes	in	kep	value	from	baseline	to	week	2	showed	a	p	value	
of	0.033	between	 the	 two	groups	 suggesting	a	 statistical	 significance,	 this	was	not	
sustained	in	the	changes	noted	at	week	6	and	with	the	small	sample	size	(n=5,	group	
1)	this	is	unlikely	to	represent	a	true	change.	
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4.5.5.5. Circulating	endothelial	cell	quantification	
Exploratory	 analysis	 assessing	 circulatory	 endothelial	 cell	 quantification	 was	
performed	 to	 assess	 effects	 of	 treatment	 on	 circulating	 endothelial	 cells	 (CEC)	 in	
peripheral	blood	at	similar	 time	points	as	DCE-MRI.	The	assay	was	performed	with	
multi-parametric	 flow	 cytometer	 analysis	 using	 a	 BD	 LSRII	 machine	 (Beckton	
Dickinson).	The	technique	of	assessment	is	explained	in	the	methods	Section	3.2.4.8.	
Baseline	and	variation	of	WBC	and	MNC	showed	that	for	most	patients,	WBC	counts	
appear	to	decrease	between	baseline	and	week	2,	but	generally	no	change	in	WBC	
counts	were	noted	over	 the	course	of	 treatment.	WBC	and	MNC	count	are	mainly	
within	normal	range	at	baseline	and	on	treatment	for	majority	of	patients		
Figure4.5a	&	b.	
	
	
	
	
	
	
	
	
	
Figure	4.5(a)	 Box	plot	-	WBC	count	at	different	time	points	in	trial.	
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Figure	4.5(b)	 Box	plot	-	MNC	count	at	different	time	points	in	trial.	
	
Boxes	represent	Inter-Quartile	Range	(25-75%);	‘whiskers’	represent	95%	confidence	
(2.5-97.5%);	middle	 line	 represents	median.	 Outliers	 are	 shown	 as	 circles	 or	 stars	
labelled	with	patient	number.	Circle	=	between	1.5	and	3	IQR	(inter-quartile	range)	
from	the	end	of	the	box	(ends	of	box	denote	25th	and	75th	percentile)	
	
CD34	 counts	 appear	 to	 lie	within	 the	 normal	 range	 and	 experience	 little	 variation	
during	treatment	with	baseline	values	falling	between	±0.02	and	±0.65	x103/ml.	One	
patient	 had	 high	 CD34	 at	 the	 baseline	which	 increased	 at	week	 2	 but	 dropped	 to	
normal	range	by	week	6.	Representing	the	CD34	as	percentage	of	MNC,	variation	in	
CD34	over	 the	course	of	 treatment	 for	 individual	patients	have	been	plotted	 -	 see	
Figure	4.6.	
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Figure	4.6	 Variation	of	CD34	as	percentage	of	MNC	in	individual	patient		
	
	
Total	and	viable	CEC	were	assessed	with	the	fluorescine	dye	CalceinM.	Total	and	viable	
CEC	showed	 large	variation	between	 the	 two	baseline	 samples.	This	persists	when	
looking	at	CD45dim/neg,	CD34+,	CD144+	or	Tie2+ve	cells.		These	are	showed	in	Figures	
4.7	a&b	and	4.8a&b.		
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Figure	4.7(a)	 Total	CEC	over	the	trial	–	Box	and	whisker	plot	with	outliers.	
	
	
Figure	4.7(b)	 Viable	CEC	over	the	trial	–	Box	and	whisker	plot	with	outliers.		
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Figure	4.8(a)	 Change	of	Total	CEC	over	the	trial	period	in	individual	patients.		
	
Figure	4.8(b)	 Change	of	Viable	CEC	over	the	trial	period	in	individual	patients.		
	
No	obvious	overall	changes	were	noted	 in	 the	CEC	numbers	with	treatment.	Some	
patients	appear	to	exhibit	an	increase	in	CEC	numbers	at	2	weeks.	It	is	unclear	whether	
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this	represents	a	real	change.	Along	with	the	CD34,	CD45	and	CD144,	Tie2	was	used	
as	these	cells	are	likely	to	represent	proangiogenic	mononuclear	cells.	There	does	not	
appear	to	be	any	obvious	change	in	Tie2	positive	cell	concentration	for	any	patients.	
This	is	represented	in	Figure	4.9.		
	
Figure	4.9	 Change	ofCD45-	Tie2+	MNC	over	the	trial	period	in	individual	
patients.	
	
	 	
Chapter	4	-	DCE-MRI	assessment	of	vascular	changes	induced	with	bevacizumab	with	or	
without	interferon	in	advanced	renal	cell	carcinoma	
 173	
4.6. Discussion.	
This	 trial	attempts	 to	address	whether	 IFN	measurably	adds	 to	 the	anti-angiogenic	
effect	of	bevacizumab.		
	
The	AVOREN	and	CALBG	90206	trials	(Escudier,	Pluzanska	et	al.	2007),	(Rini,	Halabi	et	
al.	2008)	both	compared	combination	bevacizumab	and	interferon	with	single	agent	
interferon.	Both	studies	lacked	a	single	agent	bevacizumab	arm.	Data	regarding	the	
efficacy	of	single	agent	bevacizumab	treatment	in	metastatic	RCC	is	therefore	limited	
to	 that	 available	 from	 small	 phase	 2	 trials.	 The	 additional	 benefit	 conferred	 to	
bevacizumab	 treatment	 by	 IFN	 is	 therefore	unknown,	 as	 is	whether	 any	benefit	 is	
mediated	by	anti-angiogenic	effects.	
	
The	trial	accrued	very	slowly.		Many	patients	with	metastatic	RCC	did	not	have	lesions	
of	a	size	or	location	that	enabled	DCE-MRI	analysis.	Additionally,	competing	first	line	
studies	and	the	inability	to	access	sunitinib	in	the	NHS	at	some	Centres	after	patients	
had	been	treated	with	bevacizumab	on	trial	resulted	in	the	very	slow	recruitment	and	
one	centre	being	unable	to	recruit	any	patients.	
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As	evident	from	the	MRI	analysis,	even	among	patients	with	lesions	suggested	to	be	
suitable	 for	analysis,	5	 (25%)	patients	were	unable	to	be	analysed	due	to	technical	
issues	 including	 movement	 artefacts	 despite	 attempts	 to	 correct	 motion,	 cardiac	
artefacts,	technical	failure	of	MRI	to	load	and	breath	hold	failure.		
	
Among	the	patients	analysed,	no	correlation	was	found	between	change	in	Ktrans	and	
addition	of	IFN	to	bevacizumab.	Effect	size	analysis	was	performed	due	to	the	smaller	
sample	size	recruited	and	the	change	in	Ktrans	was	still	not	noted	to	be	significant.		
	
Change	in	Ktrans	and	kep	may	identify	a	group	of	patients	likely	to	have	PFS	>	6	months	
(p	0.03),	but	 this	observation	needs	to	be	tested	 in	a	 larger	sample	size.	The	small	
sample	size	makes	it	difficult	in	this	case	to	analyse	the	significance	of	this	change.		
	
Although	Ktrans	is	the	best-studied	DCE-MRI	parameter,	the	importance	of	kep	or	rate	
constant,	 which	 measures	 the	 efflux	 of	 the	 contrast	 from	 the	 extravascular	
extracellular	space	is	increasingly	recognised.	Pre-clinical	studies	in	a	mouse	xenograft	
model	have	suggested	that	kep	might	be	a	better	parameter	in	assessing	response	to	
anti-angiogenic	agents	(Song,	Cho	et	al.	2013).	This	need	to	be	evaluated	in	a	larger	
cohort.		
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In	summary,	in	this	small	study	we	were	unable	to	demonstrate	significant	differences	
in	 vascular	 parameter	 change	 between	 RCC	 patients	 receiving	 single	 agent	
bevacizumab	 or	 combination	 bevacizumab	 and	 IFN.	 	 The	 study	 was	 technically	
demanding	and	patients	were	difficult	to	accrue.	Change	in	Ktrans	and	kep	may	identify	
patients	likely	to	have	more	durable	benefit	from	anti-angiogenic	treatment	but	this	
observation	needs	to	be	replicated	in	a	larger	sample	size.	
	
	
	
	
	 176	
Chapter	5. 	
	
CT	response	assessment	
combining	reduction	in	size	
and	arterial	enhancement	in	
metastatic	RCC	patients	
treated	with	targeted	therapy	
	
Chapter	5.0	-	CT	response	assessment	criteria	–	“modified	Choi”	
 177	
5.1. Introduction	
In	 this	chapter	 I	compare	the	use	of	existing	standard	 imaging	guided	methods	 for	
therapeutic	 response	 assessment	 in	metastatic	 RCC	 patients	 treated	with	 tyrosine	
kinase	 inhibitors	and	propose	a	new	criterion,	 the	“modified	Choi”	 criterion,	as	an	
enhanced	method	for	this	purpose,	with	the	help	of	a	retrospective	clinical	study.	This	
study	 has	 been	 published	 in	 the	 Journal	 of	 Cancer	 Biology	&	 Therapy	 9(1);	 15-19;	
January,	2010	(see	list	of	abstracts	and	publications).	
	
As	 discussed	 in	 previous	 chapters,	 accurate	 therapeutic	 response	 assessment	 is	 of	
paramount	importance	in	a	clinical	setting	where	decisions	need	to	be	taken	about	
whether	to	continue	or	change	a	treatment	regime.	Validated	methods	of	therapeutic	
response	 assessment	 may	 identify	 potential	 responders	 or	 non-responders	 and	
identify	the	at	risk	population	for	side	effects.	This	would	distinguish	the	patient	who	
will	obtain	maximum	benefit	from	a	specific	intervention	and	avoid	exposing	patients	
to	unnecessary	side	effects	and	allow	an	early	change	to	a	more	potentially	beneficial	
therapy		
	
Imaging	as	a	tool	for	response	assessment	has	the	advantage	of	being	non-invasive	
and	 can	 be	 performed	 repeatedly	 at	 intervals.	 CT	 scanning	 is	 the	 most	 common	
imaging	technique	used	 in	oncology	for	treatment	response	assessment.	Using	this	
technique	has	the	advantage	of	wide	availability	of	equipment	and	interpretational	
skills	and	less	inter-observer	reporting	variability.		
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Current	methods	of	response	assessment	
Current	accepted	standard	for	treatment	assessment	for	many	anticancer	treatment	
is	based	on	an	imaging-defined	response	assessment	criteria	called	RECIST	(Response	
Evaluation	Criteria	in	Solid	Tumours)	(Patrick	Therasse,	Richard	S.	Kaplan	et	al.	2000).	
It	 is	 based	 entirely	 on	 the	 size	 change	 of	 the	 tumours.	 	While	 RECIST	 is	 clinically	
relevant	in	the	response	assessment	of	conventional	chemotherapeutic	agents,	this	
appears	not	 to	be	 the	case	 for	 the	new	generation	of	 targeted	anti-cancer	agents.	
Many	 targeted	 agents	 have	 profound	 anti-tumour	 effects	 with	 resulting	 clinical	
benefit	yet	have	low	RECIST	defined	response	rates.	The	first	attempt	to	move	away	
from	the	framework	of	using	criteria	solely	based	on	size	was	proposed	by	Choi	et.al	
(Choi	2008).	The	Choi	criteria	was	proposed	to	re-evaluate	the	response	assessment	
in	 Gastro	 Intestinal	 Stromal	 Tumours	 (GIST)	 treated	 with	 Imatinib	 (Glivec®)	
considering	either	change	in	size	or	tumour	enhancement	as	a	response	to	systemic	
therapy.	Reduction	or	absence	of	tracer	uptake	post	therapy	has	also	been	proposed	
as	a	method	of	response	assessment	with	FDG-PET	scan.	Despite	these	suggestions,	
RECIST	remains	the	most	established	and	widely	used	technique	to	assess	treatment	
response	in	metastatic	RCC.		 	
Chapter	5.0	-	CT	response	assessment	criteria	–	“modified	Choi”	
 179	
5.1.1. RECIST	(Response	Evaluation	Criteria	in	Solid	tumours)	
	
RECIST	1.0	was	introduced	in	2000	as	a	standardised	method	to	evaluate	response	to	
treatment	with	chemotherapeutic	agents	(Patrick	Therasse,	Richard	S.	Kaplan	et	al.	
2000).	This	was	further	updated	in	2009	(Eisenhauer,	Therasse	et	al.	2009).	Treatment	
response	 defined	 by	 RECIST	 is	 based	 on	 the	 change	 in	 size	 of	 the	 sum	 of	 uni-
dimensional	 measurements	 of	 tumour	 target	 lesions	 performed	 with	 a	 specific	
imaging	modality.		
	
The	tumours	are	classified	as	measurable	(target)	and	non-measurable	(non-target)	
lesions.	Lesions	that	measure	more	that	2.0cm	by	non-helical	CT	methods	and	1.0cm	
by	 helical	 CT	 and	 those	 that	 can	 be	 measured	 accurately	 and	 repeatedly	 are	
considered	measurable	lesions.	With	RECIST	1.1,	the	target	lesions	(maximum	five	per	
organ	and	ten	in	total)	are	defined	with	an	imaging	technique	(eg:	CT/MRI/USS	etc)	
performed	prior	to	treatment	initiation.	The	maximum	diameters	of	the	target	lesions	
are	noted	in	the	axial	plane	(short	axis	measurement	is	used	if	lymph	nodes	are	used	
as	target	lesion)	and	the	sum	of	the	largest	diameter	of	the	target	lesions	is	calculated.	
The	follow	up	scans	for	response	assessment	are	performed	using	the	same	modality	
with	the	target	lesions	measured	the	same	way.		
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5.1.1.1. Response	categorisation	using	RECIST	criteria	
	
1. Complete	response	
(CR):	
Disappearance	of	all	target	lesions	
2. Partial	response	(PR):	 >30%	decrease	in	sum	of	longest	diameter	of	
target	lesions	
3. Progressive	disease	
(PD):	
1) >20%	increase	in	sum	of	longest	
diameter	of	target	lesions	taking	as	
reference	the	smallest	noted	since	
treatment	initiation	
2) Appearance	of	new	lesion	
4. Stable	disease	(SD):	 Response	not	fitting	with	any	of	the	above	
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5.1.2. Choi	criteria	
With	increasing	use	of	targeted	agents	in	pharmacological	management	in	oncology,	
it	has	been	noted	that	the	response	obtained	as	defined	by	RECIST	criteria	does	not	
correlate	 with	 the	 clinical	 benefit	 gained	 from	 these	 agents.	 Choi	 et	 al.	 (2008)	
proposed	 an	 alternative	 method	 (Choi	 criteria)	 for	 response	 assessment	 of	 GIST	
(Gastro	Intestinal	Stromal	Tumour)	treated	with	Imatinib	(a	tyrosine	kinase	inhibitor	
blocking	activated	c-kit).	It	was	noted	that	a	significant	change	in	CT	assessed	density	
inside	the	tumour	occurred	quite	early	in	the	treatment	of	patients	who	had	a	good	
clinical	response	to	treatment.	This	was	despite	only	a	minimal	decrease	in	tumour	
size	 thus	 failing	 to	meet	 the	 response	 criteria	 (RECIST)	 (Choi,	 Charnsangavej	 et	 al.	
2007,	Choi	2008).	The	criteria	took	into	consideration	the	change	in	size	or	change	in	
enhancement	after	a	contrast	enhanced	CT	scan	to	define	responders	to	treatment	
and	non-responders.	 Size	was	measured	 as	 per	 the	RECIST	 criteria	 guidelines.	 The	
enhancement	of	 tumour	 in	HU	(Hounsefield	Units)	was	calculated	from	CT	 images.	
The	 Choi	 criteria	 proposed	 either	 a	 decrease	 in	 size	 of	 10%	 OR	 decrease	 in	
enhancement	by	15%	for	a	response.	97%	of	patients	with	a	good	response	fell	into	
this	category	thus	providing	a	good	prognostic	indicator.		
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5.1.2.1. Response	categorisation	according	to	Choi	criteria	
	
a) Complete	response	
(CR):	
Disappearance	of	all	target	lesions	
b) Partial	response	(PR):	 c) ≥10%	decrease	in	sum	of	longest	
diameter	of	target	lesions	OR	
d) ≥15%	decrease	of	mean	contrast	
enhancement	of	target	lesions	
e) Progressive	disease	
(PD):	
a) Increase	in	tumour	size	>10%	and	does	
not	meet	criteria	of	PR	by	contrast	
enhancement	
b) New	lesion	or	intra-tumoural	nodule	
f) Stable	disease	(SD):	 Response	not	fitting	with	any	of	the	above	
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5.1.3. Proposed	new	criteria	-	“modified”	Choi	
Anti-angiogenic	 targeted	 treatment	 as	 sunitinib,	 sorafenib	 and	 bevacizumab	 +	
interferon,	 have	 transformed	 the	 treatment	 of	 RCC.	 Progression	 free	 survival	 has	
doubled	 compared	 to	 either	 standard	 treatments	 or	 placebo.	 Yet,	 RECIST	 defined	
response	 rates	 are	 relatively	 low	 (sunitinib	 31%,	sorafenib	 10%	and	bevacizumab	+	
interferon	30%)	(Motzer,	Hutson	et	al.	2007,	Escudier,	Bellmunt	et	al.	2010).	Many	
patients	who	derive	significant	clinical	benefit	from	these	drugs	never	attain	a	RECIST	
defined	response.		
	
As	discussed	earlier	in	the	thesis,	RCC	is	highly	vascular	driven	in	part	by	the	VEGF-HIF	
pathway	 (see	 section1.1.2).	 RCC	 and	 its	 metastasis	 enhance	 effectively	 with	
intravenous	 contrast.	With	 the	 increased	 vascularity	 it	 has	 been	 noted	 that	 these	
tumours	enhance	well	in	the	arterial	phase	of	the	CT	image	acquisition	(Raptopoulos,	
Blake	et	al.	2001,	Lee,	Heiken	et	al.	2005).	In	this	study,	Raptopoulos	and	colleagues	
suggested	that	up	to	10%	of	RCC	metastases	could	be	even	missed	by	not	acquiring	
arterial	phase	images.	
	
With	 “modified”	 Choi	 criteria,	we	 chose	 to	 use	 a	 CT	 defined	 criteria	 including	 the	
change	 in	 size	 and	 enhancement	 in	 arterial	 phase.	 Response	 according	 to	
“modified”Choi	criteria	were	defined	as	below.	
 	
Chapter	5.0	-	CT	response	assessment	criteria	–	“modified	Choi”	
 184	
5.1.3.1. Response	 categorIsation	 according	 to	 “modified”	 Choi	
Criteria	
	
g) Complete	response	
(CR):	
Disappearance	of	all	target	lesions	
h) Partial	response	(PR):	 i) ≥10%	decrease	in	sum	of	longest	
diameter	of	target	lesions	AND	
j) ≥15%	decrease	of	mean	contrast	
enhancement	of	target	lesions	
k) Progressive	disease	
(PD):	
a) Increase	in	tumour	size	>10%		
b) New	lesion	or	intra-tumoral	nodule	
l) Stable	disease	(SD):	 Response	not	fitting	with	any	of	the	above	
	
	
	
5.2. Materials	and	Methods	
This	was	 a	 retrospective	 analysis	 on	metastatic	RCC	patients	 treated	with	 tyrosine	
kinase	inhibitors.	Patient	selection	and	exclusion,	methods	of	clinical	and	radiological	
assessment,	 response	 evaluation	 and	 statistical	methods	 used	 for	 this	 study	 have	
been	previously	detailed	in	chapter	3.0	(section	3.3)	
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5.3. Results	
5.3.1. Patient	recruitment	
Data	from	a	total	of	32	patients	with	mRCC	who	had	treatment	with	tyrosine	kinase	
inhibitors	(cediranib/sunitinib)	were	analysed.	These	patients	received	treatment	on	
2	 studies	 as	 detailed	 in	 section	 3.3.1	 (Eudract	 2006-002455-33	 or	 Eudract	 2005-
002097-30).		
Patients	received	treatment	with	sunitinib	(n	=	18)	or	cediranib	(n	=	14).	10	patients	
were	 noted	 to	 have	 renal	 impairment	 and	 hence	 were	 unable	 to	 have	 contrast	
enhanced	 CT	 scans.	 These	 patients	 were	 excluded	 from	 the	 study.	 A	 further	 two	
patients	were	excluded	as	these	patients	discontinued	the	treatment	due	to	toxicity	
rather	than	disease	progression.	The	remaining	20	patients	were	evaluated	for	 the	
study.	Among	the	20	evaluable	patients,	11	had	treatment	with	sunitinib	and	9	had	
treatment	 with	 cediranib.	 Of	 the	 evaluated	 patients,	 14	 patients	 had	 disease	
progression	on	treatment	at	the	time	of	analysis.	Time	to	progression	in	these	patients	
was	260	days	(median).	Of	all	the	remaining	6	evaluable	patients	all	had	more	than	1	
year	follow	up	with	a	median	of	483	days.	
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5.3.2. Response	assessment	analysis	
Separate	 analyses	 with	 each	 of	 the	 three	 response	 criteria	 were	 performed	 to	
categorise	the	partial	response	(PR)	or	stable	disease	(SD)	as	defined	by	each	of	the	
criteria.		
	
	
Table	5.1	 Response	assessment	and	categorisation	using	three	different	criteria	
Criteria	 Partial	response	 Stable	disease	 Progressive	
disease	
RECIST	 5	 15	 0	
Choi	 19	 1	 0	
“Modified”	Choi	 13	 7	 0	
	
	
	
5.3.3. Clinical	benefit	analysis	
Clinical	benefit	analysis	was	performed	by	initially	assessing	the	time	to	progression	
(TTP)	of	the	disease.	TTP	was	defined	as	the	time	in	days	from	the	start	of	systemic	
therapy	with	the	planned	tyrosine	kinase	agent	to	the	date	where	disease	progression	
was	documented	radiologically.	Please	refer	to	chapter	3.0	(section	3.3.1.7).		
The	 time	 to	 progression	 of	 the	 disease	 was	 then	 correlated	 with	 the	 response	
assessment	categories	as	defined	by	 the	 three	different	criteria	separately.	 	This	 is	
detailed	in	table	5.2	and	represented	in	figure	5.1	
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Table	5.2	 Response	classification	and	association	with	TTP	
Classification Partial response (PR) Stable disease (SD) Log rank 
 No. of patients 
TTP days 
median   
(95% CI) 
No. of 
patients 
TTP days 
median        
(95% CI) 
Test 
sign. 
RECIST	 5	 168	(50–286)	 15	 428	(129–726)	 0.643	
Choi	 19	 399	(85–713)	 1	 *	 *	
Modified	
Choi	
13	 448	(99–797)	 7	 89	(79–99)	 0.002	
Table	adapted	from	(Nathan,	Vinayan	et	al.	2010)	*	single	patient	in	a	group	hence	no	
statistical	comparison	
	
Figure	5.1	 Median	TTP	(days)	for	PR	and	SD	groups	as	defined	by	three	criteria	
SD	-	stable	disease,	PR	-	partial	response	
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With	 the	 response	 assessment	 after	 2	 cycles,	 none	 of	 the	 patients	 progressed	 on	
treatment	 with	 any	 of	 the	 response	 criteria.	When	 association	 between	 response	
criteria	and	TTP	were	analysed,	modified	Choi	criteria	showed	the	greatest	association	
with	TTP.	According	to	modified	Choi,	median	TTP	for	patients	who	attained	partial	
response	(PR)	was	448	days	(95%	CI	99–797)	while	patients	with	stable	disease	(SD)	
had	a	median	TTP	of	89	days	(95%	CI	79–99).	With	RECIST	criteria,	patients	who	had	
PR	had	a	median	TTP	of	168	(95%	CI	50–286)	days	and	428	(95%	CI	129–726)	days	for	
patients	 categorised	 as	 SD.	With	 the	 standard	Choi	 criteria,	median	 TTP	of	 the	 PR	
group	was	399	(95%	CI	85–713)	days.	Only	one	patient	had	Choi	criteria-defined	stable	
disease.	Kaplan-Meier	analyses	were	performed	for	the	groups	as	shown	in	Figures	
5.2a,	5.2b	&	5.2c.		
	
Statistically	significant	difference	was	noted	in	median	time	to	progression	between	
PR	and	SD	groups	when	defined	according	to	modified	Choi	criteria	(Log	Rank	test	p	=	
0.002).	No	significant	difference	in	median	TTP	was	noted	with	Kaplan-Meier	curves	
for	 SD	&	 PR	 groups	 defined	 by	 RECIST	 criteria	 (Log	 Rank	 test:	 p	 values	 of	 0.643).	
Statistical	significance	with	log	rank	test	was	not	performed	between	the	two	groups	
with	Choi	criteria	as	there	was	only	a	single	patient	defined	as	having	SD	according	to	
Choi.		
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Figure	5.2	 Kaplan-	Meier	survival	curve	assessment	for	RECIST	5.2a,	Choi	5.2b	
and	modified	Choi	(5.2c)	
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Figures	adapted	from	(Nathan,	Vinayan	et	al.	2010)	
	
a) RECIST	estimated	median	TTP	168	and	428	days	for	PR	and	SD	group	with	log	
rank	P	value	0.643.		
b) Choi	criteria	estimated	median	TTP	was	399	for	the	PR	group.	As	only	1	patient	
had	Choi	defined	SD,	no	statistical	analysis	was	performed.		
c) Modified	choi	criteria	showing	a	TTP	448	and	95	days	for	PR	and	SD	groups	
with	a	significance	of	p=0.002	with	log	rank	p	test.	
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5.3.4. Exploratory	analysis.	
To	identify	other	potential	thresholds	besides	the	15%	change	in	enhancement	and	
10%	change	in	size,	patients	were	sub-grouped	into	TTP	a	<100days,	100-299	days,	
200-300	days.	A	scatter	plot	was	corrected	according	to	these	groups	against	change	
in	size	and	contrast	enhancement.	
	
	
Figure	5.3.	Scatter	plot	of	change	in	density	and	change	in	size	for	all	patients.		
TTP	groups	as	indicated	figure	from		(Nathan,	Vinayan	et	al.	2010).	
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5.4. Discussion	
Response	 assessment	 based	 on	 imaging	 modalities	 have	 been	 an	 important	 and	
unavoidable	 part	 of	 oncological	 management.	 With	 cytocidal	 chemotherapies,	
response	 assessment	 using	 criteria	 based	 solely	 on	 tumour	 size	 change	 may	 be	
entirely	appropriate.		With	use	of	targeted	treatments,	it	was	noted	that	the	RECIST	
defined	respond	rate	did	not	correspond	to	the	extent	of	clinical	benefit.	Response	
rate	as	per	RECIST	were	only	in	the	range	of	10-30	%	(Escudier,	Pluzanska	et	al.	2007,	
Motzer,	Hutson	et	al.	2007).		Even	patients	who	did	not	achieve	the	partial	response	
status	 experienced	 significant	prolongation	of	 progression	 free	 survival.	Hence	 the	
role	of	RECIST	based	response	assessment	is	questionable	in	the	setting	of	cytostatic	
targeted	treatments.		
	
Arterial	 based	 imaging	 is	 highly	 suitable	 in	 RCC	 due	 to	 its	 increased	
vascularity(Raptopoulos,	 Blake	 et	 al.	 2001).	 This	 is	 particularly	 so,	 given	 that	 anti-
angiogenic	 targeted	therapies	are	significantly	active	 in	 the	 treatment	of	advanced	
RCC.	Arterial	 based	 imaging	 is	 thought	 to	be	a	 suitable	method	 to	 assess	 clinically	
relevant	anti-angiogenic	drug	induced	changes	in	this	disease.	Arterial-phase	contrast	
enhanced	 CT	 scans	 has	 been	 used	 here	 to	 evaluate	 standard	 RECIST,	 Choi,	 and	
modified	criteria.		
	
In	this	retrospective	analysis	we	compared	RECIST,	Choi	and	the	proposed	“modified”	
Choi	criteria	in	which	both	a	minimum	of	a	10%	reduction	in	size	and	a	15%	reduction	
in	density	were	 required	 to	define	a	 response	 in	metastatic	RCC	patients	 receiving	
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either	sunitinib	or	cediranib.	Response	categorisation	as	defined	by	each	criterion	was	
correlated	with	RECIST	defined	time	to	progression.	
	
With	our	analysis,	“modified”	Choi	criteria	was	noted	to	be	superior	to	RECIST	and	
conventional	Choi	criteria	to	successfully	identify	a	group	of	patients	with	extended	
TTP	(median	448	days)	with	non-responders	having	a	significantly	shorter	TTP	(median	
89	days).		
	
CT	based	imaging	has	a	number	of	advantages	over	other	methods	evaluating	vascular	
changes	in	response	to	drug	therapy	such	as	DCE-MRI	and	DCE-US.	Firstly,	CT	scanning	
is	widely	 available.	With	 the	 advent	 of	 CT	 scanners	which	 acquire	 images	 quicker,	
obtaining	arterial	phase	images	will	be	easily	achievable.	DCE-MRI	is	not	available	at	
most	 centres.	USS	 based	 imaging	 has	 the	 disadvantage	 that	 it	 is	 not	 suited	 for	 all	
anatomical	sites.	also	has	significant	 inter	observer	variation.	All	target	 lesions	that	
are	currently	assessed	by	RECIST	criteria	should	be	amenable	to	assessment	by	our	
modified	criteria.		
	
Evaluation	 of	 region	 of	 interest	 (ROI)	 is	 one	 area	 where	 inter-observer	 and	 intra-
observer	variability	could	creep	through.	This	applies	to	all	 imaging	modalities.	The	
best	method	to	perform	ROI	delineation	remains	a	topic	of	dispute,	whole	tumour	ROI	
may	be	the	most	reproducible	method	rather	than	arbitrary	smaller	ROI	(Goh,	Halligan	
et	al.	2008).	We	used	the	whole	tumour	ROI	delineation	for	this	study.		
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This	small	study	requires	validation	on	a	larger	dataset,	ideally	with	images	taken	from	
a	 variety	 of	 scanning	 centres	 to	 demonstrate	 the	 broader	 applicability	 of	 this	
technique.	With	 some	of	 the	other	 centres	 assessing	CT	 in	 single	portal-venous	as	
standard,	it	remains	to	be	seen	if	the	modified	response	criteria	could	still	be	used.	
This	is	more	so	as	in	the	portal	venous	phase,	change	or	reduction	in	enhancement	is	
less	likely	to	be	as	distinct	as	in	the	arterial	phase.		
	
With	this	study,	we	have	observed	that	response	criteria	combining	changes	in	both	
size	 and	 enhancement	 of	 arterial	 perfusion	 in	 advanced	 RCC	 categorises	 the	
responders	better.	This	in	turn	leads	to	a	better	prediction	for	outcome	with	TKI	based	
treatment	compared	to	standard	RECIST	or	Choi	criteria.		
	
A	cross	validation	of	the	modified	Choi	criteria	was	performed	with	the	dataset	used	
for	 the	 textural	 analysis	 project	 where	 modified	 choi	 criteria	 was	 tested	 against	
RECIST,	Choi	and	textural	analysis.	This	project	is	explained	in	chapter	6.0	of	this	thesis.	
Even	though	some	of	the	patients	used	for	the	current	analysis	were	included	in	the	
textural	analysis,	this	constituted	less	than	50%	of	the	cohort.	The	results	the	textural	
analysis	cohort	also	showed	an	advantage	for	modified	choi	criteria	over	RECIST	 in	
differentiating	responders	vs	non-responders	with	a	statistical	significance	p=0.042.		
If	further	validation	with	a	larger	dataset	confirms	superiority	of	modified	Choi	criteria	
over	 RECIST,	 it	 may	 essentially	 become	 a	more	 appropriate	method	 for	 response	
assessment	in	therapeutic	response	assessment	in	these	group	of	patients.			
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Chapter	6. 	
	
CT	texture	as	a	potential	
biomarker	of	treatment	
response	to	TKI	in	metastatic	
renal	cell	carcinoma	
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6.1. Introduction	
 
Post	demonstration	of	the	use	of	CHOI	criteria,	changes	in	measurement	of	CT	scan	
based	mean	contrast	enhancement	with	treatment	have	been	of	significant	interest	
for	researchers.	Different	criteria	have	been	proposed	incorporating	changes	in	size	
and	density	to	measure	treatment	response	and	to	act	as	predictive	biomarkers	for	
the	response.	These	includes	the	“modified”	Choi	criteria	proposed	by	us,	explained	
in	the	previous	chapter	5.0.	Other	criteria	which	tried	to	utilize	the	difference	in	CT	
enhancement	includes	SACT	criteria:	favourable	response	defined	by	>20%	reduction	
in	size,	or	>10%	reduction	in	size	and	>	50%	of	non-lung	target	 lesions	with	>20HU	
(House	field	Unit)	reduction	in	mean	attenuation,	or	one	or	more	target	lesions	>40HU	
reduction	 in	 mean	 attenuation	 (Smith,	 Lieber	 et	 al.	 2010)	 and	 MASS	 criteria:	
favourable	response	defined	by	a	decrease	in	tumour	size	of	 20%	or	one	or	more	
predominantly	 solid	 enhancing	 lesions	 with	 marked	 central	 necrosis	 or	 marked	
decreased	attenuation	( 	40	HU)	(Smith,	Shah	et	al.	2010).			
	
Heterogeneity	in	malignant	tumours	is	well	recognized	with	variability	between	the	
cancer	 cells	 in	 a	 single	macroscopic	 tumour.	Differences	 in	 genetic	 and	 epigenetic	
make	up	would	contribute	to	this	heterogeneity	(Beca	and	Polyak	2016,	Gay,	Baker	et	
al.	 2016).	 Along	 with	 variation	 in	 the	 cancer	 cells,	 heterogeneity	 is	 seen	 in	 the	
surrounding	matrix	and	tumour	blood	supply.	Variability	seen	in	treatment	response	
could	possibly	be	attributed	to	these	genetic	and	epigenetic	changes.	
	Primary	renal	cell	carcinoma	tumours	are	very	heterogeneous.	The	heterogeneity	has	
been	assessed	by	deep	sequencing	and	chromosome	aberration	analysis	(Gerlinger	,	
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Rowan		et	al.	2012).	In	this	study	showing	branched	evolutionary	growth,	up	to	69%	
of	somatic	mutations	were	not	detectable	across	every	tumour	region.	These	 intra	
tumour	heterogeneity	represents	variation	in	protein	function	and	result	in	tumour	
adaptation	to	its	surroundings	with	resultant	significant	challenges	to	the	therapeutic	
effectiveness.	Identification	and	assessment	of	intra-humoral	heterogeneity	would	be	
a	promising	way	to	optimize	biomarkers	which	is	predictive	and	prognostic.		
	
All	 the	 current	 proposed	 CT	 based	 criteria,	 including	 the	 modified	 Choi	 that	 we	
discussed	in	chapter	5.0	does	not	take	into	account	this	heterogeneity.	A	mean	value	
of	density	is	used	in	these	studies	to	account	for	this	heterogeneity.	It	is	also	uncertain	
the	 extent	 to	 which	 this	 heterogeneity	 is	 of	 clinical	 importance.	 The	 pathological	
grading	of	the	RCC	tumours,	using	Fuhrman’s	grading	uses	the	highest	grade	noted	in	
the	tumour	sample	to	grade	the	tumour	(Motzer,	Bacik	et	al.	2002,	Beck,	Patel	et	al.	
2004,	 Lebret,	 Poulain	 et	 al.	 2007).	 There	 is	 emerging	 evidence	demonstrating	 that	
proportion	 of	 high-grade	 tumours	 and	 sarcomatoid	 changes	 seen	 in	 the	 tumour	
specimen	is	associated	with	poorer	prognosis	(Delahunt,	Bethwaite	et	al.	2007).			
	
Analysis	of	CT	texture	has	been	of	use	in	differentiating	malignant	and	benign	lesions	
of	the	lung	(Ganeshan,	Abaleke	et	al.	2010).	Analysis	of	CT	texture,	may	describe	the	
heterogeneity	in	tumour	morphology	that	is	not	reflected	by	CT	density	or	size.	
A	suggestion	from	computer	simulation	analysis	studies	on	textural	analysis	suggested	
that	 that	 the	 texural	 analysis	may	 in	 fact	 reflect	 changes	 in	underlying	vasculature	
(Bezy-Wendling,	Kretowski	et	al.	2001).	Exploratory	studies	provided	predictive	and	
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prognostic	information	assesed	by	the	image	brightness	and	coarseness	in	non-small	
cell	lung	cancer	and	colorectal	cancer	(Miles,	Ganeshan	et	al.	2009,	Ganeshan,	Abaleke	
et	al.	2010).	In	this	chapter	I	explain	a	pilot	study	that	was	performed	to	assess	the	
use	of	CT	textural	analysis	as	a	predictive	biomarker	in	metastatic	renal	cell	carcinoma	
patients	treated	with	Tyrosine	kinase	inhibitors	(TKI).	
	
The	aim	of	this	pilot	study	was	
1)	To	assess	the	changes	in	tumour	CT	texture	following	2	cycles	of	TKIs;	and		
2)	To	determine	if	tumour	texture	predicts	time	to	progression	in	metastatic	renal	cell	
cancer	treated	with	TKIs.		
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This	project	was	performed	in	collaboration	with	a	research	team	at	the	University	of	
Sussex	(Brighton)	who	developed	the	software	for	textural	analysis	TexRAD®.	 I	was	
involved	in	the	clinical	part	of	the	project	including	planning	of	the	study,	identification	
of	the	patients	according	to	pre-planned	inclusion	and	exclusion	criteria,	collecting	all	
necessary	clinical	data	of	patients	analysed,	selection	and	delineation	of	 the	target	
lesions,	assessment	of	response	for	each	patient	and	calculation	of	the	time	to	disease	
progression.	Textural	analysis	was	performed	Dr.	Balaji	Ganeshan	and	reviewed	by	
Prof	Ken	Miles	who	were	the	scientific	and	clinical	director	of	the	TexRAD®.		TexRAD®	
team	were	unaware	of	the	clinical	data	and	treatment	outcome.	Once	the	radiological	
analyses	 were	 complete,	 statistical	 analysis	 comparing	 the	 textural	 analysis	 and	
clinical	outcome	were	performed	by	both	team.	Results	have	been	published	in	a	peer	
reviewed	 journal	 with	 all	 authors	 having	 control	 of	 the	 data	 and	 information	
submitted	for	publication.	
	
V.Goh,	 B.Ganeshan,	 P.Nathan,	 A.Vinayan,	 K.Miles	 “Assessment	 of	 response	 to	
tyrosine	kinase	 inhibitors	 in	metastatic	 renal	cell	cancer:	CT	 texture	as	a	predictive	
biomarker”	Radiology:	2011	Oct;26(1):	165-71	(Goh,	Ganeshan	et	al.	2011)		
	
In	this	Chapter	I	explain	the	above	mentioned	study	with	due	reference	to	the	role	of	
other	authors.		
 	
Chapter	6.0	-	CT	texture	as	potential	biomarker	of	treatment	response	to	TKI	in	mRCC	
 200	
6.2. Materials	and	methods	
Methods	employed	in	this	retrospective	analysis	has	been	detailed	earlier	in	chapter	
3.0.	This	 involves	methods	used	 for	patient	selection,	predetermined	 inclusion	and	
exclusion	 criteria,	 Theory	behind	 textural	 analysis	 and	 radiological	 assessment	 and	
statistical	analysis.	Please	refer	to	section	3.4	for	details.	
	
6.3. Results	
6.3.1. Patient	selection	
	
After	 assessing	 our	 institutional	 database,	 68	 patients	 with	 metastatic	 renal	 cell	
carcinoma	 treated	 with	 tyrosine	 kinase	 inhibitors	 were	 identified.	 This	 cohort	 of	
patients	was	 considered	 as	 the	 potential	 subjects	who	 could	 be	 enrolled	 into	 the	
textural	 analysis	 study.	 Inclusion	and	exclusion	criteria	have	been	assessed	against	
these	individual	patients	to	assess	their	eligibility	for	analysis.	Inclusion	and	exclusion	
criteria	 are	 explained	 in	 section	 3.4.1.	 Of	 the	 68	 patients	 identified,	 20	 had	 to	 be	
excluded	 as	 they	 had	 non-contrast	 enhanced	 CT	 scans.	 Main	 reasons	 for	 not	
proceeding	with	contrast	enhanced	CT	was	low	renal	function	defined	as	increased	
creatinine	 >150µmol/L	 or	 low	 glomerular	 filtration	 rate	 (GFR).	 No	 patients	 in	 this	
cohort	 had	 previous	 allergic	 reactions	 to	 iodinated	 contrast	 or	 failure	 to	 access	
intravenous	cannula	documented	as	a	reason	for	not	having	contrast	enhanced	CT.	
Another	18	patients	had	to	be	excluded	as	the	contrast	enhancement	in	their	scans	
were	noted	to	be	suboptimal.	A	total	of	40	patients	were	selected	who	had	baseline	
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contrast	 enhanced	 CT.	 1	more	 patient	 had	 to	 be	 excluded	 as	 the	 patient	 did	 not	
complete	2	cycles	of	treatment	due	to	toxicities.	Remaining	39	patients	were	selected	
for	analysis.	Flow	chart	of	the	study	population	and	selection	has	been	demonstrated	
in	figure	6.1.	
Figure	6.1	 CT	Texture	assessment	-	Trial	flow	chart		
 
	
	
mRCC	 =	 metastatic	 renal	 cell	 carcinoma,	 TKI	 =	 Tyrosine	 Kinase	 Inhibitors,	 IV	 =	
intravenous,	ceCT	=	contrast	enhanced	CT.		
 	
mRCC	patients	treated	with	TKI		
(1
st	
or	2
nd	
Line)	
N=	68	
Patients	with	CeCT	at	baseline	
N=	40	
Eligible	patients	for	Textural	
analysis	
N=	39	
Renal	Impairment	(n	=	20)	
Suboptimal	enhancement	(n	=	8)	
Allergy	(n	=	0)	
Failure	to	cannulate	(n	=	0)	
Failed	to	complete	2	cycles	of	
treatment	(n	=	1)	
Exclusions	
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Patients	selected	for	textural	analysis	included	23	males	and	16	female	patients	with	
a	mean	age	of	61.43	years.	Age	range	was	between	38.6	to	75.8	years.	Tumours	in	37	
patients	were	 categorized	 as	 clear	 cell	 RCC	whilst	 1	 patient	 had	papillary	RCC	 and	
another	 had	 higher	 percentage	 of	 sarcomatoid	 elements	 in	 the	 RCC	 histology.	 A	
variety	of	Tyrosine	kinase	inhibitors	(TKI’s)	were	used	in	treatment	of	these	patients.	
Patients	 were	 treated	 with	 sunitinib	 (n=26),	 cedirinib	 (n=6),	 pazopanib	 (n=4)	 and	
regorafenib	(n=3).	With	the	39	patients,	a	total	of	87	target	lesions	were	analysed	with	
a	mean	of	2	and	a	median	of	3	lesions	per	patients.		
	
All	patients	had	CT	scans	prior	to	initiation	of	treatment.	All	had	CT	scans	done	within	
4	weeks	of	treatment	and	average	days	of	difference	between	baseline	CT	scan	and	
treatment	initiation	was	14.2	days.	Follow	up	CT	scans	were	performed	after	2	cycles	
of	treatment,	which	was	done	between	week	10	and	12	of	initiation	of	treatment.	On	
region	of	 interest	 selection	 (ROI),	Mean	ROI	 size	was	2791	pixels	 (range,	72-17442	
pixels).	
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6.3.2. Treatment	response	assessment	
Treatment	response	categorization	was	performed	by	RECIST,	Choi	and	modified	Choi	
criteria	following	two	cycles	of	treatment.	
Of	 the	39	patients,	according	 to	RECIST	criteria,	6	patients	had	partial	 response	 to	
treatment	(PR)	and	32	patients	had	Stable	disease	(SD).	One	patient	was	noted	to	have	
progressed	with	in	the	time.	Categorization	with	Choi	criteria	showed	33	responders	
with	3	patients	each	had	stable	disease	and	progressive	disease.	With	the	modified	
Choi	criteria,	the	numbers	were	22,	14	and	3	for	PR,	SD	and	PD	respectively	(Table	
6.1).	
  
Table	6.1	 Response	Categorization	after	2	cycles	of	treatment	with	TKI’s	
	
Response	Criteria	 Partial	Response	 Stable	Disease	 Progressive	Disease	
RECIST	 6	(15)	 32	(82)	 1	(3)	
Choi	 33	(84)	 3	(8)	 3	(8)	
Modified	Choi	 22	(56)	 14	(36)	 3	(8)	
 
Data	given	are	in	absolute	numbers	with	percentages	in	parentheses.	Table	adapted	
from	our	publication	(Goh,	Ganeshan	et	al.	2011)	
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6.3.3. Textural	analysis	
	
Textural	analysis	was	performed	as	explained	in	the	materials	and	methods	section	
3.4.2.	Images	underwent	a	second	degree	Gaussian	filtration	followed	by	application	
of	Laplacian	filter	as	per	the	equations	
 
Equation	3.5:	
!(#, %) = ()#*+,**-*  
 
Equation-3.6:	
.*! #, % = 	 −12-3 1 − #* + %**-* 5 #*+%**-*  
 “∇2”	-	Laplacian	of	Gaussian	distribution.	“G”	–	Gaussian	distribution		“x”	and	“y”	are	co-ordinates	of	the	image	matrix.	 “σ”	-	Standard	deviation	of	the	Gaussian	distribution.	
	
After	filtration,	S	values	of	1.0,	1.5,	1.8,	2.0	and	2.5	were	used	in	images	quantification	
of	texture	(described	in	section	3.4.2.2).	This	was	followed	by	calculation	of	entropy	
“e”	and	uniformity	“u”.		
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Equation	3.7:		
5 = 	− [U(V)WXY1 VZ[* U V  
Equation	3.8:		
\ = 	 U V *WVY1  
I	is	the	pixel	value	(between	I	=1	to	k)	in	the	the	ROI	and		
p(I)	the	probability	of	the	occurrence	of	that	pixel	value.		
	
Table	6.2a	and	6.2b	summarizes	the	mean	absolute	scale	values	of	entropy	(e)	and	
uniformity	(u)	with	and	without	filtration.	For	filtration,	S	values:	1,	1.5,	1.8,	2	and	2.5	
were	used	at	baseline	and	following	2	cycles.	
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Table	6.2a	 Entropy	at	baseline	and	after	2cycles	with	different	filter	scales	
Filter	scale	value	 Baseline	 After	2	treatment	 Change	(%)	
No	filtration	 6.95	(±	0.37)	 6.7	(±	0.43)	 -3.08	(±4.34)	
1.0	 3.06	(±	0.55	)	 2.6	(±	0.84)	 -15.20	(±	23.35	)	
1.5	 2.31	(±	0.72)	 1.81	(±	0.92)	 -21.73	(±39.66	)	
1.8	 1.89	(±	0.81)	 1.53	(±	0.92)	 -16.96	(±	50.40)	
2.0	 1.62	(±	0.85)	 1.35	(±	0.88)	 -9.51	(±	133.76)	
2.5	 1.23	(±	0.81)	 1.08	(±	0.77)	 -45.77	(±	139.91)	
 
Table	6.2b	 Uniformity	at	baseline	and	after	2cycles	with	different	filter	scales	
Filter	scale	value	 Baseline	 After	2	treatment	 Change	(%)	
No	filtration	 0.012	(±	0.002)	 0.012	(±	0.004)	 +21.0	(±	28.36)	
1.0	 0.47	(±	0.07)	 0.53	(±	0.13)	 +14.72	(±	20.80)	
1.5	 0.59	(±	0.11)	 0.67	(±	0.16)	 +14.91	(±	20.21)	
1.8	 0.66	(±	0.13)	 0.72	(±	0.16)	 +10.61	(±	19.48)	
2.0	 0.71	(±	0.15)	 0.76	(±	0.15)	 +8.15	(±	17.99)	
2.5	 0.78	(±	0.14)	 0.80	(±	0.13)	 +	4.96	(±	17.26)	
	
Table	6.2a	and	6.2b	showing	mean	value	of	entropy	and	uniformity	for	
baseline	and	after	two	cycles	of	treatment.	Change	between	mean	and	
after	 two	 cycles	 recorded	 in	 column	 4	 as	 percentage.	 Values	 in	
parentheses	 are	 standard	 deviation.	 Tables	 are	 adapted	 from	 our	
publication	(Goh,	Ganeshan	et	al.	2011)	
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Of	the	39	patients	included	and	analysed	in	the	study,	26	patients	have	had	disease	
progression	within	 the	 time	of	data	 collection.	On	analysis	 of	 time	 to	progression,	
median	time	to	progression	in	days	was	336	in	this	cohort	with	a	range	57	to	1364	
days.		
	
Ability	of	textural	parameters	to	identify	responders	and	non-responders	to	treatment	
was	 assessed.	 Imaging	 textural	 characteristics	 including	 entropy	 and	 uniformity	 at	
baseline,	post	completion	of	two	cycles	of	treatment	and	percentage	change	in	the	
textural	 characters	 after	 two	 cycles	 of	 treatment	were	 analysed	 to	 assess	 if	 these	
could	correlate	with	time	to	progression.		
	
ROC	curve	and	Kaplan-Meier	analyses	were	performed	for	entropy	and	uniformity	at	
different	scale	values.	With	statistical	significance	(p)	calculated	from	Kaplan-Meier	
analyses.	This	is	summarized	in	Table	6.3	
	
At	baseline,	significant	p	values	defined	as	<0.05	were	noted	for	entropy	at	2.5	filter	
scale	 (p=0.02).	 	With	uniformity	assessment	significant	p	value	were	noted	at	 filter	
scales	 1.8	 and	 above	 (p=0.02).	 With	 analysis	 of	 change	 in	 these	 parameters	 (as	
percentages)	from	baseline	to	cycle	2,	entropy	and	uniformity	showed	significance	at	
different	 filter	values.	For	percentage	entropy	change,	 significance	was	noted	with	
filter	1.8	(p=0.05)	and	2.0	(p=0.03)	whilst	filters	1.0	(p	=	0.02),	2.0	(p=0.02)	and	2.5	
(p=0.0008)	showed	significance	with	percentage	change	in	uniformity.		
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With	a	filter	scale	value	of	2.5,	both	baseline	entropy	and	uniformity	and	percentage	
change	of	uniformity	were	significant	thus	predictors	of	time	to	progression.		
 
With	the	ROC	curve	analysis,	using	a	threshold	change	of	≤-2%	in	uniformity	at	a	scale	
value	of	2.5,	the	area	under	the	ROC	curve	was	statistically	significant	(p=0016)	and	
AUC=0.71	(95%	CI	0.53,	0.85).	This	is	shown	in	Figure	6.2.		
	
	
	
Figure	6.2	 ROC	curve	showing	percentage	change	in	uniformity.		
Adapted	from	our	publication	(Goh,	Ganeshan	et	al.	2011)	
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Change	 in	 uniformity	was	 compared	 to	 RECIST,	 Choi	 and	modified	 Choi	 criteria	 in	
separating	 responders	 from	 non-responders	 to	 treatment.	 Kaplan-Meier	 curves	
analyses	was	performed	for	all	three	criteria	and	uniformity	and	difference	between	
these	techniques	were	assessed.		
	
At	a	threshold	change	of	-2%	with	uniformity,	textural	change	was	able	to	separate	
responders	 from	 non-responders.	 With	 Kaplan-Meier	 analysis	 comparing	 all	 four	
criteria,	percentage	change	 in	uniformity	was	 statistically	more	 significant	 than	 for	
RECIST,	Choi,	and	Modified	Choi	criteria	(p=0.008	versus	p=0.267,	p=0.053,	p=0.042	
respectively;	see	Figure	6.3.			
	
Cox	regression	analysis	indicated	that	the	percentage	change	in	coarse	uniformity	was	
an	independent	predictor	(odds	ratio,	OR	=4.02	(95%	CI	1.52,10.65);	p=0.0053),	while	
Modified	Choi	criteria	were	not	significant	(OR=1.07	(95%	CI	0.38,3),	p=0.8911).	This	
indicated	 that	 there	 was	 no	 interaction	 between	 texture	 uniformity	 and	 the	
enhancement	and	size	change	(assessed	by	the	modified	Choi	criteria).			
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Figure	6.3	 Kaplan	Meier	curve	according	to	different	criteria	
	
Fig	6.3	Kaplan	Meier	curve	for	responder’s	vs	non-responder’s	with	different	criteria	
RECIST,	Choi,	modified	Choi	and	percentage	change	in	uniformity.		
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Table	6.3	 Summary	of	ROC	curve	and	Kaplan-Meier	analysis		
	
Filter	 scale	
value	
Entropy	 Uniformity	
ROC	
threshold	%	
P	value	
ROC	
threshold	%	
P	value	
Baseline	
Unfiltered	 >6.33	 0.28	 <0.01	 0.54	
1.0	 >2.48	 0.10	 <0.52	 0.21	
1.5	 >1.46	 0.09	 >0.4	 0.17	
1.8	 >1.07	 0.09	 >0.48	 0.02	
2.0	 ≤2.65	 0.07	 >0.48	 0.02	
2.5	 ≤2.33	 0.02	 >0.55	 0.02	
Percentage	change	
Unfiltered	 <-5.26	 0.19	 >13.96	 0.13	
1.0	 >-6.66	 0.11	 ≤2.58	 0.02	
1.5	 >-7.80	 0.15	 <3.14	 0.07	
1.8	 >-13.11	 0.05	 ≤5.23	 0.07	
2.0	 >-5.35	 0.03	 ≤0.49	 0.02	
2.5	 >4.02	 0.11	 ≤2.00	 0.0008	
		
Summary	 of	 ROC	 curve	 and	 Kaplan-Meier	 analysis	 with	 different	 filter	 values	 at	
baseline	 and	 change	 of	 the	 parameters	 after	 treatment.	 P	 value	 is	 obtained	 from	
Kaplan-Meier	analysis.	Adapted	from	our	publication	(Goh,	Ganeshan	et	al.	2011)	 	
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6.4. Discussion	
Heterogeneity	is	a	well-recognized	feature	of	malignancy.	Heterogeneity	in	renal	cell	
carcinoma	 is	 well	 documented.	 Genetic	 and	 epigenetic	 changes	 contribute	 to	 the	
heterogeneity	 in	 cancer	 cells	 and	 in	 the	 surrounding	matrix.	 Heterogeneity	 of	 the	
tumour	 blood	 supply	 is	 suggested	 to	 be	 associated	with	multiple	 factors	 including	
oxidative	stress,	promotion	of	survival	factors,	and	genomic	instability	(Nelson,	Tan	et	
al.	2004).	With	change	in	vascularity,	cellular	fraction	of	the	tumour	may	be	altered	
and	changes	in	cell	behaviour	which	could	impact	on	the	response	of	these	cells	to	
treatment.	Poor	delivery	of	chemotherapeutic	agents	to	areas	of	low	vascularity	could	
be	a	significant	problem.	It	is	also	well	recorded	that	tumours	with	hypoxia	are	more	
radiation	resistant.		
	
Assessing	heterogeneity	with	standard	CT	scan	alone	is	difficult	as	much	of	the	visible	
heterogeneity	 in	CT	 is	due	 to	photon	noise.	This	has	no	biological	 significance	and	
could	in	fact	mask	any	underlying	heterogeneity.	
	
CT	 textural	 analysis	 with	 filters	 that	 select	 for	 image	 features	 can	 reduce	 the	
interference	 of	 photon	 noise	 and	 end	 up	 enhancing	 the	 heterogeneity	 that	 is	
biologically	relevant.	Quantification	of	the	parameters	with	entropy	and	uniformity	at	
relevant	scales	can	thus	be	of	clinical	relevance.		
	
In	the	study	described	here	we	found	that	tumour	heterogeneity	had	reduced	after	
two	cycles	of	treatment.	This	was	evident	from	the	change	in	entropy	(which	reflect	
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irregularity)	and	increase	in	uniformity.	These	changes	are	consistent	with	change	in	
vascularity	of	the	tumour	with	development	of	necrosis.		
	
Textural	 changes	 in	 uniformity	 after	 two	 cycles	 of	 treatment	 have	 been	 the	 best	
parameters	which	correlate	to	clinical	effectiveness	measured	as	time	to	progression.	
In	our	cohort	of	patients,	percentage	change	in	textural	uniformity	after	two	cycles	of	
treatment	(above	2.0)	was	superior	than	the	standard	RECIST	criteria	or	the	combined	
size	 and	 enhancement	 criteria	 (Choi	 and	modified	 Choi)	 in	 predicting	 the	 time	 to	
progression.	Percentage	change	 in	uniformity,	using	a	threshold	of	 -2%	or	 less	at	a	
coarse	scale	(filter	value	2.5)	selected	the	patients	who	responded	to	treatment	than	
partial	 response	 suggested	 by	 RECIST,	 Choi	 or	 modified	 Choi	 criteria.	 Hence	 the	
textural	analysis	provides	additional	 information	which	could	be	complementary	to	
assess	and	select	patients	who	are	unlikely	to	respond	to	a	treatment	thus	avoiding	
toxicities	in	those	individuals.		
Along	with	the	change	in	uniformity,	baseline	entropy	and	uniformity	at	a	coarse	scale	
also	correlated	with	time	to	progression,	thus	indicating	that	baseline	heterogeneity	
be	potentially	useful	as	a	predictive	biomarker	of	treatment	response	
	
An	advantage	of	texture	analysis	is	that	it	imposes	no	additional	burden	on	a	patient,	
as	it	is	an	additional	post	processing	step	of	standard	CT	images	that	were	obtained	
for	standard	response	assessment.		
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One	of	 the	 limitations	with	 this	 technique	 is	 that	 it	 requires	 contrast	enhanced	CT	
scanning.	Our	study	suggested	approximately	29%	of	patients	had	to	be	excluded	due	
to	 renal	 function	abnormality.	 Thus	 this	 test	may	not	be	of	use	 in	 around	1/3rd	of	
patients	in	this	disease	(Nathan,	Vinayan	et	al.	2010).	Textural	analysis	may	still	give	
some	valuable	information	on	underlying	heterogeneity	without	the	use	of	contrast.	
This	has	been	assessed	in	non-small	cell	lung	cancer	and	colorectal	cancer	but	never	
been	assessed	in	renal	cell	carcinoma	(Miles,	Ganeshan	et	al.	2009,	Ganeshan,	Abaleke	
et	al.	2010).			
	
Phase	 of	 contrast	 enhancement	 and	 acquisition	 parameters	 could	 also	 affect	 the	
textural	 parameters.	 However,	 to	 date	 there	 have	 been	 no	 studies	which	 explore	
these	issues	reliably.	
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In	summary,	this	thesis	incorporates	three	studies	assessing	metastatic	RCC	patients	
treated	with	anti-angiogenic	therapy.	All	studies	aimed	at	evaluating	imaging	based	
techniques	 to	 calculate	 changes	 related	 to	 antiangiogenic	 therapy	 and	 treatment	
response.	
	
Vascular	parameters	of	DCE-MRI	were	used	to	assess	whether	addition	of	interferon-]2a	improved	the	antiangiogenic	effect	of	bevacizumab.	Ability	of	DCE-MRI	vascular	
parameters	to	act	as	predictive	biomarker	of	treatment	response	was	also	evaluated	
in	this	study.	With	two	contrast	enhanced	CT	based	studies	were	aimed	at	evaluating	
a)	“modified”	Choi	criteria	and	b)	Textural	analysis	as	possible	predictive	biomarker	of	
treatment	response.		
	
The	 two	 major	 phase-3	 trials	 (AVOREN	 &	 CALBG	 90206),	 lacked	 a	 single	 agent	
bevacizumab	 arm	 and	 the	 additional	 benefit	 supplemented	 by	 interferon	 on	
bevacizumab	is	therefore	unknown.	With	a	phase-2	clinical	trial,	we	aimed	to	answer	
this	important	scientific	question	using	DCE-MRI	as	the	method	of	assessment.		
	
The	 trial	designed	as	a	prospective,	multi-centric,	 randomised	control	 trial	with	10	
patients	in	each	arm.	The	trial	was	powered	so	as	to	identify	the	true	differences	of	
DCE-MRI	parameters	with	 in	the	treatment	arm	before	and	after	treatment	and	to	
assess	the	between	arms	robustly.		
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Randomisation	was	performed	by	an	independent	person	with	no	clinical	input	with	
the	patients	to	avoid	any	treatment	bias.	The	three	arms	of	randomisation	gave	us	the	
opportunity	to	explore	the	dose	response	to	IFN	if	a	synergistic	effect	was	noted	on	
the	 anti-vascular	 effect	 of	 bevacizumab.	 Continued	 effect	 of	 lower	 dose	 IFN	 in	
response	and	a	better	toxicity	profile	was	seen	 in	a	previous	retrospective	analysis	
published	by	Melicher	et.al	 (Melichar,	Koralewski	et	al.	2008).	Our	 trial	hence	also	
aimed	to	reaffirm	these	findings	in	a	prospective	phase	2	trial.	Furthermore,	using	two	
DCE-MRI	at	the	baseline	gave	us	a	unique	opportunity	to	assess	and	account	for	the	
natural	variation	of	vascular	and	perfusion	changes	to	these	tumours.	These	perfusion	
changes	 could	 have	 otherwise	 confounded	 the	 results	 of	 the	 DCE-MRI	 vascular	
parameters	calculated	in	the	trial.	A	statistical	calculation	of	repeatability	co-efficient	
(r)	 and	 assessment	 of	 r-value	 individually	 in	 each	 group	 based	 on	 the	 number	 of	
patients	(n)	was	hence	used	to	analyse	the	results	so	as	to	reaffirm	that	the	results	
obtained	are	likely	to	be	statistically	robust.		
	
Introduction	of	dose	escalation	of	interferon	in	Arm-C	at	two	weeks	gave	us	enabled	
the	investigators	to	assess	the	toxicity	of	IFN	in	all	patients	at	the	lower	dose	prior	to	
escalation.	Having	a	DCE-MRI	scan	at	two	weeks	prior	to	dose	escalation	also	gave	us	
an	opportunity	 to	directly	compare	 the	bev	only	arm	(Arm-A)	with	bev	+	 IFN	arms	
(Arm	B+C)	with	a	larger	sample	number	in	order	to	validate	the	statistics.			
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The	 trial	 was	 technically	 challenging	 and	 was	 difficult	 to	 accrue.	 It	 portrays	 the	
difficulties	that	an	investigator	driven	phase	2	trial	in	NHS	could	face.	Competing	first	
line	trials	and	inability	to	access	sunitinib	in	NHS	at	some	centre’s	after	patient	had	
been	treated	on	bevacizumab	on	trial	resulted	in	very	slow	recruitment	and	one	of	
the	three	centre	being	unable	to	recruit	any	patients.	Many	patients	even	though	had	
metastatic	disease	did	not	have	 lesions	which	could	be	reliably	assessed	with	DCE-
MRI.	Even	among	patients	with	lesions	thought	to	be	suitable	for	analysis,	25%	were	
unable	to	be	analysed	due	to	technical	issues.	This	was	a	major	limitation	in	accrual	
and	hence	impacted	on	the	reliable	analysis	of	the	trial	outcome.		
	
Analysis	of	DCE-MRI	is	dependent	of	the	choice	of	ROI	assessment.	As	performed	in	
the	previous	studies	where	DCE-MRI	technique	have	been	used,	we	have	opted	to	use	
the	whole	tumour	volume	in	the	MRI	slice	as	the	region	of	interest.	A	possible	criticism	
of	this	approach	could	be	related	to	the	 impact	of	necrotic	tissue,	 if	present	 in	the	
tumour,	 to	the	DCE-MRI	derived	vascular	parameters.	One	approach	 in	this	setting	
would	be	to	restrict	the	ROI	to	the	periphery	of	the	tumour.	This	approach	need	to	be	
investigated	in	further	studies.	We	decided	against	this	as	it	was	felt	that	restricting	
the	 ROI	 to	 some	part	 of	 the	 tumour	 is	 likely	 to	 introduce	 sampling	 bias	 given	 the	
heterogenous	 nature	 of	 RCC	 tumours.	 Previous	 work	 from	 Goh	 et.al	 assessing	
different	methods	of	ROI	delineation	using	perfusion	CT	suggested	that	whole	tumour	
ROI	would	be	the	most	reproducible	method	of	assessment	(Goh,	Halligan	et	al.	2008).	
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One	 of	 the	 limitations	 that	 we	 had	 in	 this	 trial	 is	 that	 the	 ROI	 assessment	 was	
performed	 by	 a	 single	 investigator.	 Inter-investigator	 and	 even	 intra-investigator	
variability	have	been	documented	 in	 the	assessment	of	ROI	 in	different	 trials.	 It	 is	
important	 that	 the	 technique	 suggested	 is	 reproducible	 in	 other	 centres	 by	 other	
investigators	and	the	discordance	in	assessment	of	the	ROI	is	minimised.	In	order	to	
minimise	 the	 impact	 of	 a	 single	 investigator	 effect,	 the	 ROI	 volumes	 were	 cross	
assessed	 by	 a	 consultant	 radiologist	with	more	 than	 15years	 experience	 in	 cancer	
imaging.	ROI	discordance	were	discussed	and	modified	if	necessary.		
	
We	concentrated	on	the	changes	in	Ktrans	to	the	proposed	treatment	as	this	was	the	
most	 studied	 and	 associated	 DCE-MRI	 variable	with	 changes	 in	 vascularity.	 In	 our	
study,	 considering	 the	 limitations	 of	 the	 study,	 no	 definite	 correlation	 was	 found	
between	 change	 Ktrans	 and	 addition	 of	 interferon	 to	 bevacizumab	 which	 was	 the	
primary	endpoint	of	the	study.	This	was	despite	the	effect	size	analysis	calculation	to	
account	for	the	low	recruitment.	Exploratory	analysis	showed	that	the	changes	in	Ktrans	
and	Kep	with	treatment	could	be	potential	candidates	to	be	investigated	further	to	act	
as	predictive	biomarker	to	therapy.	Patients	with	a	clinical	benefit	measured	as	PFS	of	
>6months	were	noted	to	have	significant	reduction	in	Kep	as	early	as	week2	(p=0.03).	
With	the	small	sample	size	that	was	analysed,	we	were	unable	to	determine	whether	
this	represented	a	true	change	and	hence	would	warrant	assessment	in	a	large	cohort	
for	confirmation.		
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Combining	 change	 in	 size	 and	arterial	 enhancement,	 “modified”	Choi	 criterion	has	
been	 able	 to	 identify	 a	 group	 of	 patients	 who	 derived	 more	 clinical	 benefit	 with	
extended	 time	 to	 disease	progression.	 By	 combining	decrease	 in	 size	 by	 10%	with	
reduction	 of	 arterial	 enhancement	 by	 15%	 to	 define	 responders,	 “modified”	 Choi	
criteria	was	found	to	be	statistically	superior	than	standard	RECIST	and	Choi	criteria	in	
differentiating	responders	reliably	in	our	cohort	of	patients.	If	this	effect	is	to	hold	to	
true	 in	a	 larger	cohor,	modified	choi	criterion	may	become	an	appropriate	tool	 for	
assessing	these	cohort	of	patients.		
	
Contrast	 enhanced	 CT	 based	 textural	 analysis	 requires	 post	 processing	 with	 the	
support	of	a	computer	based	algorithm.	This	technique	has	the	advantage	that	it	has	
the	ability	to	evaluate	imaging	based	heterogeneity	in	mRCC	(calculated	by	entropy	
and	uniformity)	which	the	other	response	criteria	are	unable	to	account	for.	Tumour	
heterogeneity	 is	 a	 well-recognised	 feature	 of	 renal	 cell	 carcinoma.	 Complex	
heterogeneity	seen	in	the	cancer	cells,	surrounding	matrix	and	the	vasculature	could	
result	 in	 differential	 response	 to	 a	 therapy	 and	 is	 likely	 due	 to	 the	 genetic	 and	
epigenetic	changes	acquired	by	the	tumour	during	its	pathogenesis	or	as	response	to	
therapeutic	 intervention	 by	 natural	 selection.	 As	 discussed	 earlier	 in	 section	 6.4,	
heterogeneity	of	the	tumour	blood	supply	is	suggested	to	be	associated	with	multiple	
factors	 including	 oxidative	 stress,	 promotion	 of	 survival	 factors,	 and	 genomic	
instability	(Nelson,	Tan	et	al.	2004).	With	the	change	in	vascularity,	the	cellular	fraction	
of	the	tumour	and	its	behaviour	varies	and	this	can	also	impact	on	the	response	of		
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these	 cells	 to	 treatment.	 This	 could	 result	 in	 poor	 delivery	 of	 chemotherapeutic	
agents.	 Resistance	 to	 radiotherapy	 has	 also	 been	 well	 documented	 in	 areas	 with	
significant	 hypoxia.	 Previous	 studies	 with	 computer	 simulation	 and	 also	 human	
studies	 have	 suggested	 that	 the	 textural	 changes	 reflect	 change	 in	 vascularization	
(Bezy-Wendling,	Kretowski	et	al.	2001).	
	
Assessing	heterogeneity	with	standard	CT	scan	alone	is	difficult	as	much	of	the	visible	
heterogeneity	 in	CT	 is	due	 to	photon	noise.	This	has	no	biological	 significance	and	
could	in	fact	mask	any	underlying	heterogeneity.	CT	textural	analysis	with	filters	that	
select	 for	 image	 features	 can	 reduce	 the	 interference	of	photon	noise	and	end	up	
enhancing	 the	 heterogeneity	 that	 is	 biologically	 relevant.	 Quantification	 of	 the	
parameters	 with	 entropy	 and	 uniformity	 at	 relevant	 scales	 can	 thus	 be	 of	 clinical	
relevance	
	
In	our	cohort	of	patients,	ability	of	textural	analysis	to	act	as	a	predictive	biomarker	
was	 consistently	 demonstrated.	 Increase	 in	 textural	 uniformity	 after	 two	 cycles	 of	
treatment	 was	 recognized	 to	 be	 good	 surrogate,	 better	 than	 standard	 RECIST	 or	
combined	size	and	enhancement	criteria	in	identifying	patient	subgroup	who	is	likely	
to	benefit	from	treatment.	Baseline	entropy	and	uniformity	at	a	coarse	scale	was	also	
noted	to	have	some	correlation	in	predicting	the	response	to	therapy.	This	suggests	
the	possibility	of	predicting	whether	a	patient	is	likely	to	have	a	good	benefit	from	the	
proposed	therapy	even	before	initiating	it.	
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Advantage	of	both	modified	Choi	criteria	and	textural	assessment	are	that	they	do	not	
impose	any	additional	burden	on	a	patient	as	it	is	the	standard	contrast	enhanced	CT	
images	which	are	used	for	additional	processing	and	analysis.	CT	scans	are	currently	
available	in	majority	of	centres	in	the	western	world.	Clinical	expertise	to	analyse	the	
images	and	availability	of	this	technique	is	much	more	widespread	than	the	DCE-MRI	
technique.	CT	scans	also	have	the	advantage	that	this	is	less	operator	dependent	than	
techniques	as	USS.	
	
A	 significant	 limitation	 of	 both	 these	 studies	 is	 the	 small	 number	 of	 patients	who	
underwent	analysis.	A	cross	validation	was	attempted	for	the	modified	choi	criterion	
using	the	cohort	used	for	textural	analysis.	But	even	here	the	sample	numbers	remain	
low	and	 it	need	to	be	seen	 if	 the	benefits	seen	would	hold	true	 in	a	 larger	cohort.	
Validation	of	the	technique	on	a	prospective	clinical	database	or	use	of	large	cohorts	
from	registration	trials	of	the	VEGF	TKI’s	may	be	options	to	validate	these	techniques	
effectively.		
	
Efficacy	of	 textural	 analysis	 is	 being	 assessed	 in	 different	 tumour	 types.	 There	has	
been	studies	of	this	technique	in	small	cell	 lung	cancer,	colorectal	cancer	and	brain	
tumours.	With	each	tumour	type	showing	differing	degrees	of	heterogeneity,	it	will	
be	curious	 to	see	whether	 the	 textural	 changes	hold	 true	 in	different	 tumour	 type	
assessment.	There	may	also	be	potential	 to	correlate	 the	 textural	 changes	as	 seen	
with	contrast	enhanced	CT	with	spatially	matched	histological	results	obtained	from	
the	surgical	resection	specimen.	
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It	is	well	recognised	that	the	phase	of	intravenous	contrast	enhancement	influences	
the	detection	of	lesion	in	RCC	(Hollett,	Jeffrey	et	al.	1995,	Ascenti,	Visalli	et	al.	2004).	
RCC	metastases	are	highly	vascular	and	is	likely	to	show	early	enhancement	and	rapid	
washout	(Namasivayam,	Martin	et	al.	2007,	Muglia	and	Prando	2015).	It	is	likely	that	
the	 enhancement	 changes	 detected	 in	 the	 portal-venous	 phase	 alone	will	 be	 less	
prominent	and	may	not	be	representative	in	characterising	differences	post	therapy.	
With	some	centres	assessing	the	abdomen	and	pelvis	with	CT	scan	in	single	portal-
venous	 phase	 as	 standard	 and	 in	 those	 conditions,	 “modified”	 Choi	 based	
categorisation	may	not	be	precise	in	its	categorisation.		
	
As	a	 follow	up	study	 from	the	 results	discussed	 in	chapter	5.0,	we	have	compared	
difference	 in	 treatment	 response	 assessment	 between	 arterial	 and	 portal-venous	
enhancement	 in	 renal	 cell	 carcinoma.	This	 study	presented	as	an	abstract	 in	RSNA	
(Juttla.J	2010),	demonstrated	the	importance	of	the	use	of	the	appropriate	phase	of	
image	 enhancement	 for	 response	 categorisation.	 Results	 from	 this	 analysis	 shows	
change	in	response	type	for	some	patients	with	suggestion	that	arterial	phase	imaging	
may	be	better	in	assessing	the	vascular	effects	on	anti-angiogenic	therapy	in	RCC.		
	
The	phase	of	image	capture	will	be	an	area	to	concentrate	in	future	trials	and	also	in	
assessing	 to	 expand	 these	 techniques	 to	 perform	 response	 assessment	 in	 other	
disease	 types.	 It	may	 be	 that	 the	 timing	 of	 image	 acquisition	 could	 end	 up	 being	
significant	 in	 different	 tumour	 types	 or	 subtypes.	 With	 improvement	 in	 the	 CT	
technology	 and	 faster	 acquisition	 of	 images,	 it	 is	 possible	 that	we	may	 be	 able	 to	
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develop	specific	or	combination	of	imaging	sequences	according	to	different	disease	
types	or	the	therapeutic	agents	that	the	patients	are	are	being	treated	with	so	as	to	
get	the	maximum	clinically	significant	information	out	of	these	imaging	techniques.		
	
With	 the	 prospective	 trial	 reported	 in	 this	 thesis	 where	 DCE-MRI	 technique	 was	
utilised,	Ktrans	induced	response	was	used	as	the	primary	end	point	as	it	has	been	the	
most	researched	and	validated	vascular	parameter	associated	with	this	technique.		
	
Our	study	suggests	the	possibility	that	effusion	constant	Kep	could	be	an	important	
parameter	 that	 we	 have	 to	 investigate	 in	 further	 studies	 where	 effects	 of	 anti-
angiogenics	 are	 monitored.	 This	 is	 supported	 by	 early	 mouse	 xenograft	 studies	
reported	 by	 Song	 and	 colleagues	 (Song,	 Cho	 et	 al.	 2013).	 This	 study	 described	
statistical	significant	association	between	Kep	and	tumour	volume	changes	suggesting	
the	 use	 of	 Kep	 as	 a	 biomarker	 of	 anti-angiogenic	 therapy.	 Effects	 that	 we	 have	
observed	in	these	studies	need	to	be	validated	by	observation	in	a	larger	sample	size.		
	
The	land	scape	of	treatment	of	malignancies	including	metastatic	renal	cell	carcinoma	
continues	 to	 evolve	 with	 new	 research.	 Immunotherapy	 modalities	 as	 anti-CTLA4	
antibody	 ipilimumab	and	 check	point	 inhibitor	 drugs	 such	 as	 nivolumab	have	now	
shown	benefit	in	treatment	of	mRCC	(Motzer,	Escudier	et	al.	2015,	George,	Motzer	et	
al.	 2016,	 Sidaway	 2016).	 This	 is	 resulting	 in	 a	 change	 in	 treatment	 paradigm	 in	
treatment	 naive	metastatic	 RCC	 patients	 especially	 with	 a	 high	 risk	Motzer	 score.	
VEGF-TKI	still	remains	an	important	treatment	modality	in	metastatic	RCC	treatment.	
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Appropriate	sequencing	or	combination	of	these	immune-stimulant	drugs	and	VEGF	
TKI	are	still	unknown	and	is	a	field	of	ongoing	research.		
	
It	 is	also	worth	to	note	that	the	effect	of	immunotherapeutic	drugs	and	the	clinical	
benefits	 obtained	 from	 these	 treatment	modalities	 does	 not	 correlate	 to	 the	 size	
change	as	predicted	by	RECIST	critieria.	It	has	been	reported	that	on	treatment	with	
immunotherapeutic	 agents,	 the	 response	 obtained	 could	 follow	 different	 patterns	
including	 an	 initial	 increase	 in	 tumour	 burden	 which	 if	 classified	 with	 traditional	
RECIST	criteria	would	be	regarded	as	progressive	disease	resulting	in	recommendation	
of	 treatment	 withdrawal.	 A	 new	 modified	 iRECIST	 criteria	 have	 been	 recently	
proposed	for	assessment	of	response	to	treatment	with	immunotherapeutic	agents	
(Seymour,	Bogaerts	et	al.	2017).	
	
With	 any	 modality	 of	 treatment,	 accurate	 therapeutic	 assessment	 is	 vital.	 RECIST	
continue	to	be	the	tool	to	assess	response	despite	being	imperfect	and	being	unable	
to	 identify	 all	 subgroups	 who	 may	 derive	 clinical	 benefit	 from	 these	 targeted	
therapies.	Advanced	 imaging	 techniques	have	 the	potential	 to	 serve	 as	diagnostic,	
prognostic	 and	 predictive	 biomarkers.	 Further	 studies	 are	 required	 to	 identify	 the	
appropriate	 imaging	biomarker	 for	a	meaningful	 response	assessment.	The	studies	
reported	here	signifies	the	opportunity	of	using	imaging	modality	or	combination	of	
imaging	modalities	 to	 act	 as	 prognostic	 or	 predictive	 biomarkers	 in	 a	 therapeutic	
setting.	This	would	open	the	way	for	further	studies	to	improve	our	understanding	for	
imaging	based	response	assessment	of	renal	cell	carcinoma	and	other	malignancies.
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9.1. RECIST	criteria		
Evaluation	of	Target	lesions	
Complete Response 
(CR): 
Disappearance of all target lesions 
Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, 
taking as reference the baseline sum LD 
Progressive Disease 
(PD): 
At least a 20% increase in the sum of the LD of target lesions, 
taking as reference the smallest sum LD recorded since the 
treatment started or the appearance of one or more new lesions 
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum LD 
since the treatment started 
	
Evaluation	of	non-target	lesions	
Complete Response 
(CR): 
Disappearance of all non-target lesions and normalization of 
tumor marker level 
Incomplete response / 
Stable Disease (SD):  
Persistence of one or more non-target lesion(s) or/and 
maintenance of tumor marker level above the normal limits 
Progressive Disease 
(PD): 
Appearance of one or more new lesions and/or unequivocal 
progression of existing non-target lesions (1)  
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9.2. Motzer	score	
Variable	 Good	 Poor	
Performance	status	 0-1	 >1	
Histology	 Clear	cell	 Other	
LDH	 <1.5	x	ULN	 >1.5	x	ULN	
Corrected	calcium	 Normal		 >10mg/dl	
Hameoglobin	 Normal	 <LLN	
Previous	nephrectomy	 Yes	 No	
	
Good	prognosis	=	0	poor	factor	
Intermediate	prognosis	=	1-2	poor	factors	
Poor	prognosis	=	>2	poor	factors	
 	
Chapter	9.0	–	Appendices	
 243	
9.3. ECOG	performance	score	
	
Activity	 Score	
Fully	 active,	 able	 to	 carry	 out	 on	 all	 pre-disease	 performance	
without	restriction	
0	
Restricted	in	physically	strenuous	activity	but	ambulatory	and	able	
to	carry	out	work	of	a	light	or	sedentary	nature	eg	light	house	work,	
office	work.	
1	
Ambulatory	and	capable	of	all	 self-care.	Unable	 to	carry	out	any	
work	activities.	Up	and	above	more	than	50%	of	waking	hours	
2	
Capable	of	only	 limited	 self	 care.	Confined	 to	bed	or	 chair	more	
than	50%	of	waking	hours	
3	
Completely	 disabled.	 Cannot	 carry	 out	 any	 self-care.	 Totally	
confined	to	bed	or	chair	
4	
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9.4. Cockcroft-Gault	formula		
Reported	by	Cockcroft	and	Gault	in	1976	to	estimate	creatinine	clearance	from	serum	
creatinine	(Cockcroft	and	Gault	1976)	
	
^_`a = 	 140 − ef^ ×	heii	 jk	ljmnfoep ×	_nkiqekqr^osp	_o^eqjkjk^	(jk	µpnm/v) 	
	
 
Constant	=	1.23	for	Male	and	1.04	for	female	
This	remains	the	most	common	formula	for	determining	creatinine	clearance,	which	
act	as	a	surrogate	estimate	for	GFR;	10-20%	overestimation	of	GFR	could	happen	with	
creatinine	clearance.		
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9.5. Patient	information	leaflet	
 
DYNAMIC	 CONTRAST	 ENHANCED	 MRI	 (DCE-MRI)	 ASSESSMENT	 OF	 THE	
VASCULAR	CHANGES	INDUCED	BY	BEVACIZUMAB	ALONE	AND	IN	COMBINATION	
WITH	 INTERFERON	 –ALPHA	 IN	 PATIENTS	 WITH	 ADVANCED	 RENAL	 CELL	
CARCINOMA	
Patient information leaflet 
Version 1.2 
Dated:  26th January 2009 
 
1. Study Title 
 
“Dynamic Contrast Enhanced MRI (DCE-MRI) assessment of the vascular changes induced with 
bevacizumab alone and in combination with interferon – alpha in patients with advanced renal cell 
carcinoma.” 
 
2. Invitation 
 
We would like to invite you to participate in a research study. Please take time to read through the 
following leaflet prior to making a decision to partake in this study. It is extremely important for you to 
understand why the research is being done and what it will involve.  
 
3. Purpose of the study 
 
The combination of interferon-α and bevacizumab is proven to be active in the treatment of advanced 
renal cell carcinoma.  
 
Bevacizumab acts by interfering with blood vessel growth in the tumour and has been shown to delay 
disease progression in advanced kidney cancers. Interferon-α is a biological therapeutic agent that has 
many actions including boosting immunity and also affecting the growth of new blood vessels which feed 
the tumour. 
  
Previously, research has been carried out with bevacizumab alone and bevacizumab plus interferon. Both 
of these have been proved to be active in treatment of advanced kidney cancer. The combination of 
bevacizumab and interferon has been compared against interferon, which was the standard of care for this 
disease. This study showed that the combination treatment resulted in a significant improvement in the 
length of time before the cancer started growing again compared with interferon only treatment. The 
average time before the cancer started growing again was 10.2 months for the combination and 5.4 
months for interferon only treatment.  
 
Even though the combination of bevacizumab and interferon was found to be better than interferon alone, 
we are still unsure whether interferon adds significantly to the activity of bevacizumab, and if so in what 
way. One possibility is that the inhibitory effect on tumour blood vessels by bevacizumab is enhanced by 
the addition of interferon.  
 
Bevacizumab on its own was tested previously against placebo and is found to be active against advanced 
kidney cancer, However it is not known if the addition of interferon to bevacizumab will increase the 
treatment efficacy.  
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This study is looking to find out whether the combination of interferon-α and bevacizumab has a greater 
effect on the blood vessels feeding the cancer than bevacizumab alone and also if the dose on interferon 
has any importance in this effect.The effect of the treatment on tumour blood vessels can be measured 
with a special MRI scan called Dynamic Contrast Enhanced MRI (DCE-MRI).  
  
This trial will also be exploring markers present in blood which may correlate with the anti-blood vessel 
effect of these medications. We will see if any of these could predict response to treatment. These are 
referred to as biomarkers. 
 
To summarise, your participation in the study will enable us to determine; 
a) Whether the addition of interferon-α to bevacizumab increases the anti-tumour blood vessel effect 
of bevacizumab. 
b) Whether the dose of interferon-α is important in this effect. 
c) Whether there are biomarkers that can be used to predict response to treatment. 
 
4. Do I have to take part 
 
No, it is up to you to decide whether or not to take part. If you decide to take part, you will be given this 
information sheet and will be asked to sign a consent form. If you decide to take part, you are still free to 
withdraw at any time and without giving any reason. A decision to withdraw at any time, or a decision 
not to take part, will not affect the standard of care that you receive. 
 
5. What does the study involve 
 
In this research study thirty patients will be randomly allocated to one of the three arms receiving;  
a) Bevacizumab alone 
b) Bevacizumab + Interferon-α at 3MU 
c) Bevacizumab + Interferon- α at 9MU 
 
After 8 weeks everybody on the trial will receive both drugs as directed by their treating doctor. .  
 
The study is “randomised” and “open-labelled”. This means that once you have agreed to enter into the 
trial, you will be allocated to one of the three groups mentioned above. The allocation of groups is done 
by a computer so that each group has a similar mixture of people. Neither the doctor nor the patient can 
decide which group they are going to be in. This will help us to analyse the effectiveness of the treatment 
reliably.  As the study is open-labelled, both doctor and patient will know which group they are in. 
  
You will stay on the treatment for as long as it is benefitting you, with scans assessing response at 8 weeks 
and twelve weekly thereafter. If the treatment has any unacceptable side effects which cannot be simply 
managed, your doctor may withdraw you from the study. You can also withdraw from the study at 
anytime without giving any reason.  
 
Bevacizumab is given into the vein as a drip running for 30-60 minutes. This is repeated every two weeks. 
Interferon-alpha is given subcutaneously (under the skin) three times each week. Many patients or family 
members learn to inject the interferon however a district nurse can administer the treatment if the patient 
wishes. Patients in group B will receive low dose interferon for the 8 weeks. Patients in group C will have 
low dose interferon in the first two weeks and stepped up to a higher dose for the next six weeks.  
 
You will have two DCE-MRI scans done before treatment begins and another two once treatment has 
started - at week 2 and week 8. CT scans will be performed prior to the treatment, repeated at week 8 
and twelve weekly thereafter.  
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All patients will have blood tests done prior to starting treatment and during the visits to the hospital. In 
addition to the normal blood tests assessing your blood counts, kidney and liver functions, additional 
blood test will be taken to look for biomarkers in the blood. For the purpose of biomarkers, the equivalent 
of five tea spoons of blood will be taken, twice before treatment and at weeks 2, 6, 8 and when treatment 
is discontinued. Please refer to the patient diary on page 6 of this leaflet for more details. 
 
You will be asked to give permission for us to gain access to any tissue samples from previous operations 
or biopsies. Further tests will be performed on these samples to correlate with the results obtained from 
the biomarker blood tests.  
 
6. What are the risks involved 
 
6.1. Bevacizumab side effects 
 
Bevacizumab is routinely used to treat patients with many cancers. It has also been used worldwide in 
different trials for kidney cancer treatments.  
Either on its own or in combination with other medications bevacizumab is tolerated very well, overall. 
The most common side effects associated with bevacizumab (more than 10%) are: 
a) Fatigue. 
b) Raised blood pressure. 
c) Protein in urine. 
d) Diarrhoea. 
e) Nausea 
f) Minor bleeding as nose bleeds 
g) Difficulty in wound healing. 
 
Less common effects (less than 10%) 
a) Bowel perforation – seen approximately in 2% of patients with bowel cancer and treated with 
bevacizumab and chemotherapy. 
b) Increased risk of serious bleeding from the lining of the mouth, gut and vagina. There may be 
bleeding into the tumour as well.  
c) An increased risk of thrombosis (blood clots) leading to heart attack, stroke or clots in lungs 
d) Allergic reaction. 
Rare side effects that may be serious. 
Some rare side effects will have serious consequences if not reported to the doctors and treated 
appropriately. It is important that you report to your doctors at anytime if you are concerned about any 
of the side effects you are experiencing. Rarely (<1 in 1,000 patients) patients may experience symptoms 
of severe headaches, blurring of vision, altered mental status with confusion or seizures, drowsiness and 
coma. One of these conditions is called reversible posterior leukoencephalopathy (RPLS). Another 
condition that occurs very rarely (<1 in 10,000 patients) is called hypertensive encephalopathy related to 
the rapid increase in blood pressure. If patients experience these symptoms, they should seek medical help 
immediately. In most cases, the blood pressure can be controlled with medications and the conditions are 
reversible.   
Most of these serious side effects have occurred in patients receiving chemotherapy along with 
bevacizumab rather than bevacizumab alone.  
You will be monitored closely throughout the study period for any side effects. We will offer supportive 
treatment as anti-sickness, anti-hypertensive medications etc or may have to stop treatment if it is 
necessary. 
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6.2. Side effects of Interferon-α. 
Interferon-α is a protein which is present naturally in our body in very small amounts. The most common 
side effects associated with the use of interferon-α include 
a) Flu-like symptoms 
b) Fatigue 
Flu like symptoms can occur early, within a couple of hours after the injection and does not last long. The 
symptoms are usually more marked with the first injection and become much less of a problem with 
further injections.  
Less common side effects are nausea and vomiting, irritation of skin at the injection site, emotional 
changes, and temporary reduction in the production of blood cells by the bone marrow leading to 
infection, anaemia or bleeding.  
 
7. What are the benefits of participating 
 
Bevacizumab and bevacizumab plus interferon are proven to be useful in the treatment of advanced kidney 
cancer. You therefore may benefit from receiving these medications. By carrying out the trial we hope to 
find out the mechanism by which these medications act together. This will help us to improve the way in 
which we combine these medications together and thus ultimately improving the treatment of kidney 
cancers. We also aim to find out if we can predict the response to treatment earlier with the help of MRI 
scans or biomarkers.  
 
 
8. Alternative treatment possibilities 
 
There will be alternate treatment options available to you. Your doctor will go through this with you in 
detail before enrolling on to the trial. If during the trial new information becomes available, your doctor 
will discuss this with you.    
 
9. What happens after the 8 week MRI scan is completed 
 
After the initial 8 week study period, you will receive both bevacizumab and interferon and will continue 
on them for as long as they benefit you. Your response will be assessed with scans twelve weekly after the 
study.  If the treatment has any unacceptable side effects which cannot be managed with medications, your 
doctor may withdraw the medications. You can also withdraw from the study at anytime without giving 
any reason.  
 
10. Will the participation be kept confidential 
 
All of the information collected about you during the period of the study will be kept strictly confidential. 
No individual patient details will be identified while the results of the study are published.  
 
If you agree to participate in the study, some parts of your medical records and the data collected will be 
reviewed by an independent safety monitor. Data may be discussed with responsible persons from Roche 
pharmaceuticals who are providing treatment support for the study, but no information which identifies 
you will be passed to them.  
 
Your GP will be informed of your participation in the study if you agree to it. All procedures for handling, 
processing, storage and destruction of any data will be according to the data protection act. 
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11. What if something goes wrong 
 
If you have concerns about any aspects of the study you should speak to the researchers who will do their 
best to answer your questions (please refer to contact details below). There are no special compensatory 
mechanisms if you are harmed by taking part in the study other than those available to all NHS patients. 
If you wish to complain, the normal National Health Service complaints mechanisms are available to you. 
Formal complaints should be addressed to: 
Mr.Nick Carver, Chief Executive, Lister Hospital, Corey’s Mill Lane, Stevanage SG1 4AB  
(Tel: 01438 314333 extn 5112). 
 
12. Independent advice 
If you want to get independent advice regarding the trial or the conduct of the trial, you can contact 
The Lynda Jackson Support and Information centre 
Mount Vernon Hospital. 
Tel: 01923844014 
 
The patient advice and Liaison Service ‘PALS’ is also available for the patient to be contacted to get 
independent advice in each of the study sites. 
 
13. Organisation and funding 
 
The study is sponsored by the East and North Hertfordshire trust. This will be conducted in three centres 
A) Mount Vernon Hospital, Northwood, Middlesex. 
B) Royal Marsden Hospital, Sutton, Surrey. 
C) Addenbrooke’s Hospital Cambridge. 
 
The study is funded by the Roche Phamaceuticals® who manufactures the bevacizumab and will be 
supplying the medicines ie both bevacizumab and interferonα-2a to the patients free of cost.  
 
14. Contact details for the trial 
 
Chief Investigator:  Dr. Paul Nathan 
    Consultant Medical Oncologist 
    Mount Vernon Hospital 
    Rickmansworth Road, Northwood 
    Middlesex HA6 2RN 
    Tel: +44 1923 844 966 
    Fax: +44 1923 844 840 
     
Study Coordinator & 
Clinical co investigator Dr. Anup Vinayan 
    Clinical research Fellow 
    Mount Vernon Hospital 
    Rickmansworth Road, Northwood 
    Middlesex HA6 2RN 
    Tel: + 44 1923 844 637 
    Fax: +44 1923 844 840 
 
 
Thank you for taking your time to read through this information leaflet. 
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9.6. Patient	informed	consent	form	
 
Dynamic contrast enhanced MRI (DCE-MRI) assessment of the 
vascular changes induced with bevacizumab alone and in combination 
with interferon-α in patients with advanced renal cell carcinoma 
Centre no……………. 
Patient identification number for the trial*……………………….. 
(*To be completed post randomisation) 
 
Consent form 
Please initial 
1 
 
I confirm that I have read and understood the information sheet, 
version……. Dated....……………………, regarding the above 
mentioned study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
 
2 
 
I understand that the participation in this study is voluntary and 
that I can withdraw from it at any time, without giving any reason and 
without my medical care or legal rights being affected. 
 
 
3 
 
I understand that the relevant sections of my medical notes and 
data collected during the study may be looked at by responsible 
individuals involved in the study and from regulatory authorities where 
it is relevant to my taking part in the study. I give permission for these 
individuals to have access to my records 
 
 
4 
 
I understand that the blood samples collected are considered as a 
gift and will be used for laboratory research related to this trial. 
 
 
 
5 
I give consent to the research team to collect the previously stored 
biopsy or histopathology sample of my kidney cancer for further 
testing 
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6  
I give permission to the research team to transfer the samples 
collected to designated research laboratories at oxford for further 
analysis. 
 
6 
 
I agree that the samples collected from me and the data gathered 
about me can be stored for use in future research regarding kidney 
cancer. I understand that some of these studies may be conducted by 
those other than researchers involved in this study, but that all future 
projects will be ethically approved. 
 
 
7 
 
I give my consent to take part in the above mentioned study. 
 
 
8 
 
I agree to my GP being informed of my participation in the study. 
 
 
 
 
______________________   ______________________ -
 ________________ 
Name of Patient   Signature    Date   
(To be completed by patient) 
  
 
 
______________________   ______________________ -
 ________________ 
Name of Person taking consent  Signature    Date 
  
(If different from Investigator) 
 
 
 
______________________   ______________________ -
 ________________ 
Name of Investigator   Signature    Date 
  
 
 	
Chapter	9.0	–	Appendices	
 252	
9.7. Sample	handling	manual	
DCE-MRI	assessment	of	the	vascular	changes	induced	by	bevacizumab	
alone	or	in	combination	with	IFN	in	patients	with	advanced	RCC		
SAMPLE	HANDLING	INSTRUCTIONS	
	
A) Blood	samples	for	biomarker	analysis	
	
Samples	
Blood	sample	for	haematology,	clinical	chemistry	and	coagulation	will	be	collected	as	
per	the	study	site’s	standard	procedure.		
 
SAMPLES	FOR	BIOMARKER	ANALYSIS	COLLECTED	AT	
a. SCREENING	–	TWICE	
b. WEEK	2	on	treatment	
c. WEEK	6	on	treatment	
d. WEEK	8	on	treatment		
e. DISCONTINUATION	of	treatment	
	
Samples	to	be	collected	for	biomarker	analysis	
2x10ml	samples	in	EDTA	vial	
1x5ml	sample	in	a	lithium	heparin	vial.		
 
Sample	Handling	instructions	
 
a) CEC,CEPC	&	Angiogenic	marker	analysis	(10ml	EDTA	sample)	
	
1. 10ml	of	the	blood	to	be	collected	in	EDTA	vacutainer	tubes	(purple	top).		
2. Label	the	tube	appropriately	with	the	trial	code,	trial	number	of	the	patient	and	date	
of	collection	and	time	of	collection.	
3. The	sample	should	be	transported	by	courier	same	day	at	room	temperature	to	the	
stem	 cell	 research	 laboratory	 at	 John	 Radcliffe	 hospital	 by	 4:00pm	 on	 the	 day	 of	
collection	(transported	at	room	temperature).	
4. Log	patient	details,	date,	time	point	in	trial,	time	of	collection	&	despatch	onto	lab	log	
sheets	
	
NOTE:	24	HR	NOTICE	TO	BE	GIVEN	TO	THE	LABORATORY	PRIOR	TO	SENDING	SAMPLE	
	
b) Peripheral	blood	analysis	for	MicroRNA	(10ml	EDTA	sample)	
	
1. 10	ml	of	blood	to	be	collected	into	EDTA	vacutainer	tubes	(purple	top),		
2. Place	the	sample	in	an	ice	bucket	immediately	after	drawing.		
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3. The	sample	should	be	centrifuged	within	3	hrs	of	collection	at	2000	G	for	10	minutes	
in	a	refrigerated	centrifuge	(4°C).		
4. The	plasma	is	removed	carefully	to	avoid	disturbing	the	buffy	coat	and	transferred	
to	a	new	tube.		
5. Centrifuge	the	plasma	again	at	minimum	of	2000	G	for	10	minutes	in	a	refrigerated	
centrifuge	(4°C).		
6. Aliquots	(1	or	2)	of	1.6ml	plasma	will	be	transferred	to	new	tubes	
7. Add	2ml	of	TRIZOL	LS	to	the	sample.		
8. Samples	vortexed,	left	for	5	minutes	at	room	temperature,		
9. Label	the	sample	appropriately	(trial	code,	site	and	trial	number,	date	of	collection)	
10. Store	in	a	freezer	at	-80°C.	
11. Samples	should	be	despatched	in	batched	to	the	laboratory	in	dry	ice.		
12. Log	patient	details,	time	point	in	trial,	times	of	collection	&	centrifugation	in	log	sheet.	
	
c)	Proteomics		
	
1. 5mls	of	blood	will	be	collected	in	lithium	heparin	vacuum	tubes.		
2. Centrifuge	the	sample	at	500G	for	10minutes.		
3. Plasma	isolated	should	then	be	transferred	to	1.5	–	2	ml	tubes.		
4. The	samples	are	labelled	appropriately	(site	and	trial	number,	date	of	collection)	and	
stored	at	-80oC.		
5. The	samples	from	an	individual	patient	should	be	batched	and	shipped	on	dry	ice	after	
all	time	points	are	collected.	
6. Log	details	–	patient	details,	time	point	in	study,	time	of	collection	and	centrifugation	
onto	lab	log	sheets.		
	
B) Immuno-histochemistry	
	
Archival	samples	requested	from	original	path	labs	to	be	sent	to	sponsor	site.		
Samples	will	be	anonymysed,	Mark	with	patient	initials,	trialcode,	site	and	patient	
number.		
Samples	despatched	to	Oxford	at	ambient	temperature.	
Please	log	the	details	in	the	log	sheet.	
	
C) Urine	sample	for	proteomics	
	
15	mls	of	urine	sample	collected	once	in	the	screening	period.		
Samples	labelled	appropriately		
Store	in	-80oC	freezer	and	despatched	in	batches	to	the	lab	with	other	proteomics	
sample	in	dry	ice	
Log	details	into	lab	log	sheet.	
CONTACT	ADDRESS	FOR	SENDING	SAMPLES	
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9.8. Management	of	IMP	related	toxicities	
Dose Modifications and Delays 
	
The	 observed	 toxicity	 will	 be	 graded	 according	 to	 the	 CTCAE	 v3.0	 guidelines.	 Dose	
modifications	 will	 be	 implemented	 according	 to	 the	 observed	 toxicity	 grade	 as	 specified	
below.	
Dose	Modifications	for	patients	receiving	Interferon	alpha-2a		
	
Any	grade	3	toxicity	attributable	to	interferon	alpha-2a	will	require	interferon	alpha-2a	to	be	
withheld.	If	toxicity	resolves	to	≤grade	1	within	2	weeks,	interferon	alfa-2a	may	be	
reintroduced.	
For	patients	receiving	9MU	of	IFN,	if	toxicity	takes	>2	weeks	to	resolve	to	grade	1,	or,	in	the	
opinion	of	the	investigator,	if	the	patient	would	benefit	from	dose	reduction,	the	following	
dose	levels	should	be	used:	
§ Highest	target	dose:	9	MIU	of	interferon	alfa-2a	3x/week	
§ Dose	Level	-1:	6	MIU	of	interferon	alfa-2a	3x/week	
§ Dose	Level	-2:	3	MIU	of	interferon	alfa-2a	3x/week	
	
In	case	of	unacceptable	toxicity	at	this	lowest	dose	of	interferon	alpha-2a	(as	defined	
above),	interferon	alpha-2a	must	be	discontinued.	In	the	absence	of	disease	progression,	
bevacizumab	may	be	continued.	Any	patient	who	develop	any	one	of	the	following	should	
discontinue	interferon	alpha	therapy	
• Grade	4	toxicity	
• Any	Grade	3	toxicity	after	two	dose	reductions	and	unsuccessful	schedule	
modification	
• Grade	3	toxicity	that	does	not	resolve	to	grade	1	or	less	within	4	weeks	
Treatment	modifications	in	case	of	events	attributable	to	bevacizumab	
No	dose	reduction	of	bevacizumab	is	allowed.	
Any	 patient	 who	 develop	 any	 one	 of	 the	 following	 toxicities	 should	 not	 receive	 further	
bevacizumab	
• Gastrointestinal	perforation	
• Arterial	thromboembolic	events	
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• Grade	3/4	haemorrhagic	events	
• Symptomatic	Grade	4	thrombosis	
• Grade	4	hypertension	(hypertensive	crisis)	
• Grade	4	proteinuria	(nephrotic	syndrome)	
In	case	bevacizumab	is	discontinued,	continuation	of	interferon	alpha	may	be	considered.	
	
Bevacizumab-specific	toxicities	
Gastrointestinal	Perforation	
Bevacizumab	should	be	permanently	discontinued	in	patients	who	develop	gastrointestinal	
perforation.	
Surgical	Procedures/Wound	Healing	Complications	
Bevacizumab	therapy	should	not	be	initiated	for	at	least	28	days	following	surgery	or	until	
the	surgical	wound	is	fully	healed.		
Hypertension	
Patients	should	be	monitored	for	the	development	or	worsening	of	hypertension	via	
frequent	blood	pressure	measurement.	Blood	pressure	measurements	should	be	taken	after	
the	patient	has	been	in	a	resting	position	for	≥	5	minutes.	Repeat	measurement	of	blood	
pressure	for	verification	should	be	undertaken	if	the	initial	reading	is	≥	140	mmHg	systolic	
and/or	≥	90	mmHg	diastolic	blood	pressure.	
• Grade	1	hypertension:	Asymptomatic,	transient	(<	24	hrs)	increase	by	>	20	mmHg	
(diastolic)	or	to	>	150/100	mmHg	if	previously	within	normal	limits-	No	Intervention.	
• Grade	2	hypertension:	Recurrent	or	persistent	(>	24	hr)	or	symptomatic	increase	by	>	20	
mmHg	(diastolic)	or	to	>	150/100	mmHg	if	previously	within	normal	limits.	Bevacizumab	
should	be	withheld.	Monotherapy	of	anti-hypertensive	is	indicated	as	per	the	local	
policy.	Once	controlled	to	<	150/100	mmHg,	patients	continue	bevacizumab	therapy.	
• Grade	3	hypertension:	Requiring	more	than	one	anti-hypertensive	or	more	intensive	
therapy	than	previously.	Bevacizumab	should	be	withheld	for	persistent	or	symptomatic	
hypertension	and	should	be	permanently	discontinued	if	hypertension	is	not	controlled.	
• Grade	4	hypertension:	Life	threatening	consequence	(e.g.	hypertensive	crisis)	
Occurrence	of	grade	4	hypertension	should	lead	to	permanent	discontinuation	of	
bevacizumab.	All	doses	of	anti-hypertensive	medicines	should	be	recorded	at	all	visits.	
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Proteinuria	
All	patients	will	have	a	dipstick	urinalysis	or	24	hour	protein	determination	performed,	prior	
to	each	bevacizumab	dose.	A	24	hour	urine	collection	for	protein	determination	is	mandatory	
at	baseline	if	dipstick	shows	≥2+	proteinuria.	All	proteinuria	toxicity,	as	determined	by	24	hour	
urine	 collection,	 will	 be	 graded	 according	 to	 CTCAEv3.0	 guidelines.	 Adjustment	 of	
bevacizumab	administration	for	proteinuria	will	occur	according	to	the	following	guidelines:	
First	occurrence	of	proteinuria:	
• <	2+	(dipstick):	Administer	bevacizumab	as	scheduled,	NO	additional	evaluation	is	
required.	
• 2+,	3+	and	4+	proteinuria	(dipstick):	Administer	bevacizumab	as	scheduled.	
	
Collection	of	24-hour	urine	to	determine	the	total	protein	within	3	days	prior	to	the	next	
scheduled	dose	is	required:	
• 24-hour	proteinuria	≤	2	g:	Administer	bevacizumab	as	scheduled.	Repeat	dipstick	is	
required	before	each	scheduled	administration	of	bevacizumab.	
• 24-hour	proteinuria	>	2	g:	Bevacizumab	treatment	should	be	withheld	pending	next	24	
hour	total	protein.	
Repeat	24-hour	urine	protein	≤	2	g:	Administer	bevacizumab	as	schedule.	24-hour	protein	
should	be	further	monitored	prior	to	each	administration	of	bevacizumab	until	it	has	
decreased	to	≤	1	g/24	h.	
Repeat	24-hour	urine	protein	>	2	g:	Bevacizumab	dose	should	be	withheld	until	24-hour	
protein	has	decreased	to	≤	2	g.	24-hour	protein	should	be	further	monitored	prior	to	each	
administration	of	bevacizumab	until	it	has	decreased	to	≤	1	g/24	h.	
Second	and	subsequent	occurrence	of	proteinuria:	
• <	3+	proteinuria	(dipstick):	administer	bevacizumab	as	planned.	
• ≥3+	proteinuria	(dipstick):	administer	bevacizumab	as	planned	and	collect	24-hour	urine	
for	determination	of	total	protein	within	3	days	before	the	next	scheduled	bevacizumab	
administration.	
o 24-hour	proteinuria	≤	2	g:	Administer	bevacizumab	as	scheduled.	Repeat	dipstick	is	
required	before	each	scheduled	administration	of	bevacizumab.	
o 24-hour	proteinuria	>	2	g:	Bevacizumab	treatment	should	be	withheld	pending	next	
24	hour	total	protein.	
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Repeat	24-hour	urine	protein	≤	2	g:	Administer	bevacizumab	as	schedule.	24-hour	protein	
should	be	further	monitored	prior	to	each	administration	of	bevacizumab	until	it	has	
decreased	to	≤	1	g/24	h.	
Repeat	24-hour	urine	protein	>	2	g:	Bevacizumab	dose	should	be	withheld	until	24-hour	
protein	has	decreased	to	≤	2	g.		24-hour	protein	should	be	further	monitored	prior	to	each	
administration	of	bevacizumab	until	it	has	decreased	to	≤	1	g/24	h.	
Nephrotic	syndrome	(Grade	4,	CTCAE	v3.0):	Discontinue	bevacizumab	treatment	
	Thrombosis/Embolism	
All	toxicity	will	be	graded	according	to	CTCAEv3.0	guidelines.	For	patients	who	develop	
Grade	3	or	4	thrombosis/embolism	the	following	action	is	recommended:	
• Bevacizumab	should	be	permanently	discontinued	in	patients	who	develop	arterial	
thrombo-embolic	events.	
• Grade	3	or	4	venous	thrombosis:	Hold	study	drug	treatment	for	2	weeks.	
Bevacizumab	may	be	resumed	after	initiation	of	the	therapeutic	dose	anticoagulant	therapy	
as	soon	as	all	of	the	following	criteria	are	met:	
§ The	patient	must	be	on	a	stable	dose	of	anticoagulant	and,	if	on	warfarin,	have	an	
INR	within	the	target	range	(usually	between	2	and	3)	prior	to	restarting	study	drug	
treatment	
§ The	patient	must	not	have	had	a	Grade	3	or	4	haemorrhagic	event	since	entering	the	
study	
§ The	patient	must	not	have	had	any	evidence	of	tumour	invading	or	abutting	major	
blood	vessels	on	any	prior	disease	assessment.	
• Symptomatic	Grade	4	thrombosis:	Discontinue	the	patient	from	the	study.	
Haemorrhage	
All	toxicity	will	be	graded	according	to	CTCAEv3.0	guidelines.	Patients	who	develop	
Grade	3	or	4	haemorrhage	should	discontinue	bevacizumab	treatment.	
	
Dose	Adjustment	of	bevacizumab	due	to	Changes	in	Body	Weight	
Body	weight	at	baseline	is	to	be	used	to	calculate	the	required	dose,	and	no	dose	
modifications	are	foreseen	unless	the	patient’s	body	weight	changes	by	more	>10%	from	
baseline.	
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9.9. DCE-MRI	QA	and	QC	
Version 1 Jane Taylor 3.5.13 
DCE-MRI	Trial	QA	and	QC	
 
DCE-MRI	assessment	of	vascular	changes	using	bevacizumab	and	Interferon	in	reanl	
cell	carcinoma	trial	includes	quantitative	Dynamic	Contrast-Enhanced	MRI.	This	need	
to	have	specialised	QA	carried	out	to	ensure	their	ability	to	produce	accurate	data.		
	
This	should	include	a	dry	run	of	the	entire	protocol	on	the	Eurospin	T1	phantom	(T05),	
and	then	on	a	volunteer	(minus	the	contrast	injections).	This	will	minimise	the	chance	
of	 the	 first	 patient’s	 data	 being	 incorrect,	 wasting	 the	 patient’s	 time	 and	 PSSC	
resources.	It	will	also	give	a	realistic	idea	of	the	study	timings.	
	
The	primary	QA	needed	for	DCE-MRI	trials	 is	 in	testing	the	T1	quantification	of	the	
sequences	to	be	used.	Summary	methodology	can	be	found	in	the	VIBE	subsection	in	
Q:\protocols and check sheets\analysis and QA methodology \ MR QAData acquisition_V3.doc	which	
is	expanded	in	this	document.	
 
VIBE	sequences	for	measuring	T1.	
VIBE	 (Volume-interpolated	 breathhold	 examination)	 sequences	 acquire	 a	 three-
dimensional	 block,	 subsequently	 reconstructed	 into	 thin	 slices.	 They	were	 initially	
designed	for	rapid	liver	imaging,	and	have	the	option	of	using	rapid	and	specialised	RF	
pulses	at	low	flip	angles	in	order	to	select	very	precise	blocks.	These	fast	pulses	use	
high	RFPA	voltages,	and	are	not	necessarily	suitable	for	all	patients	or	studies.	This	is	
mainly	due	to	approaching	the	RFPA	power	limit	or	exceeding	21o.	At	such	a	point,	the	
scanner	provides	a	pulse	of	lesser	flip	than	programmed,	a	fact	which	is	only	apparent	
on	examining	data	after	acquisition.	 It	 is	 therefore	more	useful	 to	use	RF	pulses	 in	
‘normal’	 mode,	 as	 these	 do	 not	 exhibit	 this	 uncertainty	 and	 the	 subsequent	
quantification	is	more	reliable.	
	
To	use	VIBE	sequences	to	measure	T1	requires	the	use	of	a	pair	of	images:	a	baseline	
image	with	very	 low	flip	angle	(proton	density	weighted)	and	a	T1-weighted	 image	
with	much	larger	flip	angle.	More	relaxation	will	occur	with	the	PD,	giving	an	image	
which	 is	 fully	 relaxed.	The	T1-w	 image	will	depend	on	how	much	relaxation	occurs	
between	repeats,	given	the	flip	angle,	and	it	is	possible	to	work	out	the	T1	of	a	sample	
given	the	PD	and	T1w	 images.	Optimising	the	T1-w	flip	angle	 for	a	given	TR	 is	also	
useful.		
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Analysis	
This	is	performed	using	the	MRIW	program.	There	are	two	ways	of	analysing	the	data,	
one	 using	 the	 dedicated	 T1	 QA	 function,	 accessed	 via	 XML	 files,	 and	 a	 simpler	
summary	method.	
	
Simple	 summary	
method	
	
	
Open	 MRIW.	
Click	 File	 and	
then	Import	DCE-
MRI…	
	
	
	
	
	
	
	
	
	
	
	
	
The	DICOM	import	dialogue	box	will	pop	up.	Navigate	to	the	relevant	directory	and	
then	 select	 the	
pre-contrast	
scan	 (Proton-
density	
weighted)	 for	
Reference	 and	
the	 contrast-
enhanced	 scan	
(T1-weighted)	
for	Dynamic.		
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Click	 Advanced…	 and	 then	 select	 AUC	 from	 the	
drop-down	menu	on	the	Model	tab.	Press	OK,	then	
OK	 again	 on	 the	 DICOM	 import	 box.	 	 Data	 will	
load.		
	
Click	 on	 the	
Analysis	 menu,	
and	 choose	
ROI…	
	
	
	
	
	
	
	
	
	
	
	
	
Click	on	the	ROI	
menu	 and	
choose	Define…	
	
	
A	 Region	of	 Interest	 box	
will	pop	up.	Choose	Circle	
from	 the	 drop-down	
menu.	
	
	
Click	the	point	where	you	
wish	 the	centre	of	 the	 circle	 to	be,	
and	then,	holding	down	the	mouse	
button,	 drag	 the	 mouse	 pointer	
outwards.	Let	go	of	the	button	when	
the	circle	is	the	desired	size.	
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Click	with	 the	 right	 mouse	 button	
anywhere.	 This	 will	 fill	 in	 the	 circle,	
then	 click	 the	 now-black	 OK	 on	 the	
Region	 of	 Interest	box.	The	ROI	will	go	
back	 to	 an	 outline.	
	
	
	
	
Click	ROI	tab	then		
Save…		a	box	will	pop	up.	Enter	a	filename	and	
press	Save.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
At	this	site,	the	phantom	vials	are	conventionally		
placed	in	the	cylinder	as	shown	at	right.	Number		
the	ROIs	accordingly.		
	
If	in	doubt,	1	is	the	very	brightest		
followed	by	2	and	3.	Then	the	
signal	drops	off	rapidly,	allowing	
the	order	of	gels	to	be	deduced.	
	
Press	OK	in	the	ROI	screen	to	return	to	the	main	MRIW	screen.		
	
Press	Analysis	then	Dynamic…		
1
0 
1
1 
1
2 
1
3 1
4 1
5 
1
6 1
7 1
8 
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When the calculation has finished, images will pop up.  
Press Analysis then Post-Process… and select Initial T1 from the Map dropdown menu 
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Choose	File	>	Export	>	Results	as	Text…	
 
	
Name	 the	 output	 the	 same	 as	 the	
gel	number.		
Press	 Save.	 Close	 down	 the	
PostProcess	 box,	 and	 return	 to	 the	
Analysis	 >	 ROI	 box.	 Draw	 the	 next	
ROI	around	the	next	gel,	and	repeat	
the	whole	procedure	until	all	18	gels	
have	been	drawn	and	calculated.	
	
Close	MRIW.	
	
	
	
	
	
	
Open	MS	Excel.	
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Open	the	directory	with	the	gel	results	in,	and	then	select	all	.txt	files.	
	
	
Press	Open.	It	will	open	the	Text	Import	Wizard.	
	
	
Tick	Delimited,	then	press	Next	>	
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Tick	Tab	and	Space	then	press	Finish	
	
	
Repeat	for	all	the	gels.		
	
In	the	first	converted	file,	Scroll	down	to	the	last	line	of	the	summary	(Lines	70	and	71)	
and	select	cells	B72	–G72	inclusive.	Copy	and	paste	them	into	a	new	workbook.	Close	
that	text	file	and	repeat	for	02.txt	–	18.txt.	
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Now	you	will	have	in	the	summary	file:	
	
	
The	median	values	need	multiplying	by	1000	to	get	their	units	to	milliseconds,	and	
then	the	reference	values	of	T1	for	the	gels	at	the	measured	room	temperature	need	
to	be	added.	
	
This	should	give	
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Select	columns	G,	H	and	I	and	press	the	graph	icon	 	
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Choose	XY	(Scatter)	and	Finish.	
	
Edit	graph	to	how	you	want	it,	and	fit	a	line	to	the	GH	columns	to	show	the	line	of	
identity	(ideal	plot).		This	will	show	how	the	measured	gel	values	deviate.		
 
 
This	plot	shows	that	to	about	1000ms,	VIBE	T1	measurements	are	fairly	accurate,	then	
overestimate	the	T1s	as	they	get	higher.	This	is	typical	of	a	Siemens	Avanto.		
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9.10. Regulatory	approvals	
	
rlmj
National Research Ethics Service
Charing Cross Research Ethics Committee
Room 4W/12, 4th Floor
Charing Cross Hospital
Fulham Palace Road
London,W6 8RF
Telephone: 020 8846 7283
Facsimile: 0208846 7280Dr Paul Nathan
Consultant Medical Oncologist
East and North Hertfordshire NHSTrust
MountVernon Hospital
Rickmansworth road, Northwood
Middlesex, HA62RN
21 January 2009
Dear Dr Nathan
Full title of study: Dynamic contrast enhanced MRI(DCE-MRI)assessment of
the vascular changes induced with bevacizumab alone
and in combination with interferon-a in patients withadvanced renal cell carcinoma
09/H0711/6
1.1
2008-006414-19
RECreference number:
Protocol number:
EudraCTnumber:
The Research Ethics Committee reviewed the above application at the meeting held on 19
January 2009. Thank you for attending to discuss the study.
Ethical opinion
The committee asked about the definition of advanced renal cell carcinoma. The researcher
confirmed that this meant inoperable local spread or metastatic disease.
The committee enquired about the evidence for benefits of the treatment. The researcher
explained that the latest combination therapy approximately doubled the survival of the
patients.
The committee sought clarification whether the combination therapy is substantially better
than monotherapy. The researcher explained that they are yet to establish the reasons for
effectiveness of the combination therapy.
The committee enquired about the risk to patients' long term survival from taking part in the
study, in particular receiving monotherapy. The researcher explained that the dose of
Interferon has substantial side effects. The lower dose of 3MU is better tolerated and maybe
antiangiogenic, thus more beneficial. The researcher pointed out the main disadvantages
for the patients which are the 6 week MRI scan and the 8 week CT scan. The researcher
also explained that after that the patient could switch to anything that their physician would
consider appropriate.
The committee noted that there would be quite number of scans. The researcher
acknowledged that the MRI scans are extra to normal patient care but explained that by
doing two initial MRI scans a good baseline could be established (by assessing intra-patient
variation).
The committee enquired whether the scans would be done on outpatient basis. The
researcher confirmed this, and added that the patients are generally very motivated.
The committee was interested to know that if no difference were found, would progression
to the next study occur. The researcher confirmed that they would progress to the next
study.
The researcher explained that the present study would give information about the
This ResearchEthics Committee is an advisory committee to London Strategic Health Authority
The National Research Ethics Service (NRES)represents the NRESDirectorate within
the National Patient Safety Agency and Research Ethics Committees in England
- -- - -- - - ~----
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Introduction
Therapeutic options for patients with advanced 
renal cell carcinoma (RCC) have dramatically 
improved over the last few years with the advent 
of a number of novel agents targeting both tumour 
vasculature and tumour growth. Sunitinib [Motzer 
et al. 2007b], bevacizumab in combination with 
interferon [Escudier et al. 2007b], temsirolimus 
[Motzer et al. 2007a], sorafenib and everolimus 
[Motzer et al. 2008] have all become standard 
agents for the treatment of this disease.
There is a clinical need to identify which patients 
are likely to derive most and least benefit from 
targeted therapies early in the course of treat-
ment, that is, to predict response, and to identify 
which patients have aggressive or indolent disease, 
that is, to determine prognosis.
RCC is highly vascular, driven at least in part by 
the frequent overexpression of vascular endothe-
lial growth factor (VEGF) [Nicol et al. 1997]. As 
all of the new therapeutic agents appear to have at 
least some effect upon tumour vasculature, imag-
ing modalities that provide a quantitative assess-
ment of the change in vascularity may have a 
particular role in this disease.
This review discusses imaging modalities that have 
shown promise as either predictive or prognostic 
tests in advanced RCC and identifies areas of 
future opportunity.
Predictive biomarkers
Validated tools, which could predict clinical ben-
efit from a therapy, would lead to significant 
improvements in clinical management. Early 
identification of responders, nonresponders or 
subpopulations of patients at risk for side effects 
would help to identify patients who have great-
est or least benefit from a specific intervention. 
Predictive biomarkers would therefore help to 
avoid exposing patients to the risk of unnecessary 
side effects from treatments from which they 
would be destined to derive little or no benefit.
There are now a significant number of new thera-
pies which have proven to be clinically effective, 
but which have not succeeded in passing health–
economic assessments by reimbursement author-
ities. The cost-effectiveness analyses that bodies 
such as the National Institute for Health and 
Clinical Excellence perform would be signifi-
cantly impacted upon if it were possible to iden-
tify subpopulations of patients who would derive 
most benefit from the drugs. This would lead to 
a greater possibility that new therapies would be 
available for patients once efficacy had been 
demonstrated.
Imaging-defined response evaluation criteria in 
solid tumours (RECIST) [Therasse et al. 2000] 
have been the basis of treatment response assess-
ment in oncology since their introduction. The 
criteria were developed and validated to assess 
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responses to conventional therapies such as 
chemotherapy and radiotherapy rather than the 
new generation of targeted agents. RECIST crite-
ria are based upon change in size of target lesions. 
However, antivascular agents appear to be fre-
quently clinically active without inducing the sig-
nificant size change required for a RECIST-defined 
response. No imaging modality has yet been vali-
dated that can predict the treatment response of 
RCC treated with targeted therapies.
Primary RCC and its metastases are noted to be 
highly vascular and are associated with an upreg-
ulation of VEGF. Most sporadic and familial 
clear cell RCCs have an inactive VHL gene prod-
uct either because of bi-allelic alterations in the 
gene or post-transcriptional modification. Lack of 
functional VHL gene product results in stabiliza-
tion of hypoxia inducible factor (HIF) 1, 2 and 
increased transcription of factors such as VEGF 
and platelet-derived growth factor. Activation of 
multiple pathways driven by these and other fac-
tors results in increased angiogenesis in these 
tumours. This is thought to underpin the signifi-
cant clinical activity of antiangiogenic targeted 
therapies in RCC. Imaging techniques that can 
assess vascularity and changes in vascularity of 
these tumours may therefore have potential to be 
useful as predictive biomarkers.
Assessment of changes in vascularity
The gold standard for assessing vascularity and 
angiogenesis in a tumour is by measuring the mean 
vascular density, which is performed by counting 
vascular structures directly with histology. This 
technique has limitations as it is invasive and can-
not be performed repeatedly to assess treatment 
response in humans. Also, as it does not explore 
the whole treatment volume, there is an increased 
chance of sampling error due to tumour heteroge-
neity [Lebret et al. 2007; Renshaw et al. 1997].
A number of clinically applicable functional imag-
ing techniques are capable of quantitatively assess-
ing the vascularity of tumours in vivo pre and post 
treatment. These techniques include dynamic 
contrast-enhanced magnetic resonance imag-
ing (DCE-MRI), dynamic contrast-enhanced 
computed tomography (DCE-CT), dynamic 
contrast-enhanced ultrasound (DCE-US), dif-
fusion-weighted MRI (DW-MRI), arterial spin 
label MRI (ASL-MRI) and positron emission 
tomography (PET) with oxygen-labelled water. 
Each of these techniques provides quantitative or 
semiquantitative data related to blood flow and 
some can also provide information on blood vol-
ume, cellularity or vessel permeability. DCE imag-
ing techniques such as DCE-MRI, DCE-CT and 
DCE-US use exogenous contrast agents to differ-
entiate vascular characteristics, while other MRI 
techniques as ASL-MRI and DW-MRI use the 
inherent changes in magnetic resonance between 
tissues without the use of an external contrast 
agent. The latter group has a potential advantage 
as 20–30% of patients with RCC have impaired 
renal function, which increasingly precludes the 
use of exogenous contrast agents.
Dynamic contrast-enhanced imaging techniques.  
Dynamic functional imaging using exogenous 
contrast media centres on quantitative analysis of 
biodistribution of contrast media in tissues. These 
techniques use the difference in pharmacokinetics 
of the contrast agent between tissues and tumour 
to provide tumour-specific and tissue-specific 
information [Marcus et al. 2009].
DCE-MRI as a biomarker of angiogenesis has 
been tested and validated over the last decade in 
a variety of tumours. The gold standard correla-
tion was with immunohistochemical microves-
sel density measurements. Investigators have 
attempted to correlate imaging with tissue expres-
sion of proangiogenic growth factors including 
VEGF (broad correlations in some studies and no 
correlations in others) [Padhani and Dzik-Jurasz, 
2004; Schlemmer et al. 2004].
The relationship between contrast concentration 
and signal intensity is complex and nonlinear in 
DCE-MRI [Kiessling et al. 2007]. Along with the 
concentration, it also depends on the imaging 
sequence used, machine setup, inherent hetero-
geneity of the tumour and native relaxation rate 
of the tissues [Padhani, 2003].
The rate of delivery and washout of contrast media 
into the tumour vasculature bed depends on sev-
eral physiological characteristics of the tumour 
vascular microenvironment. Depending on the 
techniques used, parameters such as Ktrans (trans-
fer constant, related to the influx of contrast agents 
from plasma to the tumour interstitial space), Kep 
(efflux of agents back to the vasculature), Ve 
(effective volume of distribution), rBF (relative 
blood flow), rBV (relative blood volume), IAUGC 
(initial area under gadolinium curve) can be 
obtained. The values are then fitted with statisti-
cal models for analysis.
 P Nathan and A Vinayan
http://tam.sagepub.com 121
In 2008, Flaherty and colleagues published a 
pilot study, which used DCE-MRI assessment 
in patients with metastatic RCC treated with 
sorafenib. This study showed that inhibition of 
tumour vascular permeability by sorafenib, dem-
onstrated by a reduction in Ktrans, was associated 
with improved progression free survival (PFS) 
(p = 0.01). Elevated baseline Ktrans was a statisti-
cally significant predictive marker for favourable 
response to treatment (p < 0.02) [Flaherty et al. 
2008]. A prospective randomized phase II study 
again with sorafenib in RCC by Stadler and col-
leagues also showed a good correlation of high 
baseline Ktrans with improved PFS (p < 0.027). In 
this study, however, change in Ktrans or IAUGC90 
were not significantly related to PFS [Hahn et al. 
2008]. Further trials are underway to evaluate the 
use of DCE-MRI in RCC.
Most modern MRI scanners have the ability to 
perform these image acquisitions but there are 
several limitations to widespread use. Imaging 
protocols need to be optimized according to the 
area to be scanned and the type of tumour being 
analysed. The appropriate software needs to be 
available and there also remain issues regarding 
quantification, tumour heterogeneity and motion 
artefact. Low molecular weight gadolinium, 
which is used as standard, has a limitation as 
these small agents rapidly leak out of the highly 
permeable vasculature in the tumour. This in 
turn affects the data acquisition in dynamic imag-
ing as this is defined by vascular permeability and 
tumour perfusion. Gadolinium in higher molecu-
lar weight conjugates could be used to overcome 
this problem, as these are less sensitive to vascular 
permeability.
Lamuraglia and colleagues used DCE-US along 
with a new perfusion software as a predictive 
tool in metastatic RCC [Lamuraglia et al. 2006]. 
Thirty patients who were enrolled in a randomized 
clinical trial comparing sorafenib with placebo 
were recruited. DCE-US examination was per-
formed at baseline, week 3 and week 6. The good 
responders were defined by a combination of a 
decrease in contrast uptake greater than 10% and a 
stable or decrease in tumour size. The responders 
identified at week 3 had a statistically significant 
improvement in PFS (p < 0.0004) and overall sur-
vival (OS) (p < 0.0004) over the nonresponders.
A recent prospective multicentre study by Lassau 
and colleagues investigated the use of DCE-US 
as a predictive biomarker in patients treated with 
antiangiogenic agents. A total of 539 patients 
with different tumour types including 157 patients 
with RCC were recruited from 19 centres in 
France. Perfusion parameters were collected from 
these patients with DCE-US at baseline, on day 
7, day 14, day 30, day 60 and 2 monthly thereaf-
ter. This was correlated to the RECIST assess-
ment performed 2 monthly. They showed that a 
decrease in area under the curve (AUC) by more 
than 40% at 1 month was predictive of response 
for time to progression (TTP) (p < 0.01) and OS 
(p < 0.04) [Lassau et al. 2012].
A simultaneous study with DCE-US from Toronto 
by Williams and colleagues in 17 patients with 
metastatic RCC treated with sunitinib showed a 
decrease in median tumour fractional blood vol-
ume by 73.2% after 2 weeks of treatment with a 
disruption-replenishment infusion method of 
microbubble and a significant decrease in bolus 
peak with the bolus method. In this study no defi-
nite correlation was noted with best response as 
assessed by RECIST [Williams et al. 2011].
US is a widely available and inexpensive technique. 
Therefore performing frequent and serial examina-
tions at short intervals is possible when using this 
technique. However, the main problem with US is 
the limited ability to penetrate through large areas 
of tissue when trying to image deeply located 
tumours, and more specifically, the inability to 
penetrate through air or bone. Because RCC fre-
quently metastasizes to the lung and mediastinum, 
the use of DCE-US in large cohorts of patients is 
unknown. A potential advantage of DCE-US is the 
fact that the microbubbles are intravascular and 
therefore, in theory, the quantification of tumour 
perfusion should not be affected by vessel perme-
ability. However, the technique tends to be more 
operator dependent and those with the relevant 
skills are not available in all locations.
To date, no studies have been published using 
DCE-CT as a tool for treatment response predic-
tion in RCC. This technique does hold promise 
as the concentration kinetics of the contrast are 
related directly and linearly to enhancement and 
analysis is therefore relatively straight forward 
[Miles, 2002]. However, there is little general 
agreement about the techniques to use for model-
ling and further quantitative analysis. Evidence 
from rectal carcinoma showed that baseline blood 
flow and blood volume were significantly lower in 
nonresponders compared with responders treated 
with chemoradiotherapy [Bellomi et al. 2007]. 
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The study also showed a significant decrease in 
blood flow, blood volume and permeability sur-
face area product post treatment. CT scanning is 
the commonest tool used at present to monitor 
treatment response, therefore it would be a prac-
tical and easy option to incorporate DCE-CT 
protocols in almost all centres once a general 
agreement is obtained and the technique is vali-
dated further.
Imaging techniques that use no external contrast 
agent. A number of MRI techniques which do 
not resort to an external contrast agent have been 
developed and are being assessed as biomarkers 
of treatment response. Between 20% and 30% 
of patients with RCC are unable to have exter-
nal contrast due to renal impairment and tech-
niques that do not resort to external contrast are 
thus valuable[Nathan et al. 2010]. These tech-
niques use the magnetic field to modify the 
magnetic properties of the tissue including the 
tumour.
ASL-MRI uses the inherent nuclear spin of 
endogenous water protons to label arterial blood. 
Quantitative images of blood flow to the tissue can 
be generated by differential labelling inside and 
outside the tissue of interest. The technique has 
potential to be used as a quantitative marker for 
response assessment to antivascular treatment. 
The feasibility of this technique to monitor 
response to antiangiogenic therapy in RCC 
metastases was demonstrated by de Bazelaire 
and colleagues [de Bazelaire et al. 2005]. In a 
phase II trial of 10 patients, ASL-MRI and 
DCE-MRI were used to assess the treatment 
response in patients with metastatic RCC 
treated with an antiangiogenic agent (PTK787/
ZK222584). The study showed that changes in 
blood flow detected by ASL-MRI at 1 month 
correlated with the change in tumour size 
measured at 4 months or at disease progression 
(p < 0.01) [de Bazelaire et al. 2008]. If validated 
in larger studies, ASL-MRI thus might prove to 
be an important biomarker in early assessment 
of treatment response.
Techniques such as blood oxygen level dependent 
MRI (BOLD-MRI) and DW-MRI which use no 
external contrast are other methods with poten-
tial to predict treatment response. BOLD-MRI 
uses the difference in magnetic properties of oxy-
haemoglobin and deoxyhaemoglobin and hence 
BOLD signals are related to tumour hypoxia. 
DW-MRI evaluates the property of water 
diffusion depending on the Brownian motion of 
the water molecules in tissues. Desar and col-
leagues noted that sunitinib-induced antiangio-
genic effects in RCC can be reliably measured 
with DW-MRI as early as 3–10 days after starting 
the treatment [Desar et al. 2011]. This needs fur-
ther evaluation before it can be reliably used as a 
predictive biomarker. There are as yet no pub-
lished data with either of these techniques to pre-
dict responses in RCC to targeted therapies.
Assessment of change in metabolic activity
Fluorodeoxyglucose (FDG)-PET/CT scan is a 
valuable tool, which has already established its 
role in the assessment and management of many 
tumour types. By combining a short-lived radioac-
tive tracer with a biologically active molecule, 
PET scan provides a functional map of the disease 
investigated. The most common biological mole-
cule used in oncology is FDG. This glucose ana-
logue is rapidly and preferentially taken up by the 
rapidly growing malignant cells, thus leading to 
intense radiolabelling of that tissue. A combined 
CT and PET scan provides a combination of met-
abolic activity with anatomical localization of tis-
sues. The use of FDG-PET/CT in treatment 
response assessment, that is, as a predictive marker 
in RCC, looks promising but has not been fully 
evaluated. A recent study by Powles and col-
leagues looked at the use of sequential FDG-PET 
scanning as a correlative marker of OS in patients 
with RCC treated with sunitinib [Powles et al. 
2010]. A total of 44 patients were enrolled in 
this phase II study. Patients had three FDG-
PET scans: before treatment, at 4 and 16 weeks. 
Reduction in maximum standardized uptake value 
(SUVmax) by 20% was considered a response and 
was correlated with OS. The study showed that 
high baseline SUVmax suggested a trend towards 
low OS [hazard ratio (HR) 3.30; 95% confidence 
interval (CI) 1.36–8.45]. Metabolic response was 
noted on the PET scan after 4 weeks. However, 
disease progression according to the 16-week scan 
correlated with a decreased OS (HR –5.96; 95% 
CI –2.43 to +19.02).
Similar results were noted in smaller trials of 12 
patients and 14 patients by Minamimoto and 
Revheim and colleagues respectively [Minamimoto 
et al. 2010; Revheim et al. 2011]. Using a 20% 
reduction in FDG-PET uptake, Minamimoto and 
colleagues were able to separate good responders 
with a mean PFS of 233.8 days and poor respond-
ers with a PFS of 75 days.
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A pharmacodynamic study using serial 3deoxy3’ 
fluorothymidine PET (FLT-PET) scans on 
patients at baseline, during treatment with suni-
tinib and after withdrawal of drug within cycle 1 
showed an increase in cellular proliferation dur-
ing sunitinib withdrawal [Liu et al. 2011]. This is 
noted to associate with VEGF ligand levels and 
early exploratory analysis suggests that the extent 
of flare could predict poorer clinical benefit from 
the drug.
New criteria for response assessment
RECIST criteria depend upon the change in sum 
of the unidimensional measurements of target 
lesions. However, the clinical benefit does not 
always correlate with change in size alone in 
tumours treated with targeted therapies. Emerging 
evidence shows that some patients continue to 
derive clinical benefit from continuation of suni-
tinib after documented disease progression based 
on RECIST criteria [Teo et al. 2012]. This retro-
spective analysis of 39 patients treated with suni-
tinib showed that such use of a tyrosine kinase 
inhibitor (TKI) beyond progression gives pro-
longed disease control and is safe. The use of 
RECIST alone as a measure of treatment response 
is therefore arguable.
Choi criteria. Choi proposed an alternative set of 
criteria for the assessment of gastrointestinal stro-
mal tumours (GIST) treated with the targeted 
agent imatinib [Choi, 2008; Choi et al. 2007]. 
The Choi criteria require either a change in size 
or a change in density (contrast enhancement) to 
predict a response. They have been found to be 
more reliable than RECIST in monitoring GIST 
responses to treatment using PET-CT as a gold 
standard. It has been suggested that the Choi cri-
teria could be suitable for assessment of targeted 
therapies in other cancers, but this has not yet 
been extensively evaluated.
In renal cancer, van der Veldt and colleagues have 
analysed the use of Choi criteria in treatment 
response assessment in RCC and found them to 
correlate better to TTP than RECIST [van der 
Veldt et al. 2010]. A total of 55 patients with meta-
static RCC treated with sunitinib were analysed 
retrospectively. The pretreatment and first evalua-
tion post-treatment scan were analysed with 
RECIST and Choi criteria separately and corre-
lated with PFS and OS. At first evaluation, 
according to the RECIST criteria, seven patients 
had a response, 38 had stable disease and 10 had 
progressive disease. According to the Choi crite-
ria, these numbers were 36, 6 and 13 respectively. 
In patients having a partial response, the Choi cri-
teria had a significantly better predictive value for 
PFS and OS (p < 0.001 for both) than RECIST 
(p = 0.689 and 0.191 respectively). The predic-
tive value of RECIST increased to a statistically 
significant level only when best response during 
treatment was taken into account.
The Choi criteria and RECIST were again com-
pared with a smaller cohort of 22 patients treated 
with sorafenib reported by Hittinger and colleagues 
[Hittinger et al. 2011]. Even though the Choi cri-
teria defined more patients as responders, they 
did not differentiate between patients who did 
and those who did not have therapeutic improve-
ments in PFS or OS.
’Modified’ Choi criteria. We proposed a modifi-
cation of the Choi criteria in the assessment of 
treatment response to targeted therapy in meta-
static RCC in which both a change in size and 
density are required [Nathan et al. 2010]. The 
standard Choi criteria require a decrease in size 
by 10% or a decrease in CT contrast enhance-
ment by 15% for a response. We suggested a 
modification of the Choi criteria in which both a 
minimum 10% size decrease and a 15% reduc-
tion in enhancement are required to define a 
response. We performed a retrospective study of 
32 patients with metastatic RCC treated with 
TKIs. Twelve patients were excluded as they did 
not have contrast-enhanced scans due to renal 
dysfunction. Both baseline and 12-week post-
treatment contrast-enhanced scans were collected 
and analysed. According to the response obtained 
on the 12-week scan, patients were assigned to 
progressive disease, stable disease or partial 
response using RECIST, Choi and modified 
Choi criteria, correlated with TTP. Patients who 
had a partial response according to the modified 
Choi criteria had a statistically significant longer 
TTP than those who were deemed to have sta-
ble disease (mean 448 versus 89 days, p = 0.002). 
Neither RECIST nor Choi criteria defined par-
tial responders went on to have a significant 
improvement in TTP compared with those 
who had stable disease. Further larger trials are 
planned to validate these results. CT enhance-
ment was measured in the arterial phase rather 
than in the more usual portovenous phase in this 
study. This may be relevant as renal tumours are 
highly vascular and enhance well in the arterial 
phase [Lee et al. 2005; Raptopoulos et al. 2001].
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Size and attenuation CT criteria/morphology, attenu-
ation, size and structure criteria. Another study 
exploring the use of a combination of change in 
size and CT attenuation to predict treatment 
response in metastatic RCC was published by 
Smith and colleagues [Smith et al. 2010a]. Con-
trast-enhanced CT scans of 53 patients with met-
astatic RCC treated with either sunitinib or 
sorafenib were analysed. In calculating the attenu-
ation data, Smith and colleagues used volumetric 
mean attenuation of target lesions in place of mean 
attenuation in the most representative axial image. 
They proposed new imaging criteria, size and 
attenuation CT (SACT) criteria. The criteria 
defined favourable response as any of the follow-
ing: a decrease in tumour size of at least 20%; a 
decrease in tumour size of at least 10% and at least 
half of nonlung target lesions with decreased mean 
attenuation of at least 20 Hounsefield units (HU); 
or one or more lung lesions with decreased mean 
attenuation by at least 40 HU. Unfavourable 
response was defined as any of the following: an 
increase in tumour size of at least 20%; new metas-
tasis; marked central fill in of a target lesion; or new 
enhancement in a homogenously hypoattenuating 
nonenhancing mass. A comparison was made 
between the SACT criteria, RECIST criteria and a 
modification of the Choi criteria (with volumetric 
attenuation data of the whole tumour rather than 
mean attenuation in an axial slice) in predicting a 
PFS greater than 250 days in this patient popula-
tion. The favourable response defined by the SACT 
criteria had a sensitivity of 75% and a specificity of 
100% in identifying patients with PFS greater than 
250 days. These values were 16% and 100%, and 
93% and 44% for the RECIST criteria and volu-
metric modified Choi criteria, respectively.
The same group attempted to improve on the 
SACT criteria by including specific morphologic 
or structural changes (e.g. necrosis) and eliminat-
ing the need for volumetric three-dimensional 
analysis in their new criteria [referred to as mor-
phology, attenuation, size and structure (MASS) 
criteria] [Smith et al. 2010b]. According to the 
MASS criteria, favourable response was defined as 
no new lesion and any of the following: a decrease 
in tumour size of at least 20%; one or more pre-
dominantly solid enhancing lesions with marked 
central necrosis or marked decreased attenuation 
(≥40 HU). An unfavourable response was defined 
as an increase in tumour size of at least 20% in the 
absence of marked necrosis or marked decreased 
attenuation; and new metastasis, marked central 
fill-in, or new increased enhancement. Other 
changes, which did not fit in with these criteria 
were classified as an indeterminate response. The 
MASS criteria showed an increased sensitivity of 
86% and specificity of 100% in recognizing good 
responders (TTP and improved disease specific 
survival p < 0.0001).
The group further recommended that the combi-
nation of  memorial sloan kettering cancer centre 
(MSKCC) criteria and MASS criteria together 
could give a high overall accuracy in identifying 
patients with PFS less than 1 year or at least 1 
year [Smith et al. 2011].
Tumour burden and growth rate. Basappa and 
colleagues investigated the effect of tumour bur-
den (TB) with treatment with VEGF-targeted 
therapy. Sixty-nine patients were retrospectively 
analysed. Median TB and site of metastasis were 
examined. With multivariate analysis, at baseline, 
the total number of metastases (<10) and the TB 
above the diaphragm (<6.5 cm) were independent 
positive predictors of OS [Basappa et al. 2011]. 
TB (p = 0.003) and total metastases (≤12) were 
noted as predictors of OS at TTP.
Initial tumour size and the rate of size reduction 
in response to targeted therapy were predictive 
markers reported by Yuasa and colleagues[Yuasa 
et al. 2011]. In this 139-patient retrospective 
analysis, a linear, moderate to strong association 
was noted between the pretreatment tumour size 
and reduction in growth rate on therapy (correla-
tion coefficient –0.441, p < 0.001). When a thresh-
old value of 23.9 mm was applied, it was noted 
that the smaller tumours showed a better rate of 
shrinkage (p < 0.001).
Use of tumour growth rate (TGR) was retrospec-
tively analysed by Ferte and colleagues [Ferte 
et al. 2012]. Images from patients recruited to 
large phase III trials with sorafenib (TARGET) 
and everolimus (RECORD) were assessed (n = 
902). TGR was defined as the value obtained by 
dividing tumour shrinkage by time between two 
evaluations. All treatment periods, including 
before, under treatment (at first cycle), at pro-
gression and after treatment interruption, were 
noted. The results showed that the TGR under 
treatment was significantly decreased with both 
sorafenib and everolimus. High TGR under treat-
ment was associated with poor PFS (HR 2.6) and 
OS (HR 2.3) in patients treated with sorafenib 
and poor OS (HR 1.2) in the smaller everolimus 
cohort. TGR after interruption was significantly 
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higher in both sorafenib and everolimus cohorts 
than TGR at progression (14.6 versus 31 and 17.9 
versus 32.1, respectively). The inclusion of TGR 
thus allows the practitioner to evaluate the tumour 
response more carefully.
The threshold of tumour response as change in 
sum of longest diameter (∆SLD) to mammalian 
target of rapamycin inhibitor everolimus was 
investigated by Oudard and colleagues [Oudard 
et al. 2012]. The data from the phase III 
RECORD-1 trial were analysed and a series of 
arbitrary thresholds were identified to attempt to 
distinguish responders from nonresponders. With 
response defined by the optimal threshold of 
–5%∆SLD, the median PFS was 8.4 months for 
the responders and 5.0 months for the nonre-
sponders (HR 2.4).
Prognostic biomarkers
Imaging biomarkers that provide an insight into 
the natural course of the disease are of potential 
use in identifying patients who are most or least 
likely to benefit from treatment as well as in inter-
preting clinical trials. The prognosis of any malig-
nancy could be related to a variety of factors. 
RCC is a heterogeneous group of diseases. There 
are a number of histological subtypes and within 
each subtype there is a widely varying natural his-
tory between patients. Some tumours are very 
aggressive while others remaining indolent. Some 
patients experience stable metastatic disease for a 
significant period of time that does not require 
systemic treatment until progression is seen.
Several clinicopathological prognostic models are 
designed to assess survival in the postnephrec-
tomy [Leibovich score, University of California, 
Los Angeles (UCLA) score] [Leibovich et al. 
2005; Zisman et al. 2001] and metastatic setting 
(Motzer score, UCLA score) [Motzer et al. 1999]. 
These prognostic models use histological fea-
tures, including Fuhrman grade and necrosis, 
performance status and a variety of biochemical 
markers for categorization into prognostic groups.
The MSKCC (Motzer) criteria classified patients 
into good, intermediate and poor prognostic 
groups depending on five factors: primary 
tumour remaining in situ, Eastern Cooperative 
Oncology Group performance status, anaemia, 
lactate dehydrogenase level and hypercalcaemia. 
Median survival in patients with zero risk fac-
tors was 20 months but median survival in the 
intermediate-risk group (one or two risk factors) 
and the poor prognostic group (more than two 
risk factors) were 10 months and 4 months respec-
tively [Motzer et al. 1999]. The MSKCC criteria 
have been widely used in many phase III trials of 
RCC evaluating antiangiogenic agents either to 
stratify patients in trial analysis [Escudier et al. 
2007b; Motzer et al. 2007b, 2008] or to define 
entry criteria in other trials [Escudier et al. 2007a; 
Hudes et al. 2007].
Evidence from these trials showed that the benefi-
cial effects of these drugs were maintained across 
prognostic groups but were significantly greater 
in good and intermediate prognostic groups. 
Hence prognostic grouping of RCC has an impor-
tant role in selection of treatment and also in 
determining the time of introduction of systemic 
treatment. Imaging techniques can potentially act 
as noninvasive tools in identifying these prognos-
tic factors. These include assessment of histologi-
cal subtype, nuclear grading and in the accurate 
staging of disease.
Assessment of histological subtypes
There has been debate as to whether prognosis of 
RCC varies significantly with histological sub-
type. Studies have in part been hampered by 
small numbers of the rarer subtypes and associ-
ated lack of control for other prognostic factors. 
RCC can be subclassified according to histology 
as clear cell, papillary type I and II, chromophobe, 
sarcomatoid, collecting duct and a variety of 
very rare and unclassified subtypes(World Health 
Organization classification) [Ebele et al. 2004; 
Kovacs et al. 1997]. The clear cell (conventional) 
subtype is the most common and accounts for 
approximately 70% of cases. The papillary sub-
type accounts for around 15–20% of cases. The 
type II papillary and other subtypes are less 
common. There is good evidence that tumours 
with sarcomatoid elements have a poorer prog-
nosis than the majority of tumours without 
[Cangiano et al. 1999].
With the emerging possibility that treatment deci-
sions may be influenced by histological subtype, 
together with the fact that core biopsy is associ-
ated with diagnostic inaccuracy [Lebret et al. 
2007] a noninvasive technique to assess histologi-
cal subtype would be of potential clinical value. A 
number of different imaging modalities have been 
assessed for this purpose. These include multi-
slice CT, DW-MRI and DCE-MRI.
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Sheir and colleagues attempted to use multislice 
CT to differentiate histological subtypes. They 
reviewed 87 CT images of patients with RCC ret-
rospectively and compared them with histopathol-
ogy. Biphasic CT scans of the kidneys were 
performed using unenhanced, corticomedullary 
phase (CMP) and excretory phase (EP) (30 and 
300 s after contrast injection respectively) proto-
cols. It was noted that the degree of enhancement 
in the CMP and EP was the most valuable param-
eter in attempting to differentiate between histo-
logical subtypes (p < 0.001). Mean CT attenuation 
(+2 standard deviations) in the CMP was 138.2 ± 
38.0 HU for clear cell, 89.2 ± 31.4 HU for papil-
lary and 55.17 ± 24.0 HU for chromophobe 
tumours. In the excretory phase, clear cell tumours 
showed an enhancement of 73.0 ± 17.6 HU while 
papillary and chromophobe had an enhancement 
of 70.0 ± 10.4 and 33.9 ± 12.1 HU respectively. 
The difference between subtypes in both the CMP 
and EP was statistically significant (p < 0.001). 
The cutoff value for highest accuracy for diagnosis 
of clear cell carcinoma was 83.5 HU for CMP and 
64.5 HU for EP. Other factors such as presence or 
absence of cystic degeneration, tumour vascularity 
and pattern of enhancement also supplemented 
this differentiation [Sheir et al. 2005].
Pedrosa and colleagues attempted evaluation of 
malignant renal tumours with the help of noncon-
trast-enhanced and contrast-enhanced MRI and 
correlated this with histology. The study cohort 
consisted of 76 patients who had both MRI and 
histological confirmation [Pedrosa et al. 2008]. 
Renal masses were analysed for size, location, 
necrosis, haemorrhage, signal intensity and uni-
formity of signal intensity, type and extent of fat 
and contrast enhancement, peri-renal fat invasion 
and renal vein thrombosis. They were then assigned 
to one of eight different groups defined according 
to MRI appearance. The results were compared 
with the histological analysis and the sensitivity 
and specificity of these MRI groups were calcu-
lated to predict the histological diagnosis and 
nuclear grade. The MRI classification had a sen-
sitivity of 93% and specificity of 75% for the diag-
nosis of clear cell subtype, using the presence of 
solid enhancing mass with or without necrosis. 
Retroperitoneal collaterals, intravoxel fat signal 
and necrosis all correlated directly with clear cell 
subtype. MRI features such as hemorrhagic cyst 
with peripheral enhancing growth in the wall and 
solid hypo-enhancing homogeneous masses with 
low SI on T2-weighted images were predictors of 
the papillary subtype with good sensitivity (80%) 
and specificity (94%).
Sun and colleagues explored the use of DCE-MRI 
as a tool in predicting the histopathological sub-
type of RCC. They compared the difference in 
enhancement pattern in CMP and nephrographic 
phase images with histopathology. In both the 
CMP and nephrographic phase, clear cell tumours 
showed maximum signal intensity change and 
papillary tumours the least. Signal intensity change 
in the CMP was the most effective parameter dif-
ferentiating clear cell and papillary subtypes with a 
sensitivity of 93% and a specificity of 96% [Sun 
et al. 2009]. DCE-MRI was also useful in predict-
ing the nuclear grade of the tumour as reported by 
Palmowski and colleagues. Twenty-one patients 
were analysed with DCE-MRI presurgically; 
tumour perfusion and tissue–blood ratio were 
noted for the entire tumour and also for the most 
highly vascularized area in the tumour. Higher 
grade tumours had significantly higher perfusion 
values (p < 0.05) in the most vascular area [2.14 ± 
0.89 versus 1.40 ± 0.49 ml/g/min) and the entire 
tumour (1.59 ± 0.44 versus 1.08 ± 0.38 ml/g/min) 
[Palmowski et al. 2009].
These imaging techniques are of interest, how-
ever their use in clinical practice will require much 
more robust validation and they are unlikely to 
replace the use of histological diagnosis in the 
near future.
Staging of renal cell carcinoma
Accurate staging of RCC is an important factor 
influencing the prognosis. While CT, MRI, PET 
and bone scans all are used routinely in staging a 
variety of different cancers, there is debate regarding 
the usefulness of some of these techniques in RCC.
Assessment of skeletal metastasis. Nuclear 
medicine (NM) bone scans with Tc99 provide 
limited anatomical detail and only provide infor-
mation about tumour deposits where an osteoblas-
tic reaction has occurred. RCC bony metastases 
are predominantly osteoclastic, resulting in a low 
sensitivity of conventional bone scans. Stauden-
herz and colleagues showed that the sensitivity of 
bone scintigraphy varied from 10% to 60% in 
RCC [Staudenherz et al. 1999].
MRI has been suggested as a more sensitive tool 
in the assessment of skeletal metastasis than NM 
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bone scan. A recent study by Sohaib and col-
leagues compared the efficacy of whole body MRI 
scan and NM bone scan in the assessment of 
bony RCC metastasis. This prospective study of 
47 patients showed that even though both bone 
scan and MRI were highly specific (94% versus 
97%), the sensitivity of whole body MRI scan was 
much superior (94%) to bone scan (62%) in the 
detection of renal metastasis to bone (p = 0.007). 
MRI also had the advantage of assessment of soft 
tissue disease simultaneously [Sohaib et al. 2009].
Assessment of visceral disease. For assessment 
of lymph node and visceral disease, FDG-PET 
scan has been found to be extremely sensitive in 
characterizing metastases from a variety of tumour 
types. However, there is a significant incidence of 
false-positive results, which is perhaps not surpris-
ing given that FDG is not a cancer-specific tracer 
[Antoch et al. 2003; Schmidt et al. 2006]. Small 
lesions in the lung and liver may remain FDG 
occult due to smearing of the signal as a result of 
organ motion. Use of PET-CT is also inferior to 
whole body MRI in cancers with a frequent meta-
static spread to the bone, liver and central ner-
vous system [Antoch et al. 2003; Schmidt et al. 
2005]. Poor uptake of FDG has also been noted 
in tumour types such as RCC, prostatic malig-
nancy and low-grade soft tissue malignancies 
[Schmidt et al. 2006].
The value of FDG PET scans in RCC diagnosis is 
debated with multiple small studies showing sensi-
tivity ranging from 32% to 100% for initial diagno-
sis and staging of primary RCC [Montravers et al. 
2000; Nakatani et al. 2011]. The largest of these 
series, published by Kang and colleagues, included 
66 patients with RCC and showed a sensitivity of 
60% [Kang et al. 2004]. Nakatani and colleagues 
suggested a higher FDG sensitivity for RCC metas-
tasis but this has not yet been validated [Nakatani 
et al. 2011]. Larger series of studies are required to 
validate the use of FDG-PET scan in RCC but as 
the specificity of this technique was higher than 
conventional imaging in previous studies, its use 
would be limited at present as a tool to help resolve 
dilemmas in selected cases with equivocal conven-
tional imaging but high suspicion.
In a retrospective study by Le Moulec and col-
leagues, 21 patients with metastatic RCC who 
received FDG-PET/CT study at baseline and after 
2 months were evaluated [Le Moulec et al. 2010]. 
The study noted that patients with a negative PET/
CT had a better outcome (overall median survival 
not reached versus 23 months, 
p = 0.05). Patients with a median value of SUVmax 
greater than 5.7 had a short PFS and OS (3 
months versus 9 months, p = 0.03) and (23.3 months 
versus 9.1 months). Another observation in the 
study was that in eight patients the early PET/CT 
findings were consistent with the later CT results.
A recent as yet unpublished study from Japan by 
Nakaigawa and colleagues examined whether 
SUVmax from the pretreatment FDG-PET scan 
could be used as a prognostic marker for survival 
[Nakaigawa et al. 2012]. In 67patients enrolled and 
monitored in this study, the researchers noted that 
the SUVmax varied widely in RCC tumours from 
an undetectable level increasing to 16.6 (mean 7.6 
± 3.6) with an increasing trend towards poorer 
prognosis (p < 0.001, HR –1.289). The results were 
further analysed with SUVmax results stratified as 
less than 7.0, between 7.0 and 12 and greater than 
12.0. Median OS for patients was 1229 ± 991 days, 
446 ± 202 days and 95 ± 43 days respectively.
In a separate study of 35 patients, this group sug-
gested that an FDG-PET scan 1 month after 
treatment initiation could be used as a predictive 
marker for therapeutic response to TKIs based on 
whether the tumour size had increased and 
SUVmax had decreased by less than 20% or by at 
least 20% [Ueno et al. 2012].
Assessment of mechanism of drug action and role 
in drug development. Imaging biomarkers have 
an increasing role in early phase drug develop-
ment. The phase I trial end points have now 
moved away from the traditional end points of 
maximum tolerated dose and toxicity assessment 
to also incorporate pharmacodynamic end points 
which evaluate the mechanism of drug action and 
also to aid evaluation of the therapeutic window 
of these targeted agents.
With a view to streamlining the drug development 
process, the US Food and Drug Administration 
has approved performing exploratory investigator 
new drug (IND) studies (termed as phase 0 tri-
als). The purpose of these early studies is to assist 
in the go versus no-go decision for a product 
using human models than relying on inconsist-
ent animal data. Functional imaging has an 
important role in this setting as it can provide evi-
dence of drug activity as well as help in selection of 
the functional dose of the drug.
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128 http://tam.sagepub.com
Discussion
RCC appears to be more sensitive to treatment 
with antiangiogenic drugs than many other tumours 
due to the high vascularity of the tumour and its 
dependence on the VHL pathway in pathogene-
sis. With an increasing number of therapeutic 
agents in development, the need for biomarkers is 
more critical than ever for analysing efficacy and 
potentially improving the cost–benefit ratio of 
treatment. There are now emerging data about 
how these newer techniques could fit into the 
paradigm of RCC management, starting from ini-
tial diagnosis and staging to therapeutic response 
assessment. These early data need extensive and 
robust validation. Functional imaging with DCE-
MRI and DCE-CT holds promise as predictive 
and prognostic biomarkers in treatment response 
in patients with RCC. DW-MRI can give insight 
into histological subtypes and in the diagnosis of 
skeletal metastasis, which is appealing and may 
have utility in clinical practice. Evidence needs to 
be generated about the use of other techniques in 
RCC, such as ASL-MRI and MR spectroscopy.
In conclusion, in an area in which biomarker 
development is the focus of international research 
activity, imaging as a biomarker in RCC holds 
most promise in making an impact upon the clini-
cal management of this disease.
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Introduction
Imaging defined response assessment underpins evaluation of 
therapeutic effectiveness of many anti-cancer treatments in 
both routine clinical practice and drug development. Response 
Evaluation Criteria of Solid Tumors (RECIST) have been the 
standard method of treatment evaluation for solid tumors since 
their introduction in 2000. RECIST defined response depends 
on the size change in the sum of uni-dimensional measurements 
of the tumor target lesions performed with an imaging modal-
ity.1 While RECIST is clinically relevant for conventional che-
motherapeutic agents, this appears not to be the case for a new 
generation of targeted anti-cancer agents. Many targeted agents 
have profound anti-tumor effects with resulting clinical ben-
efit but low RECIST defined response rates. With sunitinib,2 
sorafenib3 and avastin + interferon,4 the treatment of renal cell 
Background: Response assessment is critical in evaluating effectiveness of anticancer treatment. Tyrosine kinase inhibitors 
(TKIs) in renal cell carcinoma (RCC) are associated with significant clinical benefit but may not result in significant tumour 
size reduction. Thus standard size-based response assessment with RECIST is insensitive, resulting in low response rates 
which do not reflect disease control measured by time to progression. We compared the use of combined size and density 
response criteria with standard size based criteria in metastatic RCC patients treated with TKI’s.
Results: Partial response (PR) and stable disease (SD) defined by modified criteria successfully identified patients with 
a long TTP (448 days) or short TTP (89 days) respectively (p = 0.002). Neither RECIST nor standard Choi criteria suc-
cessfully discriminated between patients having a short or long clinical benefit.
Patients and methods: CT scans from 32 patients with metastatic RCC treated with either sunitinib (18) or cediranib 
(14) were assessed. 12 patients were excluded from the analysis as 10 had non-contrast enhanced scans due to renal 
impairment and 2 stopped treatment due to toxicity. Scans from 20 evaluable patients at baseline and 12 weeks on treat-
ment were assessed using RECIST, Choi and modified criteria in which both a 10% decrease in size and 15% decrease in 
density were required to define a partial response (PR). Response assessment performed using each of the three methods 
was compared with time to disease progression (TTP) defined by RECIST using Kaplan-Meier statistics and Log-rank test 
with significance at 5%.
Conclusion: A combined reduction in both size and arterial phase density of RCC metastases treated with TKIs cor-
relates with TTP. RECIST and standard Choi criteria appear inferior.
CT response assessment combining reduction in 
both size and arterial phase density correlates with 
time to progression in metastatic renal cancer 
patients treated with targeted therapies
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Abbreviations: GIST, gastro intestinal stromal tumours; PR, partial response; RECIST, response evaluation criteria in solid 
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 RESEARCH PAPER
carcinoma (RCC) has been transformed. Progression free survival 
has doubled compared to either standard treatments or placebo. 
Yet, RECIST defined response rates are relatively low (Sunitinib 
31%,2 Sorafenib 10%3 and Avastin + interferon 30%4). Many 
patients who derive significant clinical benefit from these drugs 
never attain a RECIST defined response. Response criteria that 
correlate with clinical benefit are needed both in routine clinical 
practice and in clinical trials of novel targeted agents. This would 
allow early identification of non-responders which in turn would 
enable an early change in therapy and avoidance of unnecessary 
treatment-related side effects.
The first targeted therapy to demonstrate significant clinical 
benefit was imatinib, a potent c-kit antagonist, which has pro-
found activity against gastro-intestinal stromal tumors (GIST).5 
GIST tumors treated with imatinib usually shrink slowly with 
treatment but frequently develop a necrotic centre thus RECIST 
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Kaplan-Meier analyses are shown in Figure 1. Using the mod-
ified Choi criteria which combined reductions in size and den-
sity, there is a statistically significant difference in median time 
to progression between the PR and SD groups (Log Rank test 
p = 0.002). Kaplan-Meier curves for SD & PR groups defined 
by RECIST criteria showed no significant difference in median 
TTP (Log Rank test: p values of 0.643). As only a single patient 
had Choi criteria defined SD no statistical analysis was performed 
on this group.
A scatter plot (Fig. 2) demonstrates change in target lesion size 
and density for all patients between baseline scan and 3 month 
scan and identifies whether disease progressed in <100 days, 
100–199 days, 200–399 days or >400 days. It may be possible to 
identify thresholds other than 10% for size and 15% for density 
that give even greater separation between patients having long 
and short term benefit from TKIs although a larger population of 
prospectively acquired data would be required for this.
Discussion
Imaging defined response assessment is the cornerstone of mod-
ern oncological practice. For therapies which result in significant 
tumor shrinkage, imaging response criteria which are based solely 
upon change in tumor size may be entirely appropriate. A num-
ber of targeted treatments have been proven to be clinically active 
in advanced RCC and some have become standard of care. In 
large phase III trials it was observed that overall RECIST defined 
response rates were low (10–31%)2-4,11 but that (a) many patients 
had a degree of tumor shrinkage but less than a RECIST defined 
response and (b) RECIST responders were not the only patients 
who experienced clinical benefit with significant prolongation 
of progression free survival. The implication is that RECIST 
defined responses do not successfully identify groups of patients 
who either do or do not derive significant clinical benefit from 
targeted therapies.
RCC is a very vascular tumor and is therefore highly suit-
able for arterial based imaging. This is particularly so given that 
anti-angiogenic targeted therapies are significantly active in the 
treatment of advanced RCC. Arterial based imaging is therefore 
likely to be a sensitive method to detect clinically relevant anti-
angiogenic drug induced changes in this disease.
A number of modalities can be used clinically to assess changes 
in arterial blood supply. Both Dynamic Contrast Enhanced 
(DCE) MRI and DCE-Ultrasound have been demonstrated to 
be predictive of responses to sorafenib, a multi-targeted TKI, 
criteria are poor at predicting clinical benefit. Choi et al.5,6 devel-
oped a set of criteria for GIST tumors which incorporated a 
change in target lesion size of >10% or a change in density of 
>15%. These criteria have been shown to be better predictors of 
clinical response to imatinib than RECIST defined response and 
have been advocated as a more appropriate response assessment 
tool in this disease.5
It has been suggested that the Choi criteria may be suitable for 
targeted therapy assessment in other cancers6 but these criteria 
have not been extensively evaluated. A pilot study in soft tissue 
sarcoma showed that the Choi criteria were superior to RECIST 
in assessing treatment response of soft tissue sarcoma treated with 
chemotherapy and radiotherapy.7
In this study, we compare RECIST, Choi and “modified” 
Choi response criteria in which changes in both size and density 
of target lesions are required to define a response in RCC patients 
treated with the multi-targeted tyrosine kinase inhibitors suni-
tinib or cediranib, and their effect on time to progression and 
survival.
Results
Of the 32 patients, 18 had treatment with sunitinib and 14 had 
treatment with cediranib. 10 patients were excluded from the 
analysis as contrast enhanced scans were not performed due to 
impaired renal function and 2 patients ceased treatment due 
to toxicity rather than disease progression. Of the 20 evaluable 
patients, 11 were treated with sunitinib and 9 with cediranib.
Fourteen of 20 patients progressed on treatment with a 
median time to progression of 260 days. The remaining 6 evalu-
able patients remain on treatment and all have >1 year follow up 
(median: 483 days).
The number of patients having a partial response (PR) or sta-
ble disease (SD) defined by each of the three response criteria are 
shown in Table 1 together with the median time to progression 
(median TTP). No patients were seen to have progressive disease 
at the three month time point using any of the response criteria. 
The modified Choi criteria provided the greatest segregation of 
median TTP (95% CI) for the partial response (PR) and stable 
disease (SD) groups: 448 (99–797) days (PR) versus 89 (79–99) 
days (SD). On evaluation with RECIST criteria, median TTP 
(95% CI) was 168 (50–286) days in the PR and 428 (129–726) 
days in the SD group. Using Choi criteria, median TTP of the 
PR group was 399 (85–713) days. Only one patient had Choi 
criteria defined stable disease.
Table 1. Response classification according to RECIST, choi and modified choi criteria and association with time to progression (TTP)
Classification Partial response (PR) Stable disease (SD) Log rank
No. of patients TTP days median (95% CI) No. of patients TTP days median (95% CI) Test sign.
RECIST 5 168 (50–286) 15 428 (129–726) 0.643
Choi 19 399 (85–713) 1 * *
Modified criteria 13 448 (99–797) 7 89 (79–99) 0.002
Patients who had a partial response according to modified Choi criteria had a statistically significant longer time to progression than those who were 
deemed to have stable disease (mean 448 vs. 89 days, p = 0.002); Neither RECIST nor Choi criteria defined partial responders went on to have a 
significant improvement in TTP compared to those who had stable disease.
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The Choi criteria, developed for response evaluation of imatinib 
treated GIST tumors, define a partial response by either a 10% 
reduction in size or a 15% reduction in density during the portal 
venous phase of contrast.
In this study we compared RECIST, Choi and “modified” 
Choi criteria in which both a minimum of a 10% reduction in 
in patients with advanced RCC. In two small studies DCE-
MRI defined baseline Ktrans was predictive of PFS.12,13 DCE-
ultrasound defined responses in which a 10% reduction in 
enhancement were included in response criteria also correlated 
with PFS.14 We have used arterial-phase contrast enhanced CT 
scans to evaluate standard RECIST, Choi, and modified criteria. 
Figure 1. Kaplan-Meier curve for  time to disease progression: 1a)RECIST estimated  median TTP 168 and 428 days for PR and SD group with log 
rank P value 0.643. 1b) with Choi criteria estimated median TTP was 399 for the PR group. As only 1 patient had Choi defined SD, no statistical analy-
sis was performed.  1c) Modified choi criteria showing a TTP 448 and 95 days for PR and SD groups with a significance of p=0.002 with log rank p test. 
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ROI analysis remains a topic of debate, but there is 
preliminary evidence to suggest that the most repro-
ducible method is to delineate the ROI around the 
tumor outline,16 as performed in this study.
This small study requires validation on a larger 
dataset, ideally with images taken from a variety of 
scanning centres to demonstrate the broader applica-
bility of this technique.
It remains to be seen whether these modified 
response criteria are suitable for contrast enhanced 
CT studies that are acquired at a single phase, most 
commonly the portal-venous phase. It is likely, from 
clinical experience, that reduction in enhancement of 
tumors will be less marked in this contrast phase.
There is significant clinical need to be able to 
identify which patients are likely to derive most ben-
efit from targeted agents early in treatment. This 
would allow an early change in therapeutic option for 
patients who are unlikely to benefit and avoidance of 
unnecessary toxicities.
In conclusion, we have observed that response 
criteria that account for changes in both size and 
enhancement of arterial perfusion in advanced renal 
cell carcinoma better predict for outcome with TKI 
based treatment than standard RECIST or Choi cri-
teria and may be more appropriate.
Patients and Methods
32 patients with metastatic clear cell renal cell carci-
noma, who started treatment with the multi-targeted 
tyrosine kinase inhibitors (TKI’s) sunitinib or cediranib at Mount 
Vernon Cancer Centre between November 2005 and February 
2008 comprised the study group. Patients receiving cediranib 
were enrolled on a phase II clinical trial (Eudract 2006-002455-
33), patients receiving sunitinib were enrolled on an expanded 
access study (Eudract 2005-002097-30). All patients were receiv-
ing first line treatment for metastatic clear cell renal cell carci-
noma, all had a baseline CT scan performed within 4 weeks of 
starting treatment and all had a second CT scan at twelve weeks 
to assess response to treatment. At least one year of follow up 
data was available for each patient. Of the 32 patients, 10 were 
excluded from the analysis as impaired renal function precluded 
a contrast enhanced CT. A further two patients were excluded 
from the analysis as treatment was stopped due to toxicities rather 
than disease progression, leaving 20 evaluable patients.
All patients with no contraindications to intravenous con-
trast underwent contrast enhanced multidetector CT (Siemens 
Sensation 16, Siemens Medical Solutions, Forccheim, Germany). 
Following injection of 100 mL of 350 mg/mL iodinated contrast 
agent (Optiray, Covidien Healthcare, Mansfield, MA, USA) at 
4 mL/sec via a pump injector and saline chaser, the thorax and 
upper abdomen (from the supraclavicular fossa to the iliac crest) 
was imaged in the arterial phase of enhancement (25 sec delay). 
The abdomen and pelvis (from the dome of the diaphragm to the 
pubis) was imaged in the portal venous phase of enhancement 
size and a 15% reduction in density were required to define a 
response in metastatic RCC patients receiving either sunitinib or 
cediranib. The ability of each criteria defined response to corre-
late with RECIST defined time to progression was assessed.
Neither RECIST nor conventional Choi criteria defined 
responses correlated with time to progression. However “modi-
fied” Choi criteria defined responses successfully identified a 
group of patients with extended TTP (median 448 days) with 
non-responders having a significantly shorter TTP (median 89 
days). Thus the Choi criteria may not be applicable to renal 
cell carcinoma directly, but require tumor specific adaptation 
to account for differences in both tumor physiology and drug 
action. Arterial phase imaging is particularly appropriate for 
functional evaluation of RCC.
Arterial phase contrast enhanced CT imaging has a number 
of advantages over other methods evaluating arterial vascular 
changes in response to drug therapy such as DCE-MRI and 
DCE-US.13-15 The wide availability of CT scanners with fast 
scanning speeds enables arterial phase imaging at most centres. 
DCE-MRI is not available at most centres and not all tumor 
deposits are at anatomical sites assessable by DCE-US. All target 
lesions that are currently assessed by RECIST criteria should be 
amenable to assessment by our modified criteria. Nevertheless 
there are some issues with evaluation of tumor density using 
region of interest (ROI) analysis, that apply not just to CT but 
also to other imaging modalities. The best method to perform 
Figure 2. Scatter plot of change in density and change in size for all patients. TTP is 
indicated. 
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a 30% reduction in size or a 20% increase in size are assigned as 
stable disease (SD). Choi criteria require either a 10% reduction 
in size or a 15% decrease in the density of target tumors for a PR.5 
The modified criteria required both a decrease of 10% in size 
and a 15% reduction in enhancement in the arterial phase for a 
partial response (PR).
The time to disease progression (TTP) from the start of the 
treatment for individual patient was calculated from the follow 
up visit records. TTP was defined as the number of days from the 
start of therapy to the day in which progression was confirmed by 
standard RECIST radiological criteria. Patients were assigned to 
either the SD or PR groups defined by each of the three response 
criteria and an assessment of correlation with TTP performed.
Median time to disease progression (median TTP) with 95% 
confidence intervals were calculated from the Kaplan-Meier 
curves, and correlated with SD and PR classifications for the 
three response assessment criteria. The Log rank test was used to 
assess the significance of differences obtained in the analysis.
(70 sec delay). This is the standard protocol of our institution as 
evidence shows that highly vascular tumors such as renal cell car-
cinoma exhibit an early hyper-enhancement on multiphase CT.8,9
All CTs (baseline and 12 week scan) were analysed by an 
experienced oncological radiologist. This was a retrospective 
study. The radiologist was unaware of the time to progression of 
any of the patients in this study. Target lesions were selected in 
each patient. Target lesion size (cm) and Hounsfield unit (HU) 
density value at the arterial phase of enhancement were recorded 
in each patient. The HU density value was obtained by delineat-
ing a freehand region-of-interest (ROI) within the boundaries of 
the tumor outline, taking care to ensure this included the entire 
tumor visible. Patients were assigned to progressive disease (PD), 
stable disease (SD) or partial response (PR) using each criterion 
separately: RECIST, Choi and modified Choi criteria (Table 1). 
RECIST criteria1,10 mandates a 30% decrease in the size of sum 
of longest diameters of the target lesions for a partial response 
(PR) and a 20% increase in size of sum of longest diameters of 
the target lesions for progressive disease (PD). Changes less than 
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 Assessment of Response to 
Tyrosine Kinase Inhibitors in 
Metastatic Renal Cell Cancer:  CT 
Texture as a Predictive Biomarker 1 
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 Anup  Vinayan ,  FRCR 
 Kenneth A.  Miles ,  MD ,  FRCR 
 Purpose: To assess changes in tumor computed tomographic (CT) 
texture after two cycles of treatment with tyrosine kinase 
inhibitors (TKIs) and to determine if tumor texture cor-
relates with measured time to progression in patients with 
metastatic renal cell cancer who received TKIs.
 Materials and 
Methods: 
A waiver of institutional review board approval was ob-
tained for this retrospective analysis. Contrast material–
enhanced CT texture parameters were assessed in 
39 patients with metastatic renal cell cancer who received 
a TKI. A total of 87 metastases were analyzed at baseline 
and after two treatment cycles. Changes in tumor entropy 
and uniformity were derived with a software algorithm 
that selectively fi lters and extracts texture at different 
scales (fi ne to coarse detail: 1.0–2.5) and were recorded. 
Response assessment was also obtained by using response 
evaluation criteria in solid tumors (RECIST), as well as 
Choi and modifi ed Choi criteria. The correlation of texture 
parameters and standard criteria with measured time to 
progression was assessed by using Kaplan-Meier analysis 
and a Cox regression model. Statistical signifi cance was 
set at 5%.
 Results: Tumor entropy decreased by 3%–45% and uniformity in-
creased by 5%–21% for the different scale values after 
administration of a TKI. With a threshold change of  2 2% 
or less for uniformity at a coarse scale value of 2.5, Kaplan-
Meier curves of the proportion of patients without disease 
progression were signifi cantly different and better than those 
for standard response assessment ( P = .008 vs  P = .267,  P = 
.053, and  P = .042 for RECIST, Choi, and modifi ed Choi 
criteria, respectively). Cox regression analysis showed that 
texture uniformity was an independent predictor of time 
to progression (odds ratio, 4.02; 95% confi dence interval: 
1.52, 10.65;  P = .005).
 Conclusion: CT texture analysis refl ecting tumor heterogeneity is an 
independent factor associated with time to progression and 
has potential as a predictive imaging biomarker of response 
of metastatic renal cancer to targeted therapy.
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vasculature ( 15 ), and exploratory studies 
have suggested that image brightness and 
coarseness may yield predictive and prog-
nostic information in patients with non–
small cell lung cancer ( 16 ) and colorec-
tal cancer ( 17–21 ). To our knowledge, 
the potential of CT texture analysis has 
not been explored in this context in pa-
tients with renal cell cancer. 
 The aim of this study was to assess 
changes in tumor CT texture after two 
cycles of TKIs and to determine if tumor 
texture correlates with measured time 
to progression in patients with metastatic 
renal cell cancer treated with TKIs. 
 Materials and Methods 
 One author (B.G.) is the scientifi c di-
rector of TexRAD  (University of Sussex, 
Falmer, Sussex, England) , which pro-
vided the software used for analysis in 
this study. Another author (K.A.M.) is 
the clinical director of TexRAD. All other 
authors had control of the data and in-
formation submitted for publication. 
 Patients 
 Institutional review board waiver was 
obtained for this retrospective analysis. 
Patients with metastatic renal cell can-
cer who underwent treatment with TKIs 
at our institution (Mount Vernon Hospi-
tal, Northwood, England) between 2005 
and 2009 were identifi ed in a prospec-
tively recorded institutional renal cancer 
criteria and clinical outcome in patients 
with renal cell cancer ( [a] Choi criteria, 
partial response defi ned by 10% reduc-
tion in size or 15% reduction in en-
hancement [ 11 ];  [b] modifi ed Choi cri-
teria, partial response defi ned by both a 
10% reduction in size and a 15% reduc-
tion in enhancement [ 12 ];  [c] size and 
attenuation computed tomography [CT] 
criteria, favorable response defi ned 
by  . 20% reduction in size or  . 10% 
reduction in size and  . 50% of nonlung 
target lesions with  . 20 HU reduction in 
mean attenuation or one or more target 
lesions with  . 40 HU reduction in mean 
attenuation [ 13 ]; and  [d] morphology, 
attenuation, size, and structure criteria, 
favorable response defi ned by a  ! 20% 
decrease in tumor size or one or more 
predominantly solid enhancing lesions 
with marked central necrosis or marked 
decreased attenuation [ ! 40 HU] [ 14 ]). 
 Heterogeneity, such as heterogene-
ity of the tumor blood supply, is a well-
recognized feature of malignancy. CT 
texture analysis is an image processing 
algorithm that can be used to quantify 
this heterogeneity by assessing the dis-
tribution of texture coarseness and ir-
regularity within a lesion. Much of the 
heterogeneity visible at CT represents 
photon noise, which can mask any un-
derlying biologic heterogeneity. By us-
ing fi lters that select for image features 
at larger scales, CT texture analysis can 
be used to reduce the effect of photon 
noise while enhancing biologic heteroge-
neity. Heterogeneity at relevant scales 
can then be quantifi ed by using a range 
of parameters, including entropy and uni-
formity. Entropy is a measure of texture 
irregularity, while uniformity refl ects 
the distribution of gray levels within 
the tumor: higher entropy and lower 
uniformity represent increased tumor 
heterogeneity. Previous computer simu-
lation studies have shown that CT tex-
ture analysis may refl ect the underlying 
 The introduction of multitargeted ty-rosine kinase inhibitors (TKIs), in-cluding sunitinib, sorafenib, and pa-
zopanib, into clinical practice has doubled 
the duration of progression-free survival 
in patients with renal cell cancer when 
compared with standard treatment or 
administration of a placebo ( 1–3 ). As-
sessment of treatment response to TKIs 
remains a challenge. It is now well estab-
lished that conventional response evalu-
ation criteria in solid tumors (RECIST)-
defi ned response rates are far lower than 
the proportion of patients who derive 
clinically useful disease control ( 4 ). Sub-
stantial tumor necrosis may occur as a 
consequence of the antivascular effect, 
resulting in a change in tumor attenuation 
but little overall size change ( 5–8 ). This 
heterogeneity in tumor morphology is not 
taken into account by RECIST criteria, 
and a better method with which to assess 
and predict response is still needed. 
 Alternative response criteria incor-
porating size and enhancement change 
( 9,10 ) have been validated in patients 
with gastrointestinal stromal tumors 
that were treated with a targeted agent 
(imatinib) and applied to renal cell 
cancer treated with TKIs ( 11–14 ). Re-
cent studies have shown a correlation 
between various size and enhancement 
 Implication for Patient Care 
 The addition of texture analysis  n
to standard response assessment 
may improve the prediction of 
response to TKIs in patients with 
metastatic renal cell carcinoma. 
 Advances in Knowledge 
 CT texture analysis can reveal  n
changes in tumor heterogeneity 
after treatment of metastatic 
renal cell carcinoma with tyrosine 
kinase inhibitors (TKIs): tumor 
entropy decreases and uniformity 
increases. 
 Change in tumor heterogeneity  n
after two cycles of TKI therapy 
for metastatic renal cancer cor-
relates with measured time to 
progression; by using a threshold 
change of  2 2% or less for uni-
formity at a coarse scale value of 
2.5, Kaplan-Meier curves of the 
proportion of patients without 
disease progression were signifi -
cantly different and better than 
those for standard response 
assessment after two cycles of 
TKI therapy ( P = .008). 
 Published online before print 
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Figure 1
  
 Figure 1: Flowchart of study 
population and exclusion criteria. 
 ceCT = contrast-enhanced CT, 
 IV = intravenous,  mRCC = meta-
static renal cell carcinoma . 
 Table 1 
 RECIST, Choi, and Modifi ed Choi Criteria for Categorization of Response 
Response Criteria Partial Response Stable Disease Progressive Disease
RECIST  . 30% size reduction  , 30% size reduction and  , 10% size increase  . 20% size increase and new disease
Choi  . 10% size reduction or  . 15% 
 enhancement reduction
 , 10% size reduction or  , 15% enhancement 
 reduction
 . 10% size increase, enhancement criteria not 
 fulfi lled, and new disease
Modifi ed Choi  . 10% size reduction and  . 15% 
 enhancement reduction
 , 10% size reduction and  , 15% enhancement 
 reduction
 . 10% size increase, enhancement criteria not 
 fulfi lled, and new disease
database (A.V., P.N.). Inclusion criteria 
were as follows:  (a) Patients were TKI 
naïve and were receiving the drug as a 
fi rst- or second-line treatment for meta-
static renal cell carcinoma.  (b) Baseline 
contrast material–enhanced CT was per-
formed within 4 weeks before treatment 
commencement.  (c) Contrast-enhanced 
CT was performed after treatment to 
assess response. Exclusion criteria were 
as follows:  (a) Patients had contraindica-
tions to contrast-enhanced CT (previous 
iodinated contrast material hypersensi-
tivity reaction, renal impairment with 
serum creatinine level  . 120 µmol/L, 
or estimated glomerular fi ltration rate 
 , 60 mL/min).  (b) Intravenous cannula-
tion failed.  (c) Contrast enhancement 
was suboptimal (aortic enhancement 
 , 200 HU at 25 seconds). A total of 68 
patients were identifi ed in the institution 
database. Of these, 29 were excluded, 
leaving 39 patients for analysis (23 men, 
16 women; mean age, 61.43 years; age 
range, 38.6–75.8 years) ( Fig 1 ). 
 CT Examination 
 All patients underwent contrast-enhanced 
multidetector CT (Somatom Defi nition 
or Sensation 16; Siemens Healthcare, 
Forchheim, Germany) after injection of 
100 mL of an iodinated contrast agent 
(350 mg of iodine per milliliter, Optiray 
350; Covidien Healthcare, Mansfi eld, 
Mass) and a 50-mL saline chaser at a 
rate of 4 mL/sec via a pump injector. 
The thorax and upper abdomen (from 
the supraclavicular fossa to the iliac crest) 
were imaged in the arterial phase of en-
hancement (25-second delay), and the 
abdomen and pelvis (from the dome 
of the diaphragm to the pubis) were 
imaged in the portal venous phase of 
enhancement (70-second delay), as per 
the standard practice in our institution, 
with the following acquisition param-
eters: 120 kV; effective tube current, 
150 mAs (thorax) or 200 mAs (abdo-
men and pelvis) with dose modulation; 
pitch, 1.2; detector confi guration, 24.0  3 
1.2 mm; section collimation, 3 mm; fi eld 
of view, 300–450 mm; matrix, 512 mm. 
Target lesions were defi ned as per 
RECIST, version 1.1 (fi ve target lesions, 
maximum of two lesions per organ) ( 4 ). 
Initial response after two cycles of treat-
ment was categorized, as per RECIST. 
Tumor attenuation was measured with 
automated volume of interest analysis 
(syngoCT Oncology; Siemens Healthcare) 
encompassing the entire tumor (mean 
volume, 111 cm 3 ; range, 2–947 cm 3 ), and 
response was further classifi ed accord-
ing to Choi ( 9 ) and modifi ed Choi ( 12 ) 
criteria ( Table 1 ) by two radiologists 
working in consensus (V.G., J.K.J.; 
 . 12 and 7 years experience in CT im-
aging, respectively). 
 Textural Analysis 
 Arterial phase images underwent tex-
ture analysis performed with TexRAD, a 
proprietary software algorithm devel-
oped by Ganeshan et al ( 16 ) (Appendix 
E1 [online]). This was performed by an 
observer (B.G., 5 years of experience 
with texture analysis of CT images) who 
was blinded to the clinical outcome. 
The technique comprised an initial fi l-
tration step in which we used a Lapla-
cian of Gaussian spatial band-pass fi lter 
to selectively extract features of differ-
ent size and intensity variations. This 
resulted in a series of derived images 
that displayed features at different spa-
tial scales from fi ne to coarse within a 
region of interest (ROI) drawn around 
the renal metastasis ( Fig 2 ). The scale 
was selected by tuning the fi lter param-
eter between 1.0 and 2.5, where 1.0 
indicates fi ne texture (features of ap-
proximately 4 pixels in width); 1.5, 1.8, 
and 2.0 indicate varying degrees of me-
dium texture (features of approximately 
6, 8, and 10 pixels in width, respec-
tively); and 2.5 indicates coarse texture 
(features of approximately 12 pixels in 
width). After fi ltration, any pixels with 
negative values were assigned a value 
of zero. 
 ROIs were delineated around the tu-
mor outline. The ROI was further re-
fi ned by excluding areas of air with a 
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out disease progression at any given 
time. Differences between Kaplan-Meier 
curves for texture and RECIST, Choi, and 
modifi ed Choi criteria were evaluated 
by using a nonparametric log-rank test, 
with a  P value of less than .05 consid-
ered to indicate a signifi cant difference. 
After this, Cox regression analysis was 
performed to determine if any signifi cant 
parameters (texture and RECIST, Choi, 
or modifi ed Choi response criteria after 
two cycles of treatment) were indepen-
dent predictors of time to progression. 
 Results 
 All 39 patients had clear cell carcinomas, 
with the exception of two patients with 
papillary and sarcomatoid cancers. Patients 
measured time to progression were as-
sessed by using Kaplan-Meier analysis. 
The threshold values for texture param-
eters used in the Kaplan-Meier analysis 
were established with receiver operat-
ing charac teristic (ROC) analysis, which 
tested the ability of each parameter to 
help identify time to disease progres-
sion. The point on the ROC curve fur-
thest from the line of no discrimination 
was considered the optimum threshold 
for predicting a shorter time to progres-
sion. Time to progression was defi ned as 
the time from the date of baseline CT 
to the date of disease progression (de-
fi ned by RECIST criteria). Kaplan-Meier 
curves for patients with values above and 
below each threshold were constructed 
to display the proportion of patients with-
thresholding procedure that enabled us to 
remove from analysis any pixels with at-
tenuation below  2 50 HU. Mean ROI size 
was 2791 pixels (range, 72–17 442 pixels). 
Heterogeneity within this ROI was quan-
tifi ed with and without image fi ltration 
by calculating entropy (irregularity,  e ) and 
uniformity (distribution of gray level,  u ) 
with the following equations: 
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 where  I is the pixel value (between  I = 1 
to  k [where k is the highest pixel value]) 
in the ROI and  P ( I ) is the probability of 
the occurrence of that pixel value. Higher 
entropy and lower uniformity represent 
increased heterogeneity ( 18 ). 
 Entropy and uniformity were re-
corded for absolute scale values for each 
patient’s tumor on baseline CT images 
and CT images acquired after two cycles 
of treatment. The percentage change in 
image entropy and uniformity was also 
recorded. 
 Follow-up 
 This was defi ned by the clinical drug 
trial protocol. The minimum length of 
follow-up was 18 months after baseline 
CT or until disease progression if sooner. 
Disease progression during follow-up was 
defi ned with RECIST criteria and was 
confi rmed with subsequent imaging and 
clinical follow-up. 
 Statistical Analysis 
 For each patient, average texture mea-
sures from all metastases at baseline 
CT and at CT after two cycles of treat-
ment and the percentage change from 
the baseline value were used for statis-
tical analyses. Statistical analyses were 
performed by using software (MedCalc 
for Windows, version 9.2.0.0; Medcalc, 
Mariakerke, Belgium). The relation-
ship of texture parameters and RECIST, 
Choi, and modifi ed Choi response cri-
teria after two cycles of treatment and 
 Figure 2 
  
 Figure 2: Left and middle: Conventional CT image of a right upper lobe lung metastasis (upper left) 
and corresponding CT images selectively displaying fi ne (upper middle), medium (lower left), and coarse 
(lower middle) texture obtained with fi lter values of 1.0 (width, 4 pixels), 1.5 (width, 6 pixels), and 2.5 
(width, 12 pixels ). Right: Chart shows software processing steps undertaken to generate the data displayed.
 Table 2 
 Response Categorization of Patients after Two Treatment Cycles 
Response Criteria Partial Response Stable Disease Progressive Disease
RECIST 6 (15) 32 (82) 1 (3)
Choi 33 (84) 3 (8) 3 (8)
Modifi ed Choi 22 (56) 14 (36) 3 (8)
Note.—Data are numbers of patients. Data in parentheses are percentages.
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vs  P = .267,  P = .053, and  P = .042, re-
spectively) ( Fig 4 ). 
 Cox regression analysis indicated that 
the percentage change in coarse unifor-
mity was an independent predictor (odds 
ratio, 4.02; 95% confi dence interval: 
1.52, 10.65;  P = .0053), while modifi ed 
Choi criteria were not signifi cant (odds 
ratio, 1.07; 95% confi dence interval: 
0.38, 3.00;  P = .8911), indicating no in-
teraction between texture uniformity and 
enhancement and size change (assessed 
with the criteria). 
 Discussion 
 Imaging-defined response assessment 
(RECIST) is a cornerstone of modern 
oncologic practice; however, it is limited in 
a number of targeted therapies, includ-
ing treatment with TKIs. Administration 
time to progression is summarized in 
 Table 4 . With coarse texture (fi lter value, 
2.5; approximately 12 pixels in width), 
both baseline entropy and baseline uni-
formity, as well as percentage change 
in uniformity, were signifi cantly corre-
lated with time to progression ( Table 4 ). 
With a threshold change of  2 2% or less 
in uniformity at a scale value of 2.5, the 
area under the ROC curve was signifi cant 
(0.71; 95% confi dence interval: 0.53, 0.85; 
 P = .016) ( Fig 3 ). Kaplan-Meier curves of 
the proportion of patients without disease 
progression were signifi cantly different 
for percentage change in uniformity and 
were better than those for RECIST-, Choi-, 
and modifi ed Choi–defi ned response af-
ter two cycles of TKI therapy ( P = .008 
received sunitinib ( n = 26), cedirinib 
( n = 6), pazopanib ( n = 4), and rego-
rafenib ( n = 3). A total of 87 target le-
sions were analyzed. The initial treatment 
responses, as categorized with RECIST, 
Choi, and modifi ed Choi criteria, are 
summarized in  Table 2 . Subsequently, 
follow-up imaging showed that 26 of 39 
patients had progressed with treatment 
during the study period. Median time 
to progression was 336 days (range, 
57–1364 days). 
 The mean values for entropy and 
uniformity for absolute scale values at 
baseline and after two treatment cycles 
are summarized in  Table 3 . 
 Our ability to use entropy and unifor-
mity at different scale values to predict 
 Table 3
Mean Value and Percentage Change for Entropy and Uniformity for Absolute Scale Values at Baseline and after Two Treatment Cycles 
Filter Scale Value
Entropy Uniformity
Baseline After Two Treatment Cycles Change (%) Baseline After Two Treatment Cycles Change (%)
No fi ltration 6.95  6 0.37 6.73  6 0.43  2 3.08  6 4.34 0.010  6 0.002 0.012  6 0.004 +21.00  6 28.36
1.0 3.06  6 0.55 2.60  6 0.84  2 15.20  6 23.35 0.47  6 0.07 0.53  6 0.13 +14.72  6 20.80
1.5 2.31  6 0.72 1.81  6 0.92  2 21.73  6 39.66 0.59  6 0.11 0.67  6 0.16 +14.91  6 20.21
1.8 1.89  6 0.81 1.53  6 0.92  2 16.96  6 50.40 0.66  6 0.13 0.72  6 0.16 +10.61  6 19.48
2.0 1.62  6 0.85 1.35  6 0.88  2 9.51  6 133.76 0.71  6 0.15 0.76  6 0.15 +8.15  6 17.99
2.5 1.23  6 0.81 1.08  6 0.77  2 45.77  6 139.91 0.78  6 0.14 0.80  6 0.13 +4.96  6 17.26
Note.—Data are means  6 standard deviations.
 Table 4 
 ROC and Kaplan-Meier Analysis for Entropy and Uniformity at Different Scale Values 
Filter Scale Value
Entropy Uniformity
ROC Threshold  P Value ROC Threshold  P Value
Baseline
 Without fi ltration  . 6.33 .28  " 0.01 .54
 1.0  . 2.48 .10  " 0.52 .21
 1.5  . 1.46 .09  . 0.40 .17
 1.8  . 1.07 .09  . 0.48 .02
 2.0  " 2.65 .07  . 0.48 .02
 2.5  " 2.33 .02  . 0.55 .02
Percentage change
 Without fi ltration  " -5.26 .19  . 13.95 .13
 1.0  . -6.66 .11  " 2.58 .02
 1.5  . -7.80 .15  " 3.14 .07
 1.8  . -13.11 .05  " 5.23 .07
 2.0  . -5.35 .03  " 0.49 .02
 2.5  . 4.02 .11  " -2.00 .0008
Note.— P values were obtained with Kaplan-Meier analysis.
 Figure 3 
  
 Figure 3: ROC curve shows percentage change in 
uniformity. Area under the ROC curve (0.71; 95% con-
fi dence interval: 0.53, 0.85) was signifi cant ( P = .016). 
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free year gained, $67 215 per life-year 
gained, and $52 593 per quality-adjusted 
life-year gained for sunitinib versus in-
terferon ( 21 ). Cost-effectiveness would im-
prove if we were able to identify nonre-
sponding patients earlier. 
 The addition of tumor attenuation 
change to size criteria may improve 
response assessment ( 11–14 ); however, 
such analysis does not necessarily best 
refl ect changes in tumor  heterogeneity. 
Heterogeneity is a well-recognized fea-
ture of malignancy. Heterogeneity of the 
tumor blood supply is associated with ox-
idative stress, promotion of survival fac-
tors, and genomic instability ( 22 ). A het-
erogeneous blood supply will also affect 
treatment response due to poor delivery 
of chemotherapeutic agents to areas of 
low vascularity. Much of the heterogene-
ity visible at CT represents photon noise, 
of TKIs is now standard in patients 
with fi rst-line metastatic renal cell car-
cinoma. In large phase III trials, overall 
RECIST-defi ned response rates were low 
(10%–31%); however, many patients had 
a degree of tumor shrinkage, although this 
was less than a RECIST-defi ned response. 
Patients who did not have a RECIST re-
sponse also experienced clinical ben-
efi ts, with a substantial prolongation of 
progression-free survival. 
 Early identifi cation of patients who 
will not derive a clinical benefi t from 
treatment has a number of advantages. 
Patients could be saved from drug toxic-
ity, they could be switched to an alter-
native treatment earlier, and there are 
potential cost savings if drugs are used 
in only those patients who will benefi t 
from them. There has been at an esti-
mated cost of $18 611 per progression-
 Figure 4 
  
 Figure 4: Kaplan-Meier curves show proportion of patients without disease progression for RECIST, Choi, 
and modifi ed Choi criteria and percentage change in uniformity. 
which can mask any under lying biologic 
heterogeneity. By using fi lters that se-
lect for image features at larger scales, 
CT texture analysis can reduce the effect 
of photon noise while enhancing biologic 
heterogeneity. Heterogeneity at relevant 
scales can then be quantifi ed by using a 
range of parameters, including coarseness 
(entropy) and irregularity (uniformity). 
 In our study, we found that CT tex-
ture changed after two cycles of therapy: 
entropy—refl ecting texture irregularity—
decreased, while uniformity increased 
(tumor heterogeneity was reduced after 
two cycles of therapy). This would be 
consistent with a decrease in vasculariza-
tion and the development of necrosis. 
This is supported by the fi ndings of pre-
vious computer simulations and human 
studies, which have suggested that tex-
ture refl ects underlying vascularization 
( 15 ): texture has been correlated with 
hepatic blood fl ow (hepatic perfusion 
index) in patients with colorectal cancer. 
 Change in uniformity after two cycles 
of treatment also appeared to best refl ect 
time to progression. In comparison to the 
standard RECIST criteria and the com-
bined size and enhancement response 
criteria (Choi and modifi ed Choi criteria) 
used to assess initial TKI therapy effect 
after two cycles of treatment (partial re-
sponse, stable disease, or progressive dis-
ease ), the percentage change in texture 
uniformity (above the 2.0 value, which en-
hances the contribution from underlying 
vessels) was an independent predictor of 
time to progression. By using a threshold 
change of  2 2% or less for uniformity at a 
coarse scale (fi lter value, 2.5; 12 pixels in 
width), Kaplan-Meier curves of the pro-
portion of patients without disease pro-
gression were signifi cantly different from 
and better than those for RECIST, Choi, 
and modifi ed Choi partial response crite-
ria. This indicates that uniformity yields 
information in addition to enhancement 
and size change , and thus enables com-
plementary assessment. Kaplan-Meier 
curves for percentage change in entropy 
at a coarse scale were not signifi cantly 
different, indicating that these measures 
were not identical but that they refl ected 
different aspects of heterogeneity. 
 We also found that baseline entropy 
( " 2.33) and uniformity ( . 0.55) at a 
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coarse scale correlated with time to 
progression, suggesting that baseline 
heterogeneity may also yield predictive 
information. An advantage of texture 
analysis is that it imposes no additional 
burden on a patient, as it is an additional 
postprocessing step of standard CT im-
ages that were obtained for standard 
response assessment. 
 There were limitations to this study. 
First, renal impairment may preclude 
the use of intravenous iodinated contrast 
material in patients with renal disease. 
In this retrospective study, the use of in-
travenous iodinated contrast material was 
precluded by renal impairment in 29% of 
the patients. Nevertheless, texture anal-
ysis still may yield useful information on 
underlying tumor heterogeneity without 
the use of intravenous contrast material, 
as has been shown in patients with other 
cancers ( 16,17 ). Second, texture param-
eters may be affected by the phase (arte-
rial or portal venous) of acquisition. To 
our knowledge, there are no published 
data that enable one to confi rm or refute 
this supposition for fi ltered texture data. 
Third, one must consider the possibility 
that acquisition parameters (tube volt-
age or tube current) may affect texture 
parameters. A previous water phantom 
study in which researchers used varying 
tube current (100–250 mAs) at 80 and 
120 kV and then varying tube voltage 
at a fi xed tube current of 150 mAs sug-
gests this has less of an effect on unifor-
mity ( 17 ). Fourth, to date, texture anal-
ysis has been performed for a limited 
tumor area and not the whole tumor; 
however, texture analysis still shows 
promise as a predictive biomarker. This 
is likely to change in the future, as soft-
ware improvements will enable whole-
tumor segmentation and analysis. 
 In conclusion, CT entropy decreases 
and uniformity increases with multi-
targeted TKIs. CT texture has potential as 
a predictive biomarker, and it may bet-
ter refl ect time to progression than stan-
dard response criteria based on size 
change, enhancement change, or both. 
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